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ABSTRACT 
 
Introduction: The data published by the Medical Research Council of South Africa 
demonstrated that cardiovascular disease and diabetes mellitus are the second and tenth 
leading causes of death in South Africa, respectively (Bradshaw et al.,2003). The prevalence 
of obesity is higher in the African than Indian population (Puoane et al., 2002), whereas 
cardiovascular diseases (CVD) and diabetes are more common in the latter population (Omar 
et al., 1994, Joffe et al., 1994). Diabetes and hypertension has been related with abdominal 
obesity in a number of studies conducted in the African and mixed-ancestry communities of 
the Western Cape (Steyn et al., 1996, Levitt et al., 1993). The reason for the high prevalence 
of obesity in the African population is not known however it is known that the aetiology of 
obesity involves both environmental and genetic factors (Grundy, 2004). 
Objective: The main aim of this project was to ascertain the role of metabolic, hormonal, 
anthropometric and environmental factors in the pathogenesis of obesity-related disorders in 
two South African ethnic groups namely Indian and African women. These populations were 
chosen because of the wide differences in risk factors for the development of CVD and 
diabetes reported in these groups. 
Subjects and methods: Plasma and serum samples were taken during a 5-hour OGTT from 
20 lean, 20 obese, 20 obese type 2 diabetic patients, and 10 overweight women of African and 
Indian origin, i.e. 140 subjects in total. All participants were recruited from an urban 
population of women residing in the Greater Johannesburg area. Serum insulin, C-peptide, 
proinsulin and adipokines were measured using ELISA kits. Fasting plasma glucose, serum 
cholesterol, HDL-cholesterol and triglycerides levels were measured on the ROCHE 
MODULAR System. Insulin resistance was calculated using HOMA. Visceral and 
subcutaneous fat areas were measured using a 5-level CT-scan. Nutrient intake was assessed 
using a validated quantified food frequency questionnaire. Socio-economic status was 
estimated from the level of education and the number of selected household amenities. The 
data collected from the project was analysed by using SAS System for Windows Release 8.02 
SAS Institute Inc., Cary, NC, USA 1999-2001. 
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Results: Results from the study presented in the table below indicate that Indian females were 
more insulin resistant and had a worse atherogenic lipid profile than African females 
(statistically higher LDL and triglycerides levels). The greater visceral fat mass in the Indian 
subjects appears to be associated with triglycerides and correlated with insulin resistance 
(r=0.554, p<0.05). This effect was not observed in Africans. African females had a higher 
proportion of their energy intake as carbohydrates than Indians (49.3% and. 45.2%, 
respectively, p<0.05), whereas Indians had a higher proportion of their total energy intake as 
fat than Africans (34.0% and 29.9%, respectively, p<0.05). The level of educational 
attainment and possession of household amenities was lower in the African than Indian group, 
but this did not significantly influence any of the anthropometric variables. 
Conclusions:  Visceral fat accumulation was greater in diabetic and lean Indian subjects than 
in diabetic and lean African groups, which may explain their higher risk for obesity-related 
disorders at lower BMI. Significantly higher HOMA levels in obese Indians and significantly 
lower proinsulin/insulin ratio in lean and obese Indian women compared to lean and obese 
African women suggests that lean and obese Indians have better beta-cell proinsulin-
processing efficiency than Africans, probably due to the higher secretory load imposed on beta 
cells by the higher level of insulin resistance in the Indian subjects. Triglycerides, one of the 
major components in the diagnostic criteria of metabolic syndrome, were significantly 
different in the obese group (higher in Indians) and this may lead to the higher prevalence of 
CVD in the Indian population. Interethnic differences for leptin levels were observed in the 
lean group of women with higher levels in the Indian subjects. When all non-diabetic subjects 
were combined serum leptin levels were significantly higher in Indian than African subjects. 
This is an intriguing result, since obesity is more common in the African than Indian 
populations of South Africa. Caloric intake was higher in lean African than Indian females. 
However, the hypothesis that lower leptin levels in lean African females may lead to higher 
dietary intake and thus an increased prevalence of obesity in this group must be evaluated in a 
longitudinal study of leptin levels and weight gain. The impact of lower socio-economic status 
in African than Indian population is not clear; however data from the literature does 
demonstrate a negative correlation of obesity prevalence with education and income. 
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Data shown as Mean values ± SEM; adjusted for age; * excluding low energy reporters 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
Abbreviations: LI- lean Indian; OBI-obese Indian; DI-diabetic Indian; LA-lean African;  
OBA-obese African; DA-diabetic African  
 
 
 
          Groups  
 
Variables 
 
LI 
(N=20) 
 
OBI 
(N=20) 
         
DI 
(N=20) 
 
LA 
(N=20) 
 
OBA 
(N=20) 
 
DA 
(N=20) 
Age (years) 44.0±1.7 47.0±1.9 52.0±1.2 a, c 42.0±1.4 43.0±1.2 47.6±1.5 c 
BMI (kg/m2) 22.9±0.4 32.9±0.6 b 34.8±1.0 22.4±0.4 34.4±0.7 b 36.2±1.0 
Visceral Fat  
(cm2)  
51.3±6.2 a 96.7±7.8 b 117.5±9.9 a 30.3±2.9 81.4±6.4 b 93.9±6.2 
HOMA - IR 2.23±0.27 4.28±0.52 a, b 7.54±0.74 c 1.87±0.28 2.83±0.51 6.56±1.26 c 
Proinsulin/ 
insulin ratio  
0.03±0.01a 0.04±0.01a 0.11±0.02 c 0.08±0.02 0.09±0.01 0.09±0.01 
LDL (mmol/l)  3.24±0.17 a 3.30±0.18 3.10±0.22 2.58±0.17 3.12±0.18 b 2.98±0.2 
Triglycerides 
(mmol/l) 
1.05±0.11 b 1.44±0.11a 2.11±0.36 0.79±0.1 b 1.09±0.12 1.41±0.11 
TNF-α (pg/ml) 2.97±0.96 a 2.50 ±0.83 2.26 ±0.42 a 6.51 ±1.40 4.03 ±1.28 7.06±1.38 
Leptin (ng/ml) 29.5±2.66 a 50.8±2.09 b 43.6±2.07 c 13.8±2.51  51.3±2.11 b 40.6±2.49 c 
Education 3.35±0.15 a 2.70±0.16 b 2.40±0.13 2.35±0.17 2.70±0.15 2.10±0.21 c 
Household 
amenities 
3.85±0.08 a 3.80±0.09 a 3.70±0.11 a 3.00±0.16 3.35±0.15 3.15±0.18 
Dietary energy 
intake  (kJ) * 
7496±468 a 7839±420 7423±386 10151±545 9125±557 9050±702 
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A wise man should consider that health is the greatest of human blessings, and 
learn how by his own thought to derive benefit from his illnesses. 
 
Hippocrates (460 BC -377 BC), Regimen in Health 
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CHAPTER 1- LITERATURE REVIEW 
 
1.1 Hormones of the endocrine pancreas 
 
The pancreas is a complex organ with both endocrine and exocrine components that are 
integrated in function, providing both the enzymes for digestion (the exocrine pancreas) and 
the hormones to regulate the metabolism of the digested nutrients (the endocrine pancreas). 
The endocrine pancreas, only 1%-2% of the pancreatic volume, is dispersed throughout the 
exocrine tissue as micro-organs called the islets of Langerhans. Each islet is comprised of 
mainly insulin-producing β cells (60%-80%) with ~ 5% somatostatin-producing δ cells and 
15%-35% of either glucagon-producing α cells or pancreatic polypeptide-producing (PP) cells 
(Fig.1.1). 
 
 
 
Figure 1.1 Physiologic anatomy of the pancreas (http://www.rajeun.net/aadiet.html) 
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1.1.1 Physiologic effects of glucagon, somatostatin and pancreatic 
polypeptide 
 
When insulin was first crystallized, the preparations were found to contain a hyperglycaemic 
factor, which was later identified as the polypeptide hormone glucagon secreted by the alpha 
cells of the pancreatic islets with twenty-nine amino acid residues (MW 3,483). Unlike insulin, 
it consists of only a single polypeptide chain and contains no disulfide bonds (Montgomery et 
al., 1977). 
Glucagon is synthesized from a large precursor, proglucagon, in a tissue-specific manner in 
pancreatic alpha-cells and is also expressed within the intestinal tract, where it is processed not 
into glucagon, but to a family of glucagon-like peptides (enteroglucagon) (Young, 2005). 
Glucagon-like peptide 1 (GLP-1) constitutes of 30-amino acids and is involved in regulating 
secretion of insulin which is dependent on blood glucose levels.  Glucagon-like peptide 1 
(GLP-1) is created in the intestinal epithelial endocrine L-cells by differential processing of 
proglucagon, the gene that is expressed in these cells. GLP-1 also involved in inhibition of 
glucagon secretion, in that way contributing to limit postprandial glucose excursions. GLP-1 is 
immensely rapidly metabolized and inactivated by the enzyme dipeptidyl peptidase IV even 
before the hormone has left the gut, raising the possibility that the actions of GLP-1 are 
transmitted via sensory neurons in the intestine and the liver expressing the GLP-1 receptor 
(Holst, 2007). 
Glucagon's action on glucose and ketone formation by hepatocytes is mediated by increase in 
cyclic-AMP-dependent protein kinase. It is most probably at this level the opposite effect of 
insulin upon glucagon-mediated events occurs. Cyclic-AMP-dependent protein kinase activity 
is low when glucagon secretion or action is blocked even in the absence of insulin, which 
could explain why marked glucose and ketone production is absent in bihormonal deficiency 
states (Unger, 1985). Glucagon stimulates hepatic glucose output and that leads to increases in 
glycemia. Glucagon is secreted from islets in a pulsatile fashion, and such pulsatile deliveries 
of glucagon are more beneficial in inducing hepatic glucose output in vitro, ex vivo, and in 
vivo (Jiang et al., 2003). Diseases linked with excessively high or low secretion of glucagon 
are uncommon. Only in a case of cancers of alpha cells (glucagonomas) there is an excessive 
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glucagon secretion. Alpha pancreatic islet cell tumors, known as  glucagonomas, and when 
they active  they can produce a syndrome characterized by necrolytic migratory erythema, 
diabetes mellitus, weight loss, anaemia, glossitis, thromboembolism, neuropsychiatry 
disturbances and hyperglucagonemia (Carvajal et al., 2002). Glucagon itself is responsible for 
most of the known signs and symptoms, and its induction of hypoaminoacidemia is belief to 
lead to necrolytic migratory erythema. Many patients are diagnosed very late in the clinical 
course for cure, but successful palliation of symptomatology can usually be accomplished with 
surgical and medical intervention (Chastain, 2001).Hyperglucagonemia plays an important 
role in initiating and maintaining hyperglycaemia when combined with delayed or deficient 
insulin secretion, as in the cases of type 1 and type 2 diabetes (Jiang et al., 2003). 
Somatostatin is another hormone recognized to inhibit glucagon secretion. The gene for 
somatostatin is on the long arm of chromosome 3. It codes for a 116-amino-acid peptide, 
preprosomatostatin, from whose carboxyl terminus is cleaved the hormone somatostatin, a 14-
amino-acid cyclic polypeptide with a molecular weight of 1640. The name somatostatin comes 
from its ability to inhibit release of growth hormone (pituitary somatotropin) and was first 
isolated from the hypothalamus. 
Almost every known stimulator of release of insulin from pancreatic beta cells also promotes 
somatostatin release from delta cells. This includes glucose, arginine, gastrointestinal 
hormones, and tolbutamide. The metabolic clearance of exogenously infused somatostatin in 
humans is extremely rapid; the half-life of the hormone is less than 3 minutes. Somatostatin 
acts in several ways to restrain the movement of nutrients from the intestinal tract into the 
circulation (Karam et al.,1991). In pharmacologic amounts, somatostatin significantly blunts 
the ketosis associated with acute insulin deficiency (Granner, 1990). 
Pancreatic polypeptide (PP) is a 36-amino acid peptide (MW ~ 4200) is found in F cells 
located chiefly in islets in the posterior portion of the head of the pancreas. PP levels released 
rapidly into the circulation after ingestion of a meal and remain high for several hours (Adrian 
et al.,1976). In the brain, PP has a mainly orexigenic effect when administered directly 
(Asakawa et al.,1999). PP inhibits gastric emptying rate, gallbladder motility and exocrine 
pancreatic secretion in the gastrointestinal tract (Hazelwood,1993), and in contrast to its 
central effects, intraperitoneal administration of PP decreases food intake and increases energy 
expenditure (Asakawa et al.,1999). Continual administration of PP to obesity-prone animals 
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suppressed excessive weight gain (Asakawa et al.,2003), and mice who over express PP in the 
pancreas because of genetic manipulation are characterized by decreased food intake and 
lower body weight (Ueno et al.,1999). 
 
1.1.2 Biosynthesis of insulin 
 
A precursor molecule, preproinsulin, a long-chain peptide of molecular weight 11,500, is 
cleaved by microsomal enzymes to proinsulin (MW about 9000) almost immediately after 
synthesis and is formed by DNA/RNA-directed synthesis in the rough endoplasmic reticulum 
of pancreatic beta cells. Proinsulin is transported to the Golgi apparatus, where packaging into 
clathrin-coated secretory granules takes place. Maturation of the secretory granule is 
connected with loss of the clathrin coating and conversion of proinsulin into insulin and a 
smaller connecting peptide, or C-peptide. “Normal mature (uncoated) secretory granules 
contain insulin and C -peptide in equimolar amounts and only small quantities of proinsulin, a 
small portion of which consists of partially cleaved intermediates” (Karam et al.,1991). 
 
1.1.3 Proinsulin processing 
 
Proinsulin is a linear peptide of 86 amino acids. It contains within it the entire sequences of 
insulin and C-peptide and is the precursor of both of these molecules. Three intra-chain 
disulphide bridges within the insulin portion of the molecule maintain its tertiary structure 
(Kjems et al., 1997). The basis for the conversion of proinsulin, by enzymatic cleavage in the 
secretory granules of the β-cell, has been understood for some years. The two junctions of 
insulin and C-peptide are marked by pairs of basic amino acids that are target sequences for 
endopeptidases that cleave on the C-terminal side of the pair. Both pairs of amino acids are 
subsequently removed to leave C-peptide and insulin. This processing pathway is largely an 
ordered sequence rather than a random one (Halban,1994, Hutton,1994, Bailyes et al.,1994). 
Proinsulin is first cleaved at the 32-33 junctions by the proinsulin-converting enzyme (PC) 1, 
to give the cleaved molecule known as 32-33 split proinsulin (Fig.1.2). The newly exposed 
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amino acids at the C-terminal of insulin B-chain are rapidly excised by the exopeptidase 
carboxypeptidase H, producing des 31, 32 split proinsulin. A second endopeptidase, PC2, 
cleaves at the 65-66 junctions to produce mature insulin, and a further carboxypeptidase H 
(CPH) trimming of the cleaved peptide produces C-peptide. It seems that both PC1 and PC2 
are largely specific for their substrates; proinsulin is a poor substrate for PC2, thus the 65-66 
split and des 64, 65 split forms of proinsulin are probably not normally produced in significant 
quantities. Moreover, the speed of CPH processing is so rapid that normally neither split form 
survives long enough to be measurable, except as the des-split form (Kjems et al.,1997). 
It is known that PC1 activity, but not that of PC2, increases in parallel with proinsulin 
concentration as the pancreas responds to glucose. Consequently 32-33 split and des 31, 32 
split forms increase in concentration as PC2 becomes rate-limiting (Hutton,1994). The 
pancreas produces a small amount of proinsulin that escapes cleavage and secreted intact into 
the bloodstream, along with insulin and C- peptide. Because the liver does not remove 
proinsulin, it has a half-life 3-4 times that of insulin. This allows proinsulin to accumulate in 
the blood, where it accounts for 12-20% of the circulating immunoreactive “insulin” in the 
basal state in humans. Human proinsulin has about 7-8% of the biologic activity of insulin. 
The kidney is the principal site of proinsulin degradation (Karam et al.,1991). 
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Figure 1.2 Proinsulin processing (Kjems et al.,1997) 
 
 
1.1.4 C-peptide release 
 
C-peptide is a small polypeptide of 31 amino acids (MW 3020 D) and is considered 
biologically inert. C-peptide plays a role in linking A and B-chains of insulin in the proinsulin 
molecule When the granule contents are released by exocytosis C-peptide and insulin are 
secreted in equimolar quantities from the pancreatic β-cells ( Kjems et al.,1997). C-peptide is 
released into the portal vein, and passes through the liver almost unextracted (5-8% is 
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extracted). C-peptide has 2 to 5 times longer half-life than insulin therefore higher levels of C-
peptide stay in the peripheral circulation and these levels vary less than insulin. Consequently 
plasma C-peptide levels may reflect pancreatic insulin secretion more reliably than the level of 
insulin itself. Most C-peptide not removed by the liver is degraded, or excreted by the kidney 
into the urine where it remains stable and can be quantified (Haibach et al., 1987). 
 
1.1.5 Insulin structure and metabolic effects 
 
Insulin belongs to a family of structurally related regulatory proteins. Insulin-like growth 
factors and relaxin also included in this group. Molecular weight of insulin is 5808 and it 
consists of two chains linked by two disulphide bonds. One A-chain is comprises of 21 amino 
acids and the B-chain of 30 amino acids, with disulphide bonds located at positions A7-B7 and 
A20-B19. The A-chain also has an internal disulphide bond bridging A6 and A11. 
There are minor differences in the amino acid sequence of the molecule from species to 
species. These are generally not sufficient to affect the biological activity but are enough to 
make the insulin antigenic. Glucose is the primary signal that stimulates insulin secretion by 
the β-cells of the pancreatic islets. Insulin is secreted directly into the portal venous circulation 
and the half-life of the hormone in the circulation, in humans is about five minutes. Almost all 
tissues have the ability to metabolize insulin, but over 80% of secreted insulin is normally 
degraded in the liver and kidneys (Kjems et al.,1997). 
The main effects of insulin are to decrease plasma glucose and free fatty acid concentrations. 
Insulin also has a stimulatory effect on protein synthesis. The circulating insulin facilitates the 
diffusion of glucose into muscle cells and adipocytes, enhancing glucose utilization in these 
tissues. There appears to be a membrane barrier to glucose uptake in muscle and adipose tissue 
that insulin helps to overcome by increasing levels of glucose transporter 4 (GLUT4) in the 
plasma membrane. Hepatocytes, on the other hand, are freely permeable to glucose, and there 
is no need for enhancement of glucose entry into the liver. However, insulin does have a 
profound influence on hepatic glucose metabolism by inducing the synthesis of a specific 
glucokinase (Montgomery et al.,1977). 
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In addition to its role in peripheral metabolism, insulin may influence central regulation of 
energy balance (Schwartz et al.,1992). Fasting  and glucose-stimulated circulating insulin 
levels are comparatively stable during infancy and childhood, and increase during puberty owe 
to decreased insulin sensitivity (Amiel et al.,1991). Glucose counter-regulatory hormones, 
such as glucagon, glucocorticoids, growth hormone and epinephrine, decrease insulin 
sensitivity and insulin action; insulin levels may increase during exogenous administration of 
these substances (Gerich, 1988, Rasmussen et al., 1990). 
 
1.1.6 Normal insulin secretion 
 
Glucose is promptly taken up by the pancreatic β cell by the glucose transporter 2 (GLUT2), 
upon which it is phosphorylated by glucokinase, which is the rate-limiting step of β- cell 
glucose metabolism. Continue degradation leads to formation of pyruvate, which is then taken 
up in the mitochondria in which further metabolism leads to ATP formation. ATP is essential 
for the delivery of energy for the release of insulin, but it is also implicated in beta cell 
membrane depolarization. Increases in ADP/ATP ratio lead to activation of the sulphonylurea 
receptor 1 (SUR1) protein and subsequently lead to closure of the adjacent potassium channel 
(potassium inward rectifier ([KIR] 6.2 channel). The shutting of the potassium channels will 
change the membrane potential and open calcium channels, which triggers the release of 
preformed insulin-containing granules (Stumvoll et al.,2005). 
 
1.1.7 Insulin receptor and mechanism of insulin action 
 
The joining of insulin to a receptor on the surface of the target cell membrane indicates the 
start of insulin actions. The binding of these receptors in fat, liver, and muscle cells is related 
with the biologic response of these tissues to the hormone. The binding of these receptors with 
insulin is very rapid process with high specificity and with an affinity high enough to bind 
picomolar amounts (Karam et al.,1991).  
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The insulin receptor is a heterotetrameric protein includes two extracellular α subunits (MW 
130,000) and two transmembrane β subunits (MW 90,000).  The alpha subunits connected by 
a disulfide bonds to two transmembrane beta subunits. The binding of the ligand to the α 
subunit of insulin receptor accelerates the tyrosine kinase activity intrinsic to the β subunit of 
the receptor (Zhang, 2002). 
Immense number of studies have indicated that the ability of the receptor to autophosphorylate 
and phosphorylate intracellular substrates is essential for its mediation of the complex cellular 
responses to insulin (Ellis et al.,1987, Kasuga et al.,1982, Rosen et al.,1983, Yu et al.,1984). 
The two α subunits equally take part in insulin binding and the kinase domains in the two β 
subunits are juxtaposed allowing autophosphorylation of tyrosine residues in the first step of 
insulin receptor activation (Luo et al.,1999, Ottensmeyer et al.,2000). The kinase domain go 
through conformational change upon autophosphorylation, providing a basis for activation of 
the kinase and binding of downstream signaling molecules (Hubbard,1997, Hubbard et 
al.,1994). 
The insulin receptor additionally to tyrosine autophosphorylation is also subjected to ß-subunit 
serine/threonine phosphorylation, which attenuates receptor function. The chronic high levels 
of insulin that takes place as a result of insulin resistance could stimulate the relevant serine 
kinases, perhaps through the IGF-1 receptor, which can also be incited by high insulin levels. 
This kind of relation could release a mechanism for a vicious cycle of insulin-induced insulin 
resistance (Pessin et al.,2000). In the same way, counter-regulatory hormones and cytokines 
can trigger serine kinases, particularly protein kinase C (PKC), which has been involved in the 
development of peripheral insulin resistance. A number of PKC isoforms are chronically 
activated in human and rodent models of insulin resistance (Avignon et al.,1996, Considine et 
al.,1995b, Ishizuka et al.,1998). The insulin sensitivity and insulin receptor tyrosine kinase 
activity is improved by pharmacologic inhibition of PKC activity or reduction in PKC 
expression (Donnelly et. al., 1998).  
The insulin receptor, when is activated, phosphorylates a number of important proximal 
substrates on tyrosine, including members of the insulin receptor substrate family 
(IRS1/2/3/4), the Shc adapter protein isoforms, SIRP family members, Gab-1, Cbl, and APS. 
Tyrosine phosphorylation of the IRS proteins generates recognition sites for additional effector 
molecules containing Src homology 2 (SH2) domains. These contain the small adapter 
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proteins Grb2 and Nck, the SHP2 protein tyrosine phosphatase and, most significantly, the 
regulatory subunit of the type 1A phosphatidylinositol 3–kinase (PI 3-kinase) which is 
considerably important for insulin-stimulated glucose uptake via GLUT4 translocation (Czech 
et al., 1999). 
While PI 3-kinase activity is clearly necessary for insulin-stimulated glucose uptake, 
additional signals are also needed for the stimulation of GLUT4 translocation. Therefore, 
activation of PI 3-kinase by induction with IL-4 or by engagement of certain integrins does not 
induce GLUT4 translocation (Guilherme et al.,1998, Isakoff et al.,1995). However, two 
natural insulin receptor mutations that were fully proficient of activating PI 3-kinase failed to 
induce GLUT4 translocation and glucose uptake (Krook et al.,1997). “Glycogen synthase 
kinase 3 (GSK-3) is a cytoplasmic serine/theronine kinase that plays key roles in insulin signal 
transduction and metabolic regulation” (Dajani et al.,2001, Frame et al.,2001, Harwood, 
2001).  
In the insulin-signaling pathway, GSK-3 is active in the lack of insulin and it phosphorylates 
(and in that way inhibits) glycogen synthase and several other substrates. Insulin binding to 
the receptor activates a phosphorylation cascade, heading to inhibitory phosphorylation of 
GSK-3 by Akt. Therefore, insulin activates glycogen synthase by promoting its 
dephosphorylation through the inhibition of GSK-3 (Ryves et al.,2001). Additionally to 
regulating GSK-3 via Akt, insulin also accelerates compartmentalized activation of protein 
phosphatase 1 (PP1) in the complex containing glycogen particles, glycogen-targeting 
subunits and enzymes for glycogen synthesis and breakdown (Newgard et al.,2000). 
 
1.1.8 Insulin and Lipid Metabolism 
 
Insulin plays an important role in the co-ordination of whole-body lipid metabolism after the 
meal. In adipose tissue, insulin supports triacylglycerols (TAG) storage by exciting plasma 
lipoprotein uptake (Farese et al.,1991) and preventing TAG release as fatty acids in the plasma 
(Jensen et al.,1989a). Insulin affects hepatic lipid metabolism directly through its actions to 
modulate the expression of enzymes or secretory proteins [e.g. apolipoprotein B (apoB)]; and 
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indirectly by determining the rate of delivery of esterified or non-esterified fatty acids to the 
liver, through its antilipolytic effect on adipose tissue and its influence on the expression of 
lipoprotein lipase activity. Under normal conditions, the liver is regularly exposed, via the 
portal circulation, to major increases in insulin concentration in response to food intake 
(Zammit, 1996). 
Work in human subjects has provided support for the hypothesis that the hepatic sensitivity to 
the inhibitory effect of insulin is a major determinant of lipemia, and, furthermore, in insulin-
resistant subjects, that the decreased sensitivity to the inhibitory effect of insulin is an 
important contributory factor to the hypersecretion of very low density lipoprotein (VLDL) 
(Bourgeois et al.,1996, Bourgeois et al.,1995). Studies in humans have shown that intraportal 
infusion of insulin in humans results in a decrease in the secretion of VLDL-TAG (Vogelberg 
et al.,1980). Similarly, when humans are treated with insulin, the secretion of apoB100-
associated TAG is decreased. Although a large proportion of this effect can be attributed to the 
decrease in circulating NEFA concentrations due to the anti-lipolytic action of insulin, even 
when the concentration of NEFA was kept high, insulin still gave a decrease in hepatic VLDL 
secretion rate of about 30% (Lewis et al.,1995).  
Insulin has an effect on the state of phosphorylation of hormone-sensitive lipase and lipolysis 
via a cAMP-dependent pathway, involving reduction of cAMP, and via a cAMP-independent 
pathway, that involves activation of a protein phosphatase activity that dephosphorylates both 
the regulatory and basal phosphorylation sites of hormone-sensitive lipase (Stralfors et 
al.,1989).  
“Lipoprotein lipase is an endothelium-bound lipase that hydrolyses the triglyceride carried on 
lipoprotein particles to release glycerol and NEFA” (Goldberg,1996). In both the fasting and 
postprandial states diminished action of insulin on lipoprotein lipase results in decreased 
clearance of the triglyceride-rich lipoproteins, VLDL, and chylomicrons. This is a significant 
fundamental factor to hypertriglyceridaemia in type 2 diabetes (Valabhji et al.,2003). Glycerol 
is an essential intermediate of glucose and lipid metabolism by capacity of its ability to 
maintain glycogenesis in fundamental various systems, as well as serving as a precursor for 
the synthesis of triglycerides (TG) and other glycerolipids (Rognstad et al.,1974, Baba et 
al.,1995, McCabe,1995). While glycerol is a well recognized indicator of lipolysis and is a 
gluconeogenic precursor (Rognstad et al., 1974), the relationship between glycerol and 
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glucose homeostasis is complicated and not yet completely explained (Gaudet et al., 2000). 
Insulin is an important regulator of almost all aspects of adipocyte biology, and adipocytes are 
one of the most highly insulin-responsive cell types. Insulin enhances adipocyte triglyceride 
stores by a number of mechanisms that includes assisting the differentiation of preadipocytes 
to adipocytes, in mature adipocytes, accelerating glucose transport and triglyceride synthesis 
(lipogenesis), plus inhibiting lipolysis. Insulin also enhances the uptake of fatty acids derived 
from circulating lipoproteins by stimulating lipoprotein lipase activity in adipose tissue 
(Paradis et al.,1998). 
 
1.1.9 Role of PPAR-γ in adipogenesis  
 
Peroximase proliferator-activated receptor γ (PPAR-γ) is a nuclear hormone receptor which 
plays a central role in the control of adipocyte gene expression and differentiation. PPAR-γ is 
expressed predominantly in adipose tissue, and its expression is induced very early in the 
adipocyte differentiation process (Sharma et al., 2007).When expressed ectopically, PPAR-γ 
converts fibroblasts into bona fide preadipose cells. Upon application of activators or PPAR-γ 
ligands, these cells differentiate into fat cells (Spiegelman et al., 1997). 
There are two additional PPAR isoforms, PPAR-α and PPAR-δ, whose expressions are less 
restricted but also occur at some level in certain adipose depots. Although PPAR-α activates 
the differentiation program, it appears to do so less efficiently than PPAR-γ.  PPAR-δ did not 
stimulate adipogenesis even in response to the strongest PPAR-δ activators (Brun et al., 1996). 
The major role of PPAR-γ in regulating adipogenesis is supported by the fact that 
thiazolidineadiones (TZD), which are high affinity, synthetic ligands for PPARγ, are potent 
inducers of adipocyte differentiation. PPARγ and its obligate heterodimeric partner, retinoid X 
receptor α (RXBα) in gene ablation studies reporting an absence of white adipose tissue have 
been placed as important transcription factors in regulating the gene expression leading to 
adipogenesis  (Morrison et al., 2000). 
Hormones such as insulin, insulin-like growth factor (IGF)-1, growth hormone, 
glucocorticoids, and cathecholamines play a prominent role in the promotion of adipogenesis. 
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They have effects on fat differentiation both in vitro and in vivo. The activity of all three 
isoforms of PPAR may be modified by one or more of these factors and make them more or 
less adipogenic (Brun et al., 1996). 
  
 
1. 2 Type 2 Diabetes: principles of pathogenesis 
 
1.2.1 Diagnostic criteria for diabetes mellitus 
 
Diabetes mellitus is a cluster of metabolic diseases characterized by hyperglycaemia resulting 
from defects in insulin secretion, insulin action, or both. The chronic hyperglycaemia of 
diabetes is correlated with long-term damage, dysfunction, and failure of several organs, 
especially the eyes, kidneys, nerves, heart, and blood vessels. Many diabetic individuals do not 
clearly match into a single class and therefore conveying a type of diabetes to an individual 
often depends on the circumstances present at the time of diagnosis. 
Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) is immune-
mediated diabetes. This form of diabetes, which accounts for only 5–10% of those with 
diabetes, previously encompassed by the terms insulin-dependent diabetes, type I diabetes, or 
juvenile-onset diabetes, results from a cellular-mediated autoimmune destruction of the β-cells 
of the pancreas. Type 2 diabetes, which accounts for 90–95% of those with diabetes also 
referred to as non-insulin-dependent diabetes or adult-onset diabetes, encompasses individuals 
who have insulin resistance and usually have relative (rather than absolute) insulin deficiency 
(American Diabetes Association (ADA), 2005). The World Health Organization (WHO) 
criterion for diagnosing diabetes is a fasting plasma glucose at 126 mg/dl (7.0 mmol/l) or a 2-h 
glucose at 200 mg/dl (11.1 mmol/l) in an 75 g OGTT (WHO,1999). The criteria for the 
diagnosis of diabetes as specified in a position statement by ADA (2005) are presented in 
Table 1.1. Three ways to diagnose diabetes are possible, and each, in the absence of 
unequivocal hyperglycaemia, must be confirmed, on a subsequent day, by any one of the three 
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methods given in Table 1.1. The use of the haemoglobin A1c (A1C) for the diagnosis of 
diabetes is not recommended at this time. 
 
 
Table 1.1 Criteria for the diagnosis of diabetes mellitus by ADA (2005) 
 
1. Symptoms of diabetes plus casual plasma glucose concentration ≥ 11.1mmol/l (200 mg/dl) 
Casual is defined as any time of day without regard to time since last meal. The classic 
symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss, or 
2. FPG ≥ 7.0 mmol/l (126 mg/dl).  
Fasting is defined as no caloric intake for at least 8 hours, or  
3. 2-h post load glucose ≥ 11.1mmol/l (200 mg/dl) during an OGTT.  
The test should be performed as described by WHO, using a glucose load containing the 
equivalent of 75 g anhydrous glucose dissolved in water. 
In the absence of unequivocal hyperglycaemia, the above criteria should be confirmed by repeat 
testing on a different day. The third measure (OGTT) is not recommended for routine clinical use. 
 
 
The diagnostic criteria for diabetes adopted by the WHO and ADA are accepted 
internationally. Accordingly the International Diabetes Federation (IDF, 2005) has developed 
a global guideline which says detection programmes should use measurement of plasma 
glucose, preferably fasting, that following a positive screening test, diagnostic testing is 
required. For diagnosis, an OGTT should be performed in people with fasting plasma glucose 
(FPG) ≥ 5.6 mmol/l (≥ 100 mg/dl) and < 7.0 mmol/l (< 126mg/dl). Fasting or an OGTT should 
be performed where a random plasma glucose level) ≥ 5.6 mmol/l (≥ 100 mg/dl) and < 11.1 
mmol/l (< 200 mg/dl) is detected on opportunistic screening (IDF, 2005). 
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1.2.2 Pathophysiology of type 2 Diabetes 
 
Patients with type 2 diabetes have an impaired ability of insulin to stimulate muscle glucose 
disposal and inhibit hepatic gluconeogenesis and adipose tissue lipolysis (Reaven,1988, 
Reaven,1995a, Reaven, 1995b). Nonetheless as long as pancreatic β-cells can continue to 
secrete large amounts of insulin, gross decompensation of glucose homeostasis can be 
prevented. The development from normal to impaired glucose tolerance (IGT) is correlated 
with a deterioration of insulin resistance and an associated rise in both insulin and glucose. 
Further transition to diabetes incorporates overt β-cell failure with plasma insulin falling and 
glucose rising. This transition is seen as an inverted V-shape relationship of plasma insulin to 
plasma glucose (Reaven et al.,1968, Welborn et al.,1969, Savage et al.,1975, Hansen et 
al.,1986). 
Pancreatic β-cells secrete insulin in a pulsatile fashion and release insulin in a biphasic 
manner, characterized by a “spike” lasting approximately 10 minutes (first-phase release) and 
followed by slowly increasing release (second-phase release). Both phases of insulin release 
are essential for sustaining normal glucose homeostasis (Gerich,1999). Several studies have 
shown that pulsatile insulin release is more effective than sustained release in promoting 
suppression of glucose production and stimulation of glucose utilization (Bratusch-Marrain et 
al.,1986, Paolisso et al.,1989). Probably at least 75% of insulin secretion is released in a very 
regular pulsatile fashion in healthy people. In contrast, type 2 diabetic subjects exhibit 
irregular oscillations of basal plasma insulin. Additionally, disturbed pulsatile insulin release 
is also a common feature in people prone to develop diabetes e.g. first-degree relatives of 
patients with type 2 diabetes. Assessment of high-frequency insulin pulsatility may be an 
important player in future tailoring of antidiabetic drugs and may come out to be significant as 
a predictor of type 2 diabetes in people at high risk for developing the disease (Schmitz et 
al.,2002). 
It is not clear what factors would determine whether β-cells will fail in the face of prolonged 
insulin resistance. Glucose stimulation itself produces desensitization of the β-cell, or “glucose 
toxicity” (Lillioja et al.,1988a, Lillioja et al.,1987, Unger et al.,1985, Robertson,1989, Leahy 
et al.,1988). Thus, if insulin resistance results in an increase in glucose to maintain the signal 
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for increased insulin release, it is possible that eventually this over-stimulation leads to β-cell 
desensitization and initiates a vicious cycle, leading to worse and worse glycemia. Whether 
this desensitization is a general feature of the β-cell or is determined by one or two major 
genes requires further investigation (Lillioja et al.,1991). 
 
1.2.3 Beta-cell apoptosis in the pathogenesis of human type 2 diabetes 
mellitus 
 
Beta-cell mass is regulated by a balance of β-cell replication and apoptosis, as well as 
development of new islets from exocrine pancreatic ducts (neogenesis) (Finegood et al.,1995, 
Bonner-Weir,2000). Disruption of any of the pathways of β-cell formation, or increased rates 
of β-cell death, would result in decreased β-cell mass and thus reduced capacity to produce 
insulin. There is controversy as to whether β-cell mass is decreased in type 2 diabetes mellitus 
(Kloppel et al.,1985, Maclean et al.,1955,  Stefan et al.,1982, Saito et al.,1979, Rahier et 
al.,1983, Clark et al.,1988, Guiot et al.,2001, Sakuraba  et al.,2002). 
These discrepancies are in part due to the lack of available data in humans. Furthermore, it is 
controversial whether β-cell apoptosis is truly increased in type 2 diabetes. A recent study by 
Butler et al., (2003) gives new and convincing data indicating that increased apoptosis, rather 
than decreased neogenesis or replication, may be the main mechanism leading to reduced β-
cell mass in type 2 diabetics. Butler et al., (2003) reported that on autopsy obesity in non-
diabetic humans is accompanied by a 50% increase in relative β-cell volume as compared with 
lean non-diabetic humans. However, the non-diabetic obese humans died younger than the 
non-diabetic lean humans and the difference found on autopsy may be due to age difference. 
Lean subjects with type 2 diabetes had a 41% deficit in relative β-cell volume compared with 
lean non-diabetic subjects. Once β-cell mass decreases below a critical level and insulin 
production no longer meets metabolic demands hyperglycaemia develops. Humans who have 
undergone 50% pancreatectomy have impaired glucose tolerance and insulin secretion in 
response to a hyperglycaemic clamp (Dresler et al.,1991, Robertson et al.,2002, Seaquist et 
al.,1996, Seaquist et al.,1994, Seaquist et al.,1992). On this basis it is possible to assume that a 
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60% reduction in β-cell mass in the face of insulin resistance may be sufficient to result in 
hyperglycaemia (Leonardi et al.,2003). 
A series of studies (Maedler et al.,2002a, Maedler et al.,2002b) report on the roles of high 
glucose concentrations and different free fatty acids (FFAs) on β-cell proliferation, apoptosis 
and function in cultured human islets. While adipocytes store excess fatty acids in the form of 
triglyceride in lipid droplets, non-adipose tissues have a limited capacity for storage of lipids. 
In hyperlipidemic states, accumulation of excess lipid in non-adipose tissues gives rise to cell 
dysfunction and / or cell death. This lipotoxicity appears to be specific for saturated fatty acids 
in several tissues and is ameliorated by unsaturated fatty acids (Maedler et al.,2001a, De Vries 
et al.,1997, Cnop et al.,2001, Hardy et al.,2000, Listenberger et al.,2001). Although there are 
possible mechanisms to explain gluco- and lipotoxicity of β-cell apoptosis, it remains unclear 
what underlies the apoptotic loss of β-cells before hyperglycaemia and /or hyperlipidemia 
develops. A possibility for slowing the progression or even preventing type 2 diabetes may be 
to develop dietary and pharmacological strategies aimed at ameliorating increased β-cell 
apoptosis in people with a high risk for developing type 2 diabetes (Leonardi et al.,2003). 
 
1.2.4 Genetic predisposition for development of type 2 diabetes 
 
The cause of type 2 diabetes is most probably associated with a combination of genetic and 
environmental causes and, importantly, interactions between genes and environment. Despite 
the difficulties encountered, a number of genes and polymorphisms within them have now 
reproducibly been associated with risk of type 2 diabetes in a variety of studies. Disruptions of 
a variety of genes involved in insulin secretion or signalling, such as IRS-2, are known in 
animal models to result in alteration of fetal growth (Tamemoto et al., 1994) 
Recent genome-wide association studies (GWAs) have provided an important resource for 
furthering our understanding of type 2 diabetes disease mechanisms (Perry et al., 2008). At the 
moment a small number of genes recognized through linkage scans or the candidate gene 
approach have been confirmed to be linked with type 2 diabetes (e.g., PPARG, KCNJ11, 
CAPN10, and TCF7L2) (Ng et al., 2008).  
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GWAs have identified novel type 2 diabetes susceptibility loci inside or close to the FTO (fat 
mass and obesity associated), CDKAL1 (cyclin-dependent kinase 5 regulatory subunit 
associated protein 1-like 1), CDKN2A/CDKN2B (encoding the tumor suppressors p15INK4b and 
p16INK4a, respectively), IGF2BP2 (IGF2 binding protein 2), HHEX/IDE (homeobox, 
hematopoietically expressed/insulin degrading enzyme), and SLC30A8 (zinc transporter) 
genes. With the exclusion of FTO, which modifies diabetes risk through increased adiposity 
(Frayling et al., 2007), it is not proven how variation within these genes increases diabetes 
susceptibility, although initial work suggests that CDKAL1 and SLC30A8 might act via altered 
pancreatic β-cell function (Pascoe et al., 2007, Sladek et al., 2007, Steinthorsdottir et al., 
2007, Zeggini et al., 2007). Usually, GWA studies begin with a fixed phenotype such as type 
2 diabetes and subsequently search across a large range of potential genotypes for 
associations. In a reverse study it might initiate with a fixed genotype at a validated variant for 
example, the diabetes-associated single-nucleotide polymorphism (SNP) at TCF7L2, and 
explore across a range of possible phenotypes for new associations (McCarthy et al., 2008). 
 There is a 2 to 4 times increased risk for developing type 2 diabetes with a positive family 
history. 15-25% of first-degree relatives of patients with type 2 diabetes develop impaired 
glucose tolerance or diabetes. In case of one parent had type 2 diabetes the lifetime risk (at age 
80 years) to develop type 2 diabetes has been estimated to be 38% (Pierce et al.,1995).  
The prevalence of type 2 diabetes in the offspring is reckoned to approach 60% by the age of 
60 years when both parents are concerned (Tattersal et al.,1975). To differentiate genetic from 
non-genetic contributions concordance rates in monozygotic twins in additional of those in 
dizygotic twins have been used as only 50%  of dizygotic twins genes share the environment 
(both intrauterine and extrauterine) (Stumvoll et al.,2005). Type 2 diabetes had been 
associated with a genetic polymorphism on chromosome 11p found close to the insulin gene 
(INS VNTR III), but only if the associated allele was transmitted from the father (Huxtable et 
al., 2000). 
As a substitute to both the thrifty genotype and thrifty phenotype hypotheses it was proposed 
that the association of low birth weight with type 2 diabetes in the Pima population might 
signal selective survival of low birth weight infants, with genetically established metabolic 
characteristics that were also related to the later development of diabetes (Hales et al., 1992), 
Lindsay et al., (2001). In the Pima Indian population, lower birth weight is associated with 
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parental diabetes, but in fact solely with diabetes in fathers (Lindsay et al., 2000). Since 
obesity has a significant genetic component, insulin resistance occurring as a result of it could 
be considered genetic (Bouchard,1995). The ability of pancreatic β-cells to compensate for 
insulin resistance in obese individuals could explain why generally obese individuals who are 
insulin-resistant are not diabetic. So basically, one may attribute the pathogenesis of type 2 
diabetes to a genetically determined inability to compensate for decreased tissue insulin 
sensitivity (Polonsky et al.,1996, Reaven,1995a). 
 
1.2.5 Mitochondrial metabolism 
 
The accumulation of ectopic triglyceride in liver, muscle and β-cells has suggested a defect in 
mitochondrial lipid oxidation in patients with type 2 diabetes, who have impaired oxidative 
capacity and small mitochondria in skeletal muscle (Kelley et al.,2002). PPARγ co-activator 1 
(PGC1), a transcription factor for genes involved in mitochondrial fatty acid oxidation and 
ATP synthesis, was decreased in young, lean, insulin-resistant offspring of parents with type 2 
diabetes, suggesting that an inherited defect in mitochondrial oxidative phosphorylation could 
lead to cellular lipid accumulation (Petersen et al.,2004). Decreased expression of PGC1 and 
related gene products could influence mitochondrial function in people with insulin-resistance 
and type 2 diabetes as shown gene expression profiling studies (Mootha et al.,2003, Patti et 
al.,2003). 
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1.2.6 Insulin resistance 
 
1.2.6.1 Insulin resistance in obesity and type 2 diabetes 
 
The term “insulin resistance” (IR) usually signifies resistance to the effects of insulin on 
glucose uptake, metabolism, or storage. Insulin resistance in obesity and type 2 diabetes is 
marked by decreased insulin-stimulated glucose transport and metabolism in adipocytes and 
skeletal muscle and by impaired suppression of hepatic glucose output (Reaven,1995a). These 
beneficial defects may result, in part, from impaired insulin signaling in all three- target tissues 
and, from down-regulation of the major insulin-responsive glucose transporter, GLUT4. 
Insulin attachment to its receptor, receptor phosphorylation and tyrosine kinase activity, and 
phosphorylation of insulin receptor substrates (IRSs) are decreased in muscle and adipocytes 
(Kahn et al., 2000). 
The tissue-specific modifications include the following: in adipocytes from obese humans 
with type 2 diabetes, IRS-1 expression is decrease, resulting in decreased IRS-1–associated 
phosphoinositide 3’ kinase (PI3K) activity, and IRS-2 converts to the main docking protein for 
PI3K (Rondinone et al.,1997). On the contrary, in skeletal muscle of obese, type 2 diabetic 
subjects, IRS-1 and IRS-2 protein levels are normal but the PI3K activity correlated with both 
IRSs molecules is impaired (Kim et al.,1999). 
 
1.2.6.2 Hyperinsulinaemia / insulin resistance in association with cardiovascular disease 
 
The insulin resistance syndrome (IRS), also identified as the metabolic syndrome, is a cluster 
of cardiovascular risk factors often, but not always, associated with obesity. Reaven (1992) 
first drew attention to the association of insulin resistance (IR) and obesity, type 2 diabetes, 
high plasma triglycerides, and low plasma HDL cholesterol. Ever since its initial description, 
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there has been much experimental, clinical, and epidemiological data to support the 
association of this syndrome with cardiovascular disease (CVD) (McFarlane et al., 2001). 
One of the characteristic relationships between IR and cardiovascular risk factors is with 
“diabetic dyslipidaemia” (Sniderman et al.,2001). The exact mechanism by which IR causes 
CVD is not known. The increased obesity and unfavourable body fat distribution could to 
some extent explain more atherogenic features of cardiovascular risk factors in subjects with 
insulin-resistant type 2 diabetes mellitus compared to subjects with insulin-sensitive type 2 
diabetes mellitus (Haffner et al., 1999). Up to 75% of type 2 patients and 35% of type 1 
patients die from cardiovascular events, such as myocardial infarction and cerebrovascular 
accident (Miettinen et al.,1998).  In type 2 diabetic patients there is an increased insulin 
resistance that might be associated with hyperinsulinaemia, impaired glucose tolerance, 
hypertension and dyslipidaemia with especially raised serum triglycerides and decreased high 
density lipoprotein cholesterol (HDL) (Leung et al.,2001) (fig. 1.3).  
Plasma LDL cholesterol levels in insulin-resistant subjects are similar to those in insulin-
sensitive subjects. Qualitative variations in LDL cholesterol that results in “pattern B” 
distribution of LDL particles, which consists of smaller LDL particles are more sensitive to 
oxidation and therefore probably more atherogenic (Reaven et al.,1993b). Small dense LDL 
particles pass through the arterial wall faster and bind more vigorously to proteoglycans than 
larger LDL particles. The increased activity of hormone-sensitive lipase and as a result 
increased breakdown of stored triglycerides may be due to insulin resistance at the levels of 
adipose tissue (Fonseca et al.,2004). The existence of excess triglycerides in the circulation 
also influences other lipoproteins. The partial depletion of LDL and HDL cholesterol ester 
occurs as a result of exchanged VLDL triglycerides for cholesterol ester in LDL and HDL 
attributed to a protein in plasma called cholesterol-ester transfer protein (Egusa et al.,1985). 
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Figure 1.3 Association of insulin resistance with cardiovascular risk factors 
(adapted from Leung et al.,2001) 
 
 
Two large observational studies, one in Canada and one in the UK, demonstrated a non-linear 
relationship between serum insulin levels and the incidence of ischaemic heart disease events. 
The risk was greatest at the highest insulin levels and there is some suggestion for a threshold 
effect. Insulin stimulates LDL cholesterol binding in both arterial smooth muscle cells and 
monocytes macrophages. It also increases the level of circulating plasminogen activator 
inhibitor 1 (PAI-1) in an environment of increased glucose and triglycerides, typical of type 2 
diabetes mellitus (Ferri et al.,1999). 
 
1.2.6.3 Abnormal insulin signaling, hyperinsulinaemia, and the vasculature 
 
The precise role insulin plays in the pathogenesis of CVD is remains uncertain. Contrary, 
some of insulin vasodilator and anti-inflammatory properties should protect against 
atherosclerosis. Different mechanistic hypotheses have been proposed to describe this 
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controversy (McFarlane et al.,2001, Feener et al.,1997). One hypothesis is related to insulin 
being a growth factor that excites vascular cell growth and synthesis of matrix proteins. The 
other one refers to insulin signalling pathway that considers being responsible for 
abnormalities in glucose metabolism is also implicated in nitric oxide production. Therefore, 
the abnormal intracellular signalling that leads to hyperglycaemia may also be accountable for 
vascular disease due to loss of insulin’s antiatherogenic properties, whereas hyperinsulinaemia 
continues to stimulate growth-promoting enzymes such as Mitogen-Activated Protein Kinase 
(MAPK). Additionally, abnormalities in expression and action of various peptides, growth 
factors, and cytokines, that include angiotensin II, endothelin-1, and IGF-I are correlated with 
imbalances in insulin homeostasis (Feener et al.,1997). 
 
1.2.6.4 The role of Free Fatty Acid in obesity-related insulin resistance 
 
An excess of circulating fatty acids may be a contributor to the development of insulin 
resistance. Plasma albumin-bound free fatty acids are derived largely from adipose tissue 
triglyceride stores via the action of the cyclic AMP-dependent enzyme hormone sensitive 
lipase. Fatty acids are also derived via the lipolysis of triglyceride-rich lipoproteins in tissues 
by the action of lipoprotein lipase (Eckel,1989). Insulin is essential to both antilipolysis and 
the stimulation of lipoprotein lipase. The most susceptible pathway of insulin action is the 
inhibition of lipolysis in adipose tissue (Jensen et al.,1989a). Therefore, when insulin 
resistance develops, the increased amount of lipolysis of stored triacylglycerol molecules in 
adipose tissue generates more fatty acids, which could in addition inhibit the antilipolytic 
effect of insulin, creating extra lipolysis.  
Plasma FFA concentrations could be increased in obese subjects and in subjects with insulin 
resistance. Obesity-related insulin resistance precedes to reduced antilipolytic effect of insulin 
(Kishi et al.,1998). Highly increased activity of the sympathetic nervous system, which has 
been demonstrated in obese human subjects and type 2 diabetic patients might add to 
increased FFA production (Grassi et al.,1995, Scherrer et al.,1994, Hilsted et al.,1987).   
FFA is taken up in liver and skeletal muscle cells. They negate the effects of insulin by 
increasing hepatic gluconeogenesis and by inhibiting glucose uptake and oxidation in skeletal 
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muscle (Randle et al.,1963, Gonzalez-Manchon et al.,1989, Felley et al.,1989). It has been 
suggested that this fatty acid-induced insulin resistance in liver and skeletal muscle may be a 
product of increased acetyl-CoA production and subsequent inhibition of glycolysis (Randle et 
al.,1963, Boden et al.,1994). The idea of a glucose-fatty acid cycle, which was originally 
illustrated by Randle et al.,(1963), has been called into question by Wolfe (1998). Wolfe 
provided evidence that glucose oxidation could directly regulate fatty acid oxidation by 
inhibition of fatty acid transport to the mitochondria. While Randle suggested that increased 
availability of FFA and fatty acid oxidation regulates glucose oxidation, Wolfe has developed 
a vice-versa concept in which the rate of glycolysis rather than the availability of fatty acids 
regulate fatty acid oxidation (Matthaei et. al., 2000). Obesity may cause insulin resistance by a 
number of other mechanisms and these will be discussed in section 1.5. 
 
1.2.6.5 Hypertension in relation to insulin resistance 
 
Although it is well established that essential hypertension is frequently associated with IR the 
impact of this abnormality on blood pressure homeostasis is still a matter of debate. The 
association between essential hypertension and insulin resistance is a clearly established fact 
but the impact of insulin resistance on blood pressure homeostasis is still a topic of debate. 
The relationship between hypertension and IR is more significant in obese subjects. Obese 
subjects who lose reasonable amounts of weight had a significant decreases in blood pressure 
which correlated closely with the decline in fasting plasma insulin concentrations (McFarlane 
et al.,2001). A number of possible mechanisms have been suggested to explain how insulin 
resistance may cause hypertension (DeFonzo et al.,1991). Primary it is important to realise 
that insulin is a vasodilator when given intravenously to people of normal weight (Steinberg et 
al.,1994), with lesser effects on sodium reabsorption in the kidney (DeFonzo et al.,1975).  
Evidence indicates that sodium reabsorption is increased in Caucasian people but not Africans 
or Asians with the metabolic syndrome (Barbato et al.,2004). Sodium reabsorption is 
increased in Caucasian people while no increased observed in Africans or Asians with the 
metabolic syndrome (Barbato et al.,2004). Increased prevalence of hypertension in the 
metabolic syndrome could only moderately be attributed to insulin resistance when analysed 
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by concentrations of fasting insulin, or the HOMA-IR (Hanley et al.,2002). Hyperinsulinaemia 
stimulates hypertension via increased renal tubular reabsorption of sodium and water, 
increased sympathetic nervous system activity, proliferation of vascular smooth muscle cells, 
and modifications of transmembrane cation transport. Decreases in urinary sodium excretion 
by insulin at physiological concentrations mediated by binding to specific high-affinity 
receptors (Sechi et al.,1996). In black South African patients insulin resistance is an 
independent trait of essential hypertension and is to some extent rectified by treatment with a 
long-acting ACE inhibitor (Wing et al., 1994). Nevertheless not all studies support the 
association of metabolic IR with essential hypertension. Obviously, hypertension is itself a 
complex disorder with many causes of the disease, and not all subjects with essential 
hypertension are insulin resistant (Fonseca et al.,2004). 
 
1.3 Metabolic Syndrome 
 
1.3.1 Defining the metabolic syndrome 
 
Following the introduction of the concept of the ‘Metabolic Syndrome” by George Reaven 
over a decade ago the amount of literature and research on this topic has been increasing 
exponentially. In the past 10 years this syndrome has received a number of different names 
including “Reaven’s Syndrome”, “Syndrome X”, the “Metabolic Syndrome”, “The 
Dysmetabolic Syndrome”, and, more recently, the Insulin Resistance Syndrome (IRS) 
(Distiller, 2004). Reaven (1988) in his initial description of the syndrome identified five 
components. These were hyperinsulinaemia, glucose intolerance, hypertension, elevated 
triglycerides, and decreased HDL cholesterol. Since then numerous additional conditions and 
risk factors have been added, so that there is now an extensive list of metabolic abnormalities 
associated with the IRS (Table 1.2). The dominant underlying risk factors for the metabolic 
syndrome appear to be abdominal obesity and insulin resistance. Physical inactivity, aging, 
hormonal imbalance and genetic predisposition are also linked with metabolic syndrome. 
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Table 1.2 Components of the “Metabolic (Insulin Resistance) Syndrome” 
(adapted from Distiller, 2004) 
 
Some degree of glucose intolerance IFG or IGT, type 2 diabetes 
Abnormal uric acid metabolism  
Dyslipidaemia TG, HDL, LDL-particle size 
Haemodynamic changes Sympathetic nervous system activity 
Renal sodium retention 
Hypertension 
Prothrombotic factors PAI-1, Plasminogen 
Markers of inflammation CRP, WCC, IL-6, TNF-α 
Endothelial dysfunction Mononuclear cell adhesion 
Plasma concentration of cellular adhesion 
molecules 
Plasma concentration of asymmetric 
dimethylargine 
Endothelial-dependant vasodilatation 
Abbreviations: IFG-Impaired Fasting Glucose; IGT-Impaired Glucose Tolerance; TG-Triglycerides; 
HDL-High Density Lipoprotein; LDL-Low Density Lipoprotein; PAI-1-Plasminogen Activator 
Inhibitor 1; CRP-C-Reactive Protein; WCC-White Cell Count; IL-6-Interleukin-6; TNF-α-Tumor 
Necrosis Factor-Alpha 
 
 
The definition of the metabolic syndrome varies (Table 1.3). In the attempt to initiate the 
metabolic syndrome into clinical practice, several organizations have made an effort to devise 
simple criteria for its diagnosis. The first submission came in 1998 from a consultation group 
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on the definition of diabetes for the World Health Organization (Alberti et al.,1998). In 1999 it 
was suggested by the European Group for Study of Insulin Resistance (EGIR) that WHO 
definition of diabetes should be modified (Balkau et al., 1999).  
The term “insulin resistance syndrome” (IRS) was used by this group instead than metabolic 
syndrome. EGIR did not included patients with type 2 diabetes mellitus in their syndrome 
because insulin resistance was viewed primarily as a risk factor for diabetes This group 
concentrated more on abdominal obesity compared to WHO (Grundy et al.,2005). The 
European Group for the Study of Insulin Resistance and WHO both agree that either glucose 
intolerance or insulin resistance should be included for the diagnosis of IRS (Alberti et 
al.,1998, Balkau et al.,1999).  
The National Cholesterol Education Program’s Adult Treatment Panel III (NCEP: ATP III, 
2001) specified that an increased fasting blood glucose (FBG) should be adequate to diagnose 
the metabolic syndrome. They agree that insulin resistance per se is not essential in order to 
diagnose the metabolic syndrome. In 2003, the American Association of Clinical 
Endocrinologists (AACE) adapted ATP III criteria to refocus on insulin resistance as the 
primary cause of metabolic risk factors (Einhorn et al.,2003). Like the EGIR (Balkau et 
al.,1999), AACE used the name “insulin resistance syndrome” and increased triglycerides, 
reduced HDL-C, elevated blood pressure, obesity and IGT were the main points for diagnosis. 
Basically a combination of the ATP III and WHO guidelines, the AACE guidelines do not 
identify the number of risk factors required to meet the definition of metabolic syndrome but 
rather consign this matter to individual clinical judgment. A family history of atherosclerotic 
cardiovascular disease (ASCVD) or type 2 diabetes, polycystic ovary syndrome, and 
hyperuricemia were another aspects used to inform clinical judgement. By the AACE’s 
definition, once a person develops type 2 diabetes, the term insulin resistance syndrome no 
longer applies.  
International Diabetes Foundation (IDF) published in 2005 new criteria that once more 
modified the ATP III definition. The abdominal obesity is greatly correlated with insulin 
resistance and IDF believed that other, more laborious measures of insulin resistance are 
unnecessary. The IDF clinical definition thus makes the existence of abdominal obesity 
necessary for diagnosis together with two other factors originally listed in the ATP III 
definition are sufficient for diagnosis. The present American Heart Association (AHA) and the 
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National Heart, Lung, and Blood Institute (NHLBI) statement, in contrast to IDF, maintains 
the ATP III criteria except for minor modifications such as the threshold for IFG was reduced 
from 110 to 100 mg/dL (6.2 to 5.6 mmol/l); this adjustment corresponds to the recently 
modified American Diabetes Association (ADA) criteria for IFG. The metabolic syndrome 
occurs in approximately 45% to 65% of individuals with impaired glucose tolerance in the 
USA and in 75% to 85% of patients with type 2 diabetes (Khan et al.,2003). 
Lemieux and colleagues (2000) have suggested the importance of abdominal obesity and the 
so-called hypertriglyceridaemic waist phenotype as a central component. The association 
between obesity and the IRS has long been recognized. However, the level of obesity 
associated with increased risk for several diseases differs between populations. The WHO 
criteria that define overweight and obesity in terms of co morbidities are not necessarily 
appropriate for Asian populations. The International Obesity Task Force (IASO/IOTF) 
(2000c) together with the International Association for the Study of Obesity and supported by 
WHO (Western Pacific Region) redefined overweight as body-mass index (BMI) > 23 kg/m2 
and obesity as > 25 kg/m2 in Asians. Central obesity was defined as waist circumference > 80 
cm for women and > 90 cm in men (http://www.wpro.who.int). The IDF definition of IRS also 
includes ethnic specific waist circumference cut off points (see table 1.3). 
The European Association for the Study of Diabetes (EASD) and the American Diabetes 
Association (ADA) issued a joint statement that has called into question the existence and 
reliability of the metabolic syndrome as a discrete clinical entity. The number of studies that 
been completed over the years regarding the prevalence of the metabolic syndrome and its 
associated cardiovascular risk, but the precise thresholds have not been established. It was 
suggested that metabolic syndrome requires much more study before its clarification as a 
“syndrome” is truly warranted and before its clinical utility is adequately defined ( Kahn et al., 
2005, Cheng et al., 2006).  In the article published by Reaven, (2006) it was stated that the 
concept of the metabolic syndrome has little or no utility in clinical practice.   
 
 
  
29
 
Table 1.3 Comparison of diagnostic criteria for the clinical diagnosis of 
metabolic syndrome suggested by the WHO, EGIR, NCEP/ATP III and IDF 
 
CLINICAL 
MEASURE 
WHO (1999) 
 
EGIR (1999) 
 
NCEP /ATP  
III, (2001) 
IDF (2005) 
 
Insulin resistance Type 2 diabetes, 
IFG, IGT 
Plus any 2 of the 
following 
Plasma insulin 
>75 percentile 
Plus any 2 of 
the following 
None, 
 
But any 3 of the 
following 
None 
Abdominal Obesity 
Waist 
circumference   
Waist-to-hip ratio  
 
BMI   
None 
 
 
Men > 0.90 
Women > 0.85 
> 30 kg/m2 
 
Men ≥ 94 cm 
Women ≥ 80cm 
 
 
Men  > 102 cm 
Women >88 cm 
Europid ♦ 
Men ≥ 94 cm 
Women ≥ 80 cm 
 
Plus any 2 of the 
following 
Blood Pressure   ≥140/90 mm Hg ≥140/90 mm Hg ≥130/85mm Hg ≥130/85 mm Hg 
Triglycerides  ≥ 1.7 mmol/l 
(≥150 mg/dl) 
≥ 1.7 mmol/l 
(≥150 mg/dl) 
≥ 1.7 mmol/l 
(≥150 mg/dl) 
≥ 1.7 mmol/l 
(≥150 mg/dl) 
HDL-Cholesterol 
Men 
Women 
 
< 0.9 mmol/l 
<1.0 mmol/l 
 
<1.00 mmol/l 
In men or 
women 
 
< 1.03 mmol/l 
< 1.29 mmol/l 
 
<1.03 mmol/l ♣ 
<1.29 mmol/l ♣ 
 
Fasting plasma 
glucose (mmol/l) 
≥ 7.0 mmol/l 
 
 ≥ 6.16 mmol/l 
(≥ 110mg/dl) ♠ 
≥5.6 mmol/l 
(≥100mg/dl) 
Other Microalbuminuria None None None 
♠ The 2001 definition identified fasting plasma glucose of 110 mg/dl (6.1mmol/l) as elevated. This was 
modified in 2004 to be 100 mg/dl (5.6 mmol/l), in accordance with the ADA’s updated definition of IFG 
♣ These values have been updated from those originally presented to ensure consistency with ATP III cut-
points 
♦South Asian and South-East-Asian men ≥ 80cm, women ≥ 80 cm; Japanese men ≥ 85cm, women ≥ 90 cm 
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1.3.2 Obesity, fat distribution and the components of metabolic syndrome 
 
A French physician, Jean Vague, more than a half century ago first acknowledged the 
relationship between excess abdominal fat mass and insulin resistance (IR) and explained an 
association between a “masculine” or “android” obesity phenotype and diabetes (Vague,1956). 
Abdominal fat is made up of several different anatomic depots: subcutaneous fat and intra-
abdominal fat. Subcutaneous fat can be separated into anterior and posterior or superficial and 
deep layers. Intra-abdominal fat can be separated into intraperitoneal and retroperitoneal sites. 
Intraperitoneal fat, also characterized as visceral fat, is composed of mesenteric and omental 
fat masses. Obese subjects have much larger absolute amount of each of these depots in upper-
body compared to lean subjects. However, the comparative amount of abdominal fat with 
respect to total body fat mass is frequently similar in obese and lean groups. For instance, 
visceral fat constitutes about 10% of total body fat mass in lean and obese men (Abate et al., 
1995). 
Whether there is a need to develop different BMI cut-off points for different ethnic groups is a 
become a point of discussion since growing evidence that the associations between BMI, 
percentage of body fat, and body fat distribution differ across populations and therefore, the 
health risks increase below the cut-off point of 25 kg/m2 that defines overweight in the current 
WHO classification. An efforts to interpret the BMI cut-offs in Asian and Pacific populations 
were attempted twice previously (James et al., 2002, Weisell, 2002), which contributed to the 
growing debates. Consequently, to shed the light on this debates, WHO organized the Expert 
Consultation on BMI in Asian populations (Singapore, 8-11 July, 2002) 
(http://www.who.int/bmi/index.jsp). Hong Kong Chinese have high BF% (body fat 
percentage) values at low BMIs and proposed BMI cut-off points for overweight and obesity 
as low as 23 and 26 kg/m2, respectively (Ko et al., 2001). 
A WHO expert consultation reviewed scientific evidence that suggests that Asian populations 
have different associations between BMI, percentage of body fat, and health risks than do 
European populations. It reached a conclusion that the proportion of Asian people with a high 
risk of type 2 diabetes and cardiovascular disease is significant at BMIs lower than the 
existing WHO cut-off point for overweight (> or =25 kg/m2). Nevertheless, available data do 
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not necessarily point to a clear BMI cut-off point for all Asians for overweight or obesity. The 
cut-off point for investigated risk varies from 22 kg/m2 to 25 kg/m2 in various Asian 
populations; for high risk it varies from 26 kg/m2 to 31 kg/m2. Therefore, no efforts were made 
to redefine cut-off points for each population separately. The consultation also decided that the 
WHO BMI cut-off points should be reserved as international classifications (WHO Expert 
Consultation, 2004). 
Body fat distributions a better predictor of IR and cardiovascular risk than body mass (Abate 
et al.,1996). There is a better correlation between IR, type 2 diabetes, and hypertension with a 
central distribution of adiposity than with general increases in fat mass. Waist circumference 
serves as a clinical surrogate of intra-abdominal fat and correlates with insulin levels and IR 
(Fonseca et al.,2004). There are many large epidemiological and smaller physiological studies 
that have confirmed the association between abdominal obesity and insulin resistance, 
diabetes, and other components of the metabolic syndrome (Kissebah et al., 1982, Folsom et 
al.,2000, Chan et al.,1994, Pouliot et al.,1992). Actually, excess abdominal fat is even 
associated with impaired insulin-mediated glucose uptake in lean adults (Ruderman  et 
al.,1998). 
It is not clear whether large waists are due to increases in subcutaneous adipose tissue or to 
visceral fat, therefore the use of computed tomography or magnetic resonance imaging could 
help with this distinction (Lee et al.,2004). Increases in intra-abdominal or visceral adipose 
tissue promotes a higher rate of flux of adipose tissue-derived free fatty acids to the liver by 
subcutaneous fat which in turn release lipolysis products into the systemic circulation and 
avoid more direct effects on hepatic metabolism (Aubert et al.,2003). There is a proof that 
after the meal the elevated free fatty acid release in upper body obese women comes from the 
non-splanchnic upper body fat, and not from the visceral depot (Guo et al.,1999). These 
results suggested that visceral fat might be an indicator for, but not a cause of, excess 
postprandial free fatty acids in obesity. 
Results from the Framingham study show that each 10% weight gain is associated with a 6.5-
mmHg increase in systolic blood pressure (Ashley et al.,1974). The relationship between 
hypertension and body fat is not only restricted to the morbidly obese individuals, but in fact 
there is a direct correlation between hypertension and body mass index throughout the entire 
range of body weight. The mechanisms by which obesity increases blood pressure are not well 
  
32
understood (Lopez-Candales, 2001). However, increases in both plasma volume and cardiac 
output are thought to be crucial and these have been found to be sodium sensitive among 
obese adolescents. Fasting insulin is the best predictor of this sensitivity (Rocchini et 
al.,1989).  
Hyperinsulinemia increases insulin-mediated glucose uptake in central hypothalamic neurons 
promoting sympathetic stimulation, through elimination of the normally inhibited effect of 
ventromedial cells from the hypothalamus on sympathetic centers (Reaven et al.,1996). 
Additional mechanisms that contribute to hypertension in obese individuals are activation of 
the renin angiotensin system by insulin resistance producing sodium reabsorption in the loop 
of Henle (Anderson, 1993), insulin-like growth factor I (Diez,1999), leptin (Mark et al.,1999) 
and physical compression of the kidneys due to accumulation of intrarenal fat and 
extracellular matrix (Lopez-Candales, 2001). 
Free fatty acids (FFAs) released from adipocytes, particularly intra-abdominal adipocytes, can 
be transported to the liver where they stimulate synthesis of triglycerides and the assembly and 
secretion of VLDL (Fonseca et al.,2004).  In general, with increases in free fatty acid flux to 
the liver, increased production of apoB-containing triglyceride-rich very low-density 
lipoproteins (VLDL) occurs (Lewis et al.,1995). The effect of insulin on this process is 
somewhat complex. In the setting of insulin resistance, increased flux of free fatty acids to the 
liver increases hepatic triglyceride synthesis; however, under physiological conditions, insulin 
inhibits rather than increases the secretion of VLDL into the systemic circulation (Lewis et 
al.,1996). This response, in part, is an effect of insulin on the degradation of apoB 
(Taghibiglou et al.,2002).  
The increase in hepatic lipase located on the surface of hepatic endothelial cells accountable 
for an additional defect that affects lipoprotein metabolism in obesity(Nie et al., 1998, Carr et 
al., 2004). Hepatic lipase (HL) plays an essential role in LDL and HDL remodelling. High HL 
activity is related with small, dense LDL particles and with reduced HDL2 cholesterol levels 
(Deeb et al.,2003). The primary target molecule for hepatic lipase is lipoprotein phospholipids 
(Grundy, 2004).  
Central obesity-related triglyceride elevation could contribute to increases in small-dense LDL 
via cholesteryl-ester transport protein (CETP)-mediated transfer of triglyceride from VLDL 
and LDL, a process distinct from elevated hepatic lipase (Sibley et al., 2003). Patients with 
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metabolic syndrome also fail to clear triglyceride-rich particles from their circulation 
following a meal which manifests as postprandial lipaemia and which is an independent 
cardiovascular risk factor (Reaven, 2002b). 
 
1.3.3 Genetic susceptibility to metabolic syndrome 
 
The pattern of metabolic syndrome alters significantly among individuals and populations, 
which indicates that genetic variability in regulation of the different risk components is 
responsible for these different patterns (Hanley et al.,2003). Additional data comes from 
differences in predisposition to metabolic risk factors and their patterns in different ethnic 
groups. Some populations (i.e. South Asians) demonstrate a high prevalence of metabolic 
syndrome even in the event of mild obesity (McKeigue,1996). The control of the pathways 
underlying the metabolic risk factors is highly complicated and vulnerable to genetic 
variations. Only when the nature of the genetic variation will be discovered we could fully 
comprehend the pathogenesis of the metabolic syndrome (Grundy, 2004). 
 
1.3.4 Other manifestations of insulin resistance syndrome 
 
Many other changes could accompany insulin resistance and they are not included in the 
diagnostic criteria for the metabolic syndrome. The list of these changes incorporates increases 
in apoB and C-III, uric acid, prothrombotic factors (fibrinogen, plasminogen activator 
inhibitor 1), serum viscosity, asymmetric dimethylarginine, homocysteine, white blood cell 
count, pro-inflammatory cytokines, the existence of microalbuminuria, non-alcoholic fatty 
liver disease and/or non-alcoholic steatohepatitis, obstructive sleep apnoea, and polycystic 
ovarian disease (Eckel et al.,2005). Cigarette smoking (Eliasson et al.,1994) and sedentary 
lifestyle (Lakka et al.,2003) could also result in many of the major criteria of the syndrome. 
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1.4 Non-traditional Cardiovascular Risk Factors associated with 
obesity and diabetes 
 
Traditional cardiovascular risk factors do not sufficiently explain for the extent of 
cardiovascular disease in type 2 diabetes suggesting the presence of other risk factors which 
may include inflammation, abnormal fibrinolysis, and endothelial dysfunction (Fonseca, 
2000). The number of different therapeutic strategies that are presently used in the 
management of dyslipidaemia and diabetes can improve these non-traditional risk factors. The 
example of that could be lipid management with statins that reduces markers of inflammation 
in plasma (Jialal et al.,2001b)  and insulin sensitizers have a range of effects on many of these 
risk factors (Parulkar et al.,2001). 
 
1.4.1 The role of endothelial cell dysfunction and oxidative stress in the 
pathogenesis of CVD 
 
The control of vascular tone and maintenance of blood circulation, fluidity, coagulation, and 
inflammatory responses is influences by vascular endothelium which is an active and dynamic 
tissue. The endothelium controls vascular tone via the release of vasodilating and 
vasoconstricting substances. One of the most essential of vasodilating substance is nitric oxide 
(NO). In addition NO is vascular protective and inhibits inflammation, oxidation and vascular 
smooth muscle cell proliferation, and migration. Injure to the endothelium produces 
endothelial dysfunction with impaired release of NO and loss of its antiatherogenic protection 
(Hsueh et al.,2003).  
The primary defect that connects insulin resistance and endothelial dysfunction is associated 
with deficiency of endothelial-derived nitric oxide. NO deficiency causes from decreased 
synthesis and/or release, in combination with too much consumption in tissues by high levels 
of reactive oxygen (ROS) and nitrogen (RNS) species, which are formed by cellular 
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disturbances in glucose and lipid metabolism. The alteration of the transcapillary passage of 
insulin to target tissues caused by endothelial dysfunction adds to impaired insulin action 
(Cersosimo et al.,2006). 
Cardiovascular risk factors have an effect on many of the normal functions of the 
endothelium. Particularly, oxidized low-density lipoprotein cholesterol starts a series of events 
that begin with cell activation, endothelial dysfunction, local inflammation, and a procoagulant 
vascular surface. These events results in plaque formation and eventually plaque rupture and 
cardiovascular events (Gonzalez et al.,2003). 
Clinical markers of oxidative stress include F2-isoprostanes, which are prostaglandin-like 
compounds formed in vivo from free radical-catalyzed peroxidation of arachidonic acid and 
which have emerged as novel and direct measures of oxidative stress. In patients with type 2 
diabetes levels of F2-isoprostane found to be elevated in both urine and plasma (Gopaul et 
al.,1995, Ceriello   et al.,2001,  Davi   et al.,1999). Nitrotyrosine, another marker of protein 
oxidation and indication of oxidative damage to DNA, is increased in patients with type 2 
diabetes (Dandona et al.,1996, Gopaul et al.,1995, Ceriello et al.,2001). 
The joining of mononuclear cells, such as monocytes and T lymphocytes, to the endothelium 
indicates the next step in atherogenesis; this joining is mediated by adhesion molecules present 
on the endothelial surface, such as vascular cell adhesion molecule (VCAM), intercellular 
adhesion molecule (ICAM), and E-selectin. As soon as the monocyte migrates into the 
subendothelial space, it develops into a resident macrophage, takes up lipid largely via certain 
scavenger receptors such as SR-A and CD-36, and becomes a foam cell (Fig. 1.4). In the later 
stages of atherogenesis, smooth muscle cells travel to the surface and develop the fibrous cap 
of the lesion. Ultimately, lipid-laden macrophages discharge matrix metalloproteinase’s 
resulting in  plaque rupture and acute coronary syndromes such as myocardial infarction and 
unstable angina (Fonseca et al.,2004). 
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Figure 1.4 Binding effects of monocytes and T lymphocytes to the endothelium 
 
 
 
Endothelial dysfunction has been reported in obese insulin-resistant subjects. In particular, an 
inverse relationship between obesity and endothelial function, as assessed by flow-mediated 
dilatation, or change in blood flow responses to methacoline, acetylcholine, or L-arginine, 
have been demonstrated (Arcaro et al.,1999, Steinberg et al.,1996, Perticone et al.,2001, 
Ziccardi et al.,2002). Since endothelial NO may mediate insulin-stimulated vasodilatation in 
skeletal muscle, it has been hypothesized that the physiological vasodilator action of insulin is 
blunted in obese subjects. In fact, indexes of insulin sensitivity that are linearly related to 
indexes of body fat distribution (BMI, waist-to-hip ratio, waist girth), may explain nearly half 
of the endothelial dysfunction associated with obesity (Esposito et al.,2002a). 
 
 
  
37
1.4.2 Impaired Fibrinolysis and Prothrombotic State 
 
The presence of a prothrombotic state could accelerate development of atherothrombotic 
cardiovascular disease in type 2 diabetes. This prothrombotic state consists of a diminished 
fibrinolytic capacity and an increased coagulability. Impaired fibrinolytic capacity emerge to 
be a feature of the metabolic syndrome of type 2 diabetes and can be a direct effect of visceral 
obesity (Banga, 2002).  
Plasminogen activator inhibitor (PAI-1) is the most important physiological inhibitor of tissue-
type plasminogen activator (t-PA) in plasma (Ridker et al., 1993).The data published by Meigs 
et al.,(2000) demonstrated a positive association between fasting insulin levels and impaired 
fibrinolytic potential among people with normal glucose tolerance, independent of 
intermediary effects of obesity (such as BMI, waist circumference and waist-hip ratio) or lipid 
levels. However, markers of hypercoagulability, with the exception of von Willebrand factor 
(vWF) antigen in men did not show substantial associations with fasting hyperinsulinemia 
among subjects with glucose intolerance. Those subjects had higher PAI-1 and tPA antigen 
levels even after accounting for higher fasting insulin levels. According to the authors glucose 
intolerance may increase risk for acute thrombosis which mediated more by impaired 
fibrinolysis than by increased hypercoagulability, with fibrinolytic function in glucose 
intolerance further impaired by elevated fasting insulin levels. 
Decreased fibrinolytic activity caused by elevated PAI-1 may hasten atherosclerosis by 
exposing vascular luminal wall surfaces to persistent and recurrent thrombi. Platelet function, 
PAI-1, and transcription factors associated with coagulation are inhibited by insulin. 
Dysregulation of these actions may add to the hypercoagulability in insulin-resistant states 
(Fonseca et al.,2004). 
 
1.4.3 Inflammation and CVD in insulin resistant state 
 
Inflammatory mediators play a principal role in the induction, development and rupture of 
atherosclerotic plaques. Thus markers may provide extra data about a patient's risk of 
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developing CVD and may become new targets for treatment. Some data suggested that 
inflammation is also involved in the development of Type 2 diabetes. In a number of 
prospective studies it was confirmed that increased levels of pro-inflammatory markers such 
as C-reactive protein (CRP) or reduced levels of anti-inflammatory markers such as 
adiponectin predict the development of Type 2 diabetes (Ziegler,2005).  
Some inflammatory risk factors such as oxidized lipids, infectious agents, and cytokines 
produced from adipocytes or other inflammatory cells, accelerate production of IL-6, which 
serves as a “messenger” cytokine that stimulates the liver to produce inflammatory substances 
such as CRP (Jialal et al.,2001a). Hyperglycemia has been shown to stimulate 
proinflammatory cytokines and chemokine genes in monocyctic cells. Certain cytokines, such 
as tumor necrosis factor-α (TNF-α), impair insulin action in peripheral tissue and have a direct 
role in obesity-linked insulin resistance (Stentz et al.,2004). Figure 1.5 summarizes the 
theoretical link between cytokines secreted by adipose tissue (adipokines), inflammation, and 
CVD in obesity. 
 
Figure 1.5 Interactions between inflammation, insulin resistance and 
atherosclerosis (adapted from Fonseca et al.,2004). 
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1.4.4 Hyperhomocysteinemia 
 
Homocysteine (Hcy) have been recognized in a number of clinical and epidemiological studies 
as an important and independent risk factor for cardiovascular disease. Patients with severe 
hyperhomocysteinemia (HHcy) generally present with neurological abnormalities and 
premature arteriosclerosis. The reduced plasma Hcy improved endothelial dysfunction and 
reduced incidence of major adverse events after percutaneous coronary intervention.   
The mechanisms by which Hcy causes atherosclerosis are not well-known. Several biological 
mechanisms have been suggested to elucidate cardiovascular pathological changes associated 
with HHcy. The number one of these mechanisms is endothelial cell damage and impaired 
endothelial function. The number two is dysregulation of cholesterol and triglyceride 
biosynthesis. The number three is stimulation of vascular smooth muscle cell proliferation. 
The number four is thrombosis activation and number five is activation of monocytes. To 
elucidate the vascular pathology of Hhcy four important biochemical mechanisms have been 
suggested, which include auto-oxidation through the production of reactive oxygen species, 
hypomethylation by forming S-adenosylhomocysteine (SAH), a potent inhibitor of biological 
transmethylations,  nitrosylation by binding to nitric oxide or protein homocysteinylation by 
absorbing into protein (Yang et al.,2005).  
In high-risk patients, such as with diabetes or with history of CHD, even reasonably increased 
total homocysteine (tHcy) concentrations are associated with coronary heart disease (CHD). In 
these patients an increased tHcy levels might trigger the event, resulting in a short-term 
association with the risk of CHD. Conversely, the tHcy concentration might be a marker of the 
degree of vascular disease (De Bree et al., 2002). 
Most cross-sectional and case-control studies have indicated a strong association between 
tHcy and vascular disease however the evidence provided by many prospective cohort studies 
has been evasive (Christen et al., 2000). While elevated homocysteine levels increase risk for 
CHD in type 2 diabetes patients to a greater extent than among nondiabetic subjects 
(Hoogeveen et al., 1998), fasting levels of homocysteine per se were not different when 
subjects with type 2 diabetes were compared to nondiabetic control subjects. Furthermore, the 
co-occurrence of specific features of the insulin resistance syndrome, especially hypertension 
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and central obesity, was associated with more marked elevations in homocysteine levels 
(Meigs et al., 2001). Doncheva et al., (2007) studied a group of male patients with CHD and 
found that 40.8% of them had increased tHcy levels, not associated with other lipid and non-
lipid risk factors. The findings in the prospective, nested case-control study by Tanne et al., 
(2003) were consistent with a strong predictive role of tHcy, independent of traditional risk 
factors or inflammatory markers, for incident ischemic stroke in patients at increased risk due 
to chronic CHD. A systemic review and meta-analysis published by Humphrey et al., (2008) 
looked at homocysteine levels and CHD  incidence. The risk of developing coronary heart 
disease increased nearly by 20% for each increase of 5 µmol/L of homocysteine in the overall 
analysis and the association between homocysteine and CHD was similar when analysed by 
sex, length of follow-up, outcome, study quality, and study design. 
B vitamins are essential cofactors in the metabolism of homocysteine to methionine via the 
remethylation-pathway (vitamin B12, folic acid) and to cystathionine via the trans-
sulphuration-pathway (vitamin B6). In the western world dietary deficiencies of folic acid, 
vitamin B12, and vitamin B6 seem to be identifiable among elderly people and it correspond 
to pathogenic factor related to the incidence of hyperhomocysteinaemia. A number of studies 
showed that dietary supplementation with folic acid and the vitamins B12 and B6 is an were 
effective in means to decrease plasma homocysteine (Sydow et al.,2001). 
 
1.4.5 Vascular Wall Abnormalities - Carotid intima-media thickness (IMT) 
 
Latest progress in technology has resulted in the development of techniques to identify early 
structural and functional changes that occur in the vessel wall. These changes consist of 
measurement of carotid IMT and aortic pulse wave velocity and arterial stiffness (Bokemark 
et al.,2002). IMT signifies a structural abnormality in the arterial wall and is a mostly good 
predictor of subsequent cardiovascular risk (Hedblad et al.,2000). The abnormal carotid IMT 
in patients with diabetes had been confirmed in a number of studies (Niskanen et al.,1996, 
Bokemark et al.,2002, Hedblad et al.,2000, Bonora et al.,1997, Redberg et al.,2002). Many of 
these studies have proposed an association between increased carotid IMT and IR (Howard et 
al.,1996). This observations are compatible with the potential effect of hyperinsulinaemia on 
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growth of vascular smooth muscle cells and extracellular matrix (Hsueh et al.,1999).In newly 
diagnosed patients with type 2 diabetes even without overt CVD there is an increase in carotid 
IMT (Wagenknecht et al.,1997). Increased arterial stiffness is another marker of early 
atherosclerosis that has been observed with increased frequency in patients with diabetes 
(Lehmann et al.,1997). It could be related to glycation of arterial collagen and elastin and 
accumulation of advanced glycation end products (Chappey et al.,1997). Some genetic effect 
or perhaps an early metabolic abnormality such as IR  suggested to play role in nondiabetic 
young relatives of patients with diabetes that also had arterial stiffness (Riley et al.,1986, 
Hopkins et al.,1996, Fonseca et al.,2004). 
 
 
1.4.6 Postprandial Hyperglycemia 
 
Chronic hyperglycaemia has been shown to be responsible for multiple micro- and 
macrovascular complications as a result of hyperglycaemic damage through four major 
biochemical processes, including the polyol pathway, advanced glycation end products 
(AGEs), hyperglycaemia-induced activation of protein kinase C and increased hexosamine 
pathway flux and consequent over-modification of proteins by N-acetylglucosamine 
(Brownlee, 2005). 
The mechanism through which increased postprandial glucose levels and lipid concentrations 
may damage endothelial cells on blood vessel walls appear to be complex (Ceriello,1997, 
Ceriello,1998, Ceriello et al.,1998a, Ceriello et al.,1998b,  Ceriello et al.,1999, Ceriello et 
al.,2002). The activation of protein kinase C, increased expression of adhesion molecules, 
increased adhesion and uptake of leukocytes, increased production of proliferative substances 
such as endothelin, increased synthesis of collagen IV and fibronectin, decreased production 
of NO, and increased oxidative stress and inflammation are all included in these system. CRP 
is more strongly associated to postglucose load glucose than to fasting glucose in nondiabetic 
subjects (Festa et al.,2002a). 
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1.5 Adipocyte Endocrine System 
 
In man and other mammals, a complex system has developed to maintain a stable supply of 
metabolic energy in an environment of uncertain and often limited food supplies. The adipose 
tissue is at the centre of this system. In times of nutritional surplus the energy is stored as 
triglycerides (TG) by adipose tissue. It also released energy in the form of free fatty acids 
(FFA) and glycerol during periods of caloric deprivation (Unger et al.,1999). Body weight 
within normal situations is sustained  in narrow limits through regulation of both caloric intake 
and energy expenditure (Tataranni,1998, Ravussin et al.,1988). Neuronal systems perceive 
and react to input from hormones such as insulin and leptin that are secreted in proportion to 
body energy stores, and from the metabolism of circulating nutrients (such as glucose and 
FFAs). In feedback to this input, adaptive changes occur in energy intake, energy expenditure, 
and hepatic glucose production (fig.1.6). 
 
 
 
 
Figure 1.6 Model depicting the control of energy homeostasis and hepatic 
glucose metabolism by adiposity- and nutrient-related signals (Schwartz et al., 
2005). 
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However, obvious differences are observed in the predisposition of individuals to maintain 
energy balance, and data emerging over the past several years have established an additional 
role for the adipocyte - that of secretory cell (Fig. 1.7) (Kahn et al., 2000). Adipose tissue can 
also function as multipotential endocrine and immune organ, secreting an array of cytokines, 
hormones, and other biochemically active molecules engaged in the regulation of insulin 
sensitivity and glucose homeostasis, hypothalamic activity, central sympathetic output, 
vascular tone, and reproduction, via endocrine/autocrine and paracrine effects (Diamond et 
al.,2002). A series of adipocyte-derived biologically active molecules that may influence the 
function and structural integrity of other tissues are referred to as ‘adipocytokines’. Some 
examples of these substances are leptin, acylation-stimulating protein (ASP), tumor necrosis 
factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1) and interleukin-6. ASP increases 
triglyceride synthesis by increasing adipocyte glucose uptake, activating diaglycerol 
acyltransferase, and inhibiting hormone-sensitive lipase (Cianflone et al.,1999, Murray et 
al.,1999). More recently, resistin has been identified as a novel adipose-specific cysteine-rich 
protein with a capacity to impair insulin sensitivity and glucose tolerance in rodents (Steppan 
et al.,2001). 
 
 
 
Figure 1.7 Evolving views of the biological functions of the adipocyte  
(Kahn et. al., 2000). 
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1.5.1 Leptin and soluble leptin receptor  
 
1.5.1.1 Regulation of leptin synthesis 
 
Identification of the obese (ob) gene and its protein product, leptin, has increased our 
understanding of the pathophysiology of obesity. In ob/ob mice, a mutation in the ob gene 
prevents normal leptin production by adipose tissue, which causes both obesity and diabetes 
(Zhang et al.,1994). Treatment of ob/ob mice with leptin decreases body weight and 
normalizes blood glucose concentration (Pelleymounter et al.,1995). Leptin secretion and 
synthesis by adipocytes is shown to be in proportion to their triglyceride stores and correlate to 
body adiposity (Considine et al.,1996b) Adipose tissue is the prime source of leptin, but other 
tissues also express leptin, including placenta, ovaries, skeletal muscle and stomach (Hoggard 
et al.,1997a, Hoggard et al.,1997b, Spicer et al.,1997, Bado et al.,1998, Wang et al.,1998). 
Leptin is an adipocyte-derived hormone of 167 amino acid protein with an amino-terminal 
secretory signal sequence of 21 amino acids. The signal sequence is effective, and results in 
the translocation of leptin into microsomes with the subsequent removal of the signal peptide 
(Zhang et al., 1994). Therefore, leptin circulates in the blood as a protein of 146 amino acid 
residues. The sympathetic nervous system, especially the β-adrenoceptor (β-AR) axis, has 
been implicated in the regulation of leptin gene expression. For example, the β-AR agonists, 
noradrenaline and isoprenaline decreased leptin gene expression in WAT in mice (Trayhurn et 
al.,1996) and decreased serum leptin  (Stumvoll et al.,2000).  The significance of β-AR in the 
control of leptin production in human subjects is uncertain, although there is evidence that the 
receptor may play an important role in the control of lipolysis in human omental and 
subcutaneous adipose tissue (Enocksson et al.,1995, Trayhurn et al.,1999). 
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1.5.1.2 Tissue sites of leptin synthesis 
 
White adipose tissue (WAT) is the main location of leptin synthesis, but it is now obvious that 
leptin is also produced in other tissues. The brown adipose tissue (BAT) have been proved to 
be also a site of leptin production ( Moinat et al.,1995, Tsuruo et al.,1996, Klingenspor et 
al.,1996, Deng et al.,1997, Dessolin et al.,1997, Cinti et al.,1997, Siegrist-Kaiser et al.,1997, 
Kutoh et al.,1998). Leptin expression in humans is much higher in subcutaneous than in 
omental adipose tissue (Hube et al.,1996, Montague et al.,1997, van Harmelen et al.,1998). 
An important new aspect to leptin biology has become apparent with the recognition that the 
placenta and ovary express the leptin gene and that they are sites of production of the 
hormone. The placenta also produces the leptin receptor gene, indicating that the organ is a 
target for the action of leptin as well as being a source of the hormone (Hoggard  et al.,1997a). 
These statements propose that leptin may act in an autocrine manner (Fig.1.8). The expression 
of leptin by syncytiotrophoblasts (Hoggard et al.,1997b, Senaris et al.,1997, Bodner et 
al.,1999) has added support to the hypothesis of the significance of leptin in nutrient 
reposition. 
 
 
 
 
Figure 1.8 Multiple actions of leptin to regulate glucose homeostasis through autocrine, 
paracrine, endocrine, and neural circuits (Kahn et. al., 2000). 
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1.5.1.3 Leptin, lipogenesis and FFA oxidation 
 
In adipose tissue, insulin elevates lipoprotein lipase activity, releasing fatty acids from the 
triglycerides of VLDL and chylomicrons, and at the same time promotes glucose uptake, thus 
providing the substrate for glycerol-3-P synthesis and the storage of the fatty acids as 
triglycerides. Insulin also promotes the synthesis of fatty acids in adipose tissue by increasing 
the activity of acetyl-CoA carboxylase, the rate-limiting enzyme in fatty acid biosynthesis. In 
adipocytes, these lipogenic processes are generally suppressed by leptin, thus opposing insulin 
action (Iritani et al.,2000, Bai et al.,1996). Leptin also regulates LPL in a tissue-specific 
fashion. In adipose tissue, LPL activity is downregulated by leptin, whereas in muscle LPL 
activity is up-regulated (Arvaniti et al.,2001). 
In nonadipocytes there is also convincing proof for the existence of adipose regulation of 
triglycerides (TGs). TGs content of normal nonadipocytes is typically maintained within a 
narrow range, irrespective of caloric intake (Unger et al.,1999). This is achieved, in part, by 
fatty acid-induced up-regulation of peroxisome proliferator-activated receptor (PPAR)α, and 
the enzymes acyl-CoA oxidase (ACO), and carnitine palmitoyl transferase I, which direct fatty 
acids into oxidative rather than lipogenic pathways (Zhou et al.,1998). As a result, unwanted 
fatty acids are oxidized, preventing accumulation as TGs (Shimabukuro et al.,1997). In leptin-
insensitive or - resistant animals, the reverse action taking place when a  marked increase in 
TGs build up in nonadipose tissue develops (Lee et al.,1997). These findings are evidence that 
a homeostatic system exists that is dependent on adipose tissue and dysfunctional in the 
absence of adipose derived leptin signaling (Diamond et al.,2002). 
“The expression of two major enzymes of long chain FA oxidation, ACO, and carnitine 
palmitoyl transferase-1 (CPT-1) are remarkably increased in the adipocytes of hyperleptinemic 
rats in the course of the disappearance of their fat” (Zhou et al.,1997, Zhou et al.,1999). This 
discovery indicates that experimentally induced hyperleptinemia can transfer adipocytes from 
fat-storing cells into fat-burning cells (Wang et al.,1999b). The major increase in the 
expression of PPAR in WAT described in a studies by Kakuma et al.,(2000) and  Zhou et 
al.,(1999) suggested that PPAR might be a proximal mediator of leptin action and, by up-
regulating its target enzymes of FA oxidation, CPT-1 and ACO it play a role in the 
disappearance of adipocyte fat. In addition, it seemed possible that PPAR might be involved 
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in other changes in the expression profile of the overleptinized rats, such as the up-regulation 
of uncoupling proteins (UCP)-1 and 2, and of peroxisome proliferator-activated receptor γ 
coactivator (PGC)-1α and the down-regulation of lipogenic transcription factors and enzymes 
(Lee et al.,2002). The increase in fatty acid oxidation in non-adipose tissue is attributed to 
ability of leptin to stimulate the activity of CPT-1 and inhibit acetyl-CoA carboxylase (ACC), 
rate-limiting enzymes for fatty acid oxidation and synthesis, respectively (Bai et al.,1996). 
 
1.5.1.4 Leptin and insulin 
 
Insulin is an important regulator of energy homeostasis and stimulates glucose, free fatty acid 
and amino acid uptake by tissues and tissue anabolism. The link between leptin and insulin 
should be present in the regulation of energy homeostasis. In 1996, Kieffer and his colleagues 
reported that leptin receptors are expressed in the insulin producing β-cells within the 
pancreatic islets, suggesting that leptin might influence insulin secretion through a direct 
action on these cells. This hypothesis was investigated by several others, with apparently 
conflicting results (Dagogo-Jack et al.,1996, Fehmann et al.,1997, Poitout et al.,1998a, Poitout 
et al.,1998b, Russell et al.,1998). 
Leptin transmits its effects by using both long (OB-Rb) and short (OB-Ra) receptors, which 
are present in pancreatic β-cells (Kulkarni et al.,1997), indicating the possibility of direct 
actions on insulin secretion. Some, but not all, in vivo studies have shown acute inhibitory 
effects of leptin on insulin secretion (Kulkarni et al.,1997, Cases et al.,2001). Notably, leptin-
induced inhibition of insulin secretion has been observed in human islets (Kulkarni  et 
al.,1997, Lupi  et al.,1999), an effect that was associated with increased potassium channel 
permeability (Lupi et al.,1999). 
The direct role of peripheral leptin in controlling glucose uptake and metabolism in skeletal 
muscle, the principal site of insulin-stimulated glucose disposal, remains controversial. In rats, 
some studies have shown acute, leptin-induced increases in muscle glucose uptake (Ceddia et 
al.,1999a); whereas others found that short-term in vivo leptin administration had the opposite 
effect on muscle glycogen synthesis and 2-deoxyglucose uptake (Harris,1998). Most studies 
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report that chronic leptin treatment, in either lean or obese rodents, enhances muscle glucose 
uptake and /or insulin responsiveness (Harris,1998, Wang et al.,1999a, Yaspelkis  et al.,1999), 
suggesting that these effects might require long-term exposure. The importance of glucose in 
regulation of leptin expression and secretion have been suggested in a number of studies 
(Mizuno et al.,1996, Mueller et al.,1998). Conversely leptin modifies insulin sensitivity of 
muscle and liver to glucose uptake probably via CNS control and therefore it seems likely that 
glucose is regulated and is not a regulator (Margetic  et al.,2002). 
 
1.5.1.5 Leptin and obesity 
 
Leptin is considered to be a major player in the regulation of body weight (Blum et al.,1997, 
Pelleymounter et al.,1995). The decrease in food intake and body weight following peripheral 
administration of leptin has been demonstrated in lean and ob/ob mice(Campfield et al.,1995, 
Halaas et al.,1995, Pelleymounter et al.,1995). While the role of leptin in ob mice is clear, its 
role in the pathogenesis of obesity in humans is still not well understood. In contrast to the ob 
mouse, most obese humans do not have any mutations in the coding region for leptin.  
Leptin levels are elevated in obese subjects and a positive correlation between serum leptin 
and measures of adiposity was indicated in a number of studies. “Leptin resistance” could be 
associated with inability of elevated leptin levels to revise the obese state of obese subjects. 
Participation of a leptin receptor carrier protein in this kind of regulation has been suggested 
(Considine et al.,1995a, Considine et al.,1996a, Considine et al.,1996b).  
 
1.5.1.6 Peripheral Leptin receptor (Ob-R) 
 
Leptin receptors are divided into two groups: one group that has short (32-97 amino acid 
residues) intracellular domains and another that has a long 302-residue intracellular domain 
(Friedman,1998). The long form of the receptor (L-Rb) is predominantly expressed in the 
brain but, importantly, it is present at lower levels in multiple peripheral tissues, including 
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skeletal muscle, liver, and adipose tissue (Tartaglia et al.,1995, Lee et al.,1996, Ghilardi et 
al.,1996). Leptin receptors are part of the  class I cytokine receptor family (Tartaglia,1997), 
which is labelled by a single membrane-spanning domain that affiliates with a class of protein 
tyrosine kinase termed the Janus kinases (JAK). JAKs link ligand binding of receptors to 
tyrosine phosphorylation of known signalling proteins such as phosphatidylinositol 3-kinase 
(PI3K) and mitogen-activated protein kinase (MAPK), as well as to a family of transcription 
factors known as the signal transducers and activators of transcription (STATS) (Hirano et 
al.,1994).  
L-Rb is thought to function as the primary receptor that mediates leptin-induced signal 
transduction (Ghilardi et al.,1996); but, several studies have shown that short forms of the L-R 
are also able of transducing signals (Bjorbaek et al.,1997,  Murakami et al.,1997, Fukuda et 
al.,1999). Some alternatively joined isoforms of leptin receptor have been identified (Ob-Ra, 
Ob-Rb, and Ob-Re). Ob-Rb is enhanced in the hypothalamus, the site of leptin's action on food 
intake and body weight. The activation of Ob-Rb by leptin in the hypothalamus produces the 
inhibition of neuropeptide Y/agouti-related protein neurons and activation of pro-
opiomelanocortin/cocaine- and amphetamine-regulated transcript neurons (Huang et al., 
2001). In addition, to the membrane-bound isoforms of the leptin receptor with varying 
cytoplasmic length, a soluble form of the soluble leptin receptor (sOb-R) could be verified. 
sOb-R characterizes the main leptin-binding compound in plasma resulting in a fraction of 
bound and a fraction of free leptin in plasma (Lammert et al.,2001). In contrast, to rodents, 
where an alternative splicing results in sOb-R (Yamaguchi et al.,1998) no m-RNA coding for 
sOb-R could be detected in humans. No m-RNA coding for sOb-R could be detected in 
humans which is quite the opposite to rodents, where an alternative splicing results in sOb-R 
(Yamaguchi et al.,1998). Latest work confirmed that sOb-R is generated by cleavage of the 
membrane-bound form of the Ob-R (Maamra et al.,2001).  
During late stages of mouse pregnancy it was observed that levels of both OB-Re and leptin 
increased by up to 40-fold, which indicates that the soluble leptin receptor may modulate 
leptin's biological activity in vivo (Gavrilova et al.,1997). sOb-R levels are decreased in 
obesity compared to lean subjects and as a result of this the fraction of free leptin is increased 
(van Dielen et al.,2002). Circulating sOb-R levels are increased with the reduction of body 
weight through diet or surgical procedures. Thus in turn increases he fraction of bound leptin 
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(Laimer et al., 2002). Therefore, sOb-R might act as a modulating factor of leptin action and 
plays a significant role in leptin resistance. The precise physiological mechanisms regulating 
sOb-R plasma concentration are not identified (Sandhofer et al.,2003). 
 
1.5.2 The role of the novel adipocyte-derived hormone adiponectin in 
human disease 
 
 
Adiponectin is the product of the apM1 gene with 244 amino acid protein, which is 
exclusively and significantly expressed in human adipose cells and also ascribed to as gelatin-
binding protein-28 (Maeda et al.,1996, Nakano et al.,1996). This cytokine is a collagen-like 
protein that affiliates to the soluble defence collagen superfamily and has structural homology 
with collagen VIII and X and complement factor C1q (Kishore et al.,2000, Maeda et al.,1996, 
Scherer et al.,1995, Hu et al.,1996, Takahashi et al.,2000). The protein holds a signal 
sequence at the NH2-terminal end followed by a short hypervariable region with no homology 
between different species, a collagen-like domain, and a C1q-like globular domain at the 
COOH-terminal end (Shapiro et al.,1998, Hu et al.,1996).  
Adiponectin is ample in human plasma, with concentrations ranging from 5 to 30 µg/ml, thus 
accounting for approximately 0.01% of total plasma protein (Arita et al., 1999). Adiponectin 
is an anti-inflammatory cytokine that improves insulin sensitivity (Nawrocki et al.,2004). In 
the liver, it inhibits both the manifestation of hepatic gluconeogenic enzymes and the rate of 
endogenous glucose production (Combs et al.,2001). In muscle, it increases glucose transport 
and increases fatty acid oxidation, effects that are partially attributed to the activation of AMP-
kinase ( Xu et al.,2003). 
Yamauchi et al., (2003) described the cloning of complementary DNAs encoding adiponectin 
receptors 1 and 2 (AdipoR1 and AdipoR2) by expression cloning. AdipoR1 is profusely 
expressed in skeletal muscle, while AdipoR2 is mostly expressed in the liver. These two 
receptors are thought to be structurally and functionally distinct from G-protein-coupled 
receptors although they are predicted to contain seven transmembrane domains. Kadowaki et 
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al., (2005) have showed that AdipoR1 and AdipoR2 serve as receptors for globular and full-
length adiponectin and mediate increased AMP-activated protein kinase, peroxisome 
proliferator-activated receptor-α ligand activities. Thus, the biological effects of adiponectin 
are modified by the relative circulating concentrations and properties of the different 
adiponectin isoforms as well as the tissue-specific expression of the adiponectin receptor 
subtypes. “Adiponectin-deficient mice develop premature diet-induced glucose intolerance 
and insulin resistance, increased serum nonesterified fatty acid (NEFA) levels, severe 
neointimal thickening and increased proliferation of vascular smooth muscle cells in 
mechanically injured arteries” (Kershaw et al., 2004).  
The pharmacological effect of adiponectin in reducing insulin resistance is related to a 
decrease in plasma fatty acid levels and in triglyceride content in muscle and liver in obese 
mice (Fruebis et al.,2001, Yamauchi et al.,2001). These observations may be due to enhanced 
expression of genes involved in β-oxidation and energy dissipation, such as acyl-CoA oxidase 
and uncoupling protein-2 (Yamauchi et al.,2001). In addition to its activation of the 5’-AMP-
activated protein kinase, adiponectin also stimulated phosphorylation of acetyl-CoA 
carboxylase, fatty acid oxidation, glucose uptake and lactate production in myocytes, and 
phosphorylation of acetyl-CoA carboxylase and reduction of molecules involved in 
gluconeogenesis in the liver (Yamauchi et al.,2002). In humans a role for physiological 
concentrations of fasting plasma adiponectin in the regulation of skeletal muscle insulin 
receptor tyrosine phosphorylation has recently  been demonstrated (Stefan et al.,2002).   
A physiological role for adiponectin has not been fully recognized. Adiponectin has been 
shown to reduce tumor necrosis factor (TNF)-α-induced monocyte attachment to cultured 
human aortic endothelial cells by inhibiting the expression of vascular cell adhesion molecule, 
intercellular adhesion molecule and E-selectin (Ouchi et al.,1999). Adiponectin was shown to 
suppress phagocytic activity and lipopolysacharide-induced TNF-α production in cultured 
macrophages (Yokota et al.,2000, Ouchi et al.,2001), and was detected only in injured but not 
intact vessel walls (Okamoto et al.,2000).  
There seems to be a clear relationship between adiponectin and fat mass in humans. However, 
in contrast to leptin, adiponectin levels are significantly reduced among obese subjects in 
comparison with lean control subjects (Arita et al.,1999). Adiponectin is the only adipose-
specific protein identified to date that is negatively regulated in obesity (Matsubara et 
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al.,2002). Adiponectin  similar to leptin levels  appear to be gender-dependent, being higher 
among women than men(Yamamoto et al.,2002, Hotta et al.,2000, Nishizawa et al.,2002). In a 
large number of non-diabetic women with dyslipidaemia, Matsubara et al. (2002) have shown 
that plasma adiponectin is negatively correlated with serum triglyceride, atherogenic index, 
apoB or apoE, and positively correlated with serum HDL-cholesterol or apoA-I levels. These 
data suggest that low adiponectin concentrations are associated with some of the well-known 
risk factors for atherosclerosis (Fig.1.9). A relationship between hypoadiponectinemia and 
metabolic syndrome has been proposed (Matsuzawa et al.,1999). 
 
 
 
Figure 1.9 Role of adipocytokines in the metabolic syndrome 
http://www.jpp.krakow.pl/journal/archive/1206/articles/01_article.html 
 
 
Recently, Kadowaki et al.,( 2005) have cloned adiponectin receptors in the skeletal muscle 
(AdipoR1) and liver (AdipoR2), which appear to comprise a novel cell-surface receptor 
family. Their research showed that AdipoR1 and AdipoR2 mediate AMP-activated protein 
kinase, peroxisome proliferator-activated receptor-α ligand activities, and glucose uptake and 
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fatty-acid oxidation by adiponectin and also function as receptors for globular and full-length 
adiponectin. 
Expression Levels of AdipoR1/R2 decreased in obesity thus reducing adiponectin sensitivity, 
which may lead to insulin resistance.  The pharmacological effect of adiponectin in reducing 
insulin resistance is related to a decrease in plasma fatty acid levels and in triglyceride content 
in muscle and liver in obese mice (Fruebis et al.,2001, Yamauchi et al.,2001). These 
observations may be due to enhanced expression of genes involved in β-oxidation and energy 
dissipation, such as acyl-CoA oxidase and uncoupling protein-2 (Yamauchi et al.,2001). In 
addition to its activation of the 5’-AMP-activated protein kinase, adiponectin also stimulated 
phosphorylation of acetyl-CoA carboxylase, fatty acid oxidation, glucose uptake and lactate 
production in myocytes (Yamauchi et al.,2002). In humans a role for physiological 
concentrations of fasting plasma adiponectin in the regulation of skeletal muscle insulin 
receptor tyrosine phosphorylation has been demonstrated (Stefan et al.,2002). 
 
1.5.3 Resistin 
 
A newly discovered hormone described in Nature by Steppan and colleagues (2001) is 
proposed as the essential link between obesity and type 2 diabetes. A distinctive signaling 
protein that was secreted by adipocytes was called “resistin” which means “for resistance to 
insulin”. To build on their discovery, the researchers first examined normal mice. They 
discovered that resistin circulates normally in mouse blood. Resistin levels decreased in 
normal mice after a period of fasting, but increased again when the mice were fed. The 
researchers showed that in mice bred to have both diet-induced and hereditary diabetes the 
resistin levels are higher than in controls. The role of resistin in normal physiology is not 
known. Genetic or diet induced obese rodents as well as obese patients have significantly 
higher resistin gene expression and plasma levels (Steppan et al.,2001, Savage et al.,2001). 
Treatment with rosiglitazone, a drug that enhances insulin action by activating nuclear 
peroxisome proliferator-activated receptor γ (PPARγ), can noticeably down-regulate its 
mRNA expression in adipose tissue of obese mice (Steppan et al.,2001). “Administration of 
resistin was reported to impair glucose tolerance and insulin action, whereas administration of 
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an anti-resistin antibody significantly improved insulin action” (Steppan et al.,2001, Rajala et 
al.,2003a, Hotamisligil, 2003, Moon et al.,2003). It has been demonstrated that insulin-
stimulated glucose uptake by adipocytes was enchanced by neutralization of resistin, and 
conversely reduced by addition of resistin (Steppan et al.,2001).  
However, Savage and co-workers (2001) found that resistin mRNA levels were very low in 
freshly-isolated human adipocytes, and were undetectable in adipocytes from a severely 
insulin-resistant subject with a dominant-negative mutation in the PPARγ gene. Similarly, 
resistin is expressed at very low levels in several genetically obese rodents, its mRNA 
expression has been found to increase following treatment with thiazolidinediones (TZDs) 
PPARγ agonists and insulin itself in vivo, and yet suppressed by the same treatment in vitro 
(Way et al.,2001, Kim et al.,2001). The ambiguous function for resistin regarding the role it 
plays in obesity-induced insulin resistance in humans remains open to debate (Guo et 
al.,2004). 
 
1.5.4 Acute-phase proteins and other systemic responses to inflammation 
 
Cytokines are intercellular signalling polypeptides produced by activated cells and the 
majority of them have multiple sources, multiple targets, and multiple functions. The 
interleukin-6, interleukin-1β, tumor necrosis factor-α, interferon-γ, transforming growth factor 
β and interleukin-8 belong to the inflammation-associated cytokines (Kushner, 1993, 
Wigmore et al., 1997). They are produced by a variety of cell types, but the most important 
sources are macrophages and monocytes at inflammatory sites (Gabay et al,.1999). Although 
they are produced by a variety of cell types, but the most essential sources are macrophages 
and monocytes at inflammatory sites (Gabay et al,.1999). 
Interleukin-6 is the main stimulator of the production of most acute-phase proteins (Gauldie et 
al.,1987), while the other implicated cytokines affect subgroups of acute-phase proteins. 
Overproduction by the expanded adipose tissue mass indicated by elevated levels in 
proinflammatory cytokines including interleukin 6, resistin, and tumour necrosis factor α 
(TNFα) and C-reactive protein (Fernandez-Real et al.,2003, Trayhurn et al.,2004). Some data 
suggests that monocyte-derived macrophages exist in adipose tissue and might be in part the 
  
55
source of the proinflammatory cytokines locally and in the systemic circulation (Weisberg et 
al.,2003, Xu et al.,2003). Glucocorticoids usually improve the stimulatory effects of cytokines 
on the production of acute-phase proteins (Baumann et al.,1987), while insulin decreases their 
effects on the production of some acute-phase proteins (Campos et al.,1994). The expression 
of genes for acute-phase proteins is regulated largely at the transcriptional level, but post-
transcriptional mechanisms also take part (Jiang et al.,1995, Rogers et al.,1990). 
 
1.5.4.1 Tissue necrosis factor alpha  
 
Tumor necrosis factor α (TNF-α), also known as cachectin (Carswell et al.,1975, Beutler et 
al.,1985), is produced by neutrophils, activated T and B lymphocytes, NK cells, LAK cells, 
astrocytes, endothelial cells, smooth muscle cells and adipocytes. Mature human TNF-α is a 
polypeptide of 157 amino acid residues (mouse, rat, or rabbit TNF-α is one amino acid 
shorter). Human TNF-α shows no N-glycosylation (mouse TNF-α is N-glycosylated) (Vilcek 
et al., 1991). The biologically active native form of TNF-α is a trimer (Jones et al.,1989, Eck 
et al.,1989). TNF-α does not possess a typical signal peptide sequence. TNF-α is, however, 
initially synthesized as a larger protein with the mature 17-kDa factor comprising the C-
terminal portion of this precursor. Hydrophilic and hydrophobic domains are both present in 
the N-terminal sequence of the precursor. The presence of this precursor results in the 
occurrence of TNF-α as a membrane-bound form from which the mature factor is released by 
proteolytic cleavage (Kriegler et al.,1988, Luettig et al.,1989, Perez et al.,1990). 
Two separate receptor types have been recognized that specifically bind TNF-α. The presence 
of one or both of these receptor types have been found almost in all studied cell types. Type 
TNF RII (or Type A, Type α, 75 kDa or utr antigen), is a transmembrane glycoprotein with 
molecular weight of 75 kDa (Dembic et al.,1990) and another one, TNF RI (or Type B, Type 
β, 55 kDa or htr antigen), is a transmembrane glycoprotein with molecular weight of 55 kDa 
(Schall et al.,1990, Loetscher et al.,1990). Every receptor type can bind TNF-α with high 
affinity and there is no proof that connection between the two receptor types is necessary for 
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signal transduction (Loetscher et al.,1990, Smith et al.,1990, Engelmann et al., 1990a). 
Soluble forms of both types of receptors have been discovered in human serum and urine 
(Seckinger et al.,1989, Olsson et al.,1989, Engelmann et al.,1990b). The ability of these 
soluble receptors to neutralize the biological activities of TNF-α and function to modulate and 
localize the activities of TNF-α or function as a reservoir for the controlled release of TNFα 
had been recognized. TNF-α is an very pleiotropic molecule which is assignable to the 
ubiquity of its receptors, to its capability to trigger multiple signal transduction pathways, and 
to its capability to stimulate or restrain the expression of a vast number of genes, including 
those for growth factors and cytokines, transcription factors, receptors, inflammatory 
mediators and acute phase proteins (Vilcek et al.,1991, Kronke,1991). TNF-α plays an 
important role in normal host resistance to infections and to the growth of malignant tumors, 
function as an immunostimulant and a mediator of the inflammatory response. The extreme 
production of TNF-α has been implicated as playing a role in a number of pathological 
conditions, such as cachexia (progressive wasting) (Beutler et al.,1985, Oliff,1988), septic 
shock following infection with Gram-negative bacteria (Tracey  et al.,1987), autoimmune 
disorders (Pujol-Borrell et al.,1987), and meningococcal septicemia (Waage et al.,1987). 
TNF-α concentrations in human fat rise with obesity, correlate with abdominal adiposity, and 
decline during weight loss (Hotamisligil  et al.,1995,  Kern   et al.,1995,  Tsigos  et al.,1999). 
In some experimental settings, TNF-α and its circulating p75 receptor fraction antagonize 
insulin action through effects on calcium-dependent GLUT-4 transport and phosphorylation of 
the insulin receptor and insulin receptor substrate-1 (IRS-1) (Hotamisligil et al.,1994, 
Hotamisligil  et al.,1996, Sayeed,1996). 
Autocrine effects of TNF-α at the adipocyte promote leanness by inhibiting the activity of 
lipoprotein lipase, acetyl-CoA carboxylase, and glycerophosphate dehydrogenase, impeding 
lipogenesis, increasing lipolysis and accelerating fat cell apoptosis (Sethi et al.,1999, Torti et 
al.,1985, Zhang et al.,1996). TNF-α also reduces the deposition of triglycerides and promotes 
intracellular uncoupling (Berg et al.,1994, Greenberg et al.,1992). However, because TNF-α 
concentrations are not increased in venous output from subcutaneous fat tissue, the cytokine’s 
primary actions appear to be autocrine or paracrine (Yudkin et al.,2000). 
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1.5.4.2 Interleukin-6 
 
Human interleukin-6 [(h) IL-6] is a 184 amino acid protein with a molecular weight of 23-
30kDa, which is N-linked glycosylated. Interleukin 6 is a major proinflammatory cytokine that 
produced in a variety of tissues, including activated leucocytes, adipocytes, and endothelial 
cells (Pradhan et al.,2001). The IL-6 receptor is a heterodimeric molecule consisting of an 
80kDa IL-6 binding protein and a 130kDa accessory molecule, which is required for the high 
affinity form (1x10-10M) that can transduce signals. The IL-6 receptor has been found to be on 
a wide range of cells including B and T cells, monocytes, myelomas, hepatocytes, hepatomas 
and astrocytomas up to 10000 per cell. A soluble circulating form of the 80kDa IL-6 binding 
protein is able to form a complex with IL-6 that can then associate with the membrane bound 
130kDa molecule resulting in signal transduction (Mitsuyama et al., 2006). 
The in vivo infusion of human recombinant IL-6 in rodent models of glucose metabolism 
made known to induce gluconeogenesis, subsequent hyperglycemia, and compensatory 
hyperinsulinemia (Stith et al.,1994). In humans similar metabolic responses have been found 
after administration of subcutaneous recombinant IL-6 (Tsigos et al.,1997). Several studies 
have confirmed elevated levels of IL-6 and CRP among individuals both with features of the 
insulin resistance syndrome and clinically overt type 2 DM (Pickup et al.,1997, Grau et 
al.,1996, Ford,1999, Festa   et al.,2000, Frohlich et al.,2000). 
Up to one-third of circulating IL-6 originates from adipose tissue (Mohamed-Ali et al.,1997), 
with higher basal levels found in the preadipocytes compared to the mature fat cell. In vitro 
studies suggest a greater production of the IL-6 in visceral vs. subcutaneous fat (Fried et 
al.,1998). IL-6 release from adipose tissue is stimulated by TNFα and IL-1, and circulating 
IL-6 enters the CNS and binds to receptors present in the hypothalamus (Jones et al.,1993). 
Like TNFα, its anorexigenic effects result from stimulation of thermogenesis and satiety, with 
central effects on prostaglandin synthesis, corticotrophin releasing hormone, and activation of 
hypothalamic-pituitary-adrenal function. IL-6 is the key regulator of hepatic C-reactive protein 
and the hepatic acute phase response. IL-6 seems to correlate with insulin resistance and 
endothelial dysfunction (Yudkin et al.,1999, Galis et al.,1994). In hepatocytes in vitro, IL-6 
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reduces insulin-stimulated accumulation of glycogen (Kanemaki et al.,1998). Like TNFα, IL-
6 inhibits lipoprotein lipase and induces lipolysis (Yudkin et al.,2000), and resultant increase 
of non-esterified fatty acids (NEFA) may impede nitric oxide mediated endothelial 
vasodilation (Robinson et al.,1995, Steinberg et al.,1997). 
 
 
1.5.4.3 C - Reactive Protein 
 
C-reactive protein (CRP) is a classical acute phase reactant and a member of the pentraxin 
family of innate immune response proteins (Du Clos, 2000). The human CRP molecule (MW 
115,135) is composed of five identical nonglycosylated polypeptide subunits (MW 23,027), 
each containing 206 amino acid residues (Pepys et al., 2003). CRP demonstrates calcium-
dependent similarity for phosphate monoesters, such as phosphatidylcholine, but several other 
ligands of CRP have been labelled, including damaged cell membranes, small 
ribonucleoprotein particles, apoptotic cells and fibronectin (Du Clos et al., 2004). 
C-reactive protein is synthesized mainly within the endoplasmic reticulum of hepatocytes in 
response to proinflammatory cytokines particularly interleukin-6 (IL-6), as well as IL-1β and 
tumor necrosis factor α (TNF-α), which potentiate the IL-6 effect (Ross, 1999). Current data 
show that arterial tissue may generate CRP as well as complement proteins, and that CRP and 
complement, simultaneously with their mRNA, are substantially up-regulated in 
atherosclerotic plaque (Yasojima et al.,2001). Smooth muscle cells and macrophages seem to 
be the main producers, explaining that CRP may be generated by extra-hepatic mechanisms. 
 Cytokines, which trigger the de novo hepatic production of acute phase reactants such as C-
reactive protein (Pepys et al.,1983), have been shown to increase in acute coronary syndromes 
even in the absence of myocardial necrosis (Liuzzo et al.,1994). As a result, CRP has been 
examined as a surrogate marker of other inflammatory mediators such as IL-6 and TNF-α to 
better understand the inflammatory component of atherosclerosis (Rus et al.,1996, Sukovich et 
al.,1998). Some literature suggested that the CRP concentration might represent the 
vulnerability of the atheromatous lesion and the likelihood of a plaque to rupture (Ross,1999, 
Libby,1995, Maseri,1997).  
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High CRP levels are also observed in patients with dilated cardiomyopathy at increased risk of 
death and in patients with decompensated heart failure (Naidoo, 2003). Elevated CRP levels or 
association between CRP and disease progression have also been found in atrial fibrillation 
(Chung et al.,2001), obstructive sleep apnoea (Shamsuzzaman et al.,2002) and vascular 
dementia. Interestingly, CRP appears to be more weakly associated with measures of the 
burden of atherosclerosis, such as carotid intimal-media thickness or extent of coronary artery 
disease (Folsom et al.,2001).  
A strong positive correlation between CRP and body mass index (as well as waist: hip ratio) 
has been revealed in many studies. This association with obesity is clear because hepatic CRP 
production is stimulated by IL-6, which originates mainly from adipose tissue (Naidoo, 2003). 
CRP also predicts the development of type 2 diabetes, suggesting a direct role for 
inflammation in the pathogenesis of insulin resistance and diabetes (Pradhan et al.,2001). In 
the Multiple Risk Factor Intervention Trial (MRFIT), C-reactive protein was predictive of 
future coronary mortality among high-risk smokers (Kuller et al.,1996). Whether silent 
mutations of CRP and IL-6 genes which have been shown to influence CRP levels influence 
disease progression, is not clear, but this may be another mechanism for the predisposition to 
early onset coronary disease in subjects with risk factors (Zee et al.,2002, Vickers et al.,2002). 
C-reactive protein concentrations as a general indicator of inflammation can vary by ethnic 
origin and within ethnic groups by fitness (LaMonte et al.,2002, Chambers et al.,2001). For 
instance, a study by Chambers et al., (2001) found that concentrations of C-reactive protein 
were higher in healthy Indian Asians than in European White people and were related to 
greater central obesity and insulin resistance in Indian Asians. Currently it remains uncertain 
whether these differences when adjusted for other covariates will relate to different rates of 
development of diabetes and / or cardiovascular disease (Eckel et al.,2005). 
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1.6 Epidemiological studies of obesity and Type 2 Diabetes 
Mellitus 
 
1.6.1 Prevalence of obesity world wide  
 
On the basis of the standard WHO adult classification system (2000b), it is estimated that in 
the United States, overweight and obesity combined (BMI ≥25) affect 60% of the population; 
32.2% of US adults are obese (BMI ≥30). These statistics reflects a marked increase since the 
late 1970s, when the combined prevalence of overweight and obesity was 47% and the 
prevalence of obesity was 15% (York et al., 2004). 
Nearly 30% of the US population is composed of diverse ethnic groups that are broadly 
categorized as Black or African American, Hispanic or Latino, Asians, Pacific Islanders, 
American Indians or Alaskan Natives, and Native Hawaiians. This proportion will increase to 
nearly 40% over the next 2 decades (Population Reference Bureau, 2000). In African- 
American and Hispanic-Americans racial / ethnic minority groups in the U.S. overweight and 
obesity emerged at higher rates compared with White Americans (Table 1.4). Asian-
Americans have a comparatively low prevalence for obesity. Women and persons of low 
socio-economic status within minority populations appear to be particularly affected by 
overweight and obesity. Cultural factors that influence dietary and exercise behaviours are 
reported to play a major role in the development of excess weight in minority groups. 
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Table 1.4 The prevalence of overweight and obesity over the last decade across 
racial/ethnic groups in USA 
 
Increase in Overweight and Obesity 
Prevalence Among U.S. Adults* by Racial / Ethnic Group 
 Overweight  
(BMI ≥25)  
Prevalence (%) 
Obesity  
(BMI ≥ 30)  
Prevalence (%) 
Racial/Ethnic Group 1988 to 1994 1999 to 2000 1988 to 1994 1999 to 2000 
Black  
(non-Hispanic) 
62.5 69.6 30.2 39.9 
Mexican American 67.4 73.4 28.4 34.4 
White  
(non-Hispanic) 
52.6 62.3 21.2 28.7 
*Ages 20 and older for 1999 to 2000 and ages 20 to 74 for 1988 to 1994 
Source: CDC, National Centre for Health Statistics, National Health, and Nutrition Examination 
Survey (Flegal et al., 1998, Flegal et al., 2002). 
 
 
 
The report published in 1991 by US Centre for Disease Control and Prevention (CDC) 
indicated that the prevalence of obesity in 19 states varied between 15 and 19% with no single 
state above 20%. Eleven years later in 2002, 20 states had a prevalence between 20 and 24%, 
and in one state it exceeded 25% (Mokdad et al., 1999, Mokdad et al., 2001, Mokdad et al., 
2003). These alarming numbers are mirrored around the globe including many developing 
countries, where the adverse health consequences of overweight and obesity have begun to 
replace under nutrition and infection as the main causes of early death and disability 
(Caballero, 2001). 
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In the UK the proportion who were categorised as obese (BMI ≥30) increased from 13.2% of 
men in 1993 to 23.6% in 2004 and from 16.4% of women in 1993 to 23.8% in 2004 
(http://www.ic.nhs.uk/pubs/hlthsvyeng2004upd). The description of what represents 
“European countries” has altered after new developments in central and Eastern Europe. It 
becomes more difficult to attain exact prevalence and incidence data in all age groups, in 
varying socio-economic settings, and in both sexes. The interest in Mediterranean countries 
was always considered to be important in regard to lifestyle factors, diet, and longevity (York 
et al., 2004).  
However, in Greece the prevalence of obesity in both men and women is one of the highest in 
Europe and is about twice that of men and women in Italy, France, and Spain. Denmark, 
Norway, and Sweden are in the lowest part of the distribution, with prevalence data of ≈10% 
for men and ≈12% for women. Interestingly, however, the prevalence data for neighbouring 
Finland, which is widely known as a country with some of the highest rates for cardiovascular 
disease, are ≈50% higher than rates in other Nordic countries (Heitmann, 2000, Lahti-Koski et 
al., 2000, Lissner et al., 2000). The causes for this are not identified but genetic factors 
probably play a role similar to that played in the prevalent hyperlipoproteinemic problems of 
the country. Table 1.5 shows an update from the International Obesity Task Force (IOTF) 
(http://www.iotf.org/media/iotfaug25.htm). 
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    Table 1.5 BMI in Adults from European Countries (York et al., 2004)* 
 
 Overweight, % (BMI 25.0 –29.9) Obesity, % (BMI ≥ 30) 
Country Male Female Male Female 
Austria 48 29 12 17 
Belgium - 12 19 - 
Bulgaria 37.7 27.7 10 9.2 
Croatia 50.9 33.3 16.3 16.2 
Czech Republic 48.5 31.4 24.8 26.2 
Denmark 38.2 20.2 8.8 5.9 
Germany 48.1 31.3 18.8 20.3 
Finland 48 33 19.8 19.4 
France 35 20.3 8.3 7.7 
Hungary 42 28.3 21 21.2 
Greece 51.1 36.6 27.5 38.1 
Iceland 47.4 16.8 36.9 18.3 
Israel 43.5 30.3 14.7 20.9 
Italy 39.6 25.0 6.5 6.3 
Lithuania 41.8 32.6 11.4 18.3 
Malta 46 32 22 35 
Netherlands 42 29.1 9.9 8.5 
Norway 50.4 28.8 12.7 9.5 
Portugal 42.3 31.9 13.2 16.2 
Romania 38.8 31.5 21.1 27.4 
Russian Federation 34.7 31 9.6 25.4 
Continue……. 
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Table 1.5 (continue) BMI in Adults from European Countries (York et al., 2004)* 
 Overweight, % (BMI 25.0 –29.9) Obesity, % (BMI ≥ 30) 
Country Male Female Male Female 
Norway 50.4 28.8 12.7 9.5 
Portugal 42.3 31.9 13.2 16.2 
Romania 38.8 31.5 21.1 27.4 
Russian Federation 34.7 31 9.6 25.4 
Slovakia 37.8 23.6 13.1 13 
Spain 59.9 48.1 11.8 15.7 
Sweden 51.2 41.6 10 11.9 
Switzerland 33.1 17.1 6.1 4.7 
Tajikistan 17.8 11.4 3.2 2 
Turkey 37.3 35 11.8 24.4 
United Kingdom 43.9 32.8 18.7 21.1 
Uzbekistan 10.2 8.9 8.4 6.1 
Yugoslavia 28.1 28.4 25.5 40.9 
 *Updated data may be viewed at:  http://www.iotf.org 
 
 
 
Over the past 20 years the prevalence of obesity in Australia has been intensified. More 
recently the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) (Dunstan et al., 
2001), a nationally representative survey, measured the prevalence of obesity and diabetes in 
adults aged 25 to 65. In 1980 the prevalence of obesity was 8% in women; in 2000, the 
prevalence had increased to 21.8%. In men the prevalence was 9.3% in 1980 and 19.1% in 
2000. Currently the prevalence of obesity is 20.5% in Australian adults. Among men 67.4% 
have a BMI >25; among women, 52% have a BMI >25. The major increase in obesity has 
occurred since 1989. As reported by the Australian Institute of Health and Welfare (Armstrong 
  
65
et al., 2000) there are a number of reasons for this and one of them is drop in activity. Despite 
decrease in dietary fat intake, the daily energy intake has increased (Cook et al., 2001). 
According to the data published by Zhou et al., (2002), the prevalence of overweight (BMI 
25.0 to 29.9) in Chinese adults aged 20 to 70 in the 1990s, was 22.4%, while prevalence of 
obesity (BMI ≥ 30) was 3.01%. The prevalence of overweight in Chinese men and women 
was 20.4% and 22.4%, respectively. The prevalence of obesity in Chinese men and women 
was 2.04% and 3.89%, respectively. The differences between urban and rural population were 
apparent in 1992 when the mean BMI of the urban population was 23.57 compared with 21.94 
for rural communities (Ge,1995). Because China is a country in economic development, 
dietary fat intake increased during the 1980s and reached ≈30%, but has remained constant 
since then (Wang et al., 2000, Chen et al., 1994). The tendency of overweight and obesity 
increased rapidly in the past 17 years. The prevalence of overweight in the southern part of 
China (Guangzhou, Shanghai) increased more rapidly than in the northern part of the country. 
The prevalence of overweight reached 10% in 1998 even in the poor rural area of Shaanxi (Wu 
et al., 2002). 
Overweight and obesity are common among Hispanic women aged 15 to 49 ( Martorell et al., 
2000b, Martorell, 2002,). The levels of overweight and obesity ranged from ≈30% to ≈50% in 
Bolivia, Brazil, Colombia, the Dominican Republic, Guatemala, Honduras, Mexico, 
Nicaragua, and Peru. In some countries prevalence rates come close to those of the United 
States. Overweight and obesity are common among Hispanic women aged 15 to 49 ( Martorell 
et al., 2000b, Martorell, 2002,). The levels of overweight and obesity were ~ 10% in country 
like Haiti and in sub-Saharan Africa. In the urban areas of Haiti obesity was more prevalent 
compared to the rural areas and in women with more education compared with those that have 
only primary schooling. By contrast, in 1999 obesity in Mexico was as common in urban areas 
as it was in rural areas and was more common among poorly educated women. Consequently 
with greater economic development the prevalence of obesity rises and begins to badly affect 
rich and poor alike; in more advanced countries obesity has become more common among 
poor and less educated people, as is becoming noticeable in Mexico. In 1988 the prevalence of 
overweight and obesity were 24% and 9%, respectively. By 1999 the corresponding values 
were 35% and 24% (Rivera et al., 2002). High prevalence of overweight and obesity were 
found in North Africa and the Middle East. From 1995 to 1996 31.7% of Egyptian women 
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aged 15 to 49 were overweight; 23.5% were obese (York et al., 2004). The national survey 
conducted in 1993 from primary healthcare clinics in Kuwait established that prevalence of 
obesity was 40.2% among women older than 18 years (al-Isa, 1997). The reported prevalence 
of obesity among women aged 20 to 60 in Morocco was 18.3% in 1998, while in 1997 in 1997 
in Tunisia the prevalence was 22.7%. Rates in men remained low (i.e. 6.7% in Tunisia in 1997 
and 5.7% in Morocco) in 1998 to 1999” (Mokhtar et al., 2001). 
 
1.6.2 Epidemiology of obesity in Africa  
 
In sub-Saharan African there is a constant fight against poverty, worry about food, under-
nutrition, and infectious diseases. The situation is aggravated by the HIV/AIDS epidemic 
(Food and Agriculture  Organization  of the  United Nations, 2001). In the more industrialised 
parts of Africa obesity and overweight are rising however, leading to a coexistence of under 
nutrition and over nutrition in many African countries. The rising tendency of obesity in Africa 
also has been found in Mauritius, despite national programs to promote healthier diets and 
increased physical activity (Hodge et al., 1996). The results from the prevalence studies in 
which 3677 subjects were followed up from 1987 to 1992 had indicated that the prevalence of 
overweight and obesity (BMI ≥ 25) increased from 26.1% to 35.7% in men and from 37.9% to 
47.7% in women (York et al., 2004).  
In rural areas of Africa the prevalence of obesity is still relatively low. In Nigeria, for instance, 
only 1.2% of men and 3.2% of women had BMIs ≥ 25 (Okesina et al., 1999).  The data 
suggested that obesity in Africa is characterized by a gender difference, with women having 3 
to 5 times the rate of obesity that was observed in men. In the overweight range (BMI ≥25), 
however, these differences are smaller (Hodge et al., 1996). These data indicated that 
overweight and obesity emerges earlier in African women but that African men may 
eventually reach the same prevalence rates (Labadarios et al., 2003).  
Table 1.6 provides prevalence of obesity from some African countries, from migrant people of 
African descent and from other South-African studies. The lower rates of obesity were found 
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in countries like Ghana, Mali, and Tanzania when compared to South Africa, while in 
Mauritius the prevalence of obesity fall more or less between these extremes. African 
Americans had similar prevalence to those found in Africans from South Africa. Generally, 
these data suggest that the predominant pattern of malnutrition in adult South Africans, 
particularly in African women, is one of overweight and of remarkably high rates of 
abdominal obesity (Puoane et al., 2002). 
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Table 1.6 Prevalence of obesity (body mass index ≥ 30 kg/m2) in South Africa 
and selected countries in Africa and the US (adapted from Puoane et al., 2002) 
 
                                                                                                                    Prevalence of obesity (%) 
Country Year Ages 
(Years) 
Men Women 
 
Ghana   
Mali     
Mauritius  
USA  
Tanzania  
South Africa 
       Cape Peninsula, Africans  
       Mangaung, Africans  
       QwaQwa, Africans  
       Cape Peninsula, Mixed   
       South Western Cape, whites    
       Durban, Indians   
   Demographic& Health Survey, African 
   Demographic& Health Survey, Mixed 
   Demographic& Health Survey, Asian 
   Demographic& Health Survey, White 
 
 
1987/88 
1991 
1992 
1988-94 
1986/89 
 
1990 
1990 
1990 
1982 
1988 
1990 
1998 
1998 
1998 
1998 
 
≥ 20 
≥ 20 
25 to 74 
20 to 74 
35 to 64 
 
25 to 64 
25 to 64 
25 to 64 
25 to 64 
25 to 64 
25 to 69 
15 
15 
15 
15 
 
- 
- 
       5 
19.9 
0.6 
 
13.9 
12.9 
12.7 
7.2 
17.6 
3.5 
7.7 
9.1 
8.7 
19.8 
 
0.9 
0.8 
15 
24.9 
3.6 
 
48.6 
43.9 
40.2 
31.4 
20.4 
17.6 
30.5 
28.3 
20.2 
24.3 
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1.6.2.1 Epidemiology of obesity in South Africa 
 
Obesity in Africa is associated with urbanization and changes in dietary patterns, 
socioeconomic circumstances, and physical activity levels. The prevalence of obesity in South 
Africa, as estimated using data collected in 1998 (Puoane et al., 2002), was 10% for males and 
30% for females, compared with data from the USA  for the period 1999-2000 where the 
prevalence was 27.6% for men and 33.2% for women (Baskin et al., 2005). 
In 1940, Fox found that the African population consumed a typical traditional diet, where the 
fat intake was only 16% of the total calories. The 26% increase in fat intake was observed in 
an urban African community by 1990 (Mollentze et al., 1993). The further analysis of this data 
revealed that those people who had lived in cities for most of their lives, already consumed a 
typical Westernized diet with 30% of calories derived from total fat, whereas those who had 
spent <20% of their lives in the city, derived only 22.5% of calories from total fat (Bourne, 
1996). In South Africa an improvement in household income was positively associated with 
obesity, illustrating that at this stage of the demographic transition, obesity can be expected to 
have higher prevalence in the higher socio-economic strata. Increased in obesity in African 
women in both rural and urban areas, independent of the level of urbanization was associated 
with low physical activity (Kruger et al., 2002).  
The data about the nutritional status and dietary intake patterns in the African community, the 
large number of the South Africans with high poverty levels were gather in the past in a 
number of regional studies (Steyn et al., 1998, Vorster  et al., 2000, Mollentze et al., 1993, 
Bourne and Steyn, 2000). In the African communities that became more urbanized the rate of 
obesity increased and their diets became less sensible ( Jooste et al., 1988, Steyn et al., 1990, 
Steyn et al., 1998, Bourne and Steyn, 2000). Within South Africa abdominal obesity is the 
highest in white urban men and rural African women (Puoane et al., 2002). The connection 
between abdominal obesity with diabetes and hypertension has been previously acknowledged 
in regional prevalence studies in the both African and mixed-ancestry communities of the 
Western Cape (Steyn et al., 1996, Levitt et al., 1993). Thus WHR and waist circumference are 
an important adult health markers for ongoing observation. 
In South Africa, obesity in women appears to start at a young age. Puoane and co-workers 
(2002), show that 10% of women were obese at the ages of 15 to 24 years. Therefore it 
  
70
seems that primary prevention of obesity should begin at a young age, particularly for girls. In 
African women, the elevated rate of obesity is primarily in the urban women. It was noted that 
women without education had lower BMIs than those with schooling, therefore the 
relationship between education and BMI become important. 
These women tend to do more manual labour than their better-educated counterparts. There 
are two possible reasons to finding that women with tertiary education also had a lower BMI 
than those without. Firstly, this group of women may be aware of the connection between 
body weight and health, and secondly, one could anticipate that this female group would take 
more cognisance of the preferred body image of thinness that reaches them through the media. 
Obesity management is particularly compelled for older women in all the population groups 
(Puoane et al., 2002). 
A feature of the results reported by the various South African studies on different ethnic 
groups is the increase in the prevalence of both overweight and obesity with age in both males 
and females. After the age of 25 the increase in overweight was found to double in both males 
and females of all ethnic groups. With the exception of black subjects, the prevalence of 
overweight was found to be very similar in males and females after the age of 25. The 
prevalence rate of overweight in Indian women has been twice as high compared to White 
women of 25 years and older (Jooste et al., 1988, Seedat et al., 1990). According to the study 
by Benadé et al., (1996) obesity was found to be rare in males of all ethnic groups and more 
women than men tended to become obese, as they grew older. 
 
 
1.6.3 Epidemiology of diabetes world wide 
 
Type 2 diabetes has reached epidemic proportions and affects more than 194 million 
individuals worldwide or 5.1% in the adult population. It is estimated that this will increase to 
333 millions, or 6.3%, by 2025 (Table 1.7). 
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Table 1.7 Estimated prevalence of diabetes worldwide (adapted from Diabetes Atlas, 
second edition, © International Obesity Task Force, 2003) 
 
 
All diabetes and IGT 2003 2025 
Total world population (billions) 6.3 8.0 
Adult population (billions) (20-79 years) 3.8 5.3 
Number of people with diabetes (millions) (20-79 years) 194 333 
World diabetes prevalence (%)(20-79 years) 5.1 6.3 
Number of people with IGT (millions) (20-79 years) 314 472 
IGT prevalence (%) (20-79 years) 8.2 9.0 
 
 
 
Global estimates that the greatest increases in the prevalence of diabetes will occur in the 
developing regions of Africa, Asia, and South America (Zimmet et al., 2001). In more 
developed countries, the prevalence of diabetes mellitus has reached about 6% (King et al., 
1998), and, even more alarmingly, among obese white adolescents, 4% had diabetes and 25% 
had abnormal glucose tolerance (Sinha et al., 2002).  
Type 2 diabetes is the most widespread diabetes in the world. The European Region and 
Western Pacific Region currently have the highest number of people with diabetes (48 million 
and 43 million, respectively). However the prevalence rate of 3.1% for the Western Pacific 
Region is significantly lower than 7.9% in the North American Region and 7.8% in the 
European Region as seen in figure 1.10 (http://www.eatlas.idf.org/media/). 
 
 
 
 
  
72
 
 
 
Figure 1.10 Estimate prevalence of diabetes and impaired glucose tolerance  
(20-79 age groups) by region (Source: Diabetes Atlas, second edition, © International 
Obesity Task Force, 2003). 
Abbreviations: AFR-Africa; EMME- Eastern Mediterranean and Middle East; EUR-Europe; NA-North 
America; SACA- South and Central America; SEA- South-East Asia; WP-Western Pacific 
 
 
 
Approximately 15 million Americans will develop type 2 diabetes mellitus (DM), which is 
linked with an increased risk for cardiovascular disease, especially among women (Harris, 
1995, Manson, 1996, Harris et al., 1998). The secondary macrovascular and microvascular 
injury is a typical of this disease; the economic and functional burdens are highest during mid-
to-late adulthood. “One third of individuals with type 2 diabetes are undiagnosed, and 
approximately 20% have diabetic retinopathy or evidence of systemic vasculopathy at clinical 
presentation” (Harris et al., 1992). 
According to the National Diabetes Statistics, (2002) the Pima Indians in Arizona have the 
  
73
highest recorded prevalence of diabetes in the world. Overall, American Indian and Alaska 
Native adults are 2.6 times more prone to have diabetes than non-Hispanic whites of similar 
age (National Diabetes Statistics, 2002). The relationship between lower socioeconomic status 
or education level and higher prevalence of diabetes was described among white, black, 
Hispanic, and Japanese Americans in the United States (Auslander et al.,1992, Drury et 
al.,1987, Hazuda et al.,1992, Hendricks et al.,1991, Leonetti et al.,1992, Marshall et al.,1993). 
Known that large proportions of black and Hispanic populations live in poverty and have less 
than a high school education, socioeconomic status may strongly affect the prevalence of 
diabetes in these minority groups (Statistical Abstract of the United States,1994). 
According to the data published by Yusuf et al.,(2001b) South Asians  (in the UK and Canada) 
when compared with Europeans, do not display high rates of smoking, hypertension, or 
elevated cholesterol but still have higher rates of coronary heart disease (CHD). Conversely, 
smoking, hypertension, and diabetes are strongly linked with CHD among South Asians (Pais 
et al.,1996). High rates of diabetes has been reported among South Asian in the UK (10% to 
19%), Trinidad (21%), Fiji (25%), South Africa (22%), Mauritius (20%), and Canada (10%) 
(Anand et al.,2000, McKeigue et al.,1989). The opposite was found in rural India where the 
prevalence of diabetes is 2% to 3% and roughly 8% in urban areas (Ramachandran et 
al.,1992). There is also increase in number of studies that provide evidence that elevations in 
blood glucose even in the nondiabetic range increases CHD risk among South Asian (Pais et 
al.,1996). 
 
1.6.4 Epidemiology of cardiovascular diseases world wide 
 
Cardiovascular disease (CVD) is the number one reason of death globally and is predictable to 
remain the leading cause of death. An approximate 17.5 million people died from 
cardiovascular disease in 2005, signifying 30 % of all global deaths. Of these deaths, 7.6 
million were due to heart attacks and 5.7 million were due to stroke. Around 80% of these 
deaths occurred in low and middle-income countries (LMIC). An approximate 20 million 
people will die from CVD every year, mainly from heart attacks and strokes if right action is 
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not taken, by 2015 http://www.who.int/cardiovascular_diseases/en/. Women will remain to 
experience excessively high mortality from CVD. By 2040, women in study countries (Russia, Brazil, 
India, China, and South Africa) will represent a higher proportion of CVD deaths in comparison to 
men. It was projected that by 2040 women in China to be 49.5 percent of the population, so even if 
death rates no higher than now apply then, they will represent 54.6 percent of CVD deaths. The 
increase of CVD deaths in Brazil and China among working-aged women between 2000 and 2040 will 
be higher than for men. Projections suggest that for Coronary heart disease (CHD), mortality for all 
developing countries will increase by 120 percent for women and 137 percent for men. Estimations for 
the next two decades enclose tripling of CHD and stroke mortality in Latin America, the Middle East, 
and even sub-Saharan Africa, a proportion of increase that surpasses that for any other region, except 
for Asian and Pacific Island countries. Contrarily, the increase in more-developed nations, largely 
attributable to a growth of the population of older people at risk, will range between 30 percent and 60 
percent (Yusuf et al., 2001a). The data available from the World Health Organization (WHO) 
MONICA Project indicate that the coronary event rate (per 100,000) in men was highest in Finland 
(North Karelia, 835) and lowest in China (Beijing, 81). For women the maximum occurrence rate was 
in the UK (Glasgow, Scotland, 265) and the lowest in Spain (Catalonia, 35) and China (Beijing, 35). 
These data revealed results from 35 MONICA Project populations that were collected during the mid-
1980s until the mid-1990s (WHO, World Health Report, 2002b). 
Data from the INTERHEART study (Yusuf et al., 2004) showed that rates of CVD have risen greatly 
in low-income and middle-income countries with about 80 percent of the burden occurring in these 
countries. Nine potentially modifiable risk factors associated with myocardial infarction (MI) were 
identified. These varied by populations. The ability to prevent the premature cases of MI needs to 
apply a right attitude. The effect of the risk factors is remarkably noticeable in young men (population 
attributable risks [PAR] 93 percent) and women (PAR 96 percent), demonstrating that most premature 
MI is avoidable. Two-thirds of the PAR of an acute MI worldwide is related to smoking and abnormal 
lipids (Yusuf et al., 2004). 
 High blood cholesterol is predicted to cause about 4.4 million deaths (7.9 percent of total) which sum 
up to 18 percent of strokes and 56 percent of global CHD (WHO World Health Report, 2002b). A 
blood cholesterol level of less than 5.0 millimoles per liter (mmol/L) is recommended for both primary 
and secondary prevention of CHD.  
Approximately 66 percent of men and women in the UK have blood cholesterol levels of 5.0mmol/L 
and above (http://www.americanheart.org/downloadable/heart/). Approximately 600 million 
people with high blood pressure (HBP) are at risk of heart attack, stroke, and cardiac failure, according 
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to data published by World Health Organisation (http://www.who.int/cardiovascular_diseases/en/).  
In African-Americans hypertension develops at much earlier age compared to whites. The 
cause for this differences may be due to a complex interchange between environmental 
response to diet, stress, and a potential genetic/physiological difference in sodium/potassium 
excretion (Yusuf et al.,2001b). A study of hypertension in Canada, the United States and in six 
European countries, (Germany, Finland, Sweden, England, Spain and Italy), showed the average blood 
pressure (BP) was 136/83 mmHg in the European countries and 127/77 mmHg in Canada and the 
United States, among men and women ages 35–74. BP measurements for all age groups were 
highest in Germany and lowest in the United States (Wolf-Maier et al., 2003). The measurement 
of blood pressure in England revealed that 34 percent of men and 30 percent of women have high 
blood pressure or are being treated for hypertension. The number of men and women not being treated 
for high blood pressure are 67 % and 78%, respectively. Of those being treated, just fewer than 60 
percent carry on been hypertensive (http://www.bhf.org.uk/professionals/index.asp). In Asia, a 
steep increase in stroke mortality goes together with a rapid rise in the prevalence of hypertension. 
Projections suggest that in China, hypertension will increase from 18.6 percent to 25 percent between 
1995 and 2025. In India, the equivalent figures are 16.3 percent to 19.4 percent 
(http://cpmcnet.columbia.edu/dept/ihn/faculty/pdf/race_against_time.pdf). 
 
1.6.5 Pathophysiology of diabetes and CVD in Indian populations 
 
Coronary heart disease (CHD) mortality is at least 40% higher in UK Indian Asians compared 
with European whites (Balarajan,1991, Balarajan,1995). Traditional coronary risk factors, 
including smoking, hypercholesterolemia, and hypertension, do not clarify their increased 
CHD risk compared with whites (McKeigue et al.,1993, McKeigue et al.,1991). While 
diabetes and insulin resistance are more common among Indian Asians (Mather et al.,1985, 
McKeigue et al.,1993),  the exact mechanisms underlying the increased CHD mortality in 
Indian Asians are not known.  
Myocardial infarction (MI) was seen to occur at a lower age in Indian population compared 
with the group population of countries to which they have migrated and mortality from MI 
was ten times higher (Misra,1999). Although insulin resistance may be involved in the early 
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event of risk factors and CHD in Indians, there is some data to suggest that other aspects of the 
lipid profile, such as the lipoprotein (a) (Lp[a]) level, affect risk in Indian patients (Gambhir et 
al.,2000). Lp(a) was an independent risk factor for CHD in type 2 diabetic  patients in South 
India (Mohan et al.,1998). 
Epidemiological studies have shown that South Asians also are more likely to have central 
obesity, increased waist/hip ratio (WHR), and glucose intolerance, compared with Caucasians 
(Hughes et al.,1997, Knight et al.,1992, McKeigue et al.,1991). Dhawan et al., (1994) looked 
at the prevalence of diabetes, hyperinsulinaemia, and associated metabolic abnormalities in 
immigrant Asians, Asians in India, and native white British men. They concluded that central 
obesity in the subgroups of Asians studied showed a close association with hyperinsulinaemia 
and the risk of coronary artery disease. In this group of Asians a tendency to insulin resistance 
and its metabolic abnormalities appears to be genetically determined, environmental changes 
after migration having only a small additional effect. Studies have shown that the distribution 
of adipose tissue appears not to be markedly different in Asian Indian compared to African-
American diabetic men or Swedish men when using comparable CT methods (Banerji et 
al.,1999). Visceral/total fat was 16.8% and 18.3% in Asian Indian and African American 
diabetic men, respectively (Banerji et al.,1997) and 19% and 18.4% in Asian Indian and 
Swedish men, respectively (Chowdhury et al.,1996). Contrary, anthropometry data such as 
BMI and WHR, indicated that migrant Asian Indians had lower overall obesity than 
Europeans, with a selective increase in central obesity (McKeigue et al.,1991).  
One hypothesis that could account for the high frequency of both type 2 diabetes and 
premature CHD in Asian Indians had been proposed by Chandalia et al., (1999). This 
hypothesis maintains that Asian Indians are more susceptible to the insulin resistance 
syndrome (McKeigue et al.,1989). The development of type 2 diabetes, which is an 
independent risk factor for CHD,  associated with prolonged insulin resistance (Lillioja et 
al.,1993). The other coronary risk factors e.g. dyslipidemia and hypertension go together with 
insulin resistance  (Haffner et al.,1988, Pyorala et al.,1985, Zavaroni et al.,1989). Ultimately, 
it is possible that insulin resistance affects CHD risk status via other mechanisms that are 
independent of the established risk factors. One of the most interesting observations of 
Chandalia et al., (1999) was a strong tendency for insulin resistance in lean Asian Indians. The 
latter were much more insulin resistant than lean Caucasians. While the curve of insulin 
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sensitivity against percent body fat was relatively steep in Caucasians, this was not the case in 
Asian Indians. In the latter group increasing adiposity was accompanied by some decrease in 
insulin sensitivity, but decrements were relatively small. This finding strongly suggests that 
Asian Indian men living in the United States have relatively low insulin sensitivity even when 
their body fat content is in the normal range. The mechanisms accountable for the low insulin 
sensitivity in Asian Indians, whether due to physical inactivity, dietary differences, or 
hereditary factors, continue to be determined (Chandalia et al.,1999). 
Asian Indian women had a higher rate of CHD than do other ethnic groups, despite similar 
conventional risk factors and lipid profiles. It may partly be explained by the differences in the 
prevalence of atherogenic HDL-C and low-density lipoprotein cholesterol (LDL-C) sizes and 
their subclass concentrations among Asian Indian women compared with Caucasian women 
(Bhalodkar et al.,2005). In a study conducted by Ranjith et al., in 2005 they examined 
differences in major cardiovascular risk factors and clinical outcome in South African Asian 
Indians of different age groups and gender, who presented with acute coronary syndromes. 
Diabetes mellitus (21%) and hypertension (18%) were seen less frequently in young patients 
but this was confined to men only. Total cholesterol was elevated in 65 to 70% of all patients 
while high-density lipoprotein (HDL) levels were significantly lower in men compared with 
women for all age subsets. Hospital mortality was extremely low in young (1%) and middle-
aged patients (2%), but was expectedly higher in older patients (8%; p < 0.0001). The most 
common familial vascular disease noticed in this study was a family history of CHD. Young 
patients had more aggressive disease, with 48% of those subjected to angiographic studies 
having triple vessel disease (TVD), and 14% undergoing coronary artery bypass grafting 
(CABG). 
In the study by Chambers et al.,(2001) the researchers investigated CRP concentrations in a 
representative sample of Indian Asian and European white men living in West London, UK. 
They found that CRP levels were elevated in Indian Asians and were closely associated with 
increased central adiposity and markers of insulin resistance in Asians compared with 
Europeans. There is some conflict-ridden data in regards to increased WHR and prevalence of 
diabetes in Asian Indians are controversial (Raji et al., 2001).  
 Central adiposity and high are common features that shared by Indian Asians overseas 
(McKeigue et al.,1991),  urban Indian Asians in India (Reddy et al.,1998), and Indian Asian 
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women (McKeigue et al.,1991), the findings of elevated CRP among Indian Asian men in 
West London are likely to be universal to other Indian Asian populations. The defined reasons 
underlying increased central obesity among Indian Asians compared with European whites are 
not known. The genetic factors in the first-degree relatives of Indian Asian CHD patients may 
play a major role in explanation of increased abdominal obesity in this racial group (Chambers 
et al.,2001). That is in agreement with the data that suggested that CRP concentrations may be 
influenced by genetic factors, although the molecular basis remains to be identified (Pankow et 
al.,2001). On the basis of the reported (Danesh et al.,2000) relationship between CRP and risk 
of CHD,  Chambers et al., (2001) estimated that increased CRP concentrations and/or the 
processes underlying elevated CRP are associated with an 14% increase in population CHD 
risk among Indian Asians compared with European whites. The extent of this effect on CHD 
risk is comparable to a rise in diastolic blood pressure of 5 mm Hg (van Den Hoogen et 
al.,2000)  or an increase in total cholesterol of 0.5mmol/L (Verschuren et al.,1995). Therefore, 
their results suggested that inflammation or enhanced cytokine production and/or their acute 
phase consequences may contribute significantly to the increased CHD mortality in Indian 
Asians. Study by Chambers et al., (2001) demonstrated that CRP concentrations were also 
closely associated with levels of HDL cholesterol, triglycerides, glucose, blood pressure, and a 
composite insulin resistance score in both racial groups. The similar data was reported in 
North American and European populations, which have additionally shown that CRP 
concentrations and other inflammatory markers, including white cell count and fibrinogen, are 
strongly correlated with plasma insulin and insulin-mediated glucose uptake (Festa et al.,2000, 
Frohlich et al.,2000, Hak et al.,1999).  
In a study by Mohan et al., (2005) it was established that CRP showed a strong association 
with coronary artery disease (CAD) and diabetes, even after adjusting for age and gender in an 
urban south Indian population. The association of body fat with diabetes seems to take place 
through hs-CRP. However, CRP didn’t appear to mediate the relationship between body fat 
and CAD. The relationship between CRP and dietary nutrients was investigated in young 
Asian Indians residing in a major metropolitan city in north India. Raised CRP levels (>3 
mg/L) were noted in 9% study subjects (8.6% males and 12.8% females).  
Saturated fat appear to be the single most important nutrient contributing to increase in serum 
CRP levels after adjustment for other covariates. The probability of having a raised CRP level 
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in subjects eat more than 10% energy as saturated dietary fat were twice that compared to 
subjects having a normal saturated fat intake (Arya et al.,2006). Elevated CRP levels in 
adolescents and young adults in Asian Indians in north India were observed in 21.8% of the 
overweight subjects and 24.5% of the subjects with high (>85th percentile) percentage body 
fat (%BF). Levels of CRP correlated significantly with body fat (%), WHR, biceps skinfolds 
and triceps skinfolds for males only. The findings of significant prevalence of elevated CRP 
levels in adolescents and young adults having increased generalized and abdominal adiposity 
may be important for the development of metabolic syndrome and atherosclerosis in Asian 
Indian adults (Vikram et al.,2003). 
 
1.6.6 Prevalence of diabetes and cardiovascular diseases in South Africa 
Indian population 
 
The Indian population of South Africa is composed of two so-called races, Dravidian and 
Aryan, having distinct cultural and anthropological characteristics. The major Indian 
languages spoken in South Africa are Tamil, Telegu, Hindi, Gujarati, and Urdu. The three 
main religions are Hindu, Muslim, and Christian. The dietary habits, body build, colour of 
skin, marriage and social customs, cultural activities, home dress, and place of origin in India 
are considerably different in these groups (Seedat, 1982). 
Walker (1973) felt that from the age of 5 years onwards the South African Indian population, 
which enjoys much better economic circumstances than the indigent rural population in India, 
did not have a life expectancy advantage over the latter population; the main causes of death 
had changed from infectious to degenerative diseases. The Indian population, a migrant Asian 
Indian group, in South Africa has a high rate of coronary artery disease. Important risk factors 
such as hypercholesterolemia, diabetes and smoking in men, and hypercholesterolemia and 
smoking in women were noted in a large survey of Indian subjects in South Africa (Seedat et 
al.,1990). In another large study by Sewdarsen et al., (1991) fasting serum lipid and 
lipoprotein levels were measured in 620 consecutive male survivors of myocardial infarction 
and compared with those of 524 healthy male volunteer controls. Hypercholesterolemia and 
  
80
hypertriglyceridaemia were present in the patient group and was associated with other non-
lipid coronary risk factors. Hypercholesterolemia with or without associated 
hypertriglyceridaemia was the widely found abnormality: 125 (25%) patients showed 
hypercholesterolemia without associated hypertriglyceridaemia; 73 (12%) had both 
hypercholesterolemia and hypertriglyceridaemia and 89 (14%) had hypertriglyceridaemia 
without associated hypercholesterolemia. Obesity was significantly more common among 
hypertriglyceridaemic survivors, whereas diabetes and hypertension were seen more common 
in survivors with combined hypercholesterolemia and hypertriglyceridaemia. Among 
hyperlipidemic and normolipidaemic patients it was no significant difference in the degree of 
smoking and family history of coronary artery disease. 
South African Indians have been found to have a high prevalence of type 2 diabetes (13%), 
with the prevalence of IGT being 6.9% (Omar et al., 1985, Omar et al., 1994). A 4-year 
prospective study showed that IGT in this population is associated with a strikingly high risk 
of progression to type 2 diabetes (50.4%; rate of progression 12.6%/year) (Motala et al., 
1993). From a cross-sectional analysis of the insulin response during an oral glucose tolerance 
test (OGTT), IGT in the South African Indian population was characterized by β-cell 
dysfunction (diminished early-phase insulin response and delayed hyperinsulinemia), which 
was also present in the transient IGT group (Motala et al., 1997). 
In a survey, conducted to find the prevalence of coronary heart disease risk factors in a sub-
group of young Indian patients (< or = 45 years) who presented to the Coronary Care Unit at 
the R. K. Khan Hospital in Durban the most prevalent risk factors were: previous smoking 
(74%), and hypertriglyceridaemia (54%). Women constitute only 14% of the population that 
presented with an acute MI. Smoking was more common among men (81%) than in women 
(35%). Abnormal HDL cholesterol levels were detected in 43% and 9%, in men and women, 
respectively, showing a great gender difference. Hypertension was more common in young 
women with MI than in men, 38% and 19%, respectively. There was a strong familial link, 
54% of the patients had a family background of coronary heart disease (CHD) while 42% and 
41% had family members who suffered from diabetes mellitus and hypertension, respectively 
(Ranjith et al.,2002). 
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1.6.7 Prevalence of diabetes and cardiovascular diseases in South African 
Black population 
 
According to South African Department of Statistics death due to diabetes mellitus (3%) and 
ischaemic heart disease (2.4%) were among the ten leading underlying natural causes of death 
in 2003-2004 (http://www.statssa.gov.za). The Medical Research Council of South Africa 
(Bradshaw et al., 2003) has also published data showing that cardiovascular disease and 
diabetes mellitus are the second and tenth leading causes of death, respectively in South 
Africa. The possible explanations of these findings include availability and low cost of 
unhealthy food, and the use of labour-saving mechanical devices, which have greatly 
influenced excess calorie intake and decreased energy expenditure. The data from 
epidemiological studies have indicated that the prevalence of certain obesity-related disorders 
varies between black and white urban women in South Africa: mortality from ischaemic heart 
disease is very rare in black South Africans (8/100 000 vs. 55/100 000) (Isles and Milne, 
1987), whilst hypertension (30% vs. 15%) (Seedat, 1983) and type 2 diabetes (7.0% vs. 3.6%) 
(Joffe and Seftel, 1994a) are more prevalent in black South Africans. It appears that at this 
stage of the epidemiological and nutrition development in Africa, hypertension, stroke, and 
type 2 diabetes mellitus are becoming major public health problems (Bourne et al., 2002, 
Vorster, 2002), but that Africans are “protected” against CHD, possibly because of low total 
cholesterol levels and a high level of high-density lipoprotein cholesterol (Okesina et al., 1999, 
Vorster, 2002). 
The Heart of Soweto Study recorded data for 4162 patients with confirmed cases of 
cardiovascular disease (1593 newly diagnosed and 2569 previously diagnosed and under 
treatment) from Jan 1 to Dec 31, 2006, who attended the cardiology unit at the Chris Hani 
Baragwanath Hospital in Soweto, South Africa. Most patients were black Africans and the 
study population contained more women than men. Heart failure was the most universal 
primary diagnosis (704 cases, 44% of total). Moderate to severe systolic dysfunction was 
apparent in 415 (53%) of 844 identified cases of heart failure, 577 (68%) of which were 
attributable to dilated cardiomyopathy or hypertensive heart disease, or both. The investigators 
reported that on presentation, many patients had evidence of advanced disease and of the 844 
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patients diagnosed with heart failure, 31% of these had class III or IV heart failure according 
to the New York Heart Association (NYHA) functional classification system (Sliwa et al., 
2008). 
At King Edward VIII Hospital in Durban from 1955 to 1980 CHD was diagnosed in 30% of 
Indian but only 2.7% of black patients admitted with cardiovascular disease. However, 
clinicians have noted that the incidence of CHD is progressively rising in the black population, 
and is likely to rise further as risk factor prevalences are altered by changes in lifestyle, 
westernisation, and migration to an urban or peri-urban environment (Seedat et al., 1992). 
Type 2 diabetes is most prevalent in the South African Indian population followed by the 
African and then the white population. This trend mirrors the levels of insulin resistance, with 
the Indian population being the most resistant and the white population the most insulin 
sensitive. Although Africans are more insulin resistant than the white population, their level of 
visceral fat is lower suggesting either that visceral fat plays no role in insulin resistant or, is 
more diabetogenic in African than white subjects (van der Merwe et al., 2000, Ferris et al., 
2005). 
Some urban and rural studies have shown that in South African black women obesity does not 
necessarily accompany hypertension, diabetes or hyperlipidaemia (Walker et al., 1989, Walker 
et al., 1991). In contrast, Omar and colleagues (1993) found that black women with diabetes 
did have a higher body mass index (BMI) than women without diabetes. Waist circumference 
could highly predict type 2 diabetes mellitus and to cluster with cardiovascular risk factors in 
subjects of mixed ancestry (Levitt et al., 1999b, Charlton et al., 2001a). 
INTERHEART, an international, standardized, case-control study conducted in 52 countries, 
was designed to assess the association of CVD risk factors and acute myocardial infarction 
(AMI) (Rosengren et al.,2004, Yusuf et al.,2004). These relationships were investigated in the 
African population and in three ethnic subgroups (black, colored, and European/other 
Africans) and compared with those found in the overall INTERHEART study. The data from 
INTERHEART Africa study was the first to show that that only five risk factors account for 
89.2% of the risk for an initial myocardial infarction. These factors include current/former 
tobacco smoking, self-reported hypertension and diabetes, abdominal obesity measured as the 
WHR, and lipoprotein ApoB/ApoA-1 ratio. This data confirmed that people from Africa who 
are exposed to known major CVD risk factors are at risk to develop AMI, as are other people 
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across the globe (Yusuf et al.,2004). The INTERHEART data showed heterogeneity in 
relation to the magnitude of the risk for AMI for the level of education and income among the 
three ethnic groups. These variations reflect that the three ethnic groups are at different points 
of the epidemiological transition and therefore the development of the CVD epidemic 
(Gillum,1996). During this study it was found that the low numbers of acute myocardial 
infarction cases were recruited among black Africans, particularly outside of South Africa.  
In a recent publication by Kalk et al., (2007) it was pointed out that the  prevalence of CHD in 
the African diabetic population is much lower than in the White diabetic population of South 
Africa, 4.0 and 23.0 %, respectively. Although the lower frequency of CHD among the 
diabetic Africans was observed in this study, a substantial proportion, about 25%, were at high 
risk for CHD in the following decade, as estimated from the prevalence of traditional risk 
factors, which, however, may undervalue the risk in diabetic populations (McEwan et al., 
2004, Kalk et al., 2007). This suggests that in the less-developed areas of sub-Saharan Africa, 
AMI in black Africans may still be relatively rare, and in these countries the black African 
population may be at an even earlier stage of the epidemiological development than those in 
South Africa. However, with growing urbanization and economic growth, the rates may 
increase and resemble those seen in South Africa (Steyn et al.,2005). 
 
1.7 Nutrition and diseases of lifestyle 
 
The adverse effects on human health are the results of quicken development of civilization 
(mainly industrialization, urbanization and nutrition). A gathering of problems named as 
'civilization diseases' has become the focus of serious apprehension but review of available 
data indicates that this notion appears to add very little to our understanding of modern 
environmental effects on human health (Trnovec et al., 2001). While the primary reason of the 
obesity epidemic is still uncertain, the enormous pressures on energy balance provided by the 
modern environment and lifestyle remain the most reasonable explanation (Zheng et al., 
2007).  
The eating behaviour in modern society is characterized by the consumption of high-energy-
density diets and often-unstructured feeding patterns, largely detached from seasonal cycles of 
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food availability. The privileged groups in economically emerging and developing nations 
have generally similar patterns of eating (Ulijaszek, 2002). Worldwide marketing and the 
methodical moulding of taste by giant corporations is a central characteristic of the 
globalization of the food industry (Barnett et al.,1994). 
A recent survey in the USA found that only 38% of meals were home-made and that many 
people had never cooked a meal from basic ingredients (Gardner et al.,2000); an average 
restaurant meal supplies 1000–2000 kcal, i.e. up to 100% of the suggested daily intake for 
most adults, and the sizes of servings are mounting (Jacobsen et al.,2000). Additionally, there 
is a greater trend to snack between meals. In the United Kingdom, 75% of adults and 91% of 
children devour a snack food at least once a day. Such conduct is promoted from a young age: 
there are fast food restaurants in many schools in the USA, and soft drink vending machines 
are increasingly found in schools globally (Chopra et al.,2002). 
 
 
1.7.1 Fatty acids, diabetes, and cardiovascular disease 
 
The number of published data supports cardioprotective effects, beyond those that can be 
attributed to improvements in blood lipoprotein profiles, to the foods rich in ω-3 
polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA). The main valuable effects include a reduction in sudden death (Albert et al.,1998, 
Siscovick et al.,1995), decreased risk of arrhythmia (Kang et al.,1994),  lower plasma 
triglyceride levels (Harris,1997), and a reduced blood-clotting tendency (Agren et al.,1997, 
Mori et al.,1997). There is some evidence from epidemiological studies that α-linolenic acid 
(omega-3 fatty acid) reduces risk of myocardial infarction (Guallar  et al.,1999) and fatal 
ischemic heart disease in women (Hu  et al.,1999a). Several randomized controlled trials have 
recently demonstrated beneficial effects of both α-linolenic acid (de Lorgeril  et al.,1999) and 
marine ω-3 fatty acids (GISSI- Prevenzione Investigators,1999, Singh  et al.,1997, Von 
Schacky et al.,1999) on both coronary morbidity and mortality in patients with coronary 
disease. The food supply of ω-3 fatty acids can be found in fish, especially fatty fish such as 
salmon, as well as plant sources such as flaxseed and flaxseed oil, canola oil, soybean oil, 
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and nuts. The recommended two servings of fish per week could grant cardioprotective effects. 
Further studies are needed to agree on optimal doses of ω-3 fatty acids (including EPA, DHA, 
and α-linolenic acid) for both primary and secondary prevention of coronary disease as well as 
the treatment of hypertriglyceridemia (Krauss  et al.,2000).   
It has been recognized that dietary trans-unsaturated fatty acids can increase LDL cholesterol 
and reduce HDL cholesterol (Judd et al.,1994, Lichtenstein et al.,1999). Trans fatty acids 
found mainly in hydrogenated vegetable oils have a tendency to raise cholesterol levels 
relative to their non-hydrogenated counterparts (ASCN/AIN,1996, Report of the Expert 
Panel,1995). This increase seems to be less than take place with similar amounts of saturated 
animal fat or highly saturated vegetable oils, e.g., coconut and palm kernel oils. Some studies 
that used plasma or tissue levels of  trans fatty acids as a measure of intake proposed that CHD 
risk is correlated with trans fatty acids derived from animal products, but not with those from 
hydrogenation of oils (Wahle et al.,1993). Besides, there is no clear dose-response effect for 
trans fatty acid intake and CHD risk. Based on this limited information, the American Heart 
Association (AHA) recommends limiting trans fatty acid intake, for example, by substituting 
soft margarine for hard. The AHA also supports the food industry to create more products with 
reduced trans fatty acid content (Krauss et al., 1996). 
The attention given to dietary medium-chain fatty acids (MCFAs) is due to their ability to be 
more readily absorbed from dietary medium-chain triacylglycerols (MCTs) than are long-
chain fatty acids from, for example, vegetable oils. It has generally been declared that MCFAs 
do not increase plasma cholesterol, even though this claim is poorly documented. However, a 
study by Cater et al (1997) showed that, in comparison with oleic acid, MCTs have a 
cholesterol-increasing potential one-half of that of palmitic acid in mildly 
hypercholesterolemic  middle-aged men, which corroborates results reported in the 1960s 
(Hashim et al.,1960, Roels et al.,1962). MCTs increase plasma triacylglycerol in contrast to 
long-chain triacylglycerols (LCTs) (Uzawa  et al.,1964, Hill  et al.,1990). A recent study by 
Tholstrup et al.,(2004) found that an intake of 70 g MCT oil/d for 21day increased total 
cholesterol, LDL-cholesterol, triacylglycerol, and glucose concentrations by, 11%, 12%, 22%, 
and 4%, respectively, relative to an equivalent intake of high-oleic sunflower oil. There is thus 
some unease concerning the cardiovascular effects of MCTs. It was suggested that 
combination of plant sterols with MCT oil could possible avert undesirable cardiovascular 
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effects (St-Onge  et al.,2003c). It has been shown that when this combination is consumed, 
total and LDL-cholesterol concentrations are lower than those observed after LCTs 
consumption (St-Onge et al.,2003a, Bourque et al.,2003). 
Groups of investigators have examined whether the composition of dietary FAs, as opposed to 
total fat consumption, can modulate insulin sensitivity and cardiovascular risk factors (Hu et 
al., 2001, Rivellese et al., 2002). Some epidemiological studies demonstrated that high intake 
of total and saturated fat is associated with insulin resistance, and this relationship may be 
dependent on increased body adiposity (Mayer-Davis et al., 1997). Conversely, multiple cross-
sectional studies have found that intake of both saturated and trans FAs is correlated with 
hyperinsulinemia and with risk of type 2 diabetes, independent of general obesity (Maron et 
al., 1991, Marshall et al., 1997, Parker et al., 1993).  
High intake of polyunsaturated FAs (PUFAs) does not look to have the same adverse effects 
and could even result in an increase in insulin sensitivity (Salmeron et al., 2001). For instance, 
Summers et al. (2002) studied the effect of substituting dietary saturated fat with 
polyunsaturated fat on insulin sensitivity in healthy, obese, and type 2 diabetic subjects. Their 
results confirmed that an isocaloric diet enriched in polyunsaturated fat resulted in both an 
increase in insulin sensitivity measured by glucose clamp and a lowering of LDL cholesterol 
when compared with a diet rich in saturated FAs. Then again, it was not achievable in this 
study to conclude whether it was the increase in dietary PUFA or the decrease in saturated fat 
that created the relative benefits in the PUFA diet subgroup. Moreover, diets enriched in 
polyunsaturated fat have not reliably been shown to improve insulin sensitivity (Mayer et al., 
1993), and long-term intervention trials have not been carrying out. Inconsistency in the short-
term studies are often imputable to the lapse to control for dietary FA [e.g. amount of 
monounsaturated FAs (MUFA)] and carbohydrate composition, total calories, physical 
activity, and population characteristics such as age, gender, and adiposity (Lara-Castro et al., 
2004). Favourable results of a high-MUFA diet on glycemic control in type 2 diabetes have 
been confirmed in a meta-analysis of randomized trials using isoenergetic high-MUFA diets 
(Garg,1998). “Short-term intervention studies in healthy volunteers have shown that the 
isocaloric substitution of MUFA for saturated fat (Perez-Jimenez et al., 2001), or even 
substituting MUFA for carbohydrates, can have positive effects on insulin sensitivity” 
(Thomsen et al.,1999). Comparable findings were obtained in a 3-month trial that assessed 
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insulin sensitivity in healthy volunteers receiving diets varying in FA composition (ω-3 PUFA 
vs. MUFA vs. saturated fat). Significant increases in insulin sensitivity were achieved in the 
MUFA-enriched diet. This effect was larger when the total amount of fat was modest (<37% of 
calories) (Lara-Castro et al.,2004). 
 
1.7.2 Fibre-rich foods 
 
A number of longitudinal observational studies have described significant reverse associations 
between total fibre intake and both cardiovascular and all causes of mortality (Kromhout et 
al.,1982, Morris et al.,1977). Partly this occurrence may suggest the accompanying reverse 
association that is often observed between fibre and fat intake when calories are controlled 
(Anderson  et al.,1992). In the Zutphen Study (Kromhout et al.,1982), men in the lowest 
quintile of dietary fibre intake exhibited a four times higher rate of CHD mortality compared 
with men in the highest quintile, even though total caloric intake was about the same. The rate 
of CHD mortality was reported to be inversely associated with fibre intake across 20 
industrialized nations, but adjustment for fat intake removed the association (Liu  et al.,1979). 
Likewise a 20-year cohort study of 1001 middle-aged men in Ireland and Boston described 
significant inverse association between fibre intake and risk of CHD, but the association 
reduced when other risk factors were controlled (Kushi  et al.,1985). The 12 year study of 859 
men and women aged 50 to 79 years, showed that a 6-g increment in daily fibre intake was 
correlated with a 25% reduction in ischemic heart disease mortality, independent of calories, 
fat, and other dietary variables (Khaw  et al.,1987). In addition, various soluble fibres (e.g., oat 
products, psyllium, pectin, and guar gum) lower LDL cholesterol, mainly in 
hypercholesterolemic individuals. In one meta-analysis study it was concluded that for every 
gram increase in soluble fibre from these sources, LDL cholesterol would be expected to 
decrease by an average of 2.2 mg/dl (Brown et al.,1999). Higher intakes of fibre from oats and 
buckwheat could lower serum cholesterol and blood pressure levels as was reported in a study 
among 850 men in the Yi province of China (He et al.,1995). The mechanism by which fibre 
lowers blood cholesterol remains undefined. Evidence suggests that some soluble fibres bind 
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bile acids or cholesterol during the intraluminal formation of micelles (Anderson et al.,1986). 
As a result, decrease in the cholesterol content of liver cells leads to an up-regulation of the 
LDL receptors and thus increased clearance of LDL cholesterol, but increased bile acid 
excretion may not be adequate to account for the observed cholesterol reduction (Brown et al., 
1999). Other recommended mechanisms include inhibition of hepatic fatty acid synthesis by 
products of fermentation (production of short-chain fatty acids such as acetate, butyrate, 
propionate) (Nishina et al.,1990); changes in intestinal motility (Schneeman et al.,1985); fibres 
with high viscosity causing slowed absorption of macronutrients, leading to increased insulin 
sensitivity; and increased satiety, leading to lower overall energy intake (Brown et al., 1999). 
  
 
1.7.3 Homocysteine, folate, vitamins B6, B12, D, Coronary Artery Disease 
and Insulin Sensitivity 
 
The effects folic acid and vitamins B6 and B12 have on the metabolism of homocysteine 
aroused interest in these vitamins. Elevated homocysteine in plasma has a strong 
epidemiological association with Coronary Artery Disease (CAD), peripheral vascular, and 
cerebrovascular disease (Boushey et al.,1995). Similar with other vitamin supplements, no 
clinical trials have been conducted to investigate if there is a clinical benefit to reduced 
homocysteine levels via increased intake of folic acid, B6, or B12 (Krauss et al.,1996). 
Homocysteine is a sulphydryl-containing amino acid produced from demethylation of dietary 
methionine. The link between increased concentrations of homocysteine with vascular disease 
is independent of other risk factors and is consistent across many studies. Reduction in plasma 
homocysteine levels could be achieved by dietary supplements of folic acid and B vitamins 
(Maxwell, 2000).  
The B-Vitamin Treatment Trialists' Collaboration (2006) evaluated the design and statistical 
power of 12 randomized trials measuring the effects of lowering homocysteine with B-vitamin 
supplements on risk of cardiovascular disease. It was concluded that the individual trials may 
not have engaged a sufficient number of vascular events or have remained long enough to have 
a good chance on their own to identify reliably plausible effects of homocysteine lowering on 
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cardiovascular disease risk, but the combined analysis of these trials should have sufficient 
power to determine whether lowering homocysteine reduces the risk of cardiovascular events 
within a few years (Traber, 2007).  
The normal metabolism of homocysteine demands a sufficient supply of folate, vitamin B6 
vitamin B12, and riboflavin. Levels of these vitamins show an inverse relationship with those 
of circulating homocysteine. The association between these vitamins and vascular diseases has 
thus also come under enquiry (Pancharuniti et al.,1994). Increased coronary disease risk and 
fatal coronary artery disease have been correlated with lower folate levels. Lower levels of 
vitamin B6 also present an increased risk of atherosclerotic vascular disease in case-control 
and prospective studies. The risk of atherosclerosis associated with lower levels of vitamin B6 
is independent of high homocysteine concentrations. Vitamin B12 deficiency is not associated 
with vascular disease (Krauss et al., 2000). 
A number of studies had describe a negative relationship between various anthropometric 
measures and intake of vitamin D or circulating concentrations of vitamin D has been reported 
by a number of studies (Kamycheva   et al., 2003,  Parikh et al., 2004). Data regarding 
association of hypovitaminosis D with insulin sensitivity is relatively constraint compared to 
available data for the effect of hypovitaminosis D on ß cell function. In study of a group of 34 
men that included 7 subjects with diabetes a positive correlation was found between serum 
25(OH) D concentration and insulin sensitivity (Lind et al., 1995). The serum 25(OH) D 
concentration was negatively correlated with fasting insulin concentration, 1-h and 2-h insulin 
concentrations, and insulin area under the curve in 134 elderly nondiabetic men, independent 
of BMI, skinfold thickness, alcohol, smoking, and physical activity (Baynes et al., 1997). 
These results indicated a positive association of 25 (OH) D concentrations with insulin 
sensitivity. In patients with type 2 diabetes addition of vitamin D to their diet reduced serum 
free fatty acids levels suggesting an improvement in insulin sensitivity (Inomata et al., 1986).  
The data published by Chiu and co-workers, (2004) did show a positive correlation of 25(OH) 
D concentrations with insulin sensitivity and a negative effect of hypovitaminosis D on ß cell 
function. Subjects with low levels of vitamin D could be at higher risk of insulin resistance 
and the metabolic syndrome. Further studies will be required to explore the underlying 
mechanisms. 
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1.7.4 Antioxidants 
 
The positive role that the major antioxidant nutrients vitamin E and vitamin C, and beta-
carotene may have in prevention of several chronic disorders was confirmed in a number of 
epidemiological studies (Diplock et al., 1998). Vitamin E is the combined name for a set of 
eight related tocopherols and tocotrienols and function as a chain-breaking antioxidant, 
preventing further lipid peroxidation. Of these, α-Tocopherol has been most studied as it has 
the highest bioavailability. α-Tocopherol has the highest bioavailability and has been 
researched most extensively. α-Tocopherol inhibits some of the cellular functions that may 
transform heart attack risk via mechanisms mediated by protein kinase C. α-Tocopherol 
supplementation also decreases monocyte superoxide production through inhibition of protein 
kinase C. α-Tocopherol mediates nitric oxide production in endothelial cells. Vitamin E is 
depleted in humans during oxidative stress. Plasma vitamin E concentrations depleted much 
slower in non-smokers than in cigarette smokers as a result of their increased oxidative stress 
(Traber, 2007). The disparity in vitamin E levels were acquired by the Alpha-Tocopherol, Beta 
Carotene Cancer Prevention Study with a low-dose vitamin E supplementation (50 mg/d) and 
the Cambridge Heart Antioxidant Study (400-800 mg/d). The data from GISSI-Prevenzione 
(300 mg/d) and HOPE (400 mg/d) trials indicated the absence of relevant clinical effects of 
vitamin E on the risk of cardiovascular events (Marchioli et al., 2001).  
The recommended intake of vitamin E of 1000 mg/d is without risk, because vitamin E has 
very low toxicity. Large intake of beta-carotene must be viewed with caution because it has 
been shown to be detrimental to a population at high risk of lung cancer when administered 
after many years of high risk (smoking) behaviour (Diplock et al., 1998). Clinical trials with 
beta-carotene supplements have been inadequate, and therefore their use as a preventive 
intervention for cancer and coronary heart disease should be discouraged (Marchioli et al., 
2001). 
A number of dietary factors, such as trace elements, including selenium, copper, zinc, and 
manganese are proposed to act as antioxidants and have been recommended to protect against 
coronary heart disease. Some of them function as cofactors for enzymes with antioxidant 
activity (e.g., glutathione peroxidase and superoxide dismutase) (Tribble, 1999). Antioxidant 
  
91
dietary intake had shown in some studies to have a positive effects on cardiovascular disease 
which may be attributed to other chemicals present in foods, such as flavonoids (Cherubini et 
al., 2005). 
 
1.7.5 Carbohydrates 
 
The long-term usefulness and safety of the diets restricted in carbohydrate but high in protein 
and fat are not known, despite their popularity over some period of time(Golay  et al.,1996b). 
The relative achievement of diets severely restricted in carbohydrate calories over the first few 
days may be due to water losses (Fisler  et al.,1987). The reduction in weight over weeks to 
months associates to reductions in total energy intake, which are possible in part to be a 
consequence of the ketosis that accompanies carbohydrate restriction (Cahill  Jr.,1976).  
There are a number of safety issues during the active phases of weight reduction include 
mineral, electrolyte (Fisler et al.,1987), and vitamin deficiencies, whereas the continued 
consumption of a diet high in fat and protein and low in carbohydrate during the maintenance 
period may result in an atherogenic lipoprotein profile and reductions in renal function and 
skeletal mass (Larosa et al.,1980). Also, the relative absence of other major constituents of a 
healthy diet such as fruits, vegetables, milk products, legumes, and whole-grain products raises 
concerns about adequacy of micronutrient intake (Krauss et al.,2000). The type of 
carbohydrate consumed is now also being seen as relevant to the development of obesity. Diets 
rich in complex carbohydrates or "fibre" (i.e., nonstarch polysaccharide) are protective 
(Howarth  et al.,2001), whereas energy-dense diets, as well as drinks that are rich in refined 
sugars, promote weight gain (Yao et al.,2001). 
Samaha and co-workers, (2003) found that severely obese subjects with a high prevalence of 
diabetes and the metabolic syndrome lost more weight in a six-month period on a 
carbohydrate-restricted diet than on a fat- and calorie-restricted diet. The higher decline in 
overall caloric intake could contribute to greater weight loss in the low-carbohydrate group 
preferably than a direct effect of macronutrient composition.  
In subjects who reduced more than 5 percent of their initial weight on the carbohydrate-
restricted diet the improvements in insulin sensitivity were independent of weight loss and a 
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greater reduction in triglyceride levels. These findings must be interpreted with care, however, 
since the extent of the overall weight loss relative to the subjects severe obesity was small, and 
it is unclear whether these benefits of a carbohydrate-restricted diet extend beyond six months. 
No harmful effects on other serum lipid levels were found. The black subjects had a lesser 
overall weight loss compared to the white subjects. The researchers suggested that future 
studies should explore whether greater weight loss in this population can be achieved by more 
effective incorporation of culturally sensitive dietary counselling (Samaha et al.,2003). 
 
 
1.7.6 Proteins 
 
Most Americans consume protein in surplus of their needs (McDowell et al.,1994, National 
Research Council.Food and Nutrition Board, 1989). Since extra protein is not properly utilized 
by the body it provides a burden for its degradation. Moreover, meat protein is the most 
expensive source of calories in the food budget. Protein foods from animal sources (with the 
exemption of low-fat and non-fat dairy products) are in general higher in fat, saturated fat, and 
cholesterol. In general nutrient adequacy, long-term palatability, and maintenance of the diet 
become major worries with the diets high in protein and limited carbohydrates. An average of 
15% total energy or ≈50 to 100 g/d should be adequate to meet most needs while there are 
many conditions in which extra protein may be needed such as growth, pregnancy, lactation, 
and some disease states (Goff et al., 1995). In the epidemiological Nurses' Health Study a 
positive health advantage from a high protein intake was observed. Women in the highest 
protein intake group had a 26% lower rate of cardiovascular disease compared to women in the 
lowest protein intake group (Hu et. al.,1999b). 
Clinical intervention studies have presented reliable evidence that an ad libitum high-protein 
diet from mixed sources in free-living overweight people increases the amount of weight lost 
in a 6-month weight-loss program (by 3.8 kg) compared with a high-carbohydrate diet by 
enhancing satiety (Skov et al.,1999). Additionally, weight-loss studies in overweight women 
have shown that diets with a high ratio of protein to carbohydrate have positive effects on 
markers of disease risk, including body composition, blood lipids, and glucose homeostasis, 
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and that these benefits may be arbitrated to a degree by the effect of protein on satiety and by a 
lower glycemic load because of a lower carbohydrate intake (Layman et al.,2003a, Layman et 
al.,2003b). Insulin sensitivity may be enhanced by inevitable loss of lean body mass during 
weight loss on a higher protein intake (Baba et al.,1999, Piatti et al.,1994),  while this has not 
been observed at very low energy intakes (Vazquez et al.,1995). Subjects with insulin 
resistance or type 2 diabetes, that been overweight, showed fat loss by 1-2 kg over 12 weeks 
when using a high-protein weight-loss diet (28–30% of energy from protein) from mixed 
sources. It was particularly noticeable in women with an isocaloric high-carbohydrate weight-
loss diet (Farnsworth et al.,2003, Parker et al.,2002).  
It is recognized that different protein sources have different effects on the release of insulin 
(Gannon et al.,1988, Westphal et al.,1990), and this may be important to the mechanism of 
action of both the enhanced satiety  and the differential fat loss (Latner et al.,1999). Some 
fears have been raised out regarding the effect of high-protein diets on serum lipids and 
subsequent cardiovascular disease risk since foods and dietary patterns high in protein may 
vary in saturated fat and nutritional composition. There is some proof that high-protein diets 
increase calcium excretion and increase bone loss, which particularly needs clarification 
(Kerstetter et al.,1999). The study by Noakes et al.,(2005) showed similar reductions in 
creatinine clearance with both dietary patterns as a consequence of body mass change. These 
results call off the main concerns that diets high in meat protein may have deleterious effects 
on renal function and bone turnover. A excess of protein in the system also increases urinary 
calcium loss, which may facilitate osteoporosis (Barzel et al.,1998). 
 
1.7.7 Effect of dietary calcium and calcium supplements on body weight 
 
Calcium homeostasis is essential to a large number of physiological processes in the body. 
Previous epidemiological and experimental data have suggested that increasing dietary 
calcium accelerated weight and fat loss secondary to energy restriction, with a substantially 
greater effect exerted by dietary (dairy) sources of calcium when compared with a 
supplemental (calcium carbonate) source (Andersen et al.,1986, Fleming et al.,1994, Lind et 
al.,1993, McCarron et al.,1984). 
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A study by Cummings et al.,(2004) showed that calcium acutely stimulated postprandial fat 
oxidation and suppressed carbohydrate oxidation. The effects over the 6 h postprandial period 
were very similar in regards to dairy or non-dairy calcium meals. The subjective sensations of 
hunger and satiety after food intake have not been affected by high dairy calcium and vitamin 
D diet, but  spontaneous food intake over the subsequent 24h period was significantly 
suppressed, as stated by Ping-Delfos et al.,(2004). 
High calcium diets suppress calcitriol levels, which result in reduced lipogenesis and increases 
in lipolysis, uncoupling protein 2 expression, and adipocyte apoptosis (Shi et al.,2002, Sun et 
al.,2004a, Zemel,2004), thereby reducing lipid filling and adiposity (Shi et al.,2001a, Sun et 
al.,2004b). However, these information do not present an explanation for the substantially 
greater effects observed with dairy vs. supplemental sources of calcium (Zemel et al.,2005a).  
It was suggested by Zemel et al., (2005b), that suboptimal dairy and calcium intakes may 
contribute to increased total and central adiposity and obesity in already-obese African-
American adults. Suboptimal dairy and calcium intake may also intervene with successful 
weight and fat loss during energy restriction. These data are consistent with their other’s 
earlier studies (Zemel et al.,2004). 
Recently it was shown that 1,25-dihydroxyvitamin D stimulates 11ß-HSD-1 expression and 
cortisol production in human adipocytes (Morris et al.,2005, Zemel et al.,2003). Given that 
high calcium diets suppress 1,25-dihydroxyvitamin D levels, the authors proposed that loss of 
central adiposity on high dairy diets my be attributable, in part, to suppression of 1,25-
dihydroxyvitamin D levels and a consequent reduction in cortisol production by visceral 
adipocytes (Zemel et al.,2005a).  
Animal studies and epidemiological studies have suggested that calcium supplementation 
(with Ca++ supplements or dairy products) may be associated with weight loss in human 
adults. However, Trowman and colleagues, (2006) in their systematic review and subsequent 
meta-analysis included a total of thirteen randomized controlled trials and found no 
association between the increased consumption of either Ca++ supplements or dairy products 
and weight loss after adjusting for differences in baseline weights between the control and 
intervention groups (Trowman et al.,2006). 
The review by Barr (2003) of randomized trials of increased dairy product or calcium intake 
obtained little evidence to support the hypothesis that calcium or other components of dairy 
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products have a measurable impact on body weight in generally healthy humans. Significantly 
greater weight loss in the calcium-supplemented group was found in merely one of 17 
randomized trials of calcium supplementation (Recker et al.,1996), and it could be contended 
that this is close to what would be expected on the basis of chance alone (Barr, 2003). 
The relation between dairy intake and incidence of insulin resistance syndrome (IRS) was 
examined in the Coronary Artery Risk Development in Young adults (CARDIA) study. As a 
result of this study the researchers found that dairy consumption was inversely associated with 
the incidence of all IRS components among overweight individuals but not among leaner 
individuals. Each daily occasion of dairy consumption was associated with 21% lower odds of 
IRS and was similar for blacks and whites and for men and women. The association between 
dairy intake and IRS could not be explained by other dietary factors, including macronutrients 
and micronutrients (Pereira et al.,2002). 
 
1.7.8 Dietary salt and its affects on blood pressure 
 
The majority of available data indicates that a high intake of salt negatively affects blood 
pressure. As summarized in a recent AHA advisory (Kotchen  et al.,1998), such data include 
results from observational studies of diet and blood pressure and clinical trials of reduced salt 
intake. Meta-analyses of randomized trials have shown that on average, reducing sodium 
intake by ≈80 mmol (1.8 g)/d is correlated with systolic and diastolic blood pressure reductions 
of ≈4 and 2 mm Hg in hypertensive and lesser reductions in normotensive subjects (Cutler et 
al.,1997, Graudal et al.,1998). The blood pressure response to variations in salt intake differs 
among individuals, in part because of genetic factors (Hunt  et al.,1998)  and other host factors 
such as age (Law  et al.,1991).  
In the Dietary Approaches to Stop Hypertension (DASH) study, a healthy diet termed the 
DASH combination diet substantially reduced blood pressure in both nonhypertensive and 
hypertensive individuals (Appel et al.,1997, Svetkey et al.,1999). This dietary guide highlights 
fruits and vegetables (5 to 9 servings per day) and low-fat dairy products (2 to 4 servings per 
day). The diet was rich in potassium, magnesium, and calcium. The reduction in systolic and 
diastolic blood pressure by 3.5 and 2.1 mm Hg, respectively, was observed among 
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nonhypertensive individuals. Resultant blood pressure reductions in hypertensive were 
striking: 11.4 and 5.5 in persons with stage 1 hypertension. Black Americans had greater blood 
pressure reductions than did non-black Americans (Svetkey et al.,1999).   
The reduced risk of stroke have been linked to the diets rich in potassium (Ascherio et 
al.,1999). In order to asses whether reduction in sodium intake levels and an increase in 
potassium intake levels are critical components of blood pressure (BP) control Maseko et al., 
(2006) studied the relationship between hypertension awareness and treatment, and 24- hour 
urinary sodium and potassium excretion rates in urban, developing communities in South 
Africa. Their study showed that hypertension awareness and treatment were not associated 
with electrolyte excretion rates either when considered alone or after adjusting for age, gender, 
body mass index, alcohol and tobacco intake, the presence of diabetes mellitus and the type of 
antihypertensive therapy (multivariate regression analysis).  
In addition, the proportion of patients who were vigilant of their hypertension, were receiving 
treatment for it, and who had 24-hour sodium intake values above the RDA for sodium intake 
(80%) was similar to the proportion noted in those who were unaware of their hypertension 
(73%), and to normotensives (84%). They proposed that the lack of relationship between 
either hypertension awareness and treatment, and sodium and potassium intake levels suggests 
that current recommendations for a reduced sodium and increased potassium intake in 
hypertensives do not translate into clinical practice in urban, developing communities of South 
Africa (Maseko et al., 2006). 
In another study Charlton et al.,(2005a) investigated whether habitual intakes of sodium 
(Na++), potassium, magnesium, and calcium vary across South African ethnic groups and to 
assess whether the blood pressure-cation association differs according to ethnic status. Ethnic 
differences in calcium intake were apparent, with black subjects having particularly low 
intakes. The differences with respect to sources of dietary Na++ were obvious, with more than 
70% of total non-discretionary Na++ being provided by bread and cereals in rural black South 
Africans compared with 49% to 54% in urban dwellers.   
All ethnic groups had Na++ intakes in excess of 6 g/d of salt, whereas potassium intakes in all 
groups were below the recommended level of 90 mM/d. White normotensive subjects had 
significantly higher median urinary sodium concentrations compared to normotensive black 
and mixed-ancestry subjects, however no differences were found between white and black 
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hypertensive subjects. Mixed-ancestry normotensive subjects had a lower urinary potassium 
excretion than white normotensive subjects, but no other ethnic differences were found. 
Urinary calcium levels in both normotensive and hypertensive individuals were significantly 
different between all three groups. Black subjects had nearly less than half of those of white 
subjects. No differences were found in urinary magnesium excretion across ethnic groups. The 
authors concluded that dietary differences may contribute to ethnically related differences in 
blood pressure (Charlton et al.,2005b). The considerably high dietary intake of potassium, 
magnesium, and calcium comes from food sources and diets rich in these minerals provide a 
variety of other nutrients it recommended to increase mineral intake through foods rather than 
supplements. Women who need to meet current guidelines for osteoporosis prevention or 
treatment calcium supplement should be implemented (Krauss  et al.,2000). 
 
1.7.9 Genetics influences in nutrition 
 
The application of genomic knowledge to adjust population-based dietary recommendations is 
not without threat since gene-diet interactions are complex and poorly understood. 
Identification of genetic variation that happened as an effect of diet as a selective pressure 
helps to identify gene alleles that have an effect on nutrient utilization.  Any genetic variation 
that presents an unusual nutritional requirement will almost certainly be conflicting with life 
and early development and consequently not viable. Fascinatingly, polymorphisms for the 
aldolase B enzyme, which metabolizes fructose, have been discovered (Esposito et al., 2002b). 
The gene for this enzyme is extremely polymorphic, but until recently, many of these 
polymorphisms were regarded as silent. Polymorphisms presented as disease alleles only when 
fructose was added in high quantities to the food supply as a sweetener. This is a situation 
where a transformation in environment has threatened a normally silent allele to the degree 
that it begins to present as a disease allele (Stover, 2006). 
Some recent findings indicate a vital role for genetic susceptibility to the insulin resistance 
syndrome and dyslipidaemia. Development and progression of these diseases largely 
associated with nutrition. Genetic background may reciprocate with regular dietary fat 
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composition, affecting predisposition to the insulin resistance syndrome and individual 
responsiveness to changes in dietary fat intake (Lopez-Miranda et al., 2007). Both omega-6 
and omega-3 fatty acids control gene expression. Omega-6 fatty acids do not have these same 
anti-inflammatory effects as does omega-3 fatty acids. Since inflammation is at the base of 
many chronic diseases, dietary intake of omega-3 fatty acids it is very important particularly in 
persons with genetic variation, as for example in individuals with genetic variants at the 5-
lipoxygenase (Simopoulos, 2006). Genetic effects have been recognized for plasma lipoprotein 
reactions to dietary fatty acids, cholesterol, and fibre; blood pressure responses to sodium; and 
homocysteine responses to folic acid. Furthermore, there is increasing evidence, mainly from 
animal models, for the roles of specific genes in influencing susceptibility to diet-induced 
obesity (Krauss  et al.,2000). 
 
 
1.7.10 Prevention strategies and nutrition recommendations 
 
In a number of studies of primary and secondary prevention of coronary artery disease it was 
clearly recognised the gains of therapies intended to reduce levels of total and LDL 
cholesterol. It was recommended that individuals with LDL cholesterol levels that are higher 
than current National Cholesterol Education Program (NCEP) marks for primary or secondary 
prevention decrease their intake of dietary saturated fat and cholesterol to levels below those 
recommended for the general population (NCEP,1994). The upper limit for such individuals is 
<7% of total energy for saturated fat and <200 mg of cholesterol per day and the lower intake 
levels in both cases could be of further benefit in reducing LDL cholesterol levels.    
The American Heart Association (AHA, 1988) does not specifically advocate proportionate 
reduction in other types of fat, however diets that are very low in saturated fat may also be 
very low in total fat (<15% of energy). In recent years much attention was given to 
monosaturated fatty acids as an appropriate substitute for saturated fatty acids. Whilst their 
final outcome on serum lipids and lipoproteins is not much different from that of 
polyunsaturated fatty acids they may have some advantages (Dreon et al.,1990, Ginsberg et 
al.,1990, Grundy  et al.,1990, Mensink et al.,1989, Mensink et al.,1992). 
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Unlike polyunsaturated, monounsaturated fats are not as susceptible to oxidation, which may 
play a role in atherogenesis. As a result the AHA recommends a monounsaturated fatty acid 
intake in the range of 10% to 15% of total calories (NCEP,1994). Diets with very low total fat 
intake have been tested with favourable results in studies of persons at high risk, but such diets 
have not been demonstrated to be of value for the general population and may have adverse 
consequences, including potential nutrient deficiencies in certain subgroups such as children, 
pregnant women, and the elderly (Gould  et al.,1995, Ornish  et al.,1990, Schaefer et al.,1995). 
For this reason, the AHA supports the recommendation of the World Health Organization for 
a lower limit of 15% of calories as total fat (Food and Agriculture Organization.,1994.). 
Additionally, the AHA recommends that for the general population, the level of fat intake in 
the diet should be guided by emphasis on adequate consumption of fruits, vegetables, and 
grains; a healthy weight goal; and dietary intake of saturated fatty acids and cholesterol 
appropriate to individual risk for CHD. The AHA highlights restraint of saturated fatty acid 
intake because this is the strongest dietary determinant of plasma LDL cholesterol levels 
(Hegsted  et al.,1965). The AHA recommendation is to increase fibre intake in the diet 
(Vanhorn ,1997).  This goal can be achieved by an emphasis on consumption of vegetables, 
cereals, grains, and fruits. Although there are studies showing that specific fibre supplements 
are associated with lowered LDL or glucose, there are no long-term trials showing relations 
between these supplements and cardiovascular disease. Therefore, at this time, fibre 
supplements are not recommended for heart disease risk reduction. Diets high in unrefined 
carbohydrates also incline to be high in both soluble and insoluble fibre. The decrease in 
plasma total and LDL cholesterol levels as part of a fat-modified diet can be achieved by 
consumption of the foods rich in soluble fibre, including oats, barley, beans, soy products, guar 
gum, and pectin found in apples, cranberries, currants, and gooseberries (Bell  et al.,1990, 
Ripsin  et al.,1992, Whyte   et al.,1992). Total dietary fibre intake of 25 to 30 g/d from foods, 
not supplements, will make certain an eating pattern high in complex carbohydrates and low in 
fat.  
There is general understanding in the scientific community that salt restriction can improve 
blood pressure in hypertensive individuals, but there are no clear data that allow definition of a 
desirable upper limit for salt intake. The average of sodium chloride intake in the United 
States could range from 7.5 to 10.0 g/d. The AHA has chosen to support the recommendation 
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of the US Dietary Guideline Committee to limit sodium chloride intake to 6 g/d. There was no 
increase in cardiovascular risk or raise blood pressure in normotensive persons without other 
cardiovascular risk factors with slightly higher intakes (6.0 to 7.5 g/d).  The recommended 
guideline is an admittedly subjective recommendation for avoiding excessive salt intake 
instead than an attempt to impose low salt intake (Krauss  et al.,1996). Sodium chloride 
restriction in hypertensive persons was conducted in therapeutic trials and provided some 
evidence of modest but significant reductions in blood pressure (Australian National Health 
and Medical Research Council, 1989, Cutler  et al.,1991, Midgley  et al.,1996). However, 
there is significant variation among blood pressure responses to sodium chloride restriction, 
and there is no simple, reliable test to accurately predict salt sensitivity. 
The number of issues should be addressed to reverse dietary trends in obesogenic environment 
by public education and clear food labelling. The reduction in serum cholesterol levels and 
number of deaths from coronary heart disease was significantly reduced in Finland and 
Norway when they changed the high-fat, energy-dense diets consumed by their populations 
(Norum,1997, Puska et al.,1995). Introduction of a national intervention programme in 
Singapore has decreased the levels of some cardiovascular risk factors and of childhood 
obesity (Cutter et al.,2001). Mauritius organized a comprehensive programme that has reduced 
mean serum cholesterol levels, hypertension, smoking, and heavy alcohol use. The program 
involves the use of the mass media, pricing policy, widespread educational activity in the 
community, workplaces and schools, and other legislative and fiscal measures (Dowse et 
al.,1995). But, the resources of countries to formulate comprehensive interventions of this 
kind are increasingly limited by the norms and trade laws associated with globalization. A 
medical model approach has been the major concept in prevention strategies. The 
identification of various risks and risky behaviour and, as a result, identification of individuals 
at greatest risk should be included in this model. The International Heart Foundation has 
concentrated on the need for individuals to eat less fat and salt. However, this tactic disregards 
the repeated and expensive failures to change diets solely through the improvement of 
knowledge (Beaglehole, 2001). 
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1.7.11 Weight management programs 
 
To reach and maintain a healthy body weight it need to rely on strategies that self-sufficient of 
the expected or healthy body weight to be attained. Weight gain comes with aging, specifically 
between the ages of 25 and 44 years (Williamson et al.,1990), and independently related to 
development of coronary heart disease (Willett et al.,1995) and stroke (Rexrode et al.,1997). 
The exact definitions of weight gain persists to be uncertain with some authors suggesting 
limits of >2.27 kg (St Jeor  et al.,1997)  and <5 kg (Rexrode  et al.,1997). The balance 
between energy intake and energy expenditure need to be maintain to reach a successful 
weight management in children and adults. The improvement in blood lipids levels, blood 
pressure and reduction in a risk for heart disease, stroke, and certain cancers may accompany 
loss of excess weight and long-term maintenance of a healthy weight (Stunkard,1996).  
In many individuals with increased abdominal or visceral fat, even moderate weight reduction 
may result in improvement in many metabolic CHD risk factors, mostly those associated with 
insulin resistance, including low HDL level, elevated triglyceride level, and small dense LDL 
(Blackburn,1995; Goldstein,1992). Physical activity in combination with a diet low in calories, 
especially those coming from fat, and to a certain extent rich in complex carbohydrates and 
fibre should be encouraged to maintain a long term healthy body weight (Blair,1993, 
Grilo,1994). 
 
1.7.12 Physical Activity 
 
National Academy of Sciences, (2002) issued the dietary reference intake (DRI) report that 
targets a daily caloric intake based on the amount of physical activity performed by an 
individual. The DRI report recommends that total energy expended be at least 1.6–1.7 times an 
individual’s resting energy expenditure in order to maintain body weight in the ideal range 
(body mass index of 18.5–25 kg/m2), as well as decrease the risk of cardiovascular disease.  
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Physical activity is an essential management strategy for weight reduction (Stefanick et 
al.,1998), preservation of the reduced state (Doucet et al.,1999, McGuire et al.,1999), and 
prevention of weight gain (US Department of Health and Human Services,1996). To maintain 
physical and cardiovascular fitness it is essential to have a regular physical activity. In the 
beginning, for sedentary individuals, engaging in a moderate level of physical activity, such as 
intermittent walking for 30 to 45 minutes, is recommended (Pate et al.,1995). It may also be 
helpful to concentrate on reduction in sedentary time such as time spent watching television. 
Approximately 33% of African-American men and 43% of women report no leisure time 
physical activity compared with 25% and 28% among white American men and women, 
respectively (Yusuf et al.,2001b). 
The NCEP encourages moderate physical activity contributing to ∼ 837 kJ/day (200 kcal/day) 
of total energy expenditure. Regular exercise as a way to improve insulin sensitivity, to acutely 
lower blood glucose levels, and to improve cardiovascular status is highly recommended by 
ADA (Franz, 2003). Then again, exercise by itself has only a modest effect on weight 
(Bouchard  et al.,1993) but is essential for the long-term maintenance of weight loss (Pavlou et 
al.,1989, Maggio et al.,1997). Therefore, exercise is a useful addition to other weight loss 
strategies and is most helpful in weight maintenance. 
 
1.7.13 Nutritional status of South African population 
 
South Africa is in a state of nutrition transition and as with other societies this is reflected in 
the emergence of obesity, sometimes in conjunction with protein malnutrition. The event like 
these may be articulated differently in a multi-ethnic society with its major ethnic groups 
(Blacks, Whites, Coloureds and Indians) and diverse socio-economic status (Benadé et 
al.,1996). Not much is known about the effect of urbanization on nutritional status of South 
Africans. In KwaZulu-Natal, Margo et al. (1978) found a higher incidence of nutritional 
anaemia in urban children from a “city slum” area than in rural control children. Byarugaba 
(1991) examined the effect of urbanization on the health of black preschool children in the 
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Umtata district in the Eastern Cape. Urbanization was associated with several risk factors for 
under-nutrition, such as increased poverty, overcrowding, decreased availability of clean 
water, diarrhoea, less breastfeeding and the replacement of “mother-care” with “maid-care”. In 
this study, urbanization was associated with less underweight and stunting, but with more 
wasting (acute malnutrition). 
A comparison of fat and carbohydrate proportions of energy intake for adults aged 15-64 
years, with that of black ‘adults’ (age range not provided) from the city of Johannesburg in 
1940 shows a relative 10.9 % reduction of carbohydrate (from 69.3 % to 61.7 % of energy in 
1990) and an increase of 59.7 % in fat intake (from 16.4 % to 26.2% of energy in 1990) over 
50-year period (Bourne et al.,2002). The complexity of the effects of urbanization on 
nutritional status is further demonstrated by Bourne et al. (1993) who showed in the BRISK 
study (n=983 adult Africans, aged 15-64 years from the Cape Peninsula) that although the 
subjects followed a prudent diet regarding fat and carbohydrate intake, their diet was low in 
fibre, vitamins and minerals. Urbanization, and especially migration of men from rural areas to 
earn money in urban areas, has led to broken homes and destitution with consequent 
malnutrition in the rural areas (Westcott et al.,1977). 
A cross-sectional analytical study by Charlton et al. (1997) was undertaken to investigate the 
macronutrient intake and cardiovascular risk factor profile of community-dwelling older 
coloured (mixed descent) South Africans. A randomly drawn sample of 200 subjects aged 65 
years and above, residing in Cape Town was studied. The mean daily energy intake was 7984 
kJ and 6979 kJ for men and women, respectively. The recommended energy intakes were less 
than two-thirds in 29% of the subjects. Dietary fat intake comprised 32.4% of total energy 
intake, which is in line with the prudent dietary guidelines. The insufficient fibre intake (mean 
= 17(8) g/day) was accredited to the low consumption of fruit and vegetables. There are only a 
few regional, cross-sectional studies that have attempted to quantify physical activity patterns 
in representative samples of South Africans who are undergoing transition. In two large cross-
sectional studies of risk factors in urban black communities in the Western Cape Province, 30-
40% of men and women reported being inactive or minimally active in their work or leisure 
time (Levitt  et al.,1993, Steyn  et al.,1991). Furthermore, in a sample (n=980) from a peri-
urban community of the Western Cape, lack of physical activity was a significant risk factor 
for type 2 diabetes (relative risk =1.67) (Levitt et al.,1999b). In the past when indigenous 
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populations followed a traditional lifestyle, diabetes was virtually absent, as observed in 
Tanzania (McLarty  et al.,1990). 
 
 
1.8 Aims and objectives of the study 
 
 
It is known that type 2 diabetes and ischaemic heart disease (IHD) are more common amongst 
Indian communities that have emigrated from the Indian subcontinent to Great Britain 
(McKeigue et al.,1991) and South Africa (Omar et al.,1994, Walker et al.,1993) than amongst 
the non-migrant population. Thus, environmental factors such as diet and socio-economic 
status may be involved in the pathophysiology of these diseases in the Indian population 
residing in South Africa. 
Studies carried out in our unit have shown that visceral fat area (Punyadeera et al.,2001a) and 
total triglyceride concentration (AUC) during a 7-hour OGTT are both higher in White than 
Black South African obese women. This may explain the well known rarity of IHD within the 
Black South African population (Walker et al.,1993). Higher fasting cortisol levels have also 
been observed in White obese women in comparison to Black obese women (Punyadeera et 
al.,2001b) and this may contribute to the higher visceral fat levels of the former group.  
We initiated this study to elucidate the possible role of metabolic factors such as cortisol, lipid 
and free fatty acid levels (FFA), and body composition, diet and socio-economic factors in the 
pathogenesis of obesity-related disorders in two ethnic groups of the South African 
population, namely Indian and African. This will allow us to identify modifiable risk factors 
associated with the development of metabolic syndrome and type 2 diabetes. No studies have 
been able to establish a clear relationship between abdominal obesity, insulin resistance and 
disease prevalence in Indian and African populations.  
In the present study African and Indian subjects were investigated because of the much higher 
prevalence of CVD and type 2 diabetes in the latter group. Female subjects were studied 
because obesity is far more common in South African females than males (Puoane et al., 
2002). The hypothesis to be tested in this thesis is that ethnic differences in metabolism in 
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conjunction with environmental factors such as diet and socio-economic status explain the 
higher prevalence rates of obesity-related disorders in the South African Indian compared to 
the African population. 
 
The objectives of the present study were as follows: 
 
1. To assess the body fat distribution in both ethnic groups & to determine how it 
influences glucose & lipid metabolism.  
2. To assess the role of anthropometric, metabolic and hormonal factors in determining 
insulin resistance in each ethnic group. 
3. To compare the aetiology of type 2 diabetes between the two ethnic groups, 
particularly with reference to beta cell function and insulin resistance.  
4. To examine the relationship of anthropometric and metabolic indices with blood 
pressure, in each ethnic group. 
5. To ascertain the role adipokines play in the aetiology of insulin resistance in each 
ethnic group. 
6. To determine the impact of socio-economic and dietary status on intermediary 
metabolism in each ethnic group. 
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CHAPTER 2 - STUDY DESIGN AND METHODS 
 
2.1 Subjects selection 
 
The study population consisted of two groups of women one Indian and one African. Subjects 
were subdivided into lean, obese and overweight groups, according to WHO criteria (2000b). 
Each ethnic group included: 
• 20 lean (BMI<25) women   
• 20 obese (BMI>30) women   
• 20 obese type 2 diabetic patients 
• 10 overweight (BMI 25-29.9) women   
They all volunteered for the extended 5 hours oral glucose tolerance test (OGTT). All 
participants were recruited from an urban population of women residing in the Greater 
Johannesburg area, via word-of-mouth, newspaper advertisements & flyers distributed 
throughout Johannesburg hospital and major community centres.  
Selection criteria included: age (35-60), ethnicity (Indian or African) and diabetes status.  
An exclusion criterion was the presence of any metabolic or endocrine disorder and these 
patients were not included in our study. Those excluded from the study were:   
• 1 women with Crohn’s disease,  
• 4 women with hyperthyroidism  
• 4 women with polycystic ovarian syndrome  
Diabetic patients were disqualified from the study if they were receiving insulin treatment. 
The OGTT identified diabetes (WHO,1999) in five women from the obese Indian group and 
two from the obese African group. We advised them of their condition and they were referred 
to a diabetic clinic or to their family practitioner. The newly diagnosed diabetic patients from 
the original obese groups were moved to the diabetic obese group, and new patients were 
recruited into the obese groups. Patients having abnormal clinical or laboratory findings were 
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referred for future medical attention to their respective clinician. Each participant completed 
questionnaires relating their health history, physical activity, food intake, and socioeconomic 
status. 
This study protocol was approved by the Human Ethics Committee of the University of 
Witwatersrand, Faculty of Health Sciences, clearance number: M970618 (Appendix 1). The 
participants were required to sign an informed consent, explaining purpose, procedures, risks, 
and benefits of the study. 
 
2.2 Oral glucose tolerance test 
 
Diabetic patients were instructed to stop the intake of oral hypoglycaemic tablets 24 hours 
before the onset of the study. Twenty four-hours prior to the study the subjects were asked to 
refrain from strenuous physical exercise, smoking, alcoholic beverages, oral metabolic agents, 
(i.e. oral contraceptives, β-blockers, glucocorticoids, nicotinic acid and thiazides), and other 
drugs that might have influenced lipid or carbohydrate metabolism.  
Supine blood pressure was measured at the onset of the test using a sphygmomanometer 
(GURR, Surgical Instruments (Pty.) LTD. Johannesburg, South Africa). Blood samples were 
obtained in the morning after a 10-11 hour overnight fast. An intravenous needle was inserted 
into the antecubital vein of the forearm and normal saline (0.9% NaCl) was infused slowly 
into the line to maintain flow. The forearm was covered with a heating blanket. Only water 
was permitted during the investigation. Each subject was given a standard OGTT consisting of 
75g glucose (according to the WHO criteria, 1985) in 200ml of water over a 2 min period.  
A study of South African women of African and White origin was conducted previously in our 
department. Ethnic differences in glucose, lactate, insulin, C-peptide, des 31, 32 proinsulin and 
FFA levels were observed between 2 + 5 hours during an extended 7 hour OGTT and for this 
reason we decided to use an extended 5 hour OGTT in the present study. Throughout this 
period subjects were under the supervision of qualified nurses. 
During 5 hour OGTT blood samples were collected from each subject into 10 ml. Vacutest red 
top tubes (for serum collection), in 5 ml. grey top tubes with sodium fluoride and potassium 
oxalate anticoagulant (for glucose and lactate measurements) and in 5 ml. purple top 
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EDTA tubes (for HbA1c measurement). Samples were centrifuged for 10minutes at 2500 rpm 
and the serum/plasma transferred in aliquots to 5 ml. plastic tubes.  
Samples were assayed immediately for glucose, lactate, HbA1c, cortisol and lipids; otherwise 
they were stored at -20ºC until necessary /required. Fasting blood samples were drawn for the 
measurement of HbA1c, full lipid profile, leptin and soluble leptin receptor, TNFα, IL-6 and 
CRP concentrations. Blood samples for glucose, lactate, glycerol, insulin, proinsulin, C-
peptide and FFA were collected at baseline, 30, 60, 90, 120, 180, 240 and 300 minutes during 
a 5-hour OGTT. Samples for cortisol assay were collected at baseline, 30, 60, 90 and 120 
minutes. Most of the laboratory investigations (insulin, total proinsulin, intact proinsulin, C-
peptide, FFA, leptin, leptin receptor, IL-6 and TNF-α) were performed by the candidate. The 
other tests (HbA1c, glucose, lactate, hs-CRP, lipid profiles and glycerol) were performed in the 
routine laboratory in the Department of Chemical Pathology. The biochemical investigations 
are described in the Appendix 2. All assays were performed according to principles of good 
laboratory practice using intra-laboratory and external quality control samples.  
 
2.3 Anthropometric measurements 
 
2.3.1 Weight and height 
 
In the present study the volunteers were weighed using an electronic calibrated weighing scale 
(Modern scale Co. (Pty) Ltd., Johannesburg, South Africa). Shoes were removed and the 
subject’s height was measured to the nearest 0.5 cm with a wall-mounted stadiometer. 
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2.3.2 Waist /Hip ratio (WHR) 
 
Measurements of waist and hip circumferences were based on skeletal reference points as 
advocated by World Health Organization guidelines (1988b). To determine WHR, the waist 
circumference was measured as the midpoint between the lower rib margin and the iliac crest 
and the hip circumference was measured as the widest circumference over the great 
trochanters (Van Der Kooy et al., 1993). WHR has been the most widely used index of 
abdominal obesity in epidemiological studies, because it is easy to measure (Taskinen, 1993). 
With increasing obesity the accuracy in WHR measurement to assess visceral fat declines. 
Severe pitfalls of this measurement have been recognized (Despres et al., 1991, Busetto et 
al.,1992). The WHR is greatly influenced by obesity and it cannot be properly used to estimate 
visceral adiposity, particularly in obese women. Some data suggest that waist circumference 
might be preferential to WHR for assessment of visceral obesity (Taskinen, 1993). 
 
2.3.3 Body Mass index (BMI) 
 
The prevalence of overweight and obesity is usually determined by using BMI, defined as the 
weight in kilograms divided by the square of the height in metres (kg/m2). A BMI of 20 kg/m2 
to 25 kg/m2 is defined as normal. A BMI of 25 kg/m2 to 29.9 is defined as overweight and a 
BMI of over 29.9 kg /m2 as obese (WHO, 2000b). This cut-off points were derived primarily 
in European populations to correspond to risk thresholds for a wide range of chronic diseases 
and mortality (WHO, 1998). Nevertheless, there is ongoing discussion as to whether these 
criteria for obesity and overweight are suitable for non-European populations. Data from 
Razak et al., (2007) study supported the belief that "normal ranges" for obesity using BMI cut 
points derived in European populations may be misleading when applied to populations such 
as South Asians, Chinese, and Aboriginals. In a number of studies the use of BMI as a marker 
of body fat and metabolic abnormalities in different ethnic groups indicated that percentage 
body fat was higher for a given BMI in South Asians (Lear et al., 2007). To our knowledge 
there is no recommended cut-off points for the classification of obesity using BMI, WHR or 
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WC in Black or Indian population from South Africa and further investigation are needed to 
establish these anthropometric indices to apply to the latter groups.  
BMI is limited in its prediction of correct body fat for a given individual for a number of 
reasons: Overweight may or may not be due to increases in body fat. It may also be due to an 
increase in lean muscle. A large build person heavy in muscle relative to height can give a 
BMI in the obese range and yet not be obese. Professional athletes may be qualifying as 
‘overweight’ due to their large muscle mass, but under no circumstances could they be 
regarded as fat regardless of BMI. Likewise, BMI will categorize individuals with a small 
build mass relative to their height, as being underweight. Individuals with short legs in relation 
to their upper body height, have a higher BMI. BMI is itself not a direct measure of fatness. It 
is only a generalized measure of proportional weight (Brozek, 1963). 
 
2.3.4 Body composition analysis: tetrapolar bioelectrical impedance 
 
BODYSTAT® 1500 is the registered trademark of BODYSTAT (Isle of Man) LIMITED and 
was used to measure body composition. 
 
2.3.4.1 Principle of the BODYSTAT 1500 unit 
 
BODYSTAT 1500 unit operates on a principle that is based on Bioelectrical Impedance 
Analysis (BIA). The principle of this technique is that the body’s lean compartment, 
comprising approximately 73% of electrolytic water, conducts electricity far better than the 
body’s fat compartment, which is very low in body water content (between 5-10%). These two 
compartments have very different impedance to a high frequency electrical current. Water is a 
good conductor of electricity and the less fluid in the body the higher therefore the resistance 
factor in the body. A tiny torch-battery operated electrical current is sent via the supine body 
via electrodes attached to the right foot and hand. During the procedure the impedance value, 
which is associated to that subject’s body fat and lean mass, is registered on the BODYSTAT 
1500 LCD display screen. This number, collectively with the other details of age, height, 
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weight, and gender are used by the regression equations to analyse the data and within seconds 
produces a personal body composition analysis. 
 
2.3.4.2 Preparing subject for measurement 
 
Height and weight was accurately determined. The subject removed the right shoe and sock or 
stocking, and lay flat with the arms and legs spread slightly as shown in the diagram (Fig. 2.1). 
NO parts of the body were touching one another. 
 
 
 
 
 
Figure 2.1 Subject position (Brozek et. al.,1963) 
 
 
2.3.4.3 Placement of electrodes and leads 
 
The BODYSTAT 1500 has two sets of main leads that are then divided into a red and black 
lead. It was important to ensure that the red (injecting) leads were connected to the electrodes 
just behind the finger and toe as shown in the illustration (Fig 2.2). The black (measuring) 
leads were then connected to the electrodes on the right wrist and right ankle. 
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RIGHT HAND  
                                             Black  Red 
BLACK LEAD: On the wrist next to the ulnar head 
RED LEAD: Behind the knuckle of the middle finger 
 
RIGHT FOOT  
                                          Black          Red 
 
 
Figure 2.2 Placement of the electrodes 
BLACK LEAD: On the ankle at the level of and between the medial and lateral malleoli (the large 
protruding bones on the sides of the ankle)  
RED LEAD: Behind the second toe next to the big toe 
 
2.3.4.4 Calculation of the basal metabolic rate (BMR) 
 
Energy expenditure will be affected by the nature and level of physical activity, body 
composition, age and gender. The BMR predictive equation used by the BODYSTAT 1500 
unit is the Brozek and Grande formula (1963): 
Percentage of body fat = 457/D - 414.2, where D = body density in units of gm/cm3. 
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This is based on the measured lean weight of a subject and not on total body weight. Lean 
weight is identified as everything that is not fat and, as such, includes the skeleton, muscles, 
viscera (brain, heart, liver, intestines) and total body water content. Fat-free mass represents a 
key determinant of the energy expenditure (Nelson et al., 1992). 
 
2.3.4.5 Estimated average (Energy) Requirement (E.A.R.) 
 
To estimate the total daily energy expenditure level of a person, an assessment of the average 
activity level during a 24-hour period should be made when entering the data in the 
BODYSTAT 1500 unit. This can only be a subjective assessment as detailed in table 2.1. 
Activity level was graded from 1 to 5 (from very low to very high) for statistical analysis. 
 
Table 2.1 Activity level (Brozek  et. al.,1963) 
 
 
 
 
Level of Activity General 
Very Low - Movement Restricted Generally inactive 
Low/Medium - Office/Light Work Recreational activities for short duration and at 
low intensity 
Medium - Weekend Recreation Sporadic involvement in recreation activities for 
short duration and at moderate intensity 
Medium/High - Moderate Exercise Moderate job activity and moderate exercise 3 
times per week 
Very High - Vigorous Exercise at 
Competitive Level 
Consistent job activity and vigorous exercise 4 
times per week 
  
114
 
 
2.3.5 Computerised axial tomography (CT-Scan) 
 
2.3.5.1 Scan parameters and position of a patient 
 
Subcutaneous and visceral fat were measured using CT Toshiba X Vision scanner (Tokyo, 
Japan). This scanner is a whole-body computed tomography system, which is designed to 
acquire transverse image data from any region of the body for diagnostic purposes.  
The scan parameters were as follow: 
• 10 mm slice thickness; 120 kV; 250 mAs and 1.5s 
• 34-480 mm field of view (FOV), depending on the size of the patient. 
• The area of subcutaneous fat and visceral fat were clearly defined with CT density in 
the range of -130 to -30 Hounsfield units. 
The patient remained in a supine position when CT images were taken. Subcutaneous 
adiposity was measured using CT-Scan at 4 levels i.e. the umbilicus, L4/5 lumbar disc, widest 
diameter of the pelvis, and mid-thigh (calculated as the total distance from the iliac crest to the 
knee joint, divided by 2). These measurements were derived from two scanograms. The first 
scanogram included the umbilicus (marked with a metallic coin), iliac crest and symphysis 
pubis. The second scanogram extended from the symphysis pubis to the knees (Punyadeera et 
al., 2001a). The total subcutaneous fat area was calculated as a mean ± SEM from the four 
slices (Fig.2.3). Upper body subcutaneous fat was calculated as a mean ± SEM of the CT-scan 
measurements at the top two levels, i.e. umbilicus and iliac crest. Lower body subcutaneous 
fat was calculated as a mean ± SEM of the CT-scan measurements at the bottom two levels, 
i.e. symphysis pubis and mid-thigh. Abdominal visceral fat was the mean of measurements at 
level 1 (umbilicus) and level 2 (iliac crest). The areas of subcutaneous and visceral fat 
(Fig.2.4) were calculated separately using the anatomical boundaries as described by Kvist et 
al., (1986). 
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2.3.5.2 Region of Interest (ROI) Calculation 
 
Areas, averages, standard deviations, and other data that can be extracted from a ROI is 
automatically calculated and then displayed. The following lists some of the major features of 
the system related to ROI calculation: 
• up to a maximum of 10 ROIs can be displayed on the monitor 
• the shape of the previous rectangular or circular ROI can be reused 
• the CT data of the point indicated by the cursor can be displayed 
• the display of statistical calculation results can be vertically scrolled 
• a free ROI can be rotated and moved 
• a polygonal ROI can be rotated, moved, changed in size/shape, and made into a 
curvilinear one. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
116
 
 
 
          
         Figure 2.3 CT Scan image of measument areas  levels   
         1-Umbilicus; 2- Iliac crest; 3- Symphysis pubis; 4- Mid-thigh  
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     Subcutaneous Fat                                                     Visceral Fat 
 
Figure 2.4 CT-Scan image of subcutaneous and visceral fat in area between 
umbilicus and iliac crest   
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2.4 Evaluation of β-cell function and hepatic insulin extraction 
 
2.4.1 Evaluation of β-cell secretory ability 
 
The formula known as insulinogenic index (Kadowaki et al., 1984) was used to calculate 
pancreatic β-cell secretory ability 
∆I30 / ∆G30 = (I30 - I0) / (G30 - G0) 
Where: 
I0 = Insulin levels at fasting 
I30 = Insulin levels at 30 minutes post 75 g oral glucose load 
G0 = Glucose levels at fasting 
G30 =Glucose levels at 30 minutes post 75 g oral glucose load 
 
Several studies have documented that insulinogenic index is a more accurate method for 
assessing β-cell activity than the HOMA-derived method and is the best method for assessing 
first-phase insulin secretion (Wareham et al., 1995 Phillips et al., 1994b). 
 
2.4.2 Calculation of area-under- the- curve (AUC) 
 
To calculate total concentrations of glucose, lactate, insulin, total proinsulin, intact proinsulin, 
des-31, 32 proinsulin, C-peptide and free fatty acids during the 5-hour OGTT the trapezoidal 
rule was used to approximate the area under a curve (AUC). This method, which has sensitive 
application, consists of connecting points on the concentration-time curve with straight-line 
segments and then using the area under this polygon to approximate the actual area under the 
curve. It is named the trapezoid method since each segment of the polygon is a trapezoid. The 
total sum of these individual areas represents the total area under the curve to assess the 
overall secretion over a specific time period. 
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The area under the curve was calculated by using the formula illustrated bellow:   
AUC= ((V1+V2)/2) x (t2-t1)) + ((V2+V3)/2) x (t3-t2)) +…. + ((V8+V7)/2) x (t8-t7))   
Where: V1=baseline concentration; t1= baseline time; V2 = unit concentration at specified 
time (t2); t2 = time at the specified unit concentration (V2). 
 
2.4.3 Calculation of insulin resistance via homeostatic model analysis 
(HOMA) 
 
Insulin resistance was measured using the Homeostasis Model of Insulin Resistance, known as 
the HOMA-IR index  (Matthews et al., 1985).  Using the fasting insulin and fasting glucose 
levels in the following formula, HOMA-IR was calculated: 
 
[Fasting insulin (µU/ml) x Fasting glucose (mmol/l)] / 22.5 
Or 
[Fasting insulin (pmol/l) x Fasting glucose (mmol/l)] / 155.25 
 
There is a good correlation between the HOMA-IR and the euglycaemic clamp which is the 
“gold standard” for the measurement of insulin resistance (Matthews et al., 1985). The 
HOMA-IR is used extensively in population studies assessing insulin resistance. 
 
2.4.4 Calculation of fasting and postprandial hepatic insulin extraction 
(HIE) 
The molar ratio of C-peptide to insulin was used in this study. This ratio has been widely used 
as a non-invasive method to assess hepatic extraction of insulin in both humans and animal 
models (Osei et al., 1994; Joffe et al., 1994b). Although, Polonsky et al., (1984) have 
extensively described the pitfalls and limitations of the use of simple molar ratios at each time 
point as a reflection of HIE during a non-steady state, the use of molar ratios of C-peptide / 
Insulin was suggested as a good indication of HIE  (Radziuk et al., 1985).   
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2.5 Food intake questionnaire assessment 
 
Nutrient intake was assessed using a validated quantified food frequency questionnaire. The 
interviews were conducted in English with the assistance of the day ward nurse who is 
familiar with most of the official languages of South Africa. Food intake questionnaire used in 
our study was validated for the South African black population. In the time when we started 
our study it was not any validated food intake questionnaire available that was designed for 
the South African Indian population. 
The list of food items in the questionnaire (Appendix 3) comprised the most frequently 
consumed items by South Africans based on many years of experience of dietary intake 
studies carried out and published in PhD thesis by Mackeown J M, (1999) of the MRC/WITS 
Dental Research Institute, Johannesburg and the Birth-to Twenty (Bt20) Research Programme. 
Underreporting, often biases food intake, which obscures interpretation of the results; however 
adjustment for energy intake provides some correction (Goldberg et al., 1991). Underreporting 
of energy intake was assessed as reported by energy intake divided by basal metabolic rate 
(EI/BMR). Low energy reporters (LERs) were defined as those having an EI/BMR <1.14, 
according to data published by Lau et al., (2006). Nutrient analyses were carried out using the 
following software: Food finder III Version 1.1.2 2002 Nutritional Intervention Research Unit 
and Research Information Systems Division, Medical Research Council, South Africa. The 
data was calculated as a daily intake. Further statistical analyses were performed on the SAS 
System for Windows Release 8.02 SAS Institute Inc., Cary, NC, USA 1999-2001. 
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2.6 Socio-economic status evaluation 
 
Socio-Economic status (SES) was assessed from the education or number of household 
amenities. The level of education achieved and the numbers of household amenities 
(television, radio, microwave, telephone, fridge, motor vehicle, washing machine, electricity, 
video machine) were recorded in a Questionnaire (Appendix 4).   
 
Education status was graded as follows (adapted from Richter, 2002): 
 
Grading Educational Level                                                         Age (years) 
 
    1                   < Standard 5                                                                     <12    
    2                    Standards 5-7                                                                  12 - 14 
    3                    Standards 8-12                                                                14 - 18 
    4                    Post - matric (including tertiary education)                    >18 
 
Household amenities were graded as follows (adapted from Richter, 2002): 
 
Grading  Number of Household amenities 
      1                                        Less than 1 
      2                                        From 1-3 
      3                                        From 4-5 
      4                                            > 5 
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2.7 Statistical analysis 
 
Statistical analyses were performed using package 8.2 SAS/STAT Enterprise Guide V2 
software (SA Institute, Inc., Cary, NC, U.S.A.) in consultation with a statistician. One of the 
main aims of this study was to investigate the relationship between anthropometry and 
metabolism. Therefore, the lean, overweight and obese groups were combined and analysed 
using correlation analyses. The lean, overweight and obese subjects in each ethnic group were 
combined to increase the chance of detecting a clinically relevant effect between the ethnic 
groups. Diabetic subjects were excluded from the analysis because they display distinct 
disease-specific metabolism abnormalities from non-diabetic subjects that may unduly 
influence the results of the correlation analyses. The diabetic subjects were therefore studied 
by comparing their metabolite, anthropometric and demographic data with those of the obese, 
no-diabetic subjects with which they had similar mean BMI levels. 
All data are shown as mean ± standard error of the mean (SEM), adjusted for age. Standard 
error is defined as the ratio of the sample standard deviation to the square root of the sample 
size. The Kolmogorov-Smirnov and Shapiro-Wilcoxon tests were used to test for normality. 
The statistical significance of differences between the means across groups was evaluated 
using ANOVA two sample Student’s t-test with age included as an independent variable. 
Spearman rank correlation coefficients in parallel with canonical correlation were used to 
analyse relationships between continuous variables. The effect of age was removed by 
calculating a partial correlation coefficient. The frequency procedure, controlling for race, was 
used to establish prevalence of metabolic syndrome. Multiple linear regression models with 
step-down backward selection were used to select dominant independent variables. The 
coefficient of determination (R2) was simultaneously monitored. A major drop in R2 after 
excluding particular independent variables enabled selection of those independent variables 
that are the most important determinants of the dependent variable under analysis. All P values 
were two-tailed, and values of less than 0.05 were considered to indicate statistical 
significance. Problems of collinearity or multicollinearity were resolved by examining both 
the regression weights and zero order correlations, and where collinearity was observed, such 
variables were not included together in the same regression model. 
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CHAPTER 3 – RESULTS 
 
 
This chapter includes tables and figures containing results for the clinical and anthropometric 
data, metabolic measurements, food questionnaire evaluation and socio-economic status 
assessment in groups sub-divided by ethnicity, BMI and disease status i.e. diabetic and non-
diabetic. This was done to determine whether ethnicity, body habitus or diabetes had any 
influence on these parameters, and was further investigated using multiple regression analysis. 
Metabolic and hormonal levels were measured in the fasting and postprandial state to ensure 
that a complete picture of metabolic status and control was captured, whilst lipids and 
adipokines levels were measured in the fasting state only.  
We were able to divide the type 2 diabetic Indian patients into the following groups based on 
the anti-diabetes drugs they were taking: 
¾ 1 patient on Metformin (Glucophage).   
¾ 7 patients on Gliclazide (Diamicron).   
¾ 5 patients on combined therapy of Gliclazide and Metformin.  
¾ 1 patient on herbal medicine of unknown origin.   
¾ 6 newly diagnosed patients, not on treatment. 
The diabetic African group was similarly divided based on their anti-diabetes drugs usage as 
follows: 
¾ 3 patients on Metformin.  
¾ 9 patients received Gliclazide.  
¾ 3 patients on combined therapy of Gliclazide n and Metformin.  
¾ 4 patients (1 newly diagnosed) not on treatment 
¾ 1 patient on a diet control regimen 
Originally we had not intended to include overweight women (BMI 25-29.9) in our study, but 
as quite a number of overweight volunteers came forward we allowed them into the study to 
increase the number of the subjects. Including overweight subjects into the study would 
normalise the distribution of metabolic and anthropometric variables allowing us to use 
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parametric statistical analysis. The overweight group consisted only of 10 subjects for 
logistical reasons and it was not statistically viable to make comparisons of this group across 
the ethnic populations; however we combined overweight with lean and obese in each ethnic 
group when we examined interethnic differences in non-diabetic subjects. The main objective 
of our study was to examine the relationship of anthropometric and metabolic indices in each 
ethnic group; therefore lean, overweight and obese subjects in each ethnic group were 
combined to increase chances of detecting a clinically relevant effect between ethnic groups 
and detecting significant relationships within each ethnic group.  
We did not include diabetic patients in the combined groups because diabetic patients are 
known to exhibit a cluster of metabolic syndrome risk factors; thus it was not our aim to assess 
relationship between metabolic variables by combining diabetic patients with non-diabetics. 
Body composition and CT-scan analysis are described in this chapter in order to discover 
whether any differences in such variables between Indian and African groups, would have any 
influence on glucose and lipid metabolism, insulin sensitivity, adipokine levels and blood 
pressure. Insulin sensitivity was assessed using HOMA-IR and the prime determinants of 
HOMA-IR were analysed in each ethnic group using multiple regression analysis. Socio-
economic and dietary status may have an impact on the development of obesity-related 
disorders and therefore such data was collected using questionnaires and compared across 
subject groups. The influence of socio-economic status on metabolic and anthropometric 
variables was studied using multiple regression analysis.  
  
3.1 Clinical characteristics, body composition and CT-scan 
analysis 
 
Clinical and anthropometric data for Indian and African groups are presented in table 3.1. The 
diabetic Indian group had statistically significantly higher age (p<0.05), lower diastolic 
pressure (p<0.05) and shorter duration of diabetes (p<0.05) than the diabetic African group. 
Blood pressure and the majority of the anthropometric variables in both ethnic groups were 
higher in obese than lean subjects. Age, waist circumference and waist/height ratio were 
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significantly higher (p<0.05) in diabetic than obese subjects in both ethnic groups but systolic 
pressure and waist/hip ratio (WHR) were higher in diabetic than obese subjects only in the 
African group. 
Table 3.2 shows data for body composition and CT-scan analysis. Measurements of total 
subcutaneous fat were significantly higher in lean Indian than African women but lower in 
obese Indian than African subjects (p<0.05). The upper body subcutaneous fat (UBSF) was 
significantly higher in lean Indian than African women but lower in obese Indian than African 
subjects (p<0.05). The obese subjects had significantly higher UBSF compared to lean 
subjects in both ethnic groups (p<0.0001). Differences in lower body subcutaneous fat (LBSF) 
were found between obese Indian subjects and obese African subjects (higher in African, 
p<0.05). In the African group LBSF was significantly higher in obese compared to lean and 
diabetic subjects (p<0.05 and 0.0001, respectively). In the Indian group the obese subjects had 
significantly higher LBSF compared to lean subjects (p<0.0001). 
Visceral fat was significantly higher in diabetic and lean Indian subjects than African subjects. 
Visceral /subcutaneous fat ratio was significantly higher in diabetic and obese Indian than in 
diabetic African and obese African. Activity level was higher in obese African than obese 
Indian and diabetic African subjects (p<0.05). 
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Table 3.1 Clinical and anthropometric data 
 
  
LI 
(N=20) 
 
OBI 
(N=20) 
        
        DI 
(N=20) 
 
LA 
(N=20) 
 
OBA 
(N=20) 
 
DA 
(N=20) 
Age (years) 44.0±1.7 47.0±1.9 52.0±1.2 a, c 42.0±1.4 43.0±1.2 47.6±1.5 c 
Weight (kg) 56.1±1.4 81.2±2.3 b 85.0±2.8 56.0±1.6 85.4±2.1 b 88.7± 2.8 
BMI (kg/m2) 22.9±0.4 32.9±0.6 b 34.8±1.0 22.4±0.4 34.4±0.7 b 36.2 ±1.0 
HC (cm) 94.4±0.9 112.3±1.9 b 111.3±2.2 95.1±1.6 114.8±1.4 b 114.3 ±2.1 
WC (cm) 72.7±1.5 92.5±1.8 b  99.3±2.0 c 72.0±1.0 91.2±1.7 b  98.1±1.7 c 
Height (cm) 156.3±1.1 156.7±1.1  156.2±1.5 157.9±1.6 157.4±1.3 156.4±1.0 
Waist/Height 
Ratio 
0.47±0.01 0.59±0.011 b 0.64±0.01 c 0.46±0.01 0.58±0.01 b 0.63±0.01 c 
Waist/Hip Ratio 0.77±0.01 0.83±0.02 b 0.90±0.02 0.76±0.01 0.80±0.02 0.86±0.02 c 
Systolic BP 
(mm/Hg)               
113.5±2.7 125.4±3.9 b 132.4±3.6 114.5±1.9 122.9±2.1 b 133.5±3.8 c 
Diastolic BP 
(mm/Hg)  
72.7±2.2 81.8±2.4 b 82.5±2.0 a 75.8±1.6 82.2±1.7 b 86.8± 2.7 
Duration of 
diabetes (years) 
    -------      ------- 2.96±0.7 a     -------      ------- 4.23±1.02 
Data shown as Mean values ± SEM; adjusted for age 
 a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
Abbreviations: LI- lean Indian; OBI-obese Indian; DI-diabetic Indian; LA-lean African; OBA-obese African; 
DA-diabetic African; HC-hip circumference; WC-waist circumference  
 
Groups  
Variables 
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Table 3.2 Body composition and CT-scan analysis 
 
                     
                   Groups 
Variables       
LI 
(N=20) 
OBI 
 (N=20) 
DI 
(N=20) 
LA 
(N=20) 
OBA 
(N=20) 
DA 
(N=20) 
BMR (Kjoule) 5762 ±93.3  6226 ±106 b 6046 ±98.3 5941±129  6392±94.8 b 6216±74.9  
Fat (%)   25.6±0.8  42.5±0.7 b  45.3 ±1.1 c  23.9 ±1.0  43.4 ±0.9 b 46.2±1.1   
Activity Level  2.35 ±0.23 2.45 ±0.18 a 2.15 ±0.17 2.65 ±0.2 3.05 ±0.14 2.5 ±0.11 c 
Subcutaneous Fat 
(cm2)  
185.9 ±7  a 340.9±14 a, b 357.3 ±21 155.9 ±12  389.5±16 b 367.1±16  
UBSF (cm2) 210.0±10 a 415.7±24 a, b  467.6 ±30 152.1 ±16 486.5±23 b 488.1 ±24  
LBSF (cm2) 169.9 ± 8   290.9±11 a, b 284.4 ±21 158.5± 10 332.4±14 b 279.6±15  c 
Visceral Fat   
(cm2)  
 51.3 ±6.2 a 
 
96.7 ±7.8 b  117.5 ±9.9 a 30.3 ±2.9  
 
81.4 ±6.4 b 
 
93.9 ±6.2  
 
Visceral/Subcut 
Fat Ratio  
 0.27 ±0.03     
 
0.29 ±0.03 a 0.34 ±0.03 a 0.21±0.02   
 
0.21±0.01  
 
0.26 ±0.02 c 
Data shown as Mean values ± SEM; adjusted for age; 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
Abbreviations: UBSF –upper body subcutaneous fat; LBSF – lower body subcutaneous fat 
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Results in combined groups (excluding diabetics) are presented in table 3.3. Age, waist/hip 
ratio, visceral fat and visceral/subcutaneous fat ratio were higher (p<0.05) in the Indian than 
African group. 
 
Table 3.3 Clinical and Anthropometric data in the combined* Indian and African 
groups 
 
Data shown as Mean values ± SEM; adjusted for age;  
a p<0.05 Indian vs. African; b p<0.0001; * Obese, overweight, and lean combined 
              
                  Groups 
 
Variables 
 
INDIAN 
(N=50) 
 
AFRICAN 
(N=50) 
              
                  Groups 
 
Variables 
 
INDIAN 
(N=50) 
 
AFRICAN 
(N=50) 
Age (years) 45.4 ± 1.1 a 42.2 ± 0.9 Systolic BP 
(mm/Hg)                   
121 ± 2.2 120 ±1.6 
Weight (kg) 68.6 ± 1.9 70.4 ± 2.2 Diastolic BP 
(mm/Hg)  
78 ± 1.5 80 ± 1.1 
Height (cm) 156.2 ± 0.7 157.5 ± 0.9 BMR (Kjoule) 5941 ± 64.9 6135 ± 76.8 
HC (cm) 103.4 ±1.4 105.5 ± 1.6 Body Fat (%) 34.7 ± 1.2 33.9 ± 1.4 
WC (cm) 82.9 ±1.6 81.2 ± 1.5 Subcutaneous Fat 
(cm2)  
264.7 ± 15.0 270.3 ± 21.4 
BMI (kg/m2) 28.0 ±0.68 28.3 ± 0.83 UBSF (cm2) 313.6 ± 19.9 309.9 ± 28.3 
Waist/Height 
Ratio 
0.53 ± 0.01 0.52 ± 0.01 LBSF (cm2) 230.8 ± 11.1 242.6 ± 15 
Waist/Hip Ratio 0.80 ± 0.01 a 0.77 ± 0.01 Visceral Fat  (cm2) 77.9 ± 6.5 a 56.1 ± 5.5 
Activity Level  2.59 ± 0.14 2.83 ± 0.1 Visceral/Subcut 
Fat Ratio 
0.30 ± 0.02 b 0.21 ± 0.01 
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3.2 Fasting beta-cell parameters, intermediate metabolic indices 
and lipids levels 
 
The assessments of beta-cell function are shown in table 3.4. The obese Indians had 
significantly higher (p<0.05) fasting glucose, des 31, 32 proinsulin, C-peptide, HOMA-IR 
levels and lower proinsulin/insulin ratio than obese African subjects. The levels of intact 
proinsulin and proinsulin /insulin ratio were significantly lower in lean Indian than lean 
African women. In the diabetic groups there were statistically significant differences (higher 
in Indian, p<0.05) for intact proinsulin, des 31, 32 proinsulin and C-peptide levels. Obese 
African and Indian subjects had higher levels of Insulinogenic index than diabetics African 
and Indian (p<0.001). 
Non-diabetic subjects in both ethnic groups were divided into groups with/without metabolic 
syndrome, according to the ATP III/NCEP, (2001) criteria. HOMA-IR levels were 
significantly different between subjects with and without metabolic syndrome in the Indian 
and African groups (p=0.0127 and 0.001, respectively). Adjustment for waist circumference 
did not have any influence on the results. 
To establish the possible interference of Gliclazide and Metformin with measurements of 
fasting glucose and insulin we compared diabetic patients in the Indian and African groups, 
with and without use of Gliclazide and Metformin. The fasting glucose and insulin levels were 
not significantly different with and without use of Gliclazide and Metformin in diabetic Indian 
group (p=0.341, 0.768, 0.916 and 0.414 respectively).The fasting glucose and insulin levels 
were not significantly different with and without use of Gliclazide and Metformin in diabetic 
African group (p=0.499, 0.947, 0.763 and 0.211 respectively). Thus we may state that in our 
group of diabetic patients the use of different anti-diabetic drugs did not influence results in 
the present study. 
 Fasting lactate levels were significantly higher in the diabetic Indian than diabetic African 
group. Obese Indian subjects had significantly higher fasting lactate levels than lean Indian 
subjects. Both ethnic groups displayed significantly different fasting lactate levels between 
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diabetic and obese subjects (higher in diabetics). To establish the effect of Metformin on 
lactate levels diabetic patients in both ethnic groups were divided into group that consisted of 
the patients using Metformin and the group that was not on Metformin. There were no 
significant differences in lactate levels between the groups.  
Glycerol concentrations were significantly lower in lean Indian than obese Indian and lean 
African subjects (p=0.005 and 0.004, respectively). Obese Indian women had elevated 
triglyceride and cortisol levels compared to obese African women. Obese African women had 
lower cortisol levels than both diabetic and lean African subjects. Cholesterol and LDL 
cholesterol were higher in lean Indian than African group (table 3.5). 
In groups combined by ethnicity (excluding diabetics) the fasting glucose, insulin, C-peptide, 
des 31, 32 proinsulin, HOMA-IR levels were significantly higher and proinsulin / insulin ratio 
lower in Indian than African females (table 3.6). Cholesterol, triglycerides and LDL 
cholesterol levels were statistically significantly (p<0.05) higher and glycerol levels lower in 
Indian than African subjects (table 3.7). 
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Table 3.4 Fasting beta-cell parameters 
 
  
LI 
(N=20) 
 
OBI 
(N=20) 
       
      DI 
(N=20) 
 
LA 
(N=20) 
 
OBA 
(N=20) 
 
DA 
(N=20) 
Glucose 
(mmol/l) 
4.6 ±0.07 5.0 ±0.13 a,b 9.0 ±0.79 c 4.4 ±0.12 4.4 ±0.11 8.8 ±0.94 c 
HbA1c (%) 5.6 ±0.07 6.0 ±0.31 8.2 ±0.45 c 5.6 ±0.08 5.6 ±0.08 9.1 ±0.57 c 
Insulin 
(pmol/l) 
74.5 ±8.8 124.4±14.2 b 138.5 ±14.5 62.1±8.3 94.1±14.9 111.9 ±13.5
Intact 
proinsulin 
(pmol/l) 
2.1 ±0.34 a 4.8 ±0.85 b 12.2 ±1.73 a,c 3.4 ±0.39 5.6 ±0.74 b 7.6 ±1.01 
des 31,32-
split 
proinsulin 
(pmol/l)  
 
4.9 ±0.62 
 
13.6 ±1.97 a,b
 
26.1 ±4.4 a,c 
 
4.6 ±0.75 
 
7.0 ±2.08 
 
10.7 ±2.55 
C-peptide 
(pmol/l) 
758 ±97  1475 ±168 a,b 1031±102 a,c 756±99  672±98  678±84  
HOMA -IR 2.23 ±0.27 4.28 ±0.52 a,b 7.54 ±0.74 c 1.87 ±0.28 2.83 ±0.51 6.56±1.26 c
HIE  11.0 ±1.0 12.4 ±1.68 8.4 ±0.93 c 14.9 ±3.0 9.51 ±1.58 6.9±0.82 
Proinsulin/ 
insulin ratio  
0.03 ±0.01a 0.04 ±0.01a 0.11 ±0.02 c 0.08 ±0.02 0.09 ±0.01 0.09±0.01 
Insulinogenic 
index 
214 ±29.2  285±43.8 27.7 ±6.3 c 212 ±61.1 347±66.2 45.2±12.7 c
Data shown as Mean values ± SEM; adjusted for age 
          a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
Abbreviation: HIE-Hepatic Insulin Extraction 
Groups 
 Variables 
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Table 3.5 Fasting intermediate metabolic indices and lipids 
 
  
LI 
(N=20) 
 
OBI 
(N=20) 
      
      DI 
(N=20) 
 
LA 
(N=20) 
 
OBA 
(N=20) 
 
DA 
(N=20) 
Lactate 
(mmol/l) 
1.11 ± 0.1 b 1.51± 0.11c  2.08 ±0.12 a 1.31± 0.13 1.21± 0.12 1.72±0.10 c 
Glycerol 
(mmol/l) 
0.15± 0.01 a 0.19 ± 0.02 b 0.20 ± 0.02 0.18 ± 0.01 0.22 ± 0.02 0.22 ± 0.02 
FFA (mmol/l)  0.50± 0.04 0.58 ± 0.07 0.63 ± 0.06 0.56 ± 0.07 0.55 ± 0.05   0.56 ± 0.08  
Cortisol 
(nmol/l) 
315 ± 27.8 313 ± 20.5 a 330 ± 26.6 301 ± 22.6 238 ± 19.4 b 377± 30.0 c 
Cholesterol 
(mmol/l) 
5.25 ± 0.2 a 5.21 ± 0.18 5.24 ± 0.23 4.37 ± 0.21 4.93 ± 0.19 4.78± 0.22 
HDL (mmol/l)  1.54 ±0.09 1.25 ± 0.06 b 1.76 ± 0.40 1.45 ± 0.1  1.31 ± 0.1  1.17 ± 0.05  
LDL (mmol/l)   3.24±0.17 a  3.30 ± 0.18 3.10 ± 0.22 2.58 ± 0.17 3.12± 0.18 b 2.98 ± 0.2  
Triglycerides 
(mmol/l) 
1.05± 0.11 b 1.44 ± 0.11a 2.11 ± 0.36 0.79 ± 0.1 b 1.09 ± 0.12 1.41 ± 0.11  
Data shown as Mean values ± SEM; adjusted for age 
               a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 
 
 
 
 
 
 
 
Groups 
Variables 
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Table 3.6 Fasting beta cell parameters in the combined* Indian and African 
groups 
 
 
 
INDIAN 
(N=50) 
 
AFRICAN 
(N=50) 
Glucose (mmol/l)  4.83 ± 0.07 b 4.43 ±0.07 
HbA1c (%)      5.77 ± 0.14 5.62 ±0.05 
Insulin (pmol/l) 98.6 ±7.28 a        75.1 ±7.11 
Intact Proinsulin (pmol/l)      3.47 ±0.41 4.52 ±0.42 
des 31,32 split Proinsulin (pmol/l)      9.46 ±1.06 a 5.39 ±0.93 
C-peptide (pmol/l)      1029 ± 94.3 a       679 ± 56.9 
HOMA-IR  3.16 ± 0.28 a 2.23 ± 0.24 
HIE     11.0 ± 0.83 11.8 ±1.41 
Proinsulin / insulin ratio                  0.04 ± 0.004 b 0.08 ± 0.01 
Insulinogenic index     225.8± 23.9 276.2 ± 39.5 
            Data shown as Mean values ± SEM; adjusted for age;  
           * Obese, overweight, and lean combined; a p<0.05; b p<0.0001 Indian vs. African 
             
 
 
 
 
 
Variables 
Groups 
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Table 3.7 Fasting intermediate metabolic indices and lipids in the combined* 
Indian and African groups 
 
  
 
           INDIAN 
(N=50) 
         AFRICAN 
(N=50) 
Lactate (mmol/l) 1.34 ± 0.08 1.24 ± 0.07 
Glycerol (mmol/l) 0.16 ± 0.01 a 0.20 ± 0.01 
FFA (mmol/l)  0.55 ± 0.03 0.55 ± 0.04 
Cortisol (nmol/l)         308 ±14.0 271 ±14.6 
Cholesterol (mmol/l) 5.25 ± 0.11 a 4.66 ± 0.12 
HDL (mmol/l) 1.38 ± 0.05 1.38 ± 0.06 
LDL (mmol/l)  3.32 ± 0.11 a 2.84 ± 0.11 
Triglycerides (mmol/l) 1.21 ± 0.07 a 0.97 ± 0.07 
                Data shown as Mean values ± SEM; adjusted for age; 
                a p<0.05 Indian vs. African; * Obese, overweight, and lean combined 
 
3.3 Serum adipokines measurements 
 
Serum leptin levels were significantly (p<0.05) higher in lean Indian than lean African 
subjects. TNF-α concentrations were lower in diabetic and lean Indian subjects in comparison 
with diabetic and lean African subjects, respectively.  Leptin was lower and soluble leptin 
receptor higher in diabetic than obese and in lean than obese subjects in both ethnic groups. 
Serum CRP levels were significantly higher in obese than lean subjects in both ethnic groups 
(table 3.8). When obese, overweight and lean subjects were combined serum TNF-α 
concentrations were significantly (p<0.05) lower and serum leptin levels were significantly 
higher in Indian than African subjects (table 3.9). 
    Groups 
Variables 
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Table 3.8 Adipokines markers 
 
 LI 
(N=20) 
OBI 
(N =20) 
DI 
(N =20) 
LA 
(N =20) 
OBA 
(N =20) 
DA 
(N =20) 
CRP (mg/l) 1.74 ± 0.4   6.66 ± 1.2 b 8.97 ± 1.6 2.06 ± 0.5  9.95 ± 3.5 b 11.4 ± 3.1 
TNF-α (pg/ml) 2.97 ± 0.9 a 2.50 ± 0.8  2.26 ± 0.4 a 6.51 ± 1.4  4.03 ± 1.3 7.06 ± 1.4 
IL-6  (pg/ml)         2.17 ± 0.5 1.62 ± 0.2  3.87 ± 1.1 c 2.01 ± 0.5  2.17 ± 0.3  3.15 ± 0.6 
Leptin (ng/ml) 29.5 ± 2.7 a 50.8 ± 2.1 b 43.6 ± 2.1 c 13.8 ± 2.5  51.3 ± 2.1 b 40.6 ± 2.5 c 
Leptin Receptor 
(U/ml) 
27.2 ± 2.7 14.8 ± 1.1 b 20.5 ± 1.7 c 31.5 ± 2.9 16.2 ± 0.9 b 21.0 ± 1.7 c 
Data shown as Mean values ± SEM; adjusted for age; 
                   a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 
 
Table 3.9 Adipokines markers in the combined* Indian and African groups  
 
 INDIAN 
(N=50) 
AFRICAN 
(N=50) 
CRP (mg/l) 4.08 ± 0.6  5.14 ± 1.5 
TNF-alpha (pg/ml) 2.54 ± 0.5 a 5.22 ± 0.9 
IL-6  (pg/ml)  1.88 ± 0.2             2.04 ± 0.3 
Leptin (ng/ml)  41.3 ± 2.0 a 34.2 ± 2.9 
Leptin Receptor (U/ml) 20.3 ±1.4 22.7 ±1.6 
            Data shown as Mean values ± SEM; adjusted for age; a p<0.05 Indian vs. African 
            * Obese, overweight, and lean combined 
Groups 
Variables 
Variables
  Groups  
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3.4 Results for 5-hour OGTT 
 
Results for the 5-hour OGTT were calculated as area under the curve (AUC). Plasma glucose 
concentrations during the 5-hour OGTT are illustrated in figure 3.1. Differences in plasma 
glucose were found in diabetic vs. obese and obese vs. lean in both ethnic groups (p<0.05). 
Obese and lean Indian subjects were much more hyperinsulinemic in comparison with African 
subjects (figure 3.2), and in both ethnic groups insulin levels were higher in obese than lean 
and diabetic subjects. Significantly higher C-peptide and des 31, 32 split proinsulin values 
were observed for diabetic, obese and lean Indian women compared to the respective African 
group (figure 3.3 and 3.4, respectively). Serum intact proinsulin concentrations were higher in 
diabetic Indian than African group (figure 3.5). Hepatic insulin extraction (HIE) had 
significant difference between obese and lean Indian subjects and proinsulin/insulin ratio was 
significantly lower in obese and lean Indian than the respective African groups (figure 3.6). 
No statistically significant differences (p<0.05) were found between diabetic, obese or lean 
Indian and African subjects for serum free fatty acid, cortisol (2 hour OGTT) and plasma 
lactate (figure 3.7, 3.8, and 3.9, respectively). Plasma glycerol concentrations were lower in 
lean Indian women in comparison with African women (figure 3.10). 
In combined groups of lean, overweight and obese subjects plasma glucose, serum insulin, des 
31, 32 split proinsulin and C-peptide were significantly higher and plasma glycerol levels, HIE 
and proinsulin/insulin ratio were significantly lower in the Indian group. No statistically 
significant interethnic differences were found for plasma lactate, serum intact proinsulin, free 
fatty acids and cortisol (2 hour OGTT) concentrations (figures 3.11, 3.12, 3.13, 3.14, 3.15 and 
3.16). 
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    Figure 3.1 Plasma glucose concentrations during 5-hour OGTT 
     Data shown as Mean values ± SEM; adjusted for age 
        a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
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     Figure 3.2 Serum insulin concentrations during 5-hour OGTT 
      Data shown as Mean values ± SEM; adjusted for age 
      a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 
 
 
c     b 
  a, b 
   a 
   c 
  
139
C-PEPTIDE
0
1000
2000
3000
4000
5000
6000
FAST 30' 60' 90' 120' 180' 240' 300'
TIME
pm
ol
/l
LI
OBI
DI
LA
OBA
DA
 
C-PEPTIDE
0
200000
400000
600000
800000
1000000
1200000
AUC
pM
*m
in
LI
OBI
DI
LA
OBA
DA
               
Figure 3.3 Serum C-peptide concentrations during 5-hour OGTT 
Data shown as Mean values ± SEM; adjusted for age 
 a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
c 
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a, c 
a, b
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Figure 3.4 Serum des 31, 32 split proinsulin concentrations during 5-hour OGTT 
Data shown as Mean values ± SEM; adjusted for age 
 a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 a 
   b 
a, b 
    a 
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Figure 3.5 Serum intact proinsulin concentrations during 5-hour OGTT 
Data shown as Mean values±SEM; adjusted for age 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese  
a 
 b   b 
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 Figure 3.6 Hepatic insulin extraction (HIE) and proinsulin/insulin ratio during  
 5-hour OGTT 
   Data shown as Mean values ± SEM; adjusted for age 
   a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
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Figure 3.7 Serum free fatty acid concentrations during 5-hour OGTT 
Data shown as Mean values ± SEM; adjusted for age 
 a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 c 
   b 
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Figure 3.8 Plasma glycerol concentrations during 5-hour OGTT 
Data shown as Mean values ± SEM; adjusted for age 
 a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
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Figure 3.9 Serum cortisol concentrations during 2-hour OGTT 
 Data shown as Mean values ± SEM; adjusted for age 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
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Figure 3.10 Plasma lactate concentrations during 5-hour OGTT  
Data shown as Mean values ± SEM; adjusted for age 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
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Figure 3.11 Plasma glucose and serum insulin concentrations during 5-hour 
OGTT in the combined* Indian and African groups 
Data shown as Mean values ± SEM; adjusted for age;  
* Obese, overweight, and lean combined; a p<0.05; b p <0.0001 Indian vs. African 
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Figure 3.12 Serum C-peptide concentrations and hepatic insulin extraction 
during 5-hour OGTT in the combined* Indian and African groups 
 Data shown as Mean values ± SEM; adjusted for age;  
* Obese, overweight, and lean combined; a p<0.05; b p <0.0001 Indian vs. African;  
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Figure 3.13 Serum intact proinsulin and des 31,32 split proinsulin concentrations 
during 5-hour OGTT in the combined* Indian and African groups 
 Data shown as Mean values ± SEM; adjusted for age;  
* Obese, overweight, and lean combined; b p <0.0001 Indian vs. African;  
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Figure 3.14 Proinsulin/Insulin ratio during 5-hour OGTT in the combined* 
Indian and African group 
Data shown as Mean values ± SEM; adjusted for age;  
* Obese, overweight, and lean combined; a p<0.05 Indian vs. African   
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Figure 3.15 Serum cortisol and plasma lactate concentrations during 5-hour 
OGTT in the combined* Indian and African groups 
Data shown as Mean values ± SEM; adjusted for age;  
*Obese, overweight, and lean combined; a p<0.05 Indian vs. African; b p <0.0001  
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Figure 3.16 Serum free fatty acids and plasma glycerol concentrations during  
5-hour OGTT in the combined* Indian and African groups 
Data shown as Mean values ± SEM; adjusted for age;  
* Obese, overweight, and lean combined; a p<0.05; b p <0.0001 Indian vs. African;  
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3.5 Prevalence of metabolic syndrome 
 
The definition of metabolic syndrome is fully described in section 1.3 and was diagnosed 
using the NCEP: ATP III, (2001) criteria. The highest (85%) prevalence of metabolic 
syndrome was found in the diabetic Indian group. Obese Indian and African females exhibit 
similar prevalence of metabolic syndrome (35 and 40%, respectively). Overweight African 
group had 10% prevalence of metabolic syndrome compared to 0% in the Indian overweight 
group. Lean Indian had 5% prevalence of metabolic syndrome, while lean African had 0% 
prevalence of metabolic syndrome (Table 3.10). 
Table 3.11 represent prevalence of metabolic syndrome components according to the NCEP: 
ATP III, (2001) criteria in the combined non-diabetic and diabetic Indian and African groups, 
respectively. The data indicated that in the combined Indian group the prevalence of HDL 
<1.29 mmol/l was 42% compared to 46% in the combined African group (p=NS). The 
prevalence of triglycerides >1.7 mmol/l was higher in the combined Indian group than in the 
combined African group (20% and 6%, respectively, p<0.05). Systolic BP > 130 mmHg and 
diastolic BP > 85 mmHg were similar across the groups. No significant differences were 
found for the prevalence of increased WC or increased fasting glucose between the combined 
Indian and African groups.   
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Table 3.10 Prevalence of metabolic syndrome (NCEP: ATP III, 2001 definition) 
 
Indian 
 Diabetic 
N=20 
Lean 
N=20 
Obese 
N=20 
Overweight 
N=10 
Total 
N=70 
With MS 17 
(85) 
1 
(5) 
7 
(35) 
0 
(0) 
25 
(36) 
Without MS 3 
(15) 
19 
(95) 
13 
(65) 
10 
(100) 
45 
(64) 
 
African 
 Diabetic 
N=20 
Lean 
N=20 
Obese 
N=20 
Overweight 
N=10 
Total 
N=70 
With MS 15 
(75) 
0 
(0) 
8 
(40) 
1 
(10) 
24 
(34) 
Without MS 5 
(25) 
20 
(100) 
12 
(60) 
9 
(90) 
46 
(66) 
   Data expressed as N number (%) 
  Abbreviation: MS-Metabolic syndrome 
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Table 3.11 Prevalence of metabolic syndrome components (NCEP: ATP III, 
2001 definition) in the combined* Indian and African groups   
 
 Data expressed as N number (%)   
 * Lean, overweight and obese combined; a p<0.05 diabetic vs. non-diabetic;  
  b p<0.05 Indian  non-diabetic vs. African non-diabetic 
 
 
 
 
Indian African  
              Groups 
 
MS Components 
Non-diabetic*
N=50 
Diabetic 
N=20 
Non-diabetic* 
N=50 
Diabetic 
N=20 
Systolic BP 
(mm/Hg)      
14 
(28) 
13  
  (65) a 
14 
(28) 
 12  
   (60) a 
Diastolic BP 
(mm/Hg)   
10 
(20) 
7 
(35) 
13 
(26) 
10 
(50) 
WC (cm) 
 
14 
(28) 
 18  
   (90) a 
14 
(28) 
19 
(95) a 
Fasting Glucose 
(mmol/l) 
1 
(2) 
 18  
   (90) a 
0 
(0) 
13 
(65) a 
Triglycerides 
(mmol/l) 
10 
   (20) b 
8 
(40) 
  3  
 (6)  
7 
  (35) a 
HDL (mmol/l) 21 
(42) 
7 
(35) 
23 
(46) 
12 
(60) 
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3.6 Socio-economic status 
 
Details describing socio-economic status evaluation are given in section 2.7. Household 
amenities were found to be more prevalent (p<0.05) in the diabetic, obese and lean groups of 
Indian subjects compared to the respective groups of African subjects. Lean Indian women 
had significantly higher education status in comparison with lean African women. There were 
significant differences in education in diabetic vs. obese African and obese vs. lean Indian 
women (table 3.12). Household amenities and education displayed statistically significant 
(p<0.05) differences in the combined (obese, lean and overweight) group, the values being 
higher in the Indian subjects (figure 3.17). 
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Table 3.12 Socio-economic data 
 
  
LI 
(N=20) 
 
OBI 
(N=20) 
      
      DI 
(N=20) 
 
LA 
(N=20) 
 
OBA 
(N=20) 
 
DA 
(N=20) 
Education 3.35 ±0.15 a 2.70 ±0.16 b 2.40 ± 0.13 2.35 ± 0.17 2.70 ± 0.15 2.10 ± 0.21 c
Household 
amenities 
3.85 ± 0.08 a 3.80 ± 0.09 a 3.70 ± 0.11 a 3.00 ± 0.16 3.35 ± 0.15 3.15 ± 0.18 
Data shown as Mean values ± SEM; adjusted for age;  
 a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
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Figure 3.17 Socio-economic status in the combined* Indian and African groups 
* Obese, overweight, and lean combined; a p<0.05 Indian vs. African 
   a 
   a 
Variables 
Groups 
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3.7 Food intake questionnaire assessment 
 
Food intake data was gathered using a validated food frequency questionnaire (Appendix 3) as 
described in section 2.6. Original statistical analysis included 145 nutrients and the selection 
was made on basis of the most meaningful nutrient variables that may modify the 
anthropometric, metabolic and hormonal profiles in our study groups. The food intake 
questionnaire assessment is presented for all subjects and also with the exclusion of low 
energy reporters (LERs). Table 3.13 indicates percentage of the study population left from the 
original sample after taking into account this ratio of 1.14 as a cut-off point for discrimination 
between LERs (≤ 1.14) and “accurate” reporters. 
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Table 3.13 Data related to the number of subjects categorized as LERs 
 
* Obese, overweight, and lean combined, excl. diabetics  
 Abbreviations: LI- lean Indian; OBI-obese Indian; DI-diabetic Indian; OWI-overweight Indian;  
 LA-lean African; OBA-obese African; DA-diabetic African; OWA-overweight African  
 
 
Food intake questionnaire data is presented in tables 3.14 and 3.15. There were statistically 
significant (p<0.05) differences between lean Indian and lean African women for most of the 
variables (higher in African), with the exception of chloride, total carotenoids, vitamin C, total 
trans-FA, lycopene, chromium and starch. The diabetic group displayed interethnic differences 
(higher in Africans) in total energy, total protein, plant protein, animal protein, total 
carbohydrate, starch, total dietary fibre, magnesium, phosphorus and zinc.  
  Total before 
LERs exclusion 
(N) 
After LERs 
exclusion 
(N) 
After LERs 
exclusion 
(%) 
INDIAN * 50 19 38 
AFRICAN * 50 39 78 
LI 20 7 35 
OBI 20 6 30 
DI 20 7 35 
OWI 10 6 60 
LA 20 18 90 
OBA 20 11 55 
DA 20 9 45 
OWA 10 10 100 
Groups  
Subjects 
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Significant differences (p<0.05) were found between obese Indian and African women in total 
protein, plant protein, total carbohydrate, total dietary fibre, magnesium, phosphorus and zinc 
(higher in African) with lower intake in total sugar and starch. 
Table 3.16 and 3.17 represents food intake questionnaire data after excluding low energy 
reporters. Lean Indian females had significantly lower total energy intake, total protein, plant 
protein, and total carbohydrate, total dietary fibre, magnesium, zinc, vitamin D and vitamin E 
in comparison with lean African subjects. Similarly, there were also significant differences 
between obese Indian and obese African for consumption of plant protein, total dietary fibre, 
magnesium, phosphorus and zinc. Diabetic Indian subjects had statistically significantly lower 
intake in total protein, plant protein, animal protein, total dietary fibre, magnesium, 
phosphorus zinc, total iron but higher intake of starch, fibre and chloride in comparison with 
diabetic African patients. Added sugar was significantly lower and plant protein was higher in 
diabetic Indian patients than in obese Indian group. Diabetic African group had lower vitamin 
C intake when compared to obese African group. Obese African subjects had significantly 
lower vitamin D values compared to lean African subjects. Food intake data, after exclusion of 
LER’s, showed no interethnic differences in diabetics, obese and lean groups for the 
consumption of total fat, and saturated, monounsaturated, polyunsaturated and total trans fatty 
acids. 
The combined groups have statistically significantly higher food intake (p<0.05 and 0.0001) 
for African than Indian subjects for most of the variables with the exception of 
polyunsaturated and total trans-FA, chloride, total carotenoids, vitamin C and chromium 
where there were no differences and lycopene and starch where intake were significantly 
higher in Indians (table 3.18). Table 3.19 represents food intake in combined African and 
Indian group after excluding low energy reporters. There were statistically significantly higher 
intake (p<0.05 and 0.0001) for African than Indian women for most of the variables, with the 
exception of animal protein, total fat, monounsaturated, polyunsaturated and total trans-FA, 
sodium, chloride, vitamin C, folate, vitamin B12, total carotenoids and chromium, where 
intake were similar and lycopene and starch where intake were significantly higher in Indians. 
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Table 3.14 Food intake questionnaire assessment-Part 1 
 
  
LI 
(N=20) 
 
OBI 
(N=20) 
      
     DI 
(N=20) 
 
LA 
(N=20) 
 
OBA 
(N=20) 
 
DA 
(N=20) 
Total Energy (kJ) 5730 ±381 a 6047 ±348 5841 ±323 a 9759 ±560 7364 ±570 b 7163 ±516 
Total Protein (g) 52.6 ±5.23 a 59.9 ±4.0 a 60.2 ±3.6 a 90.9 ±5.9 76.5 ±6.1 82.2 ±6.2 
Plant Protein (g)  15.3±1.02 a 15.3±0.79 a 19.0±1.04 a,c 29.4 ±2.04 20.9±1.78 b 24.7 ±1.54 
Animal Protein (g) 35.4±4.7 a 43.6±3.7 40.4±3.0 a 60.1 ±4.7 54.9 ±4.9 57.0 ±5.3 
Total Fat (g) 50.1 ±3.8 a 53.3 ±4.4 51.9 ±4.2 75.6 ±5.7 58.7 ±5.9 b 52.9 ±5.1 
Saturated FA (g) 16.6 ±1.7 a 17.6 ±1.5 15.7 ±1.4 25.9 ±2.2 21.3 ±2.3 17.7 ±1.9 
Monounsaturated 
FA (g)  
15.5 ±1.2 a 17.7 ±1.8 16.9±1.4 23.5 ±1.9 18.9 ±1.8 17.6 ±1.7 
Polyunsaturated 
FA (g) 
13.7 ±1.0 a 13.4 ±1.1 14.9 ±1.4 19.3 ±1.5 13.0 ±1.5 b 12.7 ±1.4 
Total trans FA (g) 0.78±0.17 1.33 ±0.53 0.76 ±0.27 0.97±0.18 0.66 ±0.08 0.76± 0.14 
Total  
Carbohydrate   (g) 
161 ±12.2 a 167 ±9.2 a 156 ±8.7 a 295 ±17.2 211±15.2 b 204 ±16.0 
Added sugar (g)  33.3 ±5.3 a 34.5 ±5.3 17.2 ±3.6 c 59.1±6.0 37.3 ±3.6 b 17.6 ±4.6 c 
Total sugar (g) 50.0 ±6.2 a 48.3 ±4.4 a 36.9 ±3.7 82.1 ±7.0 68.9 ±6.4 42.4 ±7.3 c 
Starch (g) 22.8 ±4.5 29.5 ±5.2 a 32.4 ±7.4 a 20.8 ±3.9 15.7 ±4.1 12.2 ±2.3 
Total Dietary fibre 
(g) 
14.5 ±1.1 a 12.4 ±0.7 a 14.7 ±1.2 a 23.8 ±1.8 17.3 ±1.4 b 19.7 ±1.4 
Data shown as Mean values ± SEM; adjusted for age 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 
 
Groups 
  Variables 
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Table 3.15 Food intake questionnaire assessment-Part 2 
 
  
LI 
(N=20) 
 
OBI 
(N=20) 
      
      DI 
(N=20) 
 
LA 
(N=20) 
 
OBA 
(N=20) 
 
DA 
(N=20) 
Magnesium (mg)  200±15.6 a 192±8.7 a  206±12.6 a 354±22.5  274±23.0 b 298±18.3  
Phosphorus (mg)  889±82 a 903±51 a 940±59 a 1511±101 1198±105 b 1229±91 
Zinc (mg)  6.2 ±0.54 a 6.5 ±0.39 a 6.7 ±0.39 a 10.6±0.77  8.9±0.72  9.5±0.83  
Calcium (mg)  594±84.0 a 584±52.6 570±56.4 881±90.2  782±95.9     637 ±73.4  
Total iron (mg)  7.1±0.56 a 7.1 ±0.54 6.9 ±0.48 11.2 ±1.03 8.1±0.58 b 8.1 ±0.68 
Sodium (mg)  1104±91 a 1178 ±78 1221 ±80 1734 ±135 1326 ±130 b 1207 ±95 
Chloride (mg)  895±115 1008 ±121 1079±154 1193±110 1064±134  782±89  
Total carotenoids 
(mcg) 
2020±293 1826±242    1935±297    1973±310 1507±278 2124±329  
Folate (mcg) 158 ±15.0 a   159±12.5   183 ±12.6  227±18.5  181.3±15.1 165.1±13.2 
Vitamin B12 (mcg)   3.1±0.40 a 3.5±0.33  3.4 ±0.25  5.1±0.51  4.5±0.47 4.2±0.58     
Vitamin C (mg) 82.3±13.0 89.5±11.8  53.0±9.4 c 114.7±13.6 117.0±14.7 61.1±12.8 c 
Vitamin D (mcg) 2.7 ±0.36 a 3.1±0.36 3.4±0.44 6.4±0.88  3.2±0.51 b 3.9±0.73 
Vitamin E (mg) 7.7 ±0.75 a 7.0±0.63 8.4±1.06 11.2±0.99  6.9±0.92 b 7.5±0.99 
Lycopene (mcg) 71 ±21.6 132±54.4 135±45.6 60.3±16.3 35.2±15.2 40.1 ±18.8 
Chromium  (mcg) 37.2±4.9 45.3±5.7 42.8±7.3 51.5±5.5 38.4±5.6 38.8±5.0 
Data presented as Mean values ± SEM; adjusted for age 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 
 
Groups 
Variables 
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Table 3.16 Food intake questionnaire assessment (excluding LERs) -Part 1 
 
  
LI 
(N=7) 
 
OBI 
(N=6) 
 
DI 
(N=7) 
 
LA 
(N=18) 
 
OBA 
(N=11) 
 
DA 
(N=9) 
Total Energy (kJ) 7496±468 a 7839±420  7423±386 10151±545 9125 ±557 9050 ±702 
Total Protein (g) 69.9±9.3 a 79.1±6.0 77.6±2.5 a 95.0±5.8 92.7 ±6.3 103±7.1 
Plant Protein (g)  17.4±1.5 a 17.8±1.6 a 22.9±1.3 a,c 30.0±2.2 26.9 ±1.4 30.5±1.7 
Animal Protein (g) 48.1±9.6 60.3±5.5 53.5±2.4 a 63.5±4.5 64.8 ±5.4 71.7±6.7 
Total Fat (g) 68.0±4.6 71.7±8.3 69.9±6.3 79.4±5.7 74.2 ±6.6 69.4±6.8 
Saturated FA (g) 25.0±2.0 23.6±2.6 21.1±2.6 27.4±2.2 27.1 ±2.5 24.2±2.4 
Monounsaturated 
FA (g)  
20.6±1.8 25.4±3.5 22.7±2.0 24.6±1.9 23.5 ±2.2 22.6±2.3 
Polyunsaturated 
FA (g)  
16.1±1.6 16.8±2.5 20.3±2.5 20.0±1.6 16.6 ±1.9 15.9±2.0 
Total trans FA (g) 0.85±0.10 3.37±1.52  1.4±0.72 1.06±0.19 0.81 ±0.10 1.08±0.26 
Total 
Carbohydrate (g) 
207±19.0 a 213±12.0  191±14.9  304±17.4 261 ±14.6 253±25.6 
Added sugar (g)  47.5±10.9 53.5±9.2 23.1±8.9 c 62.2±6.2 43.4 ±5.0  23.8±8.5 
Total sugar (g) 77.1±7.5 66.4±7.8 46.1±6.4 85.6±7.4 83.8 ±7.9 59.1±13.8 
Starch (g) 27.9±7.8 41.7±10.0 50.6±14.9 a 19.2±3.4 20.7 ±6.5 13.4±2.0 
Total Dietary fibre 
(g) 
16.3±2.0 a 12.7±1.4 a 16.1±2.4 a 24.7±1.9 21.7 ±1.3 25.2±1.1 
Data shown as Mean values ± SEM; adjusted for age 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 
 
 
Groups   
Variables 
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Table 3.17 Food intake questionnaire assessment (excluding LERs) -Part 2 
 
  
LI 
(N=7) 
 
OBI 
(N=6) 
 
DI 
(N=7) 
 
LA 
(N=18) 
 
OBA 
(N=11) 
 
DA 
(N=9) 
Magnesium (mg)  257±20.9 a 216±16.8 a 243±21.2 a 367±22.9 345 ±23.6 371±18.7 
Phosphorus (mg)  1250±107 1098±95.4 a 1200±69 a 1580±99 1508±106  1569±96 
Zinc (mg)  8.2±0.92 a 7.7±0.78 a 8.5±0.38 a 11.1±0.75 10.8 ±0.75 12.5±1.10 
Calcium (mg)  958±121 684±95 802±75 925±95 1027 ±116 870±88 
Total iron (mg)  8.7±1.07 8.5±0.96 7.4±0.60 a 11.8±1.04 9.7 ±0.58 10.7±0.74 
Sodium (mg)  1344±181 1520±99 1561±96 1812±138 1730 ±138 1561±106  
Chloride (mg)  1359±119 1288±236 1611±265 a 1210±116 1413 ±158 1011±125 
Total carotenoids 
(mcg) 
1771±357 2338±628 1990±671 2039±341 1982 ±409 2587±456 
Folate (mcg) 201.4±27.0 201.9±27.8 210.9±20.8 234.4±19.5 226.9±15.7 211.2±13.9 
Vitamin B12 
(mcg) 4.69±0.67 4.52±0.68 4.11±0.40 5.36±0.53 5.42 ±0.49 5.53±0.68 
Vitamin C (mg) 86.8±26.2 105.3±21.2 71.0±22.3 123.2±13.6 126.8 ±20.0 66.9±18.2 c 
Vitamin D (mcg) 3.3±0.66 a 4.3±0.58 3.8±0.68 6.9±0.9 3.9 ±0.8 b 5.8±1.1 
Vitamin E (mg) 8.5±0.6 a 8.8±1.2 11.3±2.4 11.7±1.0 8.8 ±1.4 10.3±1.3 
Lycopene (mcg) 131.7±52 238.9±119 137.8±64.3 58.9±18.1 30.9±11.9 13.5±10.8 
Chromium  (mcg) 46.3±9.4 59.5±12.7 64.4±12.8 52.7±5.5 44.9±8.2 49.1±6.0 
Data presented as Mean values ± SEM; adjusted for age 
a p<0.05 Indian vs. African; b p<0.05 Obese vs. Lean; c p<0.05 Diabetic vs. Obese 
 
Groups 
Variables 
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Table 3.18 Food intake questionnaire assessment in the combined* Indian and 
African groups 
 
  
INDIAN 
(N=50) 
 
AFRICAN 
(N=50) 
  
 
 
 
INDIAN 
(N=50) 
 
AFRICAN 
(N=50) 
Total Energy (kJ) 6131± 230 b 8691± 373 Magnesium (mg)  206.7± 8.6 b 317.3± 14.6 
Total Protein (g) 60.7± 3.2 b 86.3± 3.82 Phosphorus (mg) 938.1±43.1 b 1387± 65.9 
Plant Protein (g)  16.4± 0.7 b 25.4± 1.3 Zinc (mg)  6.79± 0.33 b 9.88± 0.46 
Animal Protein (g) 42.9±2.8 b 60.1± 3.0  Calcium (mg)  586± 40.2 a 860± 61.1 
Total Fat (g) 54.5±2.5 a 68.3± 3.6 Total iron (mg)  7.32± 0.34 a 9.77± 0.56 
Saturated FA (g) 17.7±0.9 a 24.0±1.4 Sodium (mg)  1204± 54.5 a 1548± 83.0 
Monounsaturated FA 
(g) 
17.8 ±0.9 a 21.6± 1.1 Chloride (mg)  996.6± 75.9 1173±79.8 
Polyunsaturated FA (g) 14.4±0.7 16.3±0.9 Vitamin C (mg) 89.7±7.7 105.8± 9.3 
Total trans FA (g) 1.02±0.23 0.86 ±0.08 Folate (mcg) 165.8±8.5 a 209.8±11.4 
Cholesterol (mg) 200.0±13.8 b 342.5± 26.2 Vitamin B12 (mcg) 3.48±0.23 b 5.13±0.32 
Total Carbohydrate (g) 167.2 ± 6.5 b 255.7 ± 11.1 Total carotenoids 
(mcg) 
1914±173 1632±184 
Added sugar (g)  31.8± 3.2 a 49.5 ± 3.3 Vitamin D (mcg) 3.1±0.3 a 5.0± 0.5 
Total sugar (g) 47.9± 3.0 b 75.5 ± 3.9 Vitamin E (mg) 7.40± 0.41 9.38 ± 0.67 
Starch (g) 28.5 ± 3.5 a 18.9 ± 2.6 Lycopene (mcg) 88.6± 22.7 a 41.6± 9.2 
Total Dietary fibre (g) 14.3 ± 0.6 b 20.5 ± 1.1 Chromium  (mcg) 42.6± 3.6 45.9 ± 3.85 
Data shown as Mean values ± SEM; adjusted for age; 
* Obese, overweight, and lean combined; a p<0.05; b p<0.0001Indian vs. African  
 
 
Variables 
Groups  Groups 
Variables 
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Table 3.19 Food intake questionnaire assessment in the combined* Indian and 
African groups (excluding LERs) 
 
 
 
Variables 
 
INDIAN 
(N=19) 
 
AFRICAN 
(N=39) 
 
 
Variables 
 
INDIAN 
(N=19) 
 
AFRICAN 
(N=39) 
Total Energy (kJ) 7733±263 b 9699±348 Magnesium (mg)  252.4±12.6 b 353.6±14.2 
Total Protein (g) 79.0±4.82 a 95.5±3.68 Phosphorus (mg) 1203±58.4 a 1563±62.8 
Plant Protein (g)  19.6±1.1 b 28.1±1.3 Zinc (mg)  8.6±0.52 a 11.0±0.46 
Animal Protein (g) 56.6±4.5 66.2±2.9 Calcium (mg)  780±63.1 a 989±67.4 
Total Fat (g) 69.7±3.4 77.3±3.5 Total iron (mg)  8.6±0.53 a 11.0±0.61 
Saturated FA (g) 23.6±1.2 a 27.4±1.4 Sodium (mg)  1497±82.1   1766±83.4 
Monounsaturated FA 
(g) 
22.8±1.4 24.2±1.1 Chloride (mg)  1317±110 1342±85  
Polyunsaturated FA (g) 17.2±1.1 18.5±1.0 Vitamin C (mg) 100.4±12.7 109.6±10.3 
Total trans FA (g) 1.70±0.53 1.00±0.10 Folate (mcg) 202.6±14.4 235.2±12.4 
Cholesterol (mg) 247±17.8 a 394±29.7 Vitamin B12 (mcg) 4.7±0.38 5.8±0.34 
Total Carbohydrate   
(g) 
208.0±8.8 b 283.9±10.6 Total carotenoids 
(mcg) 
1949±270 1809±218 
Added sugar (g)  41.1±6.3 a 56.0±3.8 Vitamin D (mcg) 3.4±0.37 a 5.9±0.58 
Total sugar (g) 64.8±4.6 a 83.9±4.3 Vitamin E (mg) 8.3±0.50 a 10.9±0.74 
Starch (g) 36.5±6.5 a 20.8±2.9 Lycopene (mcg) 150.2±44.9 a 41.5±9.57 
Total Dietary fibre (g) 16.3±1.2 a 22.8±1.1 Chromium  (mcg) 51.8±6.4 50.7±4.42 
Data shown as Mean values ± SEM; adjusted for age; 
* Obese, overweight, and lean combined; a p<0.05; b p<0.0001 Indian vs. African 
Groups Groups 
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Table 3.20 represents a comparison of total protein, total fat and total carbohydrate expressed 
as percentage of total energy intake in combined Indian and African groups. Statistically 
significant differences were found for fat (higher in Indian) and carbohydrate (higher in 
African). Similar pattern was observed after excluding low energy reporters in these groups. 
 
Table 3.20 Percentage of total energy from macronutrients in the combined* 
Indian and African groups 
 
Data presented as percentage of total energy; a p<0.05; b p<0.0001 Indian vs. African 
* Obese, overweight, and lean combined; ** excluding LER’s 
 
 
In combined African group ratio of protein to carbohydrate (=0.34) didn’t differ from the 
results calculated in this group after exclusion of LER’s. Ratios of protein to carbohydrate in 
Indian group were as follows: 0.36 in combined group and 0.39 when LER’s were excluded. 
Ratios of protein to carbohydrate between combined African and Indian groups were 
statistically significant only when LER’s were excluded (p=0.032). 
 
 
                               Groups 
Variables 
INDIAN* 
(N=50) 
AFRICAN* 
(N=50) 
INDIAN** 
(N=19) 
AFRICAN** 
(N=39) 
 % Of Total Energy Intake 
Total Protein 16.5 16.7 17.2 16.6 
Total Fat 33.1 a 29.3 34.0 a 29.9 
Total Carbohydrate 46.2 a 49.7 45.2 a 49.3 
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3.8 Correlation and regression data analysis 
 
Spearman rank correlation coefficients were used to analyse relationships between continuous 
variables. Beta cell variables that were investigated for correlation with anthropometric 
variables were: insulin (fasting and AUC), proinsulin/insulin ratio (fasting and AUC), and 
HOMA and insulinogenic index. As the main aim of our study was to investigate the factors 
associated with obesity- related changes in metabolic and hormonal parameters in two ethnic 
groups we decided to combine lean, obese and overweight subjects. It would not be 
statistically viable to use small groups in correlation and regression analysis. It is statistically 
valid to combine the different BMI groups because many of the metabolic differences between 
obese and lean subjects are due to the BMI differences. The best way to show this is to 
combine the groups and run multiple regression analysis including BMI, or other 
anthropometric variables as an independent variable. The diabetic patients were not included 
in the combined groups for correlation and regression analysis due to the fact that diabetic 
patients are known to exhibit a cluster of metabolic disturbances that may not be due to 
anthropometric differences. Therefore, including them in regression analysis may obscure 
relationships in the non-diabetic subjects that are driven by BMI. The diabetic subjects were 
therefore analysed by comparing them with BMI-matched non-diabetic subjects.  
Multiple linear regression models for step-down backward selection were used to select 
dominant independent variables (see section 2.8) and results presented as R-Square and p 
values. All variables that stay in the model were significant at the 0.05 level. Independent 
variables included in the initial regression models were the ones that had statistically 
significant correlation with dependent variables in the Spearman test. Age was included in all 
regression models as an independent variable. Collinearity between variables was considered 
and independent variables like weight, height and waist/height ratio were excluded from the 
model where BMI also correlated significantly with dependent variables. No correlation 
analyses were performed for the food questionnaire assessment due to the small sample 
number after exclusion of low energy reporters. 
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3.8.1 Anthropometric parameters versus beta cell function in the combined 
African group (excl. diabetics) 
 
Table 3.21 shows the results of correlation analyses between beta-cell function and 
anthropometric variables in the combined African group. Waist circumference had significant 
correlation with visceral fat in the combined African group (r= 0.816, p<0.0001).  
No correlations were found between anthropometric variables and HOMA or 
proinsulin/insulin ratio. Age, WC, BMI, body fat (%), visceral and subcutaneous fat were 
included in regression model as independent variables and insulin (AUC) as the dependent 
variable. Linear regression analysis demonstrated that visceral fat could explain 26% of the 
variance in total insulin (p=0.014). Age, HC, BMI, waist/height ratio, body fat (%), visceral 
and subcutaneous fat had significant correlations with insulinogenic index.  However the 
relationship didn’t persist in a regression model.  
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Table 3.21Anthropometric parameters versus beta cell function in the combined* 
African group 
 
      Variables  Insulin AUC Insulinogenic index 
BMI 0.369 a 0.391 a 
HC 0.239 0.372 a 
WC 0.381 a 0.379 a 
Waist/Height 0.368 a 0.381 a 
Body Fat (%) 0.375 a 0.350 a 
Subcutaneous fat 0.347 a 0.386 a 
Visceral fat 0.563 a 0.414 a 
               Data presented as Spearman Correlation Coefficient (r); adjusted for age   
                  * Obese, overweight, and lean combined; a p<0.05; b p<0.0001  
 
3.8.2 Anthropometric parameters versus beta cell function in the combined 
Indian group (excl. diabetics) 
 
Table 3.22 shows the results of correlation analyses between anthropometric parameters and 
beta cell function in the combined Indian group. Waist circumference had significant 
correlation with visceral fat in the combined Indian group (r=0.778, p<0.0001).  
No correlations were found between anthropometric parameters vs. proinsulin/insulin ratio 
(AUC and fasting) and insulinogenic index. Age, waist/height ratio and visceral fat were 
included in regression model as independent variables and insulin (AUC) as dependent 
variable. Linear regression analysis demonstrated that waist/height ratio could explain 29% of 
the variance in insulin (AUC) (p=0.0012). Age, BMI, HC and visceral fat were each 
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significant predictors (58%) of fasting insulin in a regression model (p=0.021, 0.006, 0.003 
and 0.005, respectively). Age, BMI, HC, WC, body fat (%), subcutaneous and visceral fat 
were included in regression model as independent variables and HOMA as dependent 
variable. BMI, HC and visceral fat were the only independent variables that could explain 
55% of the variance in HOMA (p=0.007, 0.009 and 0.023, respectively). 
 
 
Table 3.22 Anthropometric parameters versus beta cell function in the combined* 
Indian group 
 
         Variables Insulin Fasting Insulin-AUC HOMA 
BMI 0.521 a 0.295 0.502 a 
HC 0.405 a 0.187 0.387 a 
WC 0.619 b 0.435 a 0.609 a 
WHR 0.552 a 0.464 a 0.548 a 
Waist/Height 0.664 b 0.483 a 0.657 b 
Body Fat (%) 0.548 a 0.327 0.532 a 
Subcutaneous fat 0.498 a 0.290 0.480 a 
Visceral fat 0.546 a 0.391 a 0.554 a 
             Data presented as Spearman Correlation Coefficient (r); adjusted for age 
                     * Obese, overweight, and lean combined; a p<0.05; b p<0.0001   
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3.8.3 Anthropometric parameters versus intermediate metabolic variables, 
lipids and adipokines in the combined African group (excl. diabetics) 
 
Table 3.23 represents correlation data between anthropometric parameters versus intermediate 
metabolic variables, lipids and adipokines in the combined African group (excl. diabetics). 
Not included in the table were the following correlations: fasting glucose correlated positively 
with WHR (r=0.352 a). HC had positive correlations with fasting and total (AUC) glycerol 
(r=0.395 a and 0.393 a, respectively).  
Visceral fat positively correlated with cholesterol (r=0.451 a). WC, waist/height ratio and 
visceral fat had positive correlation with triglycerides (r=0.354 a, 0.428 a and 0.403 a, 
respectively). Age, waist/height ratio and visceral fat were included in a regression model as 
independent variables and triglycerides as dependent variable. Waist/ height ratio had 21% 
association with triglycerides (p=0.021). We replaced waist/height ratio with WC in another 
regression model and likewise WC had 21% association with triglycerides (p=0.027). 
BMI and body fat (%) negatively correlated with HDL cholesterol (r=-0.355 a and -0.360 a, 
respectively). However the relationship didn’t persist in a regression model. Age was the only 
independent variable that could explain 15% of the variance in HDL cholesterol (p=0.04). No 
correlations were found between IL-6 versus CRP and TNF-α in the combined African group. 
Leptin and soluble leptin receptor didn’t have any correlations with triglycerides, FFA (AUC 
and fasting) or CRP when corrected for age and BMI. No correlations were found between 
TNF-α and glycerol (fasting and total) when corrected for age and HC. 
Age, BMI, waist/height ratio, body fat (%), visceral and subcutaneous fat were included in 
regression model as independent variables and total glucose as dependent variable. Age and 
subcutaneous fat were the only independent variables that could explain 32% of the variance 
in total glucose (p=0.015 and 0.013, respectively). We replaced in another regression model 
waist/height ratio variable with WC and results were similar, indicating a strong association 
between subcutaneous fat and glucose (AUC) in the combined African group. 
Age, WC, HC, BMI, body fat (%), visceral and subcutaneous fat were included in regression 
model as independent variables and LDL cholesterol, leptin, soluble leptin receptor and CRP 
as dependent variables. Visceral fat was the only independent variable that could explain 35 % 
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of the variance in LDL cholesterol and 40 % of the variance in CRP (p=0.001 and 0.0002, 
respectively). Body fat (%) and subcutaneous fat were significant determinants (85%) of the 
variance in leptin (p=0.0035 and 0.016, respectively). Subcutaneous fat had 49% association 
with soluble leptin receptor (p=<0.0001). Leptin level in the combined African and Indian lean 
groups correlated significantly with body fat (%), total subcutaneous and visceral fat, upper 
and lower body subcutaneous fat when corrected for age and ethnicity (r=0.390, 0.403, 0.330, 
0.366 and 0.407, respectively, with p<0.05 for all). We included age, ethnicity, body fat (%), 
subcutaneous and visceral fat, upper and lower body subcutaneous fat in a regression model as 
independent variables and leptin as dependent variable. Ethnicity and total subcutaneous fat 
were the only independent variable that could explain 44% of the variance in leptin (p=0.007 
and 0.024, respectively). 
Age, WC, BMI, visceral and subcutaneous fat were included in regression model as 
independent variables and cortisol (fasting and total) as dependent variables. Linear regression 
analysis demonstrated that WC was the only independent variable explaining 23% of the 
variance in fasting and 19% in total (AUC) cortisol (p=0.009 and 0.012, respectively). 
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Table 3.23 Anthropometric parameters versus intermediate metabolic variables, 
lipids and adipokines in the combined* African group 
 
 
Variables 
Glucose 
AUC 
Cortisol 
fasting 
Cortisol-
AUC 
LDL 
 
Leptin Leptin 
receptor 
CRP 
BMI     0.344 a -0.370 a -0.352 a 0.409 a 0.842 b -0.670 b 0.563 a 
HC 0.296 -0.329 -0.346 0.373 a 0.763 b -0.592 a 0.382 a 
WC 0.356 a -0.475 a -0.453 a 0.383 a 0.787 b -0.620 a 0.532 a 
Waist/Height 0.396 a -0.440 a -0.386 a 0.348 a 0.826 b -0.518 a 0.582 a 
Body Fat (%) 0.387 a -0.323 -0.323 0.439 a 0.837 b -0.654 b 0.558 a 
Subcutaneous fat 0.395 a -0.383 a -0.395 a 0.403 a 0.864 b -0.661 b 0.485 a 
Visceral fat 0.355 a -0.435 a -0.357 a 0.567 a 0.814 b -0.664 b 0.635 b 
Data presented as Spearman Correlation Coefficient (r); adjusted for age;  
* Obese, overweight, and lean combined; a p<0.05; b p<0.0001  
 
 
3.8.4 Anthropometric parameters versus intermediate metabolic variables, 
lipids and adipokines in the combined Indian group (excl. diabetics) 
 
Table 3.24 represents correlation data between anthropometric parameters versus intermediate 
metabolic variables, lipids and adipokines in the combined Indian group. Not included in the 
table were following correlations: Visceral fat had positive correlation with fasting lactate  
(r=0.416 a). Height had negative correlation with TNF-α (r=-0.355 a).  
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No correlations were found between IL-6 versus CRP and TNF-α in the combined Indian 
group. No correlations were found between glucose (fasting and AUC) and anthropometric 
variables in the combined Indian group. Leptin and soluble leptin receptor didn’t have any 
correlations with triglycerides, FFA (AUC and fasting) or CRP when corrected for age and 
BMI. Positive correlation was found between leptin and TNF-α (r=0.289 a). No correlations 
were found between TNF-α and glycerol (fasting and total) when corrected for age and HC. 
Age, WC, HC, BMI, body fat (%), visceral and subcutaneous fat were included in regression 
model as independent variables and FFA (AUC), glycerol (AUC), triglycerides, leptin, soluble 
leptin receptor and hs-CRP as dependent variables. Linear regression analysis demonstrated 
that HC as independent variable could explain 37% of the variance in FFA (AUC) (p=0.002). 
BMI had 32% association with glycerol (AUC), 40% association with soluble leptin receptor 
and 35% association with hs-CRP (p=0.009, 0.0002 and 0.007, respectively). Visceral fat was 
the only independent variable that could explain 36% of the variance in triglycerides 
(p=0.0017). Body fat (%) was the only independent variable that could explain 57% of the 
variance in leptin (p=<0.0001). Age, BMI and WHR were included in regression model as 
independent variables and HDL cholesterol as dependent variable. Age and WHR had 39% 
association with HDL cholesterol (p=0.016 and <0.0001, respectively). 
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Table 3.24 Anthropometric parameters versus intermediate metabolic variables, 
lipids, and adipokines in the combined* Indian group (excl. diabetics) 
 
 
Variables 
FFA 
AUC 
Glycerol 
AUC 
HDL Triglycerides Leptin Leptin 
receptor
CRP 
Weight 0.584a 0.477 a -0.337 0.490 a 0.594 a -0.652 b 0.511 a 
BMI 0.488 a 0.422 a -0.350 a 0.424 a 0.609 a -0.629 a 0.482 a 
HC 0.550 a 0.490 a -0.184 0.361 a 0.588 a -0.561 a 0.551 a 
WC 0.564 a 0.496 a -0.462 a 0.455 a 0.535 a -0.616 a 0.447 a 
Waist/Height 0.467 a 0.426 a 0.483 a 0.435 a 0.554 a 0.625 a 0.438 a 
Body Fat (%) 0.441 a 0.397 a -0.318 0.411 a 0.637 b -0.631 a 0.507 a 
Subcutaneous fat 0.508 a 0.459 a -0.152 0.353 a 0.613 a -0.584 a 0.576 a 
Visceral fat 0.528 a 0.448 a -0.255 0.671 b 0.451 a -0.534 a 0.417 a 
Data presented as Spearman Correlation Coefficient (r); adjusted for age 
* Obese, overweight, and lean combined; a p<0.05; b p<0.0001  
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3.8.5 Anthropometric parameters, beta cell, intermediate metabolic and 
adipokines levels versus blood pressure measurements in the combined 
African group (excl. diabetics) 
 
Systolic BP correlated positively with BMI, HC, WC, and waist/height ratio, body fat, 
subcutaneous and visceral fat when corrected for age (r=0.437 a, 0.373 a, 0.491 a and 0.411 a, 
0.406 a, 0.436 a, 0.402 a, respectively). We included in a regression model as independent 
variables age and anthropometric parameters that had correlation with systolic BP, excluding 
waist/height ratio due to collinearity. WC was the only independent variable that could explain 
25% of the variance in systolic BP (p=0.004). Systolic BP had negative correlation with 
lactate (AUC) when corrected for age and BMI (r=-0.378 a). 
Diastolic BP had positive correlations with BMI, WC, WHR, waist/height ratio, and body fat, 
subcutaneous and visceral fat (r=0.358 a, 0.491 a, 0.490 a, 0.420 a, 0.326 a, 0.371 a and 0.525 a, 
respectively). We included in a regression model as independent variables age and 
anthropometric parameters that had correlation with diastolic BP, excluding WHR and 
waist/height ratio due to collinearity. Age and WC were the only independent variables that 
could explain 40% of the variance in diastolic BP (p=0.038 and 0.002, respectively). Diastolic 
BP correlated positively with glucose (AUC), fasting C-peptide and HOMA (r=0.378 a, 0.310 a 
and 0.327 a, respectively) when corrected for age and BMI. We therefore performed a 
regression analyses and included in a model as independent variables age, WC, glucose 
(AUC), fasting C-peptide and HOMA. WC and glucose (AUC) were the only independent 
variables that could explain 43% of the variance in diastolic BP (p=0.001 and 0.0009, 
respectively) in combined African group. 
Systolic BP displayed a positive correlation with leptin (r=0.401, p=0.004) and a negative 
correlation with soluble leptin receptor (r=-0.363, p=0.01) in the African group. However, 
when leptin and leptin receptor were included as independent variables in a regression model 
with the anthropometric parameters, such as BMI, HC, WC, body fat (%), subcutaneous and 
visceral fat, only WC remained significant, explaining 26% of the variance in systolic BP 
(p=0.004). Diastolic BP correlated positively with leptin (r=0.457, p=0.001) and CRP 
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(r=0.373, p=0.008) and correlated negatively with leptin receptor (r=-0.428, p= 0.002) in the 
African group. We included in a regression model BMI, WC, subcutaneous and visceral fat, 
leptin, leptin receptor and CRP as independent variables and diastolic blood pressure as 
dependent variable. Age and WC were the only variables that displayed a significant 
correlation, explaining 44% of the variance in diastolic BP (p=0.038 and 0.002, respectively) 
in the African group. 
 
3.8.6 Anthropometric parameters, beta cell, intermediate metabolic and 
adipokines levels versus blood pressure measurements in the combined 
Indian group (excl. diabetics) 
 
Hip circumference and subcutaneous fat were the only anthropometric variables that had 
positive correlations with systolic BP in the combined Indian group (r=0.375 a and 0.338 a, 
respectively). Systolic BP correlated positively with fasting intact proinsulin and fasting 
proinsulin/insulin ratio when corrected for age and BMI (r=0.345 a and 0.334 a, respectively). 
Age, HC, subcutaneous fat and fasting intact proinsulin were included in regression model as 
independent variables. Age was the only independent variables that could explain 31% of the 
variance in systolic BP as dependent variable (p=0.005). 
Diastolic BP had positive correlations with BMI, HC, WC, body fat (%), subcutaneous fat and 
visceral fat (r=0.386 a, 0.405 a, 0.347 a, 0.413 a, 0.399 a and 0.380 a, respectively). When these 
variables and age were included in a multiple regression analysis BMI and body fat (%) were 
the only independent variables that could explain 46% of the variance in diastolic BP (p=0.004 
and 0.001, respectively). Diastolic BP correlated positively with glucose (AUC), fasting intact 
proinsulin, fasting proinsulin/insulin ratio and lactate (AUC) when corrected for age and BMI 
(r=0.367 a, 0.317 a, 0.316 a and 0.290 a, respectively). Age, BMI, body fat (%), glucose (AUC), 
fasting proinsulin/insulin ratio and lactate (AUC) were included in regression model as 
independent variables. BMI, body fat (%) and glucose (AUC) were the only independent 
variables that could explain 49% of the variance in diastolic BP (p=0.006, 0.001 and 0.043, 
respectively). 
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In the Indian group a positive correlation between leptin and systolic BP was observed 
(r=0.312, p=0.029). The relationship did persist in a regression model with leptin, and HC as 
independent variables and systolic BP as dependent variable: age and leptin explained 33% of 
the variance in systolic BP (p=0.002 and 0.02, respectively). No correlations were found 
between adipokines and diastolic BP in the Indian group. BMI and body fat (%) were the only 
independent variables in a regression model that could explain 45% of the variance in diastolic 
BP in the Indian group (p=0.004 and 0.001, respectively). 
 
 
3.8.7 Anthropometric parameters, insulin, intermediate metabolic variables, 
lipids levels, and blood pressure versus socio-economic status in the 
combined African group (excl. diabetics) 
 
Education and household amenities had positive correlations with insulin (AUC) and negative 
correlations with HIE (AUC) when corrected for age and BMI (r=0.440 a, 0.319 a, and -0.621 b, 
-0.312 a, respectively). Education correlated negatively with proinsulin/insulin ratio (AUC) 
and had positive correlation with insulinogenic index (r=-0.445 a, and 0.344 a, respectively). 
Household amenities had positive correlation with HDL cholesterol (r=0.332 a). No other 
correlations were found between anthropometric variables, lipids, adipokines and blood 
pressure versus socio-economic status in the combined African group when corrected for age 
and BMI. 
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3.8.8 Anthropometric parameters, insulin, lipids and blood pressure versus 
socio-economic status in the combined Indian group (excl. diabetics) 
 
Education had negative correlations with BMI, WC, waist/height and body fat (%), 
subcutaneous and visceral fat (r=-0.422 a, -0.430 a, -0.436 a, -0.456 a, -0.431 a and -0.449 a, 
respectively). In the combined Indian group education had negative correlations with insulin 
(AUC), diastolic BP and positive correlation with proinsulin/insulin ratio (AUC) when 
corrected for age and BMI (r=-0.364 a, -0.299 a and 0.353 a, respectively). Age, visceral fat and 
education were included in a regression models as independent variables with insulin (AUC) 
and diastolic BP as dependent variables. Education could explain 32% of the variance in 
insulin (AUC) (p=0.0010) whereas visceral fat was the only independent variable that had 
36% interaction with diastolic BP (p= 0.003). 
Household amenities had negative correlations with WHR and triglycerides (r=-528 a and  
- 0.459 a, respectively). Age, WHR and household amenities were included in a regression 
model as independent variables with triglycerides as dependent. Household amenities were the 
only independent variables that could explain 18% of the variance in triglycerides (p=0.004). 
No other correlations were found between socio-economic status versus anthropometric 
parameters, insulin, lipids, adipokines and blood pressure in the combined Indian group. 
 
3.8.9 HOMA-IR versus lipids, intermediate metabolic parameters, 
adipokines and socio-economic status in the combined African group (excl. 
diabetics) 
 
No correlations were found between HOMA-IR versus lipids, intermediate metabolic 
parameters, adipokines and socio-economic status when corrected for age and BMI in the 
combined African group (excl. diabetics). Diastolic BP had a positive correlation with 
HOMA-IR (r=0.374, p=0.009). HOMA-IR correlated negatively with fasting 
proinsulin/insulin ratio (r=-0.644 b), but no correlations were found with total (AUC) 
proinsulin/insulin ratio. 
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3.8.10 HOMA-IR versus lipids, intermediate metabolic parameters, 
adipokines and socio-economic status in the combined Indian group (excl. 
diabetics) 
 
HOMA-IR had positive correlations with lactate (AUC and fasting) (r=0.360 and 0.411, 
p=0.017 and 0.003, respectively) and negative correlation with HDL cholesterol (r=-0.328, 
p=0.022) when corrected for age and BMI. HOMA-IR correlated negatively with total (AUC) 
proinsulin/insulin ratio (r=-0.425, p=0.002), but no correlations were found with fasting 
proinsulin/insulin ratio. No correlations were found between HOMA-IR versus adipokines and 
socio-economic status when corrected for age and BMI in the combined Indian group (excl. 
diabetics). 
 
  
182
 
CHAPTER 4 - DISCUSSION 
 
The present study was carried out in an attempt to explain the possible role of body fat 
distribution, intermediate metabolic indices, aspects of beta-cell function, certain adipokines, 
socio-economic status and dietary intake on the development of obesity-related disorders in 
two South African ethnic groups, namely Indian and African women. To our knowledge this is 
the first time that these variables have been compared in these ethnic groups in a single study. 
 
4.1 Body fat distribution & other anthropometric variables 
 
There are many indications that in some ethnic groups (particularly of Asian origin), the risk 
of diabetes starts to increase rapidly at BMI or waist circumference levels that fall within the 
acceptable range for Europeans (Seidell,2000). This raises an important issue regarding the use 
of BMI in the definition of obesity in different races and predicting disease risk. Raji et al., 
(2001) suggested that, even at a lower BMI, Asian Indians are profoundly insulin resistant and 
have increased total abdominal fat compared to European population, which may explain their 
increased prevalence of diabetes and coronary heart disease. Lowering the BMI cut-off points 
in Asian populations may be beneficial in early identification of individuals at high risk for 
developing obesity-related disorders. In the present study the criteria used for defining high 
waist circumference were those specified by NCEP: ATP III, 2001. To our knowledge there 
are no established cut-off points for South African Indian and African population, therefore in 
our estimation of metabolic syndrome we applied equal cut-off points in both ethnic groups. 
Bioelectrical impedance analysis was used to measure percentage body fat levels. This method 
has been admonish in terms of its accuracy however, the BODYSTAT technology has been 
scientifically validated for both its accuracy of measurement of impedance in vivo and in the 
application of its unique regression equation (unpublished) to determine body composition 
with particular reference to the obese population group (Smye et al., 1993). The accuracy of 
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bioelectrical impedance in estimating the body fat-fat mass is comparable to densitometry with 
lower predictive error or standard error of 2.7% (Lukaski et al., 1986). Our results revealed a 
strong correlation between BMI and body fat (%) assessment by BODYSTAT in Indian and 
African groups (r= 0.987* and 0.987*, respectively, *p< 0.0001). Therefore, it is unlikely that 
the large ethnic difference in TNF-α, lipids, leptin or HOMA-IR were due to ethnic 
differences in body fat % levels that were undetected using the BODYSTAT technology. 
Statistically significant differences in anthropometry between the obese and overweight 
subjects were not found and this may be a result of the small sample size in the overweight 
group. In our study we found that visceral fat accumulation was greater in diabetic and lean 
Indian subjects than in diabetic and lean African groups. This fat depot is more lipolytically 
active than subcutaneous fat (Kissebah et al., 1989, Bjorntorp , 1991) due to higher β-
adrenoreceptor mediated catecholamine-induced lipolysis and greater resistance to the 
antilipolytic activity of insulin (Hoffstedt   et al., 1997). Measures of subcutaneous fat were 
higher in lean Indian than African women but lower in obese Indian than African subjects 
(Present study). Our data therefore confirms the suggestion of Raji et al., (2001) that at any 
given BMI, Indian subjects have more visceral fat than other ethnic groups and may explain 
their higher risk for obesity-related disorders at lower BMI than non-Indian populations.  
The upper body subcutaneous fat level was significantly higher in lean Indian than lean 
African women but lower in obese Indian than obese African subjects. The upper body 
subcutaneous fat was much more pronounced in obese subjects compared to the lean subjects 
in both ethnic groups. This may be an important predictor of metabolic abnormalities in the 
obese group of women. The literature suggests that individuals with peripheral obesity ('pears') 
possess fat distributed subcutaneously in gluteofemoral areas and the lower part of the 
abdomen, and are at little risk of metabolic complications. Individuals with upper-body 
obesity ('apples') accrue fat in subcutaneous and visceral deposits and predisposed to the 
development of metabolic and cardiovascular complications (Lafontan et al., 2003). On the 
other hand, accumulation of fat in lower body subcutaneous adipose tissue depots linked to a 
lower probability of insulin resistance and type 2 diabetes than when it deposits in centrally 
located sites (Livingston, 2006). Lower body peripheral fat may safeguard the effect of excess 
ingested energy, and central body fat may be involved in the pathogenesis of insulin resistance 
and type 2 diabetes (Livingston, 2006). 
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The study by Virtanen et al., (2002) demonstrated that insulin-stimulated glucose uptake rate 
per gram of tissue was higher in visceral, compared to subcutaneous adipose tissue, regardless 
of the magnitude of obesity. One reason for higher glucose uptake in visceral adipose tissue in 
comparison with subcutaneous adipose tissue may be different sizes of the adipocytes in these 
depots; visceral adipocytes are smaller than subcutaneous and visceral fat contains more 
adipocytes per gram than subcutaneous fat, which may facilitate glucose uptake (Rebuffe-
Scrive et al., 1989). Therefore, despite the fact that the intra-abdominal visceral adipose tissue 
is metabolically more active than sc adipose tissue per tissue weight, the large size of the 
subcutaneous adipose tissue depot makes it an important regulator of whole-body glucose 
metabolism (Virtanen et al., 2002). In the present study subcutaneous fat did explain some of 
the variance in total glucose levels in the combined African group while no correlations were 
found between glucose (fasting and AUC) and anthropometric variables in the combined 
Indian group. The reason for this difference needs further investigation. 
Waist/height ratio has been proposed as an alternative to waist circumference for the 
evaluation of abdominal adiposity which takes into account differences in height (Hsieh et 
al.,1995a, Hsieh et al.,1995b), but the usefulness of this parameter has been questioned (Sattar 
et al.,1998). Some previous studies reported that waist/height ratio had a stronger association 
with cardiovascular risk factors than waist circumference alone (Hsieh et al.,1995a, Hsieh  et 
al.,1995b). In our study correlations of waist/height ratio and waist circumference with 
cardiovascular risks factors demonstrated that waist/height was no better than WC at 
predicting CVD risk factor levels. However, waist/height ratio was the best predictor of 
insulin (AUC) in the Indian group. 
 
4.2 Beta-cell evaluation and insulin resistance 
 
Metformin belongs to biguanide class of oral anti-diabetic drug. The half life of metformin is 
6.2 hours. Metformin absorption is comparatively slow and may prolong over about 6 hours. 
The initial elimination of metformin is quick with a half-life varying between 1.7 and 3 hours. 
4-5% of the absorbed dose that accounts in the terminal elimination phase is slow and could 
prolong with a half-life between 9 and 17 hours (http://www.drugs.com/metformin.html). 
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Subjects with type 2 diabetes were asked to stop oral anti-diabetes drugs 24 hours prior to the 
OGTT; therefore drug-induced interference with measures of beta cell function from 
metformin was probably avoided. However for Gliclazide at the time of the OGTT drug orally 
administered 24 hours beforehand would still be present in the circulation. 
 To establish the effect of Gliclazide and Metformin on measurements of fasting glucose and 
insulin we compared diabetic patients in the Indian and African groups, with and without use 
of Gliclazide and Metformin. The fasting glucose and insulin levels were not significantly 
different between those groups. Thus we may state that in our group of diabetic patients the 
use of different anti-diabetic drugs did not influence results in the present study. 
Our results clearly indicated that obese Indians had significantly higher fasting glucose, des 
31, 32 proinsulin, C-peptide and HOMA-IR levels and lower proinsulin/insulin ratio than 
obese African subjects whilst the fasting levels of intact proinsulin and proinsulin /insulin ratio 
were significantly lower in lean Indian than lean African women. This suggests that lean and 
obese Indians have better β-cell proinsulin-processing efficiency than Africans, probably due 
to higher secretory load imposed on beta cells by a higher level of insulin resistance in the 
Indian subjects. Obese and lean Indian subjects were far more hyperinsulinemic in comparison 
with African subjects during the 5-hour OGTT, again suggesting greater insulin resistance in 
Indians. 
In the present study HOMA-IR was significantly different between groups with metabolic 
syndrome and without metabolic syndrome in non-diabetic subjects in both ethnic groups. 
Adjustment for waist circumference did not have any influence on the results suggesting that 
metabolic syndrome in both ethnic groups is associated with insulin resistance. Diabetic 
Indian women in our study had significantly higher fasting intact proinsulin, des 31, 32 split 
proinsulin and C-peptide levels than diabetic African women. The similarity in insulin levels 
of the two diabetic groups in the presence of a significant difference in C-peptide 
concentrations may reflect differences in hepatic insulin clearance. 
A hyperbolic relationship between insulin secretion and action is referred to as the disposition 
index and suggest that insulin sensitivity and insulin secretion are linked through a negative 
feedback loop. This model might explain enchanced β cell function when individuals becomes 
more insulin resistant (Bergman et al., 1981, Kahn et al., 1993). The greater insulin resistance 
and higher levels of proinsulin and split proinsulin are markers of risk for type 2 diabetes 
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(Pradhan et al., 2003) and it is known that type 2 diabetes is more common in the Indian 
population of South Africa (Omar et al., 1985, Omar et al., 1994, Motala et al., 2003a). The 
current study shows that serum insulin, des 31, 32 split proinsulin and C-peptide are 
significantly higher and hepatic insulin extraction (HIE) and proinsulin/insulin ratio 
significantly lower in the Indian group compared to the African group. This suggests higher 
insulin resistance, which is compensated for by reduced HIE and improved proinsulin-
processing in the non-diabetic Indians compared to the non-diabetic African group. The higher 
proinsulin-processing efficiency observed in the Indian compared to the African subjects in 
conjunction with the higher prevalence of diabetes in the former population group suggests 
that in Indian subjects the secretory and proinsulin-processing burden placed at the β-cells by 
the high level of insulin resistance eventually leads to β-cells “burn out” and the development 
of glucose intolerance and eventual type 2 diabetes. 
In the combined African group linear regression analysis demonstrated that visceral fat could 
explain some of the variance in insulin (AUC). In the combined Indian group linear regression 
analysis demonstrated that waist/height ratio had an association with total insulin and age, 
whilst BMI, HC and visceral fat were significant predictors of fasting insulin. BMI, HC and 
visceral fat were the only independent variables that could explain variance in HOMA-IR in 
the combined Indian group. Thus, visceral fat is a strong determinant of insulin levels in both 
ethnic groups and may partially explain higher insulin levels in Indian females. Furthermore, 
elevated insulin, proinsulin and split proinsulin levels have been shown to be CVD risk factors 
(Reaven, 1992, Haffner et al.,1993,  McFarlane et al., 2001) and the higher levels in the Indian 
group mirror the higher prevalence of CVD in this population group. 
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4.3 The relationship of anthropometric and metabolic variables 
with blood pressure 
 
In data collected annually in England between 1991-1996 that compared blood pressure (BP) 
levels and hypertension rates in people of white, black (combining black-Caribbean, black-
African and black-other), and South Asian origin (combining Indians, Pakistanis and 
Bangladeshis) the age-adjusted mean BP levels and hypertension rates of older adults were 
highest among blacks, while South Asian men showed BP levels and hypertension rates 
similar to black men and South Asian women had mean BP levels and hypertension rates 
similar to white women (Primatesta et al., 2000).The study by Morar et al., (1998), that 
compared the blood pressure profile in Indian and  black students in South Africa, showed that 
young black people had higher blood pressure readings than young Indian participants in the 
absence of metabolic abnormalities. 
We found in our study that in both ethnic groups BP was higher in obese than lean subjects. 
Systolic blood pressure was higher in diabetics than obese subjects in the African and Indian 
groups but only reached statistical significance in the Africans. In our study diabetic Indian 
women had significantly lower diastolic BP than diabetic Africans. No ethnic differences in 
BP were observed in the non-diabetic subjects. 
Some authors suggest that BMI, a general indicator of obesity, is a better correlate of blood 
pressure (BP) than the WHR among African Americans (Adams-Campbell et al.,1994), 
whereas other investigators found that waist circumference was positively correlated with BP 
in Nigerians, Jamaicans and African Americans (Okosun et al.,1998). Gupta et al., (2007) 
discussed in their study a significant positive correlation of BMI, waist-size and WHR with 
systolic BP and diastolic BP in an urban Indian population. 
The relationship between indices of adiposity (WC, waist-to-hip ratio, BMI or skin-fold 
thickness) and ambulatory or conventional BP was determined in 300 randomly selected 
individuals of African descent living in an urban community in South Africa (Majane et al., 
2007). Their results showed that WC is the only clinical index of adiposity that is associated 
with 24-h and conventional BP measurements independent of other adiposity indices in a 
community with a high prevalence of obesity.  
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This data is in agreement with our study where in the combined African group WC was the 
only independent predictor in a regression model that could explain variance in systolic BP. 
Hip circumference (HC) was the only anthropometric variable that had positive correlations 
with systolic BP in the combined Indian group. Age and WC were the only independent 
variables that had an association with diastolic BP in the combined African group. BMI and 
body fat (%) were strong predictors of the variance in diastolic BP in the combined Indian 
group. Ethnic differences in the determinants of blood pressure in relationship to 
anthropometric variables showed the importance of abdominal obesity in the African group 
whilst in Indian group the total body fat was more important. 
Leptin-mediated sympatho-activation emerge as on of the major mechanisms leading to the 
development of obesity-induced hypertension. Leptin also negatively shifts the renal pressure-
natriuresis curve, leading to relative sodium retention (Haynes, 2005). The study by Wada et 
al., (2006) showed that leptin was positively related with diastolic BP independent of insulin 
resistance among the subjects in the normal blood pressure range, but this relationship was not 
found among the subjects having higher blood pressure. Although the association between 
leptin and diastolic BP was independent of BMI, BMI adjustment had attenuated the 
association remarkably, suggesting that leptin is a physiological mediator/or a marker/ of 
diastolic BP elevation in obesity.  
The finding that increasing plasma leptin, to levels similar to those found in obesity, raises 
arterial pressure in non-obese rats is consistent with the hypothesis that leptin is an important 
link between obesity, sympathetic activity and hypertension. The complex relationships 
between leptin and long-term blood pressure regulation is further illustrated by the finding that 
lower body obesity causes greater increases in leptin than visceral obesity, even though 
visceral obesity is more closely associated with hypertension (Hall et al., 2000). A number of  
clinical studies have shown increased plasma leptin levels in subjects  with essential 
hypertension and a significant positive correlation between leptin and blood pressure 
independent of body adiposity both in normotensive and in hypertensive individuals 
(Beltowski, 2006). 
In our study systolic and diastolic BP had positive correlations with leptin and negative 
correlations with leptin receptor in the African group, but this relationship didn’t persist in a 
regression model when adjusted for BMI, HC, WC, body fat (%), subcutaneous and visceral 
  
189
fat. Waist circumference was the only variable that explained significant variance in systolic 
and diastolic BP in the African group. In the Indian group systolic BP correlated positively 
with leptin and the relationship did persist in a regression model after adjustments for 
anthropometric covariates. The reason for the presence of a correlation between leptin levels 
and BP in the Indian but not African subjects is not known, but few studies indicated similar 
results.  
El-Gharbawy et al., (2002) evaluated associations of leptin with blood pressure (BP) in 
normotensive and hypertensive, matched for BMI, African American individuals. The plasma 
leptin was higher in hypertensive women than in normotensive women. No significant 
correlations were found between leptin and BP after adjustment for obesity and insulin 
resistance; although leptin independently predicted 28% of the variability of heart rate in 
hypertensive men and 18% of the variability of lithium clearance in hypertensive women. 
Authors proposed that although there is no direct or independent association of leptin with BP 
leptin may contribute to hypertension in these women by increasing renal tubular sodium 
reabsorption. 
The study by Schutte et al., (2005a) showed that while leptin levels were the same in 
overweight/obese hypertensive and normotensive African women, it was directly and 
positively associated with systolic blood pressure and pulse pressure only in overweight/obese 
hypertensive African women after adjustment for obesity, insulin-resistance, 
hyperinsulinaemia and age. In related study leptin levels were similar in obese African and 
Caucasian women, but association with diastolic blood pressure and total peripheral resistance 
was found only in obese Caucasians, but not in obese Africans (Schutte et al., 2005b). 
Insulin resistance has been found to be a common feature of essential hypertension (Baron et 
al., 1993). Ferrannini et al., (1997) have analyzed the relationship between insulin sensitivity 
and blood pressure and have shown that insulin sensitivity contributes to blood pressure 
variability. The increase in systolic blood pressure of 1.7 mm Hg and an increase of diastolic 
blood pressure of 2.3 mm Hg were found for each 10-unit increase in insulin resistance (in a 
molar value it is a decrease of 10 µM/min per kilogram). 
Possible mechanisms by which insulin resistance and hyperinsulinaemia contribute to the 
pathogenesis of hypertension include: activation of the sympathetic nervous system, increased 
activity of the Na/H exchange pump, increased retention of renal sodium, and increased salt 
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sensitivity. These mechanisms are not well understood, and it is not clear how important 
insulin resistance is to their development (Pi-Sunyer, 2004). 
The association of essential hypertension with insulin resistance in black South Africans was 
clearly demonstrated in a case-controlled study. The fasting insulin concentration was 
significantly greater in the hypertensive than the normotensive subjects. The direct assessment 
of insulin-mediated, whole-body glucose disposal and the derived insulin sensitivity index was 
significantly reduced in hypertensive group by some 30% and 40%, respectively. The authors 
concluded that the pathogenic role of this association is unlikely to be dominant in this group 
and the overall role of insulin resistance in influencing cardiovascular risk factors in black 
South Africans remains ill-defined (Wing et al., 1994). 
 Diastolic BP in our study correlated positively with glucose (AUC), fasting C-peptide and 
HOMA-IR in the combined African group. In a regression model WC and glucose (AUC) 
were the only independent variables that could explain variance in diastolic BP. Diastolic BP 
correlated positively with glucose (AUC), fasting intact proinsulin, fasting proinsulin/insulin 
ratio and lactate (AUC) in the combined Indian group.  
In regression model BMI, body fat (%) and glucose (AUC) were the only independent 
variables that had an association with diastolic BP in the combined Indian group. Thus, in both 
ethnic groups, postprandial glucose levels were significant determinants of diastolic blood 
pressure, independently of anthropometric variables. Other studies have also demonstrated 
correlations between blood pressure and plasma glucose levels (Jarrett   et al., 1978, Khoo   et 
al., 2000, Mancia   et al., 2005) and that arterial stiffness and left ventricular diastolic 
dysfunction are both related to glucose levels (Miyazato et al., 2002, Gordin et al., 2008), and 
that responsiveness to ACE inhibitors is better in diabetic patients with good glycaemic 
control (Jenkins et al., 1990, Chan et al., 1995). 
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4.4 Lipids and markers of lipolysis 
 
In the study by Seedat et al.,(1992) on risk factors and coronary heart disease in black subjects 
resident in Durban, South Africa it has been showed that only 7.5% of the subjects (11.2%-
males and 3.5%-females) had hypertriglyceridaemia. This contrasts with their study of 
coronary artery disease in the Indian population of Durban in which they found that 20.5% had 
hypertriglyceridaemia. Coronary heart disease is not very common among African diabetic 
population which may be explained by contributions of low total cholesterol levels and 
probably lesser insulin resistance and its consequences; renal disease may be an important 
additional risk factor  (Kalk et al., 2007). 
A number of risk factors for CHD were studied by Seftel et al., (1993) in groups that included 
urban and rural blacks, Indians of higher and lower socio-economic status, Coloureds of 
higher and lower socio-economic status, and middle-class White South African male scholars. 
The prevalence and severity of CHD risk factors, such as total cholesterol, LDL, HDL, the 
HDL/LDL ratio, apolipoprotein B, apolipoprotein A-I, insulin and fibrinogen was much higher 
in Indian groups, the whites and both coloured groups than the two African groups. 
The higher socio-economic group as well as urban, but not rural blacks had poorer risk profile 
for development CHD. A cross-sectional (BRISK) study to determine the lipid and lipoprotein 
profile of the urban black South African population of the Cape Peninsula revealed that the 
cholesterol level was low compared with other South African groups studied (Oelofse et al., 
1996). 
The impact of urbanisation of black South Africans on risk factors for cardiovascular disease 
(CVD) was assessed by Vorster, (2002) when they compared  rural and urban Africans who 
participated in the Transition and Health during Urbanisation of South Africans (THUSA) 
study. The available data suggested that black South Africans might be protected against 
ischaemic heart disease (IHD) because of favourable serum lipid profiles and low 
homocysteine values. Ranjith et al., (2005) examined differences in major cardiovascular risk 
factors and clinical outcome in South African Asian Indians of different age groups and 
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gender, who presented with acute coronary syndromes (ACS). Total cholesterol was elevated 
in 65 to 70% of all patients while high-density lipoprotein (HDL) levels were significantly 
lower in men compared with women for all age subsets. 
In the present study cholesterol, triglycerides and LDL cholesterol levels were significantly 
higher in the Indian than African group thus supporting the data from the studies discussed 
above. In African and Indian subjects, anthropometric markers of abdominal obesity were 
major determinants of fasting lipid levels. Therefore the higher visceral fat and WHR in the 
Indian population may explain their more atherogenic lipid profiles. Many studies have shown 
associations between measures of abdominal fat and lipid levels (Zoratti, 1998, Banerji et al., 
1999, Despres et al., 2000, Punyadeera et al., 2001a, Crowther et al., 2006). 
Glycerol and FFA levels normally rise with increasing fat mass because adipose tissue, via 
lipolytic breakdown of triglycerides, is the major source of circulating glycerol and FFA 
(Jensen, 1997, Duncan et al., 2007). Glycerol is thought to be a better indicator of adipocyte 
lipolytic activity (Robinson et al., 1998). In the present study correlations were observed 
between both these variables and anthropometric measurements, particularly BMI (Indian 
group only) and hip circumference (both ethnic groups). The correlation with hip 
circumference is intriguing since studies in South Africa have shown that lipolytic rate is 
higher in femoral than abdominal adipose tissue in obese and diabetic African females (van 
der Merwe et al., 2001) whereas studies in European populations demonstrated the opposite 
(Arner, 2005). 
Fasting and total glycerol levels were higher in African than Indian females when all BMI 
groups were combined. This cannot be due to differences in anthropometry since BMI and hip 
circumference, which were the main determinants of glycerol levels, were the same in both 
ethnic groups. An alternative hypothesis may be that the higher TNF-α levels in African 
subjects may lead to greater lipolysis, as studies have shown that TNF-α can increase lipolytic 
rate (Arner, 2005, Langin et al., 2006). However, in our study no correlations were found 
between TNF-α and glycerol (fasting and total) in either ethnic group. 
Studies from South Africa have shown that lipolytic rate in situ is higher in subcutaneous 
adipose tissue sites in African than European males and females (van der Merwe et al., 1999) 
and that isolated adipocytes from African females are more resistant to the anti-lipolytic 
activity of insulin than adipocytes taken from white females (Buthelezi et al., 2000). These 
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data plus the data from the current study suggest that adipocyte lipolytic rate is higher in 
African than both Indian and European females, but the metabolic consequences of this are 
uncertain.  
No significant differences were observed in FFA levels between lean, obese and diabetic 
subjects in the African group, while in the Indian group there were significant differences 
between obese vs. lean and diabetic vs. obese. The exact reasons for these results are not clear. 
The high FFA levels in diabetic Indian subjects could be the result of high insulin-resistance 
and subsequent reduction of the antilipolytic effect of insulin. 
It has been suggested that the higher FFA levels observed in African than white females may 
explain the higher level of insulin resistance in the former population (van der Merwe et al., 
2000, Buthelezi et al., 2000) whereas in the present study the Indian females were more 
insulin resistant than the African females and FFA levels were not significantly different 
between the 2 groups. 
 
4.5 Cortisol and lactate 
 
It has been suggested that cortisol-metabolising enzymes may play a key role in determining 
body fat distribution. Increased regeneration of cortisol from cortisone within adipose tissue 
by 11 beta-hydroxysteroid dehydrogenase (HSD) type 1 (11HSD1) has been proposed to cause 
visceral fat accumulation (Bujalska et al., 1997). However, in a study by Westerbacka  et al., 
(2003) visceral adipose fat mass was not associated with indices of cortisol metabolism; 
indeed, after adjusting for the effects of whole-body and liver fat, increased visceral fat was 
associated with lower cortisol metabolite excretion. They concluded that alterations in 
11HSD1 and hepatic 5alpha-reductase activity are associated with generalized, rather than 
central, obesity in humans. In the present study waist circumference, but not visceral fat had a 
negative association with fasting and total cortisol (AUC) in the combined African group. The 
reasons for this association in the African and not the Indian group are not known and warrant 
further investigation.  
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The presence of enhanced cortisol secretion in patients with type 2 diabetes is debated. 
According to the study by Reynolds et al., (2003) the decline in plasma cortisol after glucose 
administration was poorly predictive of features of the metabolic syndrome.  In type 2 diabetic 
subjects, hypothalamic-pituitary-adrenal activity is enhanced in patients with diabetic 
complications and the degree of cortisol secretion is related to the presence and number of 
diabetic complications as revealed in a study by Chiodini et al., (2007). The current study 
demonstrated that diabetic African females had higher cortisol levels than non-diabetic obese 
African subjects. This difference was not observed in the Indian females. Whether this ethnic 
difference is related to a higher prevalence of diabetic complications in African than Indian 
females is not known. However, African diabetics did have a longer duration of diabetes and 
slightly higher HbA1c levels than the Indian diabetic group. 
Differences in cortisol concentration in our study were observed between obese African and 
Indian women (higher in Indian). In another South African study obese white women were 
found to have higher fasting cortisol levels than obese black women (van der Merwe   et al., 
2001). The present study also demonstrated that obese African women had lower cortisol 
(fasting and AUC) levels than lean African subjects. This supports other studies (Reynisdottir 
et al., 1994, Wabitsch et al., 1995)  and may be explained by the higher cortisol clearance 
rates observed in obese as opposed to lean subjects (Pasquali et al., 1993). This difference in 
cortisol levels was not seen in obese and lean Indian subjects, again suggesting that cortisol 
clearance by adipose tissue maybe higher in African than Indian subjects. 
Adipose tissue production of lactate is influenced in vitro by changes in glucose, insulin, and 
epinephrine concentrations, while in vivo lactate production is regulated by the animal's 
nutritional state and chronically by the degree of obesity. During fasting the adipose tissue 
may provide lactate for hepatic gluconeogenesis and for hepatic glycogen synthesis after food 
ingestion (DiGirolamo et al., 1992). 
A number of our diabetic patients were treated with Metformin as an oral anti-diabetic drug. 
The most serious potential side effect of Metformin is lactic acidosis; this complication is very 
rare, and seems limited to those with impaired liver or kidney function. To establish the effect 
of Metformin on lactate levels, diabetic patients in both ethnic groups were divided into 
groups that consisted of the patients using Metformin and the group that was not on 
Metformin.  There were no significant differences in lactate levels between the groups.  
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In a study to determine the primary mechanism by which Metformin improves glycemic 
control in patients with type 2 diabetes and its effects on lactate metabolism it has been shown 
that Metformin treatment did not significantly alter the mean fasting plasma lactate 
concentration or the rate of plasma lactate turnover. However, the rate of plasma lactate 
oxidation increased by 25 %, whereas the rate of conversion of plasma lactate to plasma 
glucose decreased by 37 % (Stumvoll et al., 1995).  
Fasting lactate levels in our study were significantly higher in the diabetic Indian than diabetic 
African group. Obese Indian subjects had significantly higher fasting lactate levels than lean 
Indian subjects. Both ethnic groups displayed significantly different fasting lactate levels 
between diabetic and obese subjects (higher in diabetics). There was a positive correlation 
between HOMA-IR and fasting lactate in the combined Indian group. No correlations were 
found in the combined African group between HOMA-IR and lactate levels.  The data from 
the Indian subjects support other data showing that fasting lactate levels rise with increasing 
insulin resistance (Digirolamo et al., 1992, Lovejoy et al., 1992).  
The absence of a relationship between fasting lactate levels and HOMA-IR in African subjects 
maybe related to the narrower range of HOMA-IR values, however fasting lactate was higher 
in diabetic than non-diabetic Africans. Studies have also shown that postprandial lactate levels 
correlate negatively with insulin resistance (Lovejoy et al., 1990, Lovejoy et al., 1992), 
however in our study there was a positive correlation between these variables in the Indian 
females and in both ethnic groups total lactate was higher in diabetic subjects. 
 
4.6 Adipokines 
 
The significant role of TNF-α in insulin resistance was confirmed in a number of studies. 
TNF-α inhibit the transduction of insulin signaling and down-regulate glucose transporter 
GLUT-4 and insulin receptor substrate-1(Hotamisligil,1999, Stephens et al.,1997, Hoffstedt et 
al.,2000, Bertin et al.,2000). Both TNF-α and IL-6 plasma levels have been found to be 
elevated in obese people, as compared with levels of age- and disease-matched normal-weight 
people (Ziccardi et al.,2002). Increased TNF-α levels amongst patients in a stable phase after 
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MI were associated with an increased risk of recurrent coronary events in a study from the 
secondary prevention Cholesterol and Recurrent Events (CARE) trial (Ridker et al.,2000b). 
Plasma levels of TNF-α have also been shown to correlate with measures of atherosclerosis as 
assessed by carotid intima-media thickness in healthy middle-aged men (Skoog et al.,2002). 
The results from our study didn’t support these findings. Serum TNF-α didn’t correlate with 
HOMA or other cardiovascular risk parameters in either of the ethnic groups. We also found 
that TNF-α concentrations were lower in diabetic and lean Indians compared to diabetic and 
lean African subjects and when obese, overweight and lean subjects were combined serum 
TNF-α concentrations were significantly lower in Indian than African subjects despite the 
higher HOMA levels in the Indian group. Not all studies report positive correlations between 
serum TNF-α levels and BMI or insulin resistance (Carey et al., 2004) and one study has 
shown that TNF-α release from adipocytes has little influence on systemic TNF-α levels and 
therefore TNF-α effects are paracrine rather than endocrine (Mohamed-Ali et al., 1997). 
Since TNF-α stimulates IL-6 production in many tissues (Heinrich et al.,1990), it is not 
surprising that exogenous TNF-α  can likewise promote IL-6 synthesis in adipocyte cell 
cultures (Berg et al.,1994). It is thus reasonable to postulate that increased production of IL-6 
by hypertrophied adipocytes is simply a direct consequence of their increased production of 
TNF (McCarty,1999). CRP was the strongest correlate of IL-6 in the data by Ridker et 
al.,(2000c), which is consistent with IL-6 being the main stimulant for the hepatic production 
of CRP. 
In the present study we didn’t find interethnic differences for IL-6 levels. Diabetic Indian 
women had significantly higher IL-6 values compared to obese Indian women and this was 
also observed in the African group although the difference was not statistically significant. 
Other studies have also found higher IL-6 levels in diabetic subjects (Deepa et al., 2006, 
Cardellini et al., 2007, Pitsavos et al., 2007) but not all studies support this (Carey et al., 
2004). No correlations were found between IL-6 and anthropometric variables in the 
combined African and Indian groups. Therefore, IL-6 cannot explain higher prevalence of 
diabetes or CVD in the Indian population. No correlations were found between IL-6 versus 
CRP and TNF-α in combined African and Indian groups in our study. 
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Pradhan et al., (2001) found a stronger relationship between baseline elevations of CRP and 
incident diabetes than that seen for IL-6. This may partially indicate the significantly longer 
plasma half-life of CRP that thereby may provide a more stable indication of sub-clinical 
inflammation. In a study by Blake et al.,(2002) of all the inflammatory and lipid parameters, 
CRP was the strongest predictor of cardiovascular risk in univariate analyses. Plasma levels of 
CRP are good independent predictor of future myocardial events, stroke, peripheral vascular 
disease and vascular death among individuals without known cardiovascular disease 
(Ridker,2001). Moreover, circulating levels of CRP are elevated in human obesity and 
correlate with body weight, visceral fat and insulin resistance (Tchernof et al.,2002). Diabetic 
patients are reported to have increased CRP values  (Ford,1999); in this regard, links between 
CRP and the insulin resistance syndrome have also been reported (Festa et al.,2000). 
Inflammatory markers such as CRP, fibrinogen and TNF-alpha were associated with type 2 
diabetes in North-Indian subjects, but only CRP was associated with development of 
accelerated atherosclerosis and subsequent CHD (Ahmad et al., (2007). As a general index of 
inflammation, CRP concentrations vary by ethnic origin and within ethnic groups by fitness 
(Chambers et al.,2001, LaMonte et al.,2002). For instance, concentrations of CRP were higher 
in healthy Indian Asians than in European white population and were related to greater central 
obesity and insulin resistance in Indian Asians (Chambers et al., 2001). 
These data were supported in the present study by the observation that serum CRP levels were 
significantly higher in diabetic and obese subjects compared to lean subjects in both ethnic 
groups. Visceral fat and BMI were the only independent predictors of CRP levels observed in 
the combined African group and in the combined Indian group, respectively. However, despite 
the fact that the Indian population of South Africa have been reported (Seedat et al., 1990, 
Omar et al., 1985, Omar et al., 1994, Motala et al., 1993) to have a higher prevalence of 
ischaemic heart disease, cardiovascular risk factors and type 2 diabetes, in the present study 
CRP levels in combined African and Indian groups were similar. Thus, within these ethnic 
groups, CRP may possibly act as a marker for increased risk of CVD and diabetes but it does 
not explain ethnic differences in obesity- related disease prevalence rates. 
The interaction between insulin sensitivity and leptin concentration may be important in the 
regulation of body weight. It has been hypothesized that insulin resistance itself protects 
against weight gain. Segal et al., (1996) suggested that insulin resistance might help prevent 
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obesity by increasing plasma leptin concentrations. They also demonstrated that insulin 
resistance, independent of adiposity, was associated with elevated plasma leptin 
concentrations. Although the researchers found that insulin did not regulate leptin production 
acutely, they proposed that chronically elevated plasma insulin concentrations possibly 
stimulate obese (Ob) gene expression. However, the increase in plasma leptin concentration 
observed with increasing adiposity suggest that obese humans may be resistant to the putative 
effects of leptin in modulating food intake and energy expenditure (Considine et al.,1996b). 
Black women had higher leptin levels compared to white women, despite comparable BMI’s 
(Der Merwe et al., (1999). The higher leptin levels in the black population may represent a 
form of leptin resistance due to defective leptin signalling, resulting in hyperglycaemia and a 
possible over-expression of hypothalamic NPY (Schwartz et al., 1996). The study by 
Buyukbese et al., (2004) in the eastern Mediterranean area of Turkey, showed that the leptin 
levels were lower in diabetic obese women than obese non-diabetic women. Tatti et al., (2001) 
in their study compared leptin concentration in moderately obese type 2 diabetics, age and 
weight matched, with non-diabetic controls. The leptin levels were lower in the diabetic 
population only when both sexes were combined and were higher in the females of both 
groups. When plasma leptin was included in a multiple linear regression model with plasma 
leptin as a dependent variable, BMI, waist/hip ratio and fasting serum insulin levels were 
significantly related to leptin in the non-diabetic population, while no relationship reached the 
level of statistical significance among the diabetics. The in vitro data by Ceddia et al., (1999b) 
provided some evidence that leptin might modulate insulin secretion from pancreatic islets. 
The above studies support data from our study. Thus, in both ethnic groups, leptin levels were 
lower in diabetic than non-diabetic obese subjects.  
The Indian group are not iso-obese with the African subjects, even when matched for BMI as 
they differ significantly with regard to visceral and subcutaneous fat area. Furthermore, lean 
Indian subjects have more visceral and subcutaneous fat than BMI-matched lean Africans and 
also have higher leptin levels. Regression analysis demonstrated that the higher leptin levels 
are partially explained by the higher subcutaneous fat mass but the major determinant of leptin 
levels in the lean subjects is ethnicity. This suggests that some unknown factor, specific to 
ethnicity is influencing leptin levels in this group of subjects. Also, in our study there was a 
significant positive correlation between serum leptin and total (AUC) insulin levels in both 
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ethnic groups. In the African group leptin had a positive correlation with total (AUC) glucose 
levels while in Indian group leptin had positive correlation with fasting insulin levels. 
Results from Hube et al., (1996) indicated that leptin expression was lower in omental than 
subcutaneous adipose tissue, possibly due to differences in fat cell size and/or sympathetic 
innervations. In another study, multiple regression analyses pointed out that percentage body 
fat was the most important determinant of leptin for all obese subjects (males and females), 
while for women subcutaneous fat was the most important parameter, and for men alone total 
abdominal fat. These results suggested that subcutaneous fat seems to be an important factor 
related to leptin levels (Wauters   et al., 1998), and this supports data from the present study 
where, in the combined African group body fat (%) and subcutaneous fat were significant 
determinants of the variance in leptin. Body fat (%) was the only independent variable that 
could explain variance in leptin in the combined Indian group. Subcutaneous fat and BMI had 
an association with soluble leptin receptor in the combined African group and in the combined 
Indian group, respectively.  No correlations were found between leptin and FFA or glycerol in 
both ethnic groups. 
Ogier et al., (2002) in their study found that soluble leptin receptor (sOB-R) levels were lower 
in obese and overweight than lean subjects and were inversely correlated to leptin and 
percentage of body fat. A gender difference was observed in sOB-R levels, which were higher 
in obese and overweight men than in obese and overweight women. The relationship of  
sOB-R with the degree of adiposity suggested that high soluble leptin receptor levels might 
enhance leptin action in lean subjects more than in obese subjects. 
Ogawa et al., (2004) in their study measured the serum soluble leptin receptor level in healthy 
Japanese subjects and in type 2 diabetic patients. Serum leptin and soluble leptin receptor 
levels were not significantly different between healthy subjects and diabetic patients. The 
researchers concluded that the serum soluble leptin receptor level was negatively correlated 
with HOMA-IR and serum leptin level and positively correlated with HDL-cholesterol level 
and serum adiponectin level, independent of age, sex, and BMI, in the Japanese population. 
Leptin and soluble leptin receptor in our study didn’t have any correlations with lipids, 
hormones or adipokines when corrected for age and BMI in the combined African group. 
However, in the Indian population a positive correlation was found between leptin and TNF-α. 
Leptin could modulate TNF-alpha production and macrophage activation (Loffreda et al., 
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1998). In adipose tissue of several rodent models of obesity the overproduction of TNF-alpha 
has an important role in the pathogenesis of insulin resistance in these species (Bastard et al., 
2006). 
Levels of the sOb-R are decreased in obese subjects compared to lean controls, which results 
in an increased fraction of free leptin. After the surgical procedures or in body weight loss 
through diet the levels of circulating sOb-R are significantly increased. sOb-R may play a role 
as a modulating factor of leptin action and leptin resistance, but the exact physiological 
mechanisms regulating sOb-R plasma concentration are not known (Sandhofer et al.,2003). 
Serum sOB-R concentrations did not differ significantly between normal-weight Japanese men 
and women, but were significantly higher in underweight subjects than in normal-weight 
subjects. In contrast, overweight and obese subjects had significantly lower sOB-R 
concentrations than did normal-weight subjects. Therefore, the researchers hypothesized that a 
reduction in serum sOB-R concentrations in overweight and obese persons may reflect down 
regulation of hypothalamic leptin receptor production as a result of an increase in circulating 
leptin and might be an important factor in leptin resistance (Shimizu et al., 2002). 
The results from the study by Lewandowski et al., (1999) indicated that there was no 
significant difference in free or bound leptin levels between the normal and insulin-dependent 
diabetic subjects either during pregnancy or postpartum, but female insulin-dependent diabetic 
subjects had significantly higher soluble leptin receptor levels and so they speculated that high 
soluble leptin receptor levels might be implicated in the development of the leptin resistance in 
this group. 
Serum leptin levels in our study were significantly lower and soluble leptin receptor higher, in 
diabetic than obese subjects in both ethnic groups. As expected, obese subjects had higher 
leptin levels and lower soluble leptin receptor than lean subjects in both ethnic groups. 
Interethnic differences for leptin levels were observed in the lean group of women with higher 
levels in the Indian subjects and when obese, overweight and lean subjects were combined 
serum leptin levels were significantly higher in Indian than African subjects. This is an 
intriguing result, since obesity is more common in the African than Indian populations of 
South Africa (Puoane et al., 2002). We may therefore hypothesize that the lower leptin level in 
lean African females may lead to higher dietary intake and thus lead to an increased 
prevalence of obesity in this group. Caloric intake was higher in lean African than Indian 
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females in this study. However, this hypothesis must be evaluated in a longitudinal study of 
leptin levels and weight gain. 
Insulin resistance are linked with low serum adiponectin concentrations. However, ethnic 
differences in adiponectin levels probably do not explain the higher levels of insulin resistance 
observed in the Indian subjects in the present study as already demonstrated in a previous 
study, which was specifically designed to investigate whether interethnic variations in insulin 
resistance might be due to differences in plasma adiponectin levels. The group of subjects 
included black, white and Asian-Indian males and females. Serum adiponectin levels were 
found to be similar in black and Asian-Indian subjects, but significantly lower compared to 
BMI-matched white subjects. The correlation between HOMA and adiponectin was analyzed 
in each ethnic group, but significant negative correlation was only observed in white subjects 
(Ferris et al., 2005). Another study aimed to determine differences in fasting adiponectin 
concentrations between Caucasian and African women. The results showed no differences for 
overweight and obese women, but normal weight African women had marginally lower 
adiponectin levels than their Caucasian counterparts. Multiple regression analyses showed that 
only HOMA-IR significantly contributed to the variance in adiponectin levels of African 
women, whereas leptin, triacylglycerol levels and HOMA-IR contributed significantly to 
adiponectin variance in Caucasian women. Ethnicity played a significant role in adiponectin 
levels (Schutte et al., 2007).  
 
4.7 Nutritional intake 
 
The rapid increase in prevalence of diabetes mellitus may emerge as a main public health 
problem in South Africa. Several epidemiological studies have shown that the prevalence of 
type 2 diabetes is soaring, at 13% in the Indian community of Durban and at 7% in black 
urban women (Omar et al., 1994, Joffe et.al.,1994a). The effect of urbanization and unhealthy 
lifestyles are important contributors to this rising prevalence (Knowler et al.,2002). One of the 
aims of lifestyle change is for the patient to lose weight. It is noteworthy that modest weight 
loss pays large dividends in correcting insulin resistance, dyslipidaemia, reducing blood 
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pressure, improving dysglycaemia and ultimately reducing cardiovascular events (Zimmet et 
al., 2003, Higgins et al.,1988). The importance of regular physical activity combined with 
education about food selection is advised. The benefits of smoking cessation are substantial in 
the short- and long-term, and go beyond a reduction in cardiovascular risk  (Buse et al., 2007). 
In the current study the total energy intake was much higher in the African group despite 
similar BMI and body fat (%) when compared to the Indian subjects. This suggests that the 
African subjects may have higher basal metabolic rate (BMR) and /or physical activity levels 
than the Indian group. Indeed our data does show higher levels of both these variables in the 
African group but only reaching statistically significant differences for physical activity in the 
obese African subjects. Future studies using more accurate measure of BMR and physical 
activity must be performed to confirm these findings. 
Trans fatty acids originate primarily in hydrogenated vegetable oils tend to elevate cholesterol 
levels in contrast to their non-hydrogenated counterparts (ASCN/AIN,1996, Report of the 
Expert Panel,1995). Much higher increases found in similar amounts of saturated animal fat or 
highly saturated vegetable oils, e.g., coconut and palm kernel oils have much higher increases. 
The intake of trans fatty acids was analysed using plasma or tissue levels of trans fatty acids 
and it was proposed that CHD risk is associated with trans fatty acids derived from animal 
products  but not with those from hydrogenation of oils (Wahle et al.,1993). Hu et al., (2001) 
and Rivellese et al., (2002) had examined whether the composition of dietary FAs, as opposed 
to total fat consumption, can modulate insulin sensitivity and cardiovascular risk factors.  
These findings indicated that a higher intake of polyunsaturated fat could be beneficial, while 
a higher intake of saturated fat and trans-fat could negatively affect glucose metabolism and 
insulin resistance. Epidemiological studies have show that high intake of saturated fat is 
associated with insulin resistance, and this relationship may be dependent on increased body 
adiposity (Mayer-Davis et al., 1997). High intake of both saturated and trans FAs is related 
with hyperinsulinaemia and with a risk of developing type 2 diabetes, independent of general 
obesity as shown in multiple cross-sectional studies (Maron et al., 1991, Marshall et al., 1997, 
Parker et al., 1993). High intake of polyunsaturated FAs (PUFAs) does not emerge to have the 
same adverse effects and may even result in an increase in insulin sensitivity (Salmeron et al., 
2001). 
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Food intake data in our study, after exclusion of LER’s, showed no interethnic differences in 
diabetics, obese and lean groups for the consumption of total fat, and saturated, 
monounsaturated, polyunsaturated and total trans fatty acids. In combined groups (excluding 
diabetics and LER’s), saturated fatty acid values were significantly higher in African group, 
but no differences were observed in total fat, monounsaturated, and polyunsaturated, and total 
trans fatty acid intake. However, it is interesting to note that dietary intake of all these 
different types of fat tended to be higher in Africans than Indian with the exception of total 
trans fatty acid intake which was higher in Indians, particularly obese Indians. However this 
difference did not reach statistical significance. 
The normal metabolism of homocysteine requires sufficient source of folate, vitamin B6 
vitamin B12, and riboflavin” (Pancharuniti et al.,1994). Increased risk of developing coronary 
disease can be associated with lower folate levels (Robinson et al.,1998). In the present study, 
folate intake was surprisingly lower in Indian subjects, but this statistical difference was lost 
when LER’s were removed. 
A study by Charlton et al.,(2005a) demonstrated ethnic differences in calcium intake across 
South African ethnic groups, with black subjects having particularly low intakes. The groups 
included black, mixed ancestry and white men and women from Cape Town. Food intake 
questionnaire data in our study, after excluding low energy reporters, show that calcium and 
magnesium intake was significantly lower in the combined Indian group than in the combined 
African group. The differences in calcium intake in this population group could be explained 
by higher consumption of dairy products, notably powdered milk. 
Food intake data from our study, after exclusion of LER’s, showed that diabetic Indian had 
statistically significant lower intake in total dietary fibre, magnesium, phosphorus zinc, but 
higher intake of starch, fibre and chloride in comparison with diabetic African patients. Added 
sugar was significantly lower in diabetic Indian patients than in obese Indian group. 
The table below (Table 4.1) compares nutritional intake in diabetic patients from the present 
study and published data from South Africa. Diabetic Africans had comparable total energy 
and total fibre intake with published data. The data for other nutrients showed significant 
differences between results from our study and the data published by Nthangeni et al., (2002). 
Such differences may be related to the different methods used for assessing dietary intake, and 
this is a well-known problem when comparing nutritional intake across different studies. 
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Furthermore, differences in socio-economic status between the study groups and differences in 
geographical location may also explain the differences in dietary intake between the studies. 
 
 
Table 4.1 The average energy estimate and nutritional intake per day in diabetic women 
 
 
 
African 
diabetic 
women 
 
   Indian 
diabetic 
women 
  
Urban 
African 
diabetic 
women 
      
      Rural 
African 
diabetic 
women 
 
                        Groups 
 
 
 
Variables 
 
(Present 
study) 
 
(Present 
study) 
 
      (Nthangeni et al., 2002) 
  
Total Energy (kJ)/d 7163 5841 7381 6987 
Total Protein (g) 82.2 60.2 65 59 
Plant Protein (g)  24.7 19.0 39 39 
Animal Protein (g) 57.0 40.4 26 20 
Total Fat (g) 52.9 51.9 28 27 
Saturated FA (g) 17.7 15.7 7.2 6.1 
Monounsaturated FA (g)  17.6 16.9 9.0 8.9 
Polyunsaturated FA (g)  12.7 14.9 7.4 8.2 
Total Carbohydrate   (g) 204 156 288 274 
Added sugar (g)  17.6 17.2 4 2.1 
Total sugar (g) 42.4 36.9 16 14 
Total Dietary fibre (g) 19.7 14.7 21 19 
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Lean Indian subjects in our study had significantly lower energy intake and total carbohydrate, 
total dietary fibre, magnesium and zinc intake in comparison with lean African subjects. 
Similarly, there were also significant differences between obese Indian and obese Africans for 
consumption of total dietary fibre, magnesium, phosphorus and zinc, with all intakes higher in 
the African group. 
Food intake data in combined African and Indian groups (excluding diabetics and LER’s) 
showed that there were statistically significantly higher intake for African than Indian women 
for most of the food variables, with the exception of sodium, chloride, vitamin C, folate, 
vitamin B12, total carotenoids and chromium, where intake were similar and lycopene and 
starch where intake were significantly higher in Indians. Lower intake of tomato-based 
products explains the lower lycopene levels in Africans. Sugar in plants is stored as starch and 
the greater starch intake in Indian subjects might be due to higher use of vegetables and fruits 
in their diet. 
The table below (Table 4.2) compares the nutritional intake in African and Indian subjects 
from the present study with published South African data. The total energy intake, total 
protein, animal protein, cholesterol, vitamins C and D, and calcium intake in the African group 
from our study was much higher than the results from the published data, and may reflect 
study differences in measurement of dietary intakes and differences in socio-economic status 
of study populations. 
Dietary macronutrient intake in urban blacks and Indians according to the data published by 
Vorster et al., (2001) were as follows: total carbohydrate 161.6  and 102.5, respectively; added 
sugar 45.8 and 48.4, respectively and total dietary fibre 14.6 and 13.1, respectively. These 
published data are similar to our results with the exception of total carbohydrate intake where 
the intakes in our study were considerably higher. However, both studies show that total 
carbohydrate intake was higher in Africans than Indians. 
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Table 4.2 The average energy estimate and nutritional intake per day in African and Indian 
population 
 
African 
group 
 
 
Indian 
group 
 
Urban 
African 
population
 
South 
African 
adult 
women 
 
Middle 
class 
urban 
African 
population
 
(Present 
study) 
(Present 
study) 
(Bourne et 
al., 1993) 
(Steyn et 
al., 2006) 
(MacIntyre 
et al., 
2002) 
Total Energy (kJ)/d 8691 6131 5799 6808 8010 
Total Protein (g) 86.3 60.7 49 59.3 59.5 
Plant Protein (g)       25.4 16.4 22 28.1 30.2 
Animal Protein (g) 60.1 42.9 28 31.0 29.1 
Total Fat (g) 68.3 54.5 42 41.9 58.8 
Saturated FA (g) 24.0 17.7 15 12.3 18.3 
Monounsaturated FA (g)        21.6 17.8 15 14.3 20.3 
Polyunsaturated FA (g) 16.3 14.4 8 9.3 14.8 
Total Carbohydrate   (g) 255.7 167.2 198 232.0 283.6 
Added sugar (g) 49.5 31.8 38 38.9 - 
Total Dietary fibre (g) 20.5 14.3 13 18.0 17.1 
Calcium (mg) 860 586 358 388.4 405 
Total iron (mg) 9.77 7.32 6 8.9 8.8 
Zinc (mg) 9.88 6.79 6.8 8.4 8.2 
Sodium (mg) 1548 1204 979 1193.4 - 
Vitamin B12 (mcg) 5.13 3.48 3.5 3.5 1.11 
Vitamin D (mcg) 5.0 3.1 - 1.8 - 
Vitamin C (mg) 105.8 89.7 32 47.0 43.2 
Folate (mcg) 209.8 165.8 147 230.8 209 
Groups 
Variables 
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Mean nutrient intakes in our study were compared to the Recommended Dietary Allowances 
(RDAs) or to the Adequate Intakes (AIs) according to the data published by National 
Academy of Sciences (http://www.nap.edu.). The results from our study showed that total 
protein intake in African and Indian groups was 47% and 24%, respectively higher than that of 
RDAs. This same pattern was observed for the total carbohydrate intake with 49% higher in 
Africans and 22% higher in Indians than that of RDAs. However, the total dietary fiber intake 
fell below the RDAs in both ethnic groups, 22% lower Africans and 75% lower in Indians. 
Our study also showed that intakes of calcium, folate and total iron appeared to be the most 
deficient in the diet in both ethnic groups when compared to that recommended by the 
National Academy of Sciences (RDAs/AIs: 1000mg, 400mcg and 18mg, respectively). 
Vitamin D deficiency has been identified as a potential novel cardiovascular disease risk 
factor but many studies suggested that the link between hypovitaminosis D and metabolic 
disorders, including obesity, metabolic syndrome, type 2 diabetes and CVD requires further 
investigation, particularly for those most at risk of these combined conditions (Martins et al., 
2007, Michos et al., 2008, McGill et al., 2008). The lack of relationship of vitamin D and 
metabolic syndrome has been reported previously (Reis et al., 2007). However, in the large 
USA NHANES dataset, it was found that abdominal obesity as measured by waist alone, in 
addition to metabolic syndrome, was related to low vitamin D3, notably affecting mixed-
ethnicity participants equally (Ford et al., 2005). 
The main source of body iron is derived from the diet. Dietary iron is present as either heme 
(derived from meat and meat products) or nonheme (cold breakfast cereal) iron. In recent 
prospective studies, intake of total or nonheme iron was not linked with the risk of type 2 
diabetes, but heme iron was associated with elevated risk (Jiang et al., 2004, Lee et al., 2004, 
Rajpathak et al., 2006). 
Development of cardiovascular disease (CVD) have been linked with involvement of Vitamin 
E in the prevention of oxidation of unsaturated lipids in the low-density lipoprotein (LDL) 
particle that activates a complex sequence of events and  directs to the development of 
atherosclerotic plaque (Pryor, 2000). The results from clinical trials with beta-carotene 
supplements have been distressing so far and the consumption of vitamin E as a preventive 
intervention for cancer and coronary heart disease should be discouraged. The relevant clinical 
affects of vitamin E on the risk of cardiovascular events were absent in the results of the 
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GISSI-Prevenzione (300 mg/d) and HOPE (400 mg/d) trials (Marchioli et al., 2001). 
The present study results also reflect those from published data suggesting a protective 
association of vitamins E, D and iron intake with development of CVD in African population. 
Lean Indian females in our study had significantly lower vitamin D and vitamin E intakes in 
comparison with lean African subjects. In combined ethnic groups (excluding diabetics and 
LER’s) African women had significantly higher vitamin E and D than Indian women. Our 
data, after exclusion of LER’s, showed that diabetic Indian subjects had statistically 
significantly lower total iron intake in comparison with diabetic African patients. In combined 
ethnic groups (excluding diabetics and LER’s) African women had significantly higher iron 
intake in comparison to Indian women (10.9 vs. 8.3, 5.9 vs. 3.4 and 11.0 vs. 8.6, respectively). 
This could be attributed to the larger consumption of eggs, beef, and chicken, fish, peanut 
butter and sunflower oil in the African population. 
A comparison of fat and carbohydrate dietary intake expressed as % of total energy intake for 
adults aged 15-64 years in 1990, with that of black ‘adults’ (age range not provided) from the 
city of Johannesburg in 1940 shows a relative 10.9% reduction of carbohydrate (from 69.3 to 
61.7% of energy in 1990) and an increase of 59.7% in fat intake (from 16.4 to 26.2 of energy 
in 1990) over a 50-year period (Bourne et al.,2002).  As a continuation of this trend we found 
a 19.4% decrease of % carbohydrate intake (49.7% of total energy intake) and 11.8% increase 
of % total fat intake (29.3% of total energy intake) in the combined African group, from the 
1990 data. 
There are not inadequate data to determine a defined level of fat intake; therefore neither an 
Adequate Intake (AI) nor Recommended Dietary Allowance (RDA) was set by National 
Academy of Sciences. The total fat as 20- 35 percent of energy have been estimated as an 
Acceptable Macronutrient Distribution Range (AMDR). The ranges for carbohydrate and 
protein intake as a percent of total energy intake were estimated in a region of 45-65 and 10-
35, respectively in adults (http://www.nap.edu.). 
Our results for total protein, total fat and total carbohydrate when expressed as % of total 
energy intake were in agreement with that recommended by National Academy of Sciences in 
both ethnic groups before and after excluding LERs. In combined African and Indian groups 
in our study a comparison of total protein, total fat and total carbohydrate proportions of 
energy intake, expressed as a %, indicated significant differences for fat (higher in Indian) and 
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carbohydrate (higher in African). A similar pattern was found after excluding low energy 
reporters in these groups. Greater proportional intake of energy from fat in the Indian diet may 
predispose this population to cardiovascular disease (Hu et al., 1997, Jakobsen et al., 2004). 
Greater total energy intake in African than Indian females may explain the higher prevalence 
of obesity in the African population. Furthermore the higher proportional intake of 
carbohydrates in the African group may promote fat storage through maintaining higher blood 
levels of insulin (Sheard et al., 2004). 
 
4.8 Influence of socio-economic status 
 
Socio-economic status in the present study was based on household items as well as education 
level of participants in the study. Although cultural differences might exist between two ethnic 
groups, the general assessment of socio-economic status should be applied to both groups 
equally. The study by Xie et al., (2003) described the overall diet and potential effects of 
gender, ethnicity, family income, and parents' education on dietary patterns in adolescents 
aged 11 to 20 years who participated in a cohort study in 12 Southern California communities 
between 1998 and 2000. Higher consumption of polyunsaturated fat, protein, calcium, and 
folate and more frequently consumed dairy products found to be in subjects form higher 
income families. In families with higher levels of education intakes of total fat, saturated fat, 
monounsaturated fat and cholesterol have been reduced. The recommended daily intake of 
dairy products, fruits, and vegetables were less likely is consumed by subjects from families 
with parents who had higher educational attainment.  
Islam et al., (2004) studied the influence of socio-economic status on energy intake, 
anthropometric characteristics and body composition in pre-menopausal women in two 
locations in Bangladesh. Based on the dietary and anthropometric results, they concluded that 
malnutrition is a common feature among low-income rural women, which is in contradiction 
to data from western countries, where obesity is prevalent in low-income groups. 
The survey conducted by Rebato et al., (2001) in the town of Bilbao found that all 
anthropometric variables, except height, were higher in women of low socio-economic status 
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compared to the local reference and control sample. Low socio-economic males had lower 
estimated percentage of body fat than the control sample, while females showed the opposite 
pattern. On the other hand, estimates of food intake in males did not reveal great differences 
among samples from different socio-economic backgrounds, while low socio-economic status 
females had greater intakes of food than the better-off control sample. A study by Dastgiri et 
al., (2006) showed a negative correlation of obesity with education and income for both 
women and men in Tabriz, one of the major cities in Iran. 
These results are in concordance with our study in the combined Indian group, but no 
correlations were found between anthropometric variables and socio-economic status in the 
combined African group. In the combined Indian group education had negative correlations 
with BMI, WC, waist/height and body fat (%), subcutaneous and visceral fat. Household 
amenities had negative correlations with WHR in the combined Indian group. Furthermore, 
household amenities and education displayed statistically significant differences in the 
combined group, the values being higher in the Indian subjects. This suggests that one of the 
reasons for the higher prevalence of obesity in the African than Indian populations maybe 
related to lower socio-economic status and educational attainment in the former population; 
however one must keep in mind the lack of correlation between anthropometry and socio-
economic status in the African population. 
Socio-economic status may influence the risk of the metabolic syndrome. Park et al., (2007) 
studied this association in Korean adults and found that lower socio-economic status was 
associated with a higher risk of the metabolic syndrome in Korean women but not in Korean 
men. The highest prevalence of type 2 diabetes was observed among the rich, and the lowest 
prevalence was observed among the poor socio-economic classes of rural and urban 
populations in Bangladesh (abu Sayeed et al., 1997). Larranaga et al., (2005) who studied 
people older than 24 years in the Basque Country, Spain, established that the prevalence of 
known Type 2 diabetes was higher in patients of lower socio-economic status, especially 
among women. These observations are in concordance with our results where we found that 
diabetic African patients had significantly lower educational level in comparison with obese 
non-diabetic subjects. In the Indian group significant differences in education were observed 
between obese and lean women (higher in lean). 
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In the present study education and household amenities had positive correlations with insulin 
(AUC) in the combined African group. Education correlated negatively with proinsulin/insulin 
ratio (AUC) and had positive correlation with insulinogenic index in the combined African 
group. In the combined Indian group education had negative correlations with diastolic blood 
pressure and insulin (AUC) and positive correlation with proinsulin/insulin ratio (AUC). 
Education was a strong independent predictor of the variance in insulin (AUC) in the 
combined Indian group. It is interesting that greater educational attainment has opposite 
influences on markers of insulin secretion in these two population groups. The reasons for this 
are unknown but highlight the complex interaction between environmental factors and 
metabolism and how these interactions vary across different ethnic and cultural groups. 
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CHAPTER-5 CONCLUSIONS AND SHORTCOMINGS 
 
 5.1 CONCLUSIONS 
 
The objectives of our study are given below and following each objective are the 
conclusions from our study that relate to that objective: 
 
1. To assess the body fat distribution in both ethnic groups & to determine how it influences 
glucose & lipid metabolism.  
• The significantly higher level of visceral fat in Indian women in comparison with 
African women could lead to increased levels of insulin resistance and may be a 
greater risk for development of type 2 diabetes in the female Indian population. 
• Low-density lipoprotein (LDL) was statistically higher in the lean group of Indian 
subjects, which suggests that Indian population might be predisposed to the 
development of IHD via raised cholesterol levels. 
• Significantly higher triglycerides levels in obese Indian subjects could lead to the 
higher prevalence of CVD in Indian population. 
2. To assess the role of anthropometric, metabolic and hormonal factors in determining insulin 
resistance in each ethnic group. 
• There may be an increased risk of type 2 diabetes in the female Indian population as a 
result of higher HOMA-IR and visceral fat levels in this group compared to African 
female subjects. 
3. To compare the aetiology of type 2 diabetes between the two ethnic groups, particularly 
with reference to beta cell function and insulin resistance.  
• Higher insulin resistance, which is compensated for by reduced HIE and improved 
proinsulin processing in the non-diabetic Indians compared to the non-diabetic African 
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group may predate glucose intolerance and type 2 diabetes in the Indian population. 
• Ethnic differences in HOMA-IR could not be explained by differences in adipokine 
concentrations; however, HOMA-IR was related to visceral fat in the Indian group. 
4. To examine the relationship of anthropometric and metabolic indices with blood pressure, 
in each ethnic group. 
• Ethnic differences in the determinants of blood pressure in relationship to 
anthropometric variables showed the importance of abdominal obesity in the African 
group whilst in Indian group total body fat was more important. 
5. To ascertain the role adipokines play in the aetiology of insulin resistance in each ethnic 
group. 
• Leptin levels correlated positively with systolic BP in the Indian, but not in the African 
subjects, suggesting that ethnic differences in the aetiology of obesity-related 
hypertension exist. 
• The significance of the higher TNF-α values measured in the African subjects is 
unknown.  
• Lower leptin concentrations observed in the lean African subjects may promote caloric 
intake and hence a rise in obesity. 
6. To determine the impact of socio-economic and dietary status on intermediary metabolism 
in each ethnic group. 
• The higher prevalence of obesity in the African population may be explained by a 
greater energy intake in this population compared to the Indian population. 
• The greater proportional intake of energy from fat, in the Indian diet, may predispose 
this population to cardiovascular disease. 
• The association between socio-economic status with anthropometric variables in the 
Indian but not in the African group suggest that the higher prevalence of obesity in the 
African than in the Indian population maybe related to lower socio-economic status 
and educational attainment in the African population. Data from the literature also 
demonstrates a negative correlation of obesity prevalence with education and income. 
 
In conclusion, we can state that there are three major findings from this study. First, the higher 
visceral fat level, higher HOMA-IR and adverse lipid profile may lead to the higher 
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prevalence of cardio vascular disease and greater risk for development of type 2 diabetes in 
the female Indian population. Second, the differences in adipokine levels do not fully explain 
the ethnic differences in the level of insulin resistance in these two groups. And third, the 
higher prevalence of obesity in female African population may be explained by the higher 
energy intake in this population which could be related to lower socio-economic status. 
Furthermore, the low leptin levels observed in the lean African females may underline the 
higher prevalence of obesity in this population group. This hypothesis must be tested by a 
longitudinal study in which weight gain in lean Indian and African females is compared and 
analysed against baseline leptin levels. 
 
5.2 SHORTCOMINGS OF THE CURRENT STUDY 
 
We acknowledge that there are shortcomings of the present study. The N numbers are 
relatively small; nevertheless, the results of our study are consistent with larger 
epidemiological studies and were sufficiently high enough to demonstrate ethnic or BMI 
related differences in a number of variables. The diabetic Indian group had statistically 
significantly higher age (p<0.05) than the diabetic African group and therefore in our 
statistical analysis it was necessary to make corrections for age.   
The CT-scan analysis performed in the current study did not allow us to measure muscle area 
at the gluteal and mid-thigh level. Such an analysis in future studies may be important for 
determining whether ethnic differences in insulin sensitivity may be due to differences in 
muscle mass. 
Although ethnic differences in variables reported in our study are robust to statistical control 
of household amenities and education in multiple regression analysis, this relatively crude 
adjustment may be insufficient to disentangle “true” race/ethnic group affects from those due 
explicitly to socio-economic status. 
The food questionnaire assessment used in our study experienced higher numbers of low 
energy reporters particularly in the Indian group. The food intake questionnaire used in our 
study was validated for the South African black population, but had not been validated for 
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the South African Indian population. In view of these shortcomings, we recommend that 
future studies examining the nutritional status of the South African Indian population should 
develop a more reliable questionnaire, tailored to the dietary intake of this population. 
Another limitation is that this study was conducted in one geographic location and results may 
not apply to women living in other parts of rural or urban South Africa. Subjects were 
recruited from the Gauteng province with the aim of gathering a sample that accurately 
represents the urban group in that region. 
The gold standard for investigating and quantifying insulin resistance is the "hyperinsulinemic 
euglycemic clamp". Given the complicated nature of the "clamp" technique and the number of 
subjects in our study we decided to use HOMA to assess insulin resistance. Another 
shortcoming in the current study is that subjects were not matched for age or socio-economic 
status, therefore all results have been age adjusted whereas socio-economic status was not a 
major predictor for any of the variables in our study. We must also state that the measurement 
of basal metabolic rate from bioelectrical impedance analysis is crude. 
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APPENDIX 1 
Human Ethics Committee Clearance Certificate 
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APPENDIX 2 
Biochemical Investigations 
1. Determination of glucose in plasma 
Glucose in plasma samples was analysed on Roche MODULAR, by using a glucose oxidase 
assay from Roche Diagnostics (used according to method specifications). 
Test principle: 
Buffer containing Adenosine 5'-Triphosphate (ATP) and Nicotinamide-Adenine Dinucleotide 
Phosphate (NADP) added to sample, followed by addition of hexokinase (HK) and Glucose-6-
Phosphate Dehydrogenase (G-6-PDH). 
                                  HK 
Glucose + ATP              G-6-P+ ADP 
 
Hexokinase catalyzes the phosphorylation of glucose to glucose-6-phosphate by ATP 
                                  G-6-PDH                                    
G-6-P + NADP+                             gluconate-6-P + NADPH + H+ 
Glucose-6-phosphate dehydrogenase oxidizes glucose-6-phosphate in the presence of NADP 
to gluconate-6-phosphate. No other carbohydrate is oxidized. The rate of NADPH-formation 
(reduced form of NADP) during the reaction is directly proportional to the glucose 
concentration and can be measured photometrically. 
Measuring/reportable range: 
Serum/plasma: 0.11-41.6 mmol/l (2-750 mg/dl)   
Precision: 
Intra-assay CV= 1 %;  Inter-assay CV=1.7 % 
Analytical sensitivity: 
Detection limit:0.11 mmol/l (2mg/dl) 
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2. Lactate determination in plasma 
Enzymatic in vitro test for the quantitative determination of lactate in plasma was performed 
on automated Roche/Hitachi MODULAR analyzer (method was used according to the 
instructions). 
Test principle: 
The method uses an enzymatic reaction to convert lactate to pyruvate. The hydrogen peroxide 
produced by this reaction is then used in an enzymatic reaction to generate a coloured dye 
(Trinder,1969, Barham et al.,1972). 
Measuring / reportable range: 0.2 – 15.5 mmol/l (2.0- 140 mg/dl) 
Precision: 
Intra-assay CV = 0.4 %; Inter-assay CV =1.0 % 
Analytical sensitivity: 
Detection limit: 0.2 mmol/l (2.0 mg/dl)   
Limitations – interference: 
At high concentrations, Dopamine (10 mg/l), Levadopa (20 mg/l) and Methyldopa (20 mg/l) 
significantly reduce the lactate results. However, Dopamine at 1 mg/l, Levadopa at 4 mg/l and 
Methyldopa at 2 mg/l do not significantly affect lactate results. No interference with the assay 
was found with any of the other drugs tested. Glycolate, a metabolite of ethylene glycol, 
causes a positive interference, which is variable from lot to lot of reagent. 
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3.  Determination of plasma FFA concentrations   
The concentration of FFAs (normal range: fasting 100-600 µM) in the plasma was analysed 
using an enzymatic colorimetric half-micro test kit from Roche Pharmaceuticals (Mannheim, 
Germany). 
Test principle:  
Free fatty acids are, in the presence of the enzyme acyl-CoA synthetase (Acyl CS), converted 
by adenosine-5’-triphosphate (ATP) and coenzyme A (CoA) into acyl-coenzyme A, (acyl-
CoA), adenosine-5’-monophosphate (AMP) and pyrophosphate. Acyl-CoA reacts with oxygen 
(O2) in the presence of   acyl-CoA oxidase (ACOD) to form 2, 3-enoyl-coenzyme A (enoyl-
CoA). Hydrogen peroxide (H2O2), which was formed converts 2, 4, 6-tribromo-3-hydroxy-
benzoic acid (TBHB) and 4-aminoantipyrine (4-AA) in the presence of peroxidase (POD) to a 
red dye that is measured at 540nm. The intensity of the red dye formed is directly proportional 
to the amount of FFA in the plasma (Shimizu et al.,1980). 
Acyl-CS 
FFA + CoA + ATP               acyl-CoA +AMP+ pyrophosphate 
                      ACOD 
Acyl- CoA + O2     enoyl-CoA + H2O2 
                                                    POD 
H2O2 + 4-AA + TBHB   red dye + 2H2O + HBr 
 
This method is applicable to monocarboxylic FFA with 6-18 carbon atoms. The original 
method from Roche diagnostics was adapted for use in NUNC 96 micro well plates (Nalge 
Nunc International, Denmark). This modification was necessary to minimize the costs 
involved in the sample analysis and to increase sample turnover time.  The volumes used in 
the modified assay were 5 times lower but in the same ratio (1/5) as those used in the original 
assay protocol. The original wavelength of 546nm was adjusted to a wavelength of 540nm, 
(which was the closest available wavelength on the plate reader). A new absorption coefficient 
(ε540) was derived from a comparison of sample absorbance in cuvette at 540nm and 546nm. 
We verified this coefficient by comparing the absorbance of a freshly prepared palmitic acid 
standard both in cuvettes and on plates. 
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Assay protocol:  
The reagent bottles and the standard were brought to room temperature prior to performing the 
assay. Reaction mixtures A consisting of: tribromohydroxybenzoic acid, MgCl2, ATP, 
coenzyme A, acyl-CoA-synthetase, peroxidase, ascorbate oxidase and 4-aminoantipyrine was 
prepared according to the original Boehringer assay protocol. Using a SMI pipette 10µl of 
blank (distilled water), 10µl of sample and 10µl of standard were dispensed into the 96-well 
plate.  Solution A (200µl) was dispensed into each well and incubated on a shaker (~500 rpm) 
for approximately 10 minutes at 25±10C. N-ethyl-maleinimide (10µl) was added and mixed on 
a shaker for a few seconds and absorbance was measured at 540nm. 
The presence of N-ethyl-maleinimide in the test is necessary for the oxidation of the activated 
fatty acids by acyl-CoA-oxidase-ACOD (ACOD). 10µl of solution B (ACOD) was added to 
each well and further incubated on a shaker at 25±10C for 20-25 minutes until the reaction was 
completed. Absorbance was measured at 540nm. 
Calculation of the molar absorption coefficient at 540nm:  
This was achieved by measuring the absorbance of the red dye in cuvettes both at 540nm 
(A540) and 546nm (A546). Thus, ε540 were calculated using the Beer-Lambert law as shown 
below. 
Cuvettes: λ = 546nm    A546 = ε546 x C x d 
Cuvettes: λ = 540nm   A540 = ε540 x C x d 
For a constant concentration (C) and a fixed light path (light path, d=1 cm) 
C x d = A546/ε546 = A540/ε540 
Therefore, ε540 = A540 x ε546/ A546 
The ε540 for the plate was calculated to be 22.494 mM-1 x cm-1 
Calculations:  
The light path (d) on a 96 well plate was derived using the published well geometry [Equation: 
Y = 0.028x + 0.2; where Y= height (mm) and x= volume in µl] (Nunc Laboratories, 1985). 
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Calculation of FFA concentrations on a micro-titre plate (adapted from the original Boehringer 
package insert) 
C = [V / (ε540 x d x v)] x ∆A (mM) 
C = 1.549 x ∆A 
V = final volume (230µl) 
v = sample volume (10µl) 
d = light path (0.66cm) 
ε = molar absorption coefficient of the dye at 540nm 
ε540= 22.494 [1 x mM-1 x cm-1] 
C = molar concentration [mM-1] 
A1 = first absorbance after adding N-ethyl-maleinimide 
A2 = final absorbance 
∆A = ∆As -   ∆Ab; 
∆As= absorbance difference of the sample (A2-A1) 
∆Ab= absorbance difference of the blank (A2-A1) 
Precision: 
Intra-assay CV = 2.4 %; Inter-assay CV = 4.8 % 
Analytical sensitivity for the plate:  
The lower limit of detection is 0.005 mM, which represents the lowest measurable FFA 
concentration that can be distinguished from zero. The upper limit of detection is 1500 mM. 
 
4. Determination of plasma glycerol concentrations 
Glycerol concentrations in plasma samples were measured using an UV-enzymatic food 
analysis method (Boehringer Mannheim / R-Biopharm Enzymatic BioAnalysis/ Food 
Analysis). The original manual assay method was modified to run on a Roche 
Modular/Hitachi 917-auto analyser instrument. Automation assisted in reducing the following:  
analysis time, plasma volume, random errors, costs and sample turnover times. We replicated 
the manual steps as closely as possible on the auto analyser, and then refined the parameters to 
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provide a working application. Reagent 1 (buffer/coenzyme) was reconstituted according to 
the instructions given in the packet insert but the two enzyme suspensions had to be pre-
diluted (1 in 31) to provide realistic sample volumes for the autoanalyser. A “2 point end 
point” reaction was selected for the application. The three reagents were added at the fixed 
intervals t1, t2 and t3 (t = time). These time intervals corresponded to 4.5 seconds, 90 seconds, 
and 5 minutes respectively after addition of a sample. At 370C, both the pre-reaction and final 
reaction reached completion within these timed intervals. 
Principal of the assay: 
Glycerol is phosphorylated with adenosine-5’-triphosphate (ATP) to L-glycerol-3-phosphate 
in the reaction catalysed by glycerolkinase (GK). 
                                     GK 
Glycerol + ATP   L-glycerol-3-phosphate + ADP 
 
The adenosine-5’-diphosphate (ADP) formed, in the above reaction is converted into ATP by 
phosphoenolpyruvate (PEP) with the aid of pyruvate kinase (PK) with the formation of 
pyruvate. 
                                 PK 
ADP + PEP                                    ATP + pyruvate 
 
In the presence of the enzyme L-lactate dehydrogenase (L-LDH), pyruvate is reduced to  
L-lactate by reduced nicotinamide-adenine dinucleotide (NADH) with the oxidation of NADH 
to NAD. 
                                                       L-LDH 
Pyruvate + NADH + H+    L-lactate + NAD+ 
 
The amount of NADH oxidised in the above reaction is stoichiometric to the amount of 
glycerol. NADH is determined by means of its light absorption at 334, 340 or 365 nm. 
Sample preparation (Eggstein et al.,1974,  Wieland,1984): 
Plasma samples were deproteinized to prevent any artifactual release of glycerol from 
triglycerides. This was accomplished by a 1 in 3 dilution of the plasma in water followed by 
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incubation for 7 minutes in a heating block set at 100°C. Samples were centrifuged at 2° C for 
25 minutes to obtain the relevant supernatant (0.5 ml). The dilution factor is obtained from the 
sample volume (1.000ml), the volume of redistilled water (2.00 ml), the specific gravity of the 
sample material (1.03 g/ml plasma or serum) and the fluid content (0.92 in the case of plasma 
or serum): 
F= (1.000 x 1.03 X0.92 + 2.000) / 1.000=2.95 
The samples were then stored at minus 200C until future analysis. 
Precision: 
Intra-assay CV = 2.5 %; Inter-assay CV =2.6 % 
Specificity: 
This method is specific for glycerol. Dihydroxyacetone is not converted under the given 
conditions. 
Sensitivity and detection limit: 
The smallest differentiating absorbance for the procedure is 0.005 absorbance units. 
The detection limit of 4.34mmol/l (0.4 mg/l) is derived from the absorbance difference of 0.02 
(as measured at 340 nm) and a maximum sample volume v= 2.000ml. 
Interference/sources of error: 0.2 mmol/l 
The slow hydrolysis of ATP and phosphoenolpyruvate as well as the air oxidation of NADH 
results in a slow creep reaction which can be taken into account by extrapolation. An 
extrapolation is not absolutely necessary if the absorbances of blank and sample are measured 
immediately one after another. 
 
5. Glycosylated haemoglobin (HbA1c) measurement in plasma 
Plasma levels of HbA1c were measured on Modular autoanalyser from Roche diagnostics 
(Munich, Germany) using an assay kit from Boehringer Mannheim, (Manheim, Germany). 
Test principle: 
The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for 
haemolysed whole blood. Glycated haemoglobin (HbA1c) reacts with the anti-HbA1c 
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antibodies to give a soluble immunocomplex. Polyhaptens from reagent R2 then bind the 
excess antibodies, and the resulting agglutinated complex is measured turbidimetrically. 
 
 
 
 
Excess anti-HbA1c antibody                    Polyhaptens 
 
 
Antibody / Polyhapten complex                     Turbidimetric Measurement 
 
Precision: 
Intra-assay CV = 2.3 %; Inter-assay CV =3.2 % 
Analytical sensitivity (lower detection limit) (Data on file at Roche): HbA1c: 0.2 g/dl 
Specificity (Data on file at Roche): 
No cross-reactivity with HbA0, HbA1a, HbA1b, acetylated hemoglobin, carbamylated 
hemoglobin, glycated albumin, labile HbA1c and HbA1d was observed for the anti-HbA1c 
antibodies used in this kit. 
 
 
 
 
 
  
225
 
6.  Insulin determination in serum 
MEDGENIX INS-EASIA kit from BIOSOURCE was used to analyze insulin levels in 
samples. It is a solid phase Enzyme Amplified Sensitivity Immunoassay performed in 
microtiter plates (used according to method specifications). 
Principle of the test: 
This assay is set up on the oligoclonal system in which several monoclonal antibodies (Mabs) 
directed against distinct epitopes of insulin are used. The use of several distinct Mabs avoids 
hyperspecificity and allows highly sensitive assays with extended standard range and short 
incubation time. Standards or samples containing insulin react with capture antibodies (Mabs 
1) coated on a plastic well and with monoclonal antibodies (Mabs 2) labeled with horseradish 
peroxidase (HRP). The microtiter plate is washed to remove unbound enzyme- labelled 
antibodies after an incubation period allowing the formation of a sandwich coated Mabs 1-
INS- Mabs2-HRP. The revelation solution [tetramethylbenzydine (TMB) – H2O2] is added and 
incubated. The reaction is stopped with H2SO4 and microtiter plate is read at 450nm. The 
amount of substrate turnover is determined colorimetrically by measuring the absorbance that 
is proportional to the insulin concentration. 
Precision: 
Intra-assay CV = 4.2 %; Inter-assay CV =7.0 % 
Sensitivity: 
The detection limit was 1.05 pmol/l (0.15 µIU/ml). 
Specificity: 
The cross-reactivity was determined by the kit manufactures by addition of different analytes 
to a serum containing 700 pmol/l (100µIU/ml) insulin and measuring the apparent insulin 
concentration. As shown hereafter, animal insulin (except rat insulin) cross-react whereas 
human, pork and beef proinsulin present no cross-reaction. A 3% cross-reaction was observed 
with 32-33 split proinsulin. 
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7. C-peptide, Total proinsulin & Intact proinsulin 
C-peptide, Total Proinsulin and Intact proinsulin were measured using DakoCytomation 
enzyme-linked immunosorbent assays (ELISA) and used according to method specifications. 
 
7.1 C-peptide measurements in serum 
The assay principle: 
DAKO C-peptide is an ELISA based on two monoclonal antibodies. Simultaneous incubation 
of sample and enzyme-labelled antibody in a microplate well coated with specific anti-C-
peptide antibody forms a complex. A simple washing step removes unbound enzyme-labelled 
antibody. The bound conjugate is detected by reaction with the substrate 3, 3’, 5, 5’-
tetramethylbenzidine (TMB). Adding acid gives a colorimetric endpoint that is read 
spectrophotometrically and stops the reaction. The inclusion of calibrators of known C-peptide 
concentration in the assay allows a calibration curve to be constructed from which the level of 
C-peptide in samples can be determined. 
Detection limit: 17pmol/l (0.05ng/ml) (Data obtained at DakoCytomation Limited). 
Precision: 
Intra-assay CV = 5.4 %; Inter-assay CV = 5.5 % 
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Cross reactivity: 
The specificity of the assay was assessed by the kit manufactures by observing cross-reaction 
with structurally related peptides and hormones. Cross reactivity (%) was calculated from the 
mass of C-peptide and the mass of cross reactant giving the same assay signal. 
 
 
 
*Insulin at concentration of 2000pmol/l was below the detection limit of the C-peptide assay. 
Fasting concentrations of intact and split proinsulin are typically only 1-2% of C-peptide 
concentrations. Cross-reactivity with these molecules, therefore, is not clinically significant. 
 
7.2 Total Proinsulin estimation in serum 
Proinsulin, the precursor of insulin and C-peptide, is made by the beta cells of the pancreas. 
The DakoCytomation Total Proinsulin assay measures biologically active proinsulin along 
with all the intermediates formed during the processing of proinsulin to insulin and C-peptide 
with a high degree of specificity, using a pair of mouse monoclonal antibodies. These 
antibodies and prototypes of the assay have been described previously (Kjems et al.,1993, 
Sobey et al.,1991). 
Principle of the test: 
Total Proinsulin is an ELISA based on two monoclonal antibodies. Sequential incubation of 
sample and enzyme-labelled antibody in a microplate well coated with a specific anti-
Analyte Cross reactivity (%) 
Human insulin  0* 
Intact human proinsulin (biosynthetic) 63 
32-33 split proinsulin 75 
65-66 split proinsulin 71 
des 64-65 split proinsulin 87 
des 31-32 split proinsulin 82 
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proinsulin antibody forms a complex. Two washing steps remove unbound sample and 
enzyme-labelled antibody. The bound conjugate is detected by reaction with DakoCytomation 
amplification system (Fig 2.5). Adding acid gives a colorimetric endpoint that is read 
spectrophotometrically and stops the reaction. The inclusion of calibrators of known 
proinsulin concentration in the assay allows a calibration curve to be constructed from which 
the level of TOTAL proinsulin in patient samples can be determined. 
 
 
 
DAKO Proinsulin assay principle 
 
Detection limit: < 0.5pmol/l 
Precision: 
Intra-assay CV = 3.4 %; Inter-assay CV = 3.3 % 
Cross reactivity: 
The specificity of the assay was assessed by observing cross reaction with structurally related 
peptides and hormones 
 
Analyte Cross reactivity (%) 
Human insulin 0 (tested up to 240 nmol/l) 
C-peptide 0 (tested up to 1000 nmol/l) 
32-33 split proinsulin 100% 
64-65 split proinsulin 100% 
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Insulin cross reactivity: 
Total Proinsulin shows no cross reactivity with insulin therefore insulin-secreting tumours 
may not be detected. 
 
7.3 Intact Proinsulin estimation in serum 
The DAKO Cytomation kit measures only the intact form of human proinsulin. It is suggested 
that term ‘intact proinsulin’ may be used for the 86-amino-acid hormone (Clark, 1999). Pure 
intact proinsulin has little, if any, insulin activity. In normal individuals intact proinsulin 
present in the circulation in very low concentrations, and in type 2 diabetic patients, especially 
obese ones; it can be significantly elevated and especially high in rare cases of proinsulinoma. 
Principle of the test: 
The same principle as for the Total Proinsulin applies to the Intact Proinsulin assay. 
Detection Limit: < 0.5 pmol/L 
Precision: 
Intra-assay CV = 3.1 %; Inter-assay CV = 4.7 % 
Cross reactivity: 
 
 
 
 
Analyte Cross reactivity (%) 
Human insulin 0 (tested up to 240 nmol/l) 
C-peptide 0 (tested up to 1000 nmol/l) 
32-33 split proinsulin 0 (tested up to 24 nmol/l) 
64-65 split proinsulin 100% 
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7.4 Calculated des 31, 32 split Proinsulin 
 
There is evidence that the des rather than the split forms are the major circulating form of the 
partially processed proinsulins, with the des 31, 32 split Proinsulin being present in higher 
concentrations in human plasma than the des 64, 65 split Proinsulin. Data are accumulating 
that elevations of intact and partially processed proinsulins are markers of beta cell 
dysfunction and may in some populations predict progression to type 2 diabetes (Clark, 1999). 
The levels of des 31, 32 split Proinsulin in our study were calculated by subtraction of intact 
proinsulin levels from the total proinsulin levels. 
 
8. Determination of Cortisol in serum 
 
(ADVIA ® Centaur System, used according to method specifications) 
Assay principle: 
The ADVIA Centaur Cortisol assay is a competitive immunoassay using direct 
chemiluminescent technology. Cortisol in the patient sample competes with acridinium ester-
labeled cortisol for binding to polyclonal rabbit anti-cortisol antibody on the solid phase. The 
polyclonal rabbit anti-cortisol antibody is bound to monoclonal mouse anti-rabbit antibody, 
which is covalently coupled to paramagnetic particles. 
Limitations: 
Structurally related steroids such as prednisolone & prednisone could cross-react with the 
assay leading to falsely elevated results. Prednisolone at concentration of 100 µg/dL has 27 % 
cross-reactivity and prednisone (1000 µg/dL) has 6.6 % cross-reactivity with the assay.    
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Expected results: 
Based on a central 95% interval, the following reference ranges were established: 
 
Sample Category                 Cortisol Range (nmol/l)                Cortisol Range (µg/dl) 
Serum (7-9 a.m.)      118.6 - 618.0                                       4.30 - 22.40 
Serum (3-5 p.m.)       85.30 - 459.6                                      3.09 - 16.66 
 
Precision: 
Intra-assay CV = 2.89 %; Inter-assay CV = 3.07 %  
Sensitivity and Assay Range: 5.5-2069 nmol/l (0.20 – 75 µg/dl)   
 
Specificity: 
The ADVIA Centaur Cortisol assay is highly specific for cortisol. Cross-reactivity by 
structurally related compounds and pharmaceuticals were determined by spiking each 
compound into separate human samples to a final level of 1000 µg/dL, unless otherwise noted. 
 
% Cross-reactivity = (cortisol in spiked sample, µg/dL-cortisol in unspiked sample, µg/dL) x 100 
                      ___________________________________________________ 
                                                  (Concentration of compound added, µg/dL)  
 
 
9.  Determination of Cholesterol in Serum  
Cholesterol CHOD-PAP, ROCHE/Boehringer Mannheim Systems (used according to method 
specifications) and measured on a MODULAR Autoanalyser. 
Test principle: 
This is an enzymatic colorimetric test. Cholesterol esters are cleaved by the action of 
cholesterol esterase to yield free cholesterol and fatty acids. 
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                                          Cholesterol esterase 
Cholesterol esters + H2O                                         cholesterol + RCOOH 
 
Cholesterol is converted by oxygen with the aid of cholesterol oxidase to cholest-4-en-3-one 
and hydrogen peroxide. 
 
                              Cholesterol oxidase 
Cholesterol + O2                                         cholest-4-en-3-one + H2O2 
 
 
The hydrogen peroxide created, forms a red color by reacting with 4-aminophenazone and 
phenol under the catalytic action of peroxidase. The color intensity is directly proportional to 
the concentration of cholesterol and can be determined photometric 
                                                                     peroxidase 
2 H2O2 + 4-aminophenazone + phenol      
 4-(p-benzoquinone-monoimino) phenazone + 4 H2O 
Precision: 
Intra-assay CV = 0.8 %; Inter-assay CV =1.7 % 
Analytical sensitivity (Data on File at Boehringer Mannheim):0.08 mmol/l (3 mg/dl) 
 
10. Measurement of high-density lipoprotein (HDL) cholesterol in serum  
HDL-Cholesterol was measured using the Boehringer Mannheim direct HDL cholesterol assay 
(used according to method specifications). This automated method for direct determination of 
HDL-cholesterol in serum and plasma uses polyethylene glycol (PEG)-modified enzymes and 
dextran sulfate. When cholesterol esterase and cholesterol oxidase enzymes are modified by 
PEG, they show selective catalytic activities toward lipoprotein fractions, with the reactivity 
increasing in the order: LDL< VLDL ≈ chylomicrons < HDL. The Boehringer Mannheim 
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direct HDL cholesterol assay meets the 1998 National Institute of Health (NIH)/ National 
Cholesterol Education Program (NCEP) goals for acceptable performance (Kimberly et 
al.,1999). 
Test principle (Sugiuchi et al., 1995, Matsuzaki et al., 1996): 
This is a homogeneous enzymatic colorimetric test. In the presence of magnesium sulphate, 
dextran sulfate selectively forms water-soluble complexes with LDL, VLDL and 
chylomicrons, which are resistant to PEG-modified enzymes. The cholesterol concentration of 
HDL-cholesterol is determined enzymatically by cholesterol esterase and cholesterol oxidase 
coupled with PEG to the amino groups. 
Cholesterol esters are broken down quantitatively into free cholesterol and fatty acids by 
cholesterol esterase. 
                                                  PEG-cholesterol esterase 
 HDL-cholesterol esters + H2O                       cholesterol + RCOOH 
 
In the presence of oxygen, cholesterol is oxidized by cholesterol oxidase to ∆4-cholestenone 
and hydrogen peroxide. 
                                      PEG-cholesterol oxidase 
Cholesterol + O2                              ∆4-cholestenone + H2O2 
 
In the presence of peroxidase, the hydrogen peroxide generated reacts with 4-aminophenazone 
and sodium N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (HSDA) to form a purple blue 
dye. The colour intensity of this dye is directly proportional to the cholesterol concentration 
and is measured photometrically. 
                                                                                 peroxidase 
2 H2O2 + 4-aminophenazone +HSDA + H + H2O       purple blue pigment + 5 H2O  
 
Measuring range: 0.08-3.12 mmol/l (3-120 mg/dl). 
Precision: 
Intra-assay CV = 1.6 %; Inter-assay CV = 2.7 % 
Analytical sensitivity (Data on file at Roche): 0.08 mmol/l (3 mg/dl) 
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11. The Friedewald Equation for calculating low-density lipoprotein (LDL) 
in serum 
The ultracentrifuge measurement of LDL is time consuming and expensive and requires 
specialist equipment. For this reason, LDL-cholesterol is most commonly estimated from 
quantitative measurements of total and HDL-cholesterol and plasma triglycerides (TG) using 
the Friedewald (1972) equation: 
[LDL-chol] = [Total chol] - [HDL-chol] - ([TG]/2.2)) 
Where all concentrations are given in mmol/L and if calculated using all concentrations in 
mg/dL then the equation is: 
[LDL-chol] = [Total chol] - [HDL-chol] - ([TG]/5)) 
The quotient ([TG]/5) is used as an estimate of VLDL-cholesterol concentration. It assumes, 
first, that virtually all of the plasma TG is carried on VLDL, and second, that the  
TG: cholesterol ratio of VLDL is constant at about 5:1. 
Limitations of the Friedewald equation: 
The Friedewald equation should not be used under the following circumstances: when 
chylomicrons are present, and when plasma triglyceride concentration exceeds 400 mg/dL 
(4.52 mmol/L) samples generally are turbid, and in patients with dysbetalipoproteinemia (type 
III hyperlipoproteinemia). In circumstances in which these conditions apply, LDL-cholesterol 
should be measured directly. Chylomicrons are visible as a floating “cream” layer when the 
specimen is allowed to stand undisturbed at 4oC overnight. The recognition of 
dysbetalipoproteinemia (type III hyperlipoproteinemia), however, requires the identification of 
b-VLDL. Since b-VLDL contains proportionately more cholesterol than normal VLDL, the 
use of the factor [TG] / 5 underestimates the amount of cholesterol in the VLDL fraction, and 
consequently the Friedewald equation overestimates LDL-cholesterol. Use of the Friedewald 
equation in this case will result in the misidentification of a dysbetalipoproteinemic (type III) 
patient as having hyperbetalipoproteinemia (type II hyperlipoproteinemia). 
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12. Measurement of triglycerides in serum 
Triglycerides were measured using the GPO-PAP triglyceride assay by Roche (used according 
to method specifications). 
Test principle (Siedel et al., 1993): 
This is an enzymatic colorimetric test based on the work by Wahlefeld using a lipoprotein 
lipase (LPL) from microorganisms for the rapid and complete hydrolysis of triglycerides to 
glycerol followed by oxidation to dihydroxyacetone phosphate and hydrogen peroxide. The 
hydrogen peroxide reacts with 4-aminophenazone and 4-chlorophenol under the catalytic 
action of peroxidase to form a red color (Trinder endpoint). Solution R1 (buffer/4-
chlorophenol/enzymes) is added to the sample to start the reaction: 
                                               LPL 
Triglycerides + 3 H2O        glycerol + 3 RCOOH 
                                             GK* 
glycerol + ATP                glycerol -3- phosphate + ADP 
                   Mg 2+ 
                                                  GPO** 
glycerol-3- phosphate + O2             dihydroxyacetone phosphate + H2O2 
                                                                                   peroxidase 
H2O2  + 4-aminophenazone + 4-chlorophenol      
4-(p-benzoquinone-monoimino)-phenazone + 2 H2O + HC 
Abbreviations : * GK – glycerol kinase; ** GPO- glycerol phosphate oxidase 
 
Precision: 
Intra-assay CV = 1.5 %; Inter-assay CV = 1.8 % 
Analytical sensitivity: (Data on file at Roche): 0.05mmol/l (4 mg/dl) 
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13. Determination of Leptin and Human Leptin Receptor in serum 
Human Leptin and Human Leptin Receptor ELISAs were obtained from BioVendor 
Laboratory Medicine, Inc. (used according to method specifications). 
Principle of the test: 
Standards, quality controls, and samples are incubated in microtitration wells coated with 
polyclonal anti-human leptin or leptin receptor antibody. After a thorough wash, anti-human 
leptin (receptor) antibody labelled with horseradish peroxidase (HRP) is added to the wells 
and incubated with the immobilized antibody-leptin (receptor) complex. Following another 
washing step, the remaining HRP-conjugated antibody is allowed to react with the substrate 
H2O2 -tetramethylbenzidine. The reaction is stopped by addition of acidic solution, and 
absorbance of the resulting yellow product is measured spectrophotometrically at 450 nm. The 
absorbance is proportional to the concentration of leptin (receptor). A standard curve is 
constructed by plotting absorbance values versus leptin (receptor) concentrations of standards, 
and concentrations of unknown samples are determined using this standard curve. 
Precision: 
Intra-assay CV -human leptin = 3.93 %; human leptin receptor = 5.03 % 
Inter-assay CV - human leptin 4.1 %; human leptin receptor = 3.68 % 
Sensitivity: 
The limit of detection of human leptin is 0.5 ng/ml. 
The limit of detection of human leptin receptor is 0.4 unit recombinant leptin receptor / 1ml 
sample. 
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14.  Determination of human tumor necrosis factor alpha (TNF-α) in serum 
The Quantikine high sensitivity (HS) TNF-α immunoassay (R&D system used to assay 
specifications) is a 6.5-hour solid phase ELISA designed to measure TNF-α in serum and 
plasma. It contains E. coli-derived recombinant human TNF-α and antibodies raised against 
the recombinant factor. Results obtained with naturally occurring TNF-α samples showed 
linear curves that were parallel to the standard curves obtained using the recombinant kit 
standards suggesting that Quantikine HS Immunoassay kit can be used to determine relative 
mass values for natural TNF-α. Since the measurement of TNF-α is insensitive to the addition 
of recombinant forms of either of the two types of soluble receptors, it is probable that this 
measurement detects the total amount of TNF-α in samples, i.e., the total amount of free TNF-
α plus the amount of TNF-α bound to soluble receptors. 
Principle of the assay: 
This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for TNF-α has been pre-coated onto a microplate. The Quantikine TNF-α 
HS Immunoassay kit uses an amplification system in which the alkaline phosphatase reaction 
provides a cofactor that activates a redox cycle leading to the formation of a coloured product  
(Self, 1985, Stanley et al.,1985, Johansson et al.,1986). The alkaline phosphatase is covalently 
linked to an anti- TNF-α detector antibody. 
In this amplification system, alkaline phosphatase dephosphorylates the reduced form of 
nicotinamide adenine dinucleotide phosphate, NADPH (Substrate), to reduced nicotinamide 
adenine dinucleotide, NADH. The NADH subsequently serves as a specific cofactor that 
activates a redox cycle driven by the secondary enzyme system consisting of alcohol 
dehydrogenase and diaphorase (Amplifier). In the reaction catalysed by diaphorase, NADH 
reduces a tetrazolium salt (INT-violet or iodonitrotetrazolium violet) to produce an intensely 
coloured formazan dye and NAD+. NAD+ in turn is reduced by ethanol, in an alcohol 
dehydrogenase-catalysed reaction, to regenerate NADH, which can then re-enter the redox 
cycle. The rate of reduction of the tetrazolium salt and thus the amount of coloured product 
formed are directly proportional to the amount of TNF-α bound in the initial step. 
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Precision: 
Intra-assay CV = 6.7 %; Inter-assay CV = 13.4 % 
Sensitivity: 
The minimum detectable dose (MDD) of TNF-α ranges from 0.06 pg/ml to 0.32 pg/ml.  
The mean MDD is 0.12 pg/ml. 
Specificity: 
This assay recognizes recombinant and natural human TNF-α. The factors related to or 
associated with TNF-α such as soluble TNF receptor I, soluble TNF receptor II and TNF-β 
does not cross react. 
 
15. Method for measurements of IL-6 in serum 
The Biotrak high sensitivity (HS) human interleukin-6 ELISA system from Amersham 
Pharmacia Biotech provides determination of IL-6 in cell culture supernatants, urine, plasma, 
and serum. 
Principle of the assay: 
The assay system is based on a solid phase ELISA, which utilizes an antibody for human IL-6 
bound to the wells of a microtitre plate together with a biotinylated antibody to human IL-6 
and Amdex amplification reagent. The Amdex amplification reagent is a high performance 
conjugate that utilizes a hydrophilic straight chain dextran backbone to which many hundreds 
of horseradish peroxidase molecules are covalently coupled, together with, on average, ten 
streptavidin molecules. The result is a multifunctional conjugate with a significantly enhanced 
activity and with well-controlled non-specific binding properties. Although the Biotrak IL-6 
immunoassay contains recombinant IL-6 and antibodies raised against recombinant IL-6, it 
has been shown to quantitate accurately both natural IL-6 and recombinant IL-6. In addition to 
the samples to be tested, a series of wells is prepared using known concentrations of the 
human IL-6 standard. A curve, plotting the optical density versus the concentration of the 
standard well, is prepared. By comparing the optical density of the samples to this curve, the 
concentration of the IL-6 in the unknown samples is then determined. 
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Precision: 
Intra-assay CV <10 %; Inter-assay CV <10 % 
Specificity: 
This assay recognizes both natural and recombinant (h) IL-6. It does not cross react with 
human IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-7, IL-8, TNF-a, IFN-γ, GM-CSF, mouse IL-6 or rat 
IL-6. 
Sensitivity: The minimum detectable dose of human IL-6 is 0.1pg/ml (0.01pg/well). 
 
16. Determination of CRP in serum  
CRP (Latex) high sensitivity (HS) assay is manufactured by Roche and performed on a 
MODULAR Autoanalyser according to assay specifications. 
Test principle: 
This is a particle-enhanced immunoturbidimetric assay. 
Sample and addition of R1 (buffer), is followed by addition of R2 (anti- CRP antibody-latex) 
and start of reaction: 
 
 
           CRP antigen                   anti-CRP antibody 
 
 
       
         Antigen / antibody complex      Turbidimetric measurement 
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Anti-CRP antibodies coupled to latex microparticles react with antigen in the sample to form 
an antigen/antibody complex. Following agglutination, this is measured turbidimetrically. 
Addition of PEG allows the reaction to progress rapidly to the end point, increases sensitivity, 
and reduces the risk of samples containing excess antigen producing false negative results. 
Limitations-interference: 
A high- dose hook effect does not occur at CRP concentrations below 1000mg/l. In very rare 
cases gammopathy, in particular type IgM (Waldenstrom’s macroglobulinemia) may cause 
unreliable results. 
Measuring range: 0.1-20 mg/l (0.0001-0.02 g/l) 
Precision: 
Intra-assay CV = 1.34 %; Inter-assay CV = 5.7 % 
Analytical sensitivity (lower detection limit): 0.03 mg/l: 
Functional sensitivity: 0.11mg/l. This functional sensitivity is the lowest CRP concentration 
that can be reproducibly measured with an inter-assay coefficient of variation of <10%. 
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APPENDIX 3 
 
Food Frequency Questionnaire 
 
 
NAME -------------------------------------------------------- 
DATE OF BIRTH -------------------------- AGE (YEAR AND MONTHS) ----------------- 
SEX ----------------------- 
ETHNIC GROUP ------------------------ 
DAY OF INTERVIEW ------------------ 
DATE OF INTERVIEW ----------------- 
 
INSTRUCTIONS 
 
The following questions are about the foods you USUALLY eat during an average week. 
Please indicate the number of days per week that you eat each item on average. Ring the 
answer as in the example: 
If you eat the food every day, ring 7   ----------------------------7 6 5 4 3 2 1 M R 
If you the food 3 days / week, ring 3 ---------------------------- 7 6 5 4 3 2 1 M R 
If you eat the food only monthly, ring M ----------------------- 7 6 5 4 3 2 1 M R 
If you never or rarely eat the food, ring R ---------------------- 7 6 5 4 3 2 1 M R 
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GRAIN AND CEREAL GROUP 
 
                                                                                                  No. Days / week 
Bread ----------------------------------------------------------------- 7 6 5 4 3 2 1 M R 
Provide/ cream crackers etc. --------------------------------------7 6 5 4 3 2 1 M R 
Do you mainly eat white, brown or whole wheat bread? ____________________ 
How many slices of bread do you have per day? __________________________ 
 
BREAKFAST CEREALS AND PORRIDGES 
            
                                                                  No. Days / week 
Cereals (Rice Krispies, Cornflakes) -------------------------------7 6 5 4 3 2 1 M R 
Sugar coated cereals (Coco Pops, Frosties) ----------------------7 6 5 4 3 2 1 M R 
W/wheat cereals (All Bran, Weetbix) ----------------------------7 6 5 4 3 2 1 M R 
Porridge (Oats, Maltabella, Maize meal)-------------------------7 6 5 4 3 2 1 M R 
Muesli --------------------------------------- -------------------------7 6 5 4 3 2 1 M R 
Pronutro -------------------------------------------------------------  7 6 5 4 3 2 1 M R 
 
OTHER STARCHES 
                    No. Days / week   
Rice, pasta ---------------------------------------------------------- 7 6 5 4 3 2 1 M R 
Stiff maize meal - with Amazi (sour milk) ----------------------7 6 5 4 3 2 1 M R 
                                  -  Without ---------------------- ----------- 7 6 5 4 3 2 1 M R 
Samp / mielie rice - with beans-----------------------------------7 6 5 4 3 2 1 M R 
                                  -  Without -----------------------------------7 6 5 4 3 2 1 M R 
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MEATS AND MEATS SUBSTITUTES 
 
                              No. Days / week 
Red meat (beef, lamb, pork or mince) --------------------------7 6 5 4 3 2 1 M R 
Processed meat (bacon, sausages, polony) ---------------------7 6 5 4 3 2 1 M R 
Chicken ---------------------------------------------------------- --7 6 5 4 3 2 1 M R 
Fish ----------------------------------------------------------------- 7 6 5 4 3 2 1 M R 
Eggs and egg dishes ----------------------------------------------7 6 5 4 3 2 1 M R 
Cheese, cheese spread and cheese dishes ----------------------7 6 5 4 3 2 1 M R 
Nuts, including peanut butter ------------------------------------7 6 5 4 3 2 1 M R 
Dried peas, beans, baked beans or legumes -------------------7 6 5 4 3 2 1 M R   
 
VEGETABLES AND FRUIT 
No. Days / week 
Green and / or yellow vegetables -------------------------------7 6 5 4 3 2 1 M R 
Potatoes ------------------------------------------------------------ 7 6 5 4 3 2 1 M R 
Fresh fruit---------------------------------------------------------- 7 6 5 4 3 2 1 M R 
Canned fruit ------------------------------------------------------- 7 6 5 4 3 2 1 M R 
Dried fruit (raisins, prunes, dates) ------------------------------7 6 5 4 3 2 1 M R 
Fresh fruit juice (Ceres, Liquifruit) -----------------------------7 6 5 4 3 2 1 M R 
Name some of the vegetables you have eaten this past week 
________________________________________________________________ 
Do you eat your vegetables mostly coked or raw? _______________________________ 
Do you mainly eat your potatoes as boiled, baked in jacket, mashed, roasted or as chips? 
________________________________________________________________ 
What types of fresh fruit have you eaten this past week? 
__________________________________________________________________ 
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FATS AND OILS 
 
                  No. Days / week 
Oil / butter / margarine-------------------------------------------7 6 5 4 3 2 1 M R 
Salad dressing / mayonnaise ------------------ -----------------7 6 5 4 3 2 1 M R 
Cream  -------------------------------------------- ---------------- 7 6 5 4 3 2 1 M R 
Non-dairy creamers (Cremora) -------------------------------- 7 6 5 4 3 2 1 M R 
Ice-cream --------------------------------------------------------- 7 6 5 4 3 2 1 M R 
 
Please estimate, on average, the total amount of fat (oil/butter/margarine/dressing/cream/non-
dairy creamers) you use per day in teaspoons. 
___________________tsp. (includes the fat on bread, in cooking and frying and on vegetables 
/salads) 
                                                                                                No. Days / week 
How often do you fry your food? ------------------------------ 7 6 5 4 3 2 1 M R 
 
MILK AND MILK PRODUCTS 
 
        No. Days / week 
Milk ---------------------------------------------------------------7 6 5 4 3 2 1 M R 
Yoghurt - Plain --------------------------------------------------7 6 5 4 3 2 1 M R 
              - Flavoured --------------------------------------------7 6 5 4 3 2 1 M R 
Milo / Nesquick /Cocoa / Horlicks--------------------------- 7 6 5 4 3 2 1 M R 
 
Please estimate on average, how much milk you have per day, including that on cereal, in tea 
or coffee and milk drinks 
____________ml or ______________cups 
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What type of milk do you use? 
Full cream _______________ 
Low-fat (2% fat) __________ 
Skimmed     ______________ 
Condensed ______________ 
Powdered ______________ 
 
MISCILLANEOUS 
 
Please estimate how many teaspoons of sugar you have in total per day?  _______ tsp. 
(In tea / coffee/ milk drinks, on cereal / porridge, added to vegetables). 
 
              No. Days / week 
Sweets (sucking / jelly type / fudge / toffee) ---------------------- 7 6 5 4 3 2 1 M R 
Chocolates / chocolate bars ------------------------------------------ 7 6 5 4 3 2 1 M R 
Jam, syrup, honey ----------------------------------------------------- 7 6 5 4 3 2 1 M R 
Jelly ----------------------------------------------------------------------7 6 5 4 3 2 1 M R 
Sweet biscuits / cakes / pastries /doughnuts / 
tarts /scones / pancakes ------------------------------------------------7 6 5 4 3 2 1 M R 
Crisps---------------------------------------------------------------------7 6 5 4 3 2 1 M R 
Popcorn (plain or candied) --------------------------------------------7 6 5 4 3 2 1 M R 
Puddings (trifle, baked puddings etc.) -------------------------------7 6 5 4 3 2 1 M R 
Cold drinks (Coke, Fanta etc) or cordials----------------------------7 6 5 4 3 2 1 M R 
                                              - Sweetened--------------------------- 7 6 5 4 3 2 1 M R 
                                               - Diet-----------------------------------7 6 5 4 3 2 1 M R 
Tea ------------------------------------------------------------------------7 6 5 4 3 2 1 M R 
Coffee---------------------------------------------------------------------7 6 5 4 3 2 1 M R 
Spreads (Bovril, marmite, fish paste, sandwich) -------------------7 6 5 4 3 2 1 M R 
How many meals do you have per day i.e. Breakfast, lunch and / or dinner ______ 
How many in between snacks do you have per day i.e. Mid-morning, mid-afternoon and or 
late evening? ________ 
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Please indicate how many portions of the following food groups you ate yesterday by circling 
the appropriate number. 
E.g. If you had 1 egg for breakfast, cheese for lunch and chicken for dinner, ring 3 for number 
2. 
If you have cereal and 1 slice of toast for breakfast, a sandwich for lunch (2 slices of bread) 
and rice for dinner, ring 5 for number 6. 
 
1. Milk, yoghurt (1 portion = 1 cup / 200 ml) ------------------------ 1 2 3 4 5 6 7 8 9 10 
2. Meat / fish / chicken / cheese / eggs / nuts / legumes--------------1 2 3 4 5 6 7 8 9 10 
3. Fruit / fruit juice --------------------------------------------------------1 2 3 4 5 6 7 8 9 10 
4. Vegetables (green and yellow) ---------------------------------------1 2 3 4 5 6 7 8 9 10 
5. Potatoes ----------------------------------------------------------------- 1 2 3 4 5 6 7 8 9 10 
6. Bread / cereal/ porridge / rice / pasta / maize meal / samp/ 
    mielie rice --------------------------------------------------------------1 2 3 4 5 6 7 8 9 10 
7. Oil / butter / margarine / cream/ non dairy creamers/ 
    salad dressings (1 portion = 1 tsp.)----------------------------------1 2 3 4 5 6 7 8 9 10 
 
Were these numbers of portions typical of what you would normally consume on an average 
day?  
Yes ______ No _______ 
If answer No, was the difference due to: 
Illness ___________ 
A party __________ 
Eating out _________ 
Other reasons __________________________________________________________ 
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APPENDIX 4 
Questionnaire for Assessment of Socio-Economic status 
 
1. Which of the following do you have in your household at the present time? 
 
Electricity --------------Y/N 
Television --------------Y/N 
Radio -------------------Y/N 
Motor vehicle----------Y/N 
Fridge -------------------Y/N 
Washing machine------Y/N 
Telephone --------------Y/N 
Video machine --------Y/N 
Microwave -------------Y/N 
 
2. Education – last standard passed 
 
No formal education 
Grade 1-2           
Std     1-3 
Std     4-5 
Std     6-7 
Std      8 
Std      9 
Matric 
Degree 
Postgraduate degree 
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